Note: Descriptions are shown in the official language in which they were submitted.
CA 03018066 2018-09-17
WO 2017/161357 PCT/US2017/023108
OLIGONUCLEOTIDE PROBES AND USES THEREOF
CROSS REFERENCE
This application claims the benefit of U.S. Provisional Patent Application
Nos. 62/310,665, filed March,
18, 2016; 62/413,361, filed October 26, 2016; 62/420,497, filed November 10,
2016; 62/432,561, filed
December 9, 2016; 62/457,691, filed February 10, 2017; and 62/472,953, filed
March 17, 2017; all of
which applications are incorporated herein by reference in their entirety.
SEQUENCE LISTING SUBMITTED VIA EFS-WEB
[0001] The entire content of the following electronic submission of the
sequence listing via the USPTO
EFS-WEB server, as authorized and set forth in MPEP 1730 JIB .2(a), is
incorporated herein by
reference in its entirety for all purposes. The sequence listing is within the
electronically filed text file that
is identified as follows:
[0002] File Name: 836601_SEQUENCES.txt
[0003] Date of Creation: March 18, 2017
[0004] Size (bytes): 40,256,606 bytes
BACKGROUND OF THE INVENTION
[0005] The invention relates generally to oligonucleotide probes, which are
useful for diagnostics of
cancer and/or other diseases or disorders and as therapeutics to treat such
medical conditions. The
invention further relates to materials and methods for the administration of
oligonucleotide probes capable
of binding to cells of interest.
[0006] Oligonucleotide probes, or aptamers, are oligomeric nucleic acid
molecules having specific
binding affinity to molecules, which may be through interactions other than
classic Watson-Crick base
pairing. Unless otherwise specified, an "aptamer" as the term is used herein
can refer to nucleic acid
molecules that can associate with targets, regardless of manner of target
recognition. Unless other
specified, the terms "aptamer," "oligonucleotide," "polynucleotide,"
"oligonucleotide probe," or the like
may be used interchangeably herein.
[0007] Oligonucleotide probes, like peptides generated by phage display or
monoclonal antibodies
("mAbs"), are capable of specifically binding to selected targets and
modulating the target's activity, e.g.,
through binding aptamers may block their target's ability to function. Created
by an in vitro selection
process from pools of random sequence oligonucleotides, aptamers have been
generated for numerous
proteins including growth factors, transcription factors, enzymes,
immunoglobulins, and receptors. A
typical aptamer is 10-15 kDa in size (30-45 nucleotides), binds its target
with sub-nanomolar affinity, and
discriminates against closely related targets (e.g., aptamers can be designed
to not bind other proteins
from the same gene family). A series of structural studies have shown that
aptamers are capable of using
the same types of binding interactions (e.g., hydrogen bonding, electrostatic
complementarity,
hydrophobic contacts, steric exclusion) that drive affinity and specificity in
antibody-antigen complexes.
-1-
CA 03018066 2018-09-17
WO 2017/161357 PCT/US2017/023108
[0008] We have previously identified oligonucleotides and libraries of
oligonucleotides useful for the
detection of microvesicles in bodily fluid samples. Microvesicles can be shed
by diseased cells, such as
cancer cells, into various bodily fluids such as blood. Thus provide a means
of liquid biopsy, including
without limitation blood based diagnostics. In some cases, tissue samples are
available. The present
invention provides methods of enriching oligonucleotide libraries against
tissues of interest. Applications
of the invention include without limitation theranostics (e.g., predicting a
drug response) and diagnostics
(e.g., detecting cancer samples). As the methods of the invention provide
aptamers that specifically
recognize diseased cells, the aptamers themselves can be used in therapeutic
applications.
INCORPORATION BY REFERENCE
[0009] All publications, patents and patent applications mentioned in this
specification are herein
incorporated by reference to the same extent as if each individual
publication, patent or patent application
was specifically and individually indicated to be incorporated by reference.
SUMMARY OF THE INVENTION
[0010] Compositions and methods of the invention provide oligonucleotide
probes that recognize tissues
having phenotypes of interest. In various embodiments, oligonucleotide probes
of the invention are used
in diagnostic, prognostic or theranostic processes to characterize a phenotype
of that sample. The
diagnosis may be related to a cancer. In other embodiments, oligonucleotide
probes of the invention are
chemically modified or composed in a pharmaceutical composition for
therapeutic applications.
[0011] In an aspect, the invention provides an oligonucleotide comprising a
region corresponding to: a) a
variable sequence as described in any one of Examples 19-31; b) a variable
sequence as described in any
one of Tables 20-23, 25, 27, 38- 40, or 45; or c) a sequence listed in any one
of SEQ ID NO. 1-206506. In
some embodiments, the oligonucleotide further comprises a 5' region with
sequence 5'-
CTAGCATGACTGCAGTACGT (SEQ ID NO. 4), a 3' region with sequence 5'-
CTGTCTCTTATACACATCTGACGCTGCCGACGA (SEQ ID NO. 5), or both. The invention
further
provides an oligonucleotide comprising a nucleic acid sequence or a portion
thereof that is at least 50, 55,
60, 65, 70, 75, 80, 85, 90, 95, 96, 97, 98, 99 or 100 percent homologous to
such oligonucleotide
sequences. In a related aspect, the invention provides a plurality of
oligonucleotides comprising at least 1,
2, 3,4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 40,
45, 50, 55, 60, 65, 70, 75, 80, 85,
90, 95, 100, 125, 150, 175, 200, 300, 400, 500, 600, 700, 800, 900, 1000,
2000, 3000, 4000, 5000, 6000,
7000, 8000, 9000, 10000, 20000, 30000, 40000, 50000, 60000, 70000, 80000,
90000, or at least 100000
different oligonucleotide sequences as described above.
[0012] In an embodiment, the oligonucleotide or the plurality of
oligonucleotides comprise a DNA,
RNA, 2'-0-methyl or phosphorothioate backbone, or any combination thereof. In
some embodiments, the
oligonucleotide or the plurality of oligonucleotides comprises at least one of
DNA, RNA, PNA, LNA,
UNA, and any combination thereof. The oligonucleotide or at least one member
of the plurality of
oligonucleotides can have at least one functional modification selected from
the group consisting of DNA,
RNA, biotinylation, a non-naturally occurring nucleotide, a deletion, an
insertion, an addition, and a
-2-
CA 03018066 2018-09-17
WO 2017/161357 PCT/US2017/023108
chemical modification. In some embodiments, the chemical modification
comprises at least one of C18,
polyethylene glycol (PEG), PEG4, PEG6, PEG8, PEG12 and digoxygenin.
[0013] The oligonucleotide or plurality of oligonucleotides of the invention
can be labeled. For example,
the oligonucleotide or plurality of oligonucleotides can be attached to a
nanoparticle, liposome, gold,
magnetic label, fluorescent label, light emitting particle, biotin moiety, or
radioactive label.
[0014] In an aspect, the invention provides a method of enriching an
oligonucleotide library using
multiple rounds of positive and negative selection. The method of enriching a
plurality of oligonucleotides
may comprise: a) performing at least one round of positive selection, wherein
the positive selection
comprises: i) contacting at least one sample with the plurality of
oligonucleotides, wherein the at least one
sample comprises tissue; and ii) recovering members of the plurality of
oligonucleotides that associated
with the at least one sample; b) optionally performing at least one round of
negative selection, wherein the
negative selection comprises: i) contacting at least one additional sample
with the plurality of
oligonucleotides, wherein at least one additonal sample comprises tissue; ii)
recovering members of the
plurality of oligonucleotides that did not associate with the at least one
additonal sample; and c)
amplifying the members of the plurality of oligonucleotides recovered in at
least one or step (a)(ii) and
step (b)(ii), thereby enriching the oligonucleotide library. In an
embodiments, the recovered members of
the plurality of oligonucleotides in step (a)(ii) are used as the input for
the next iteration of step (a)(i). In
an embodiment, the recovered members of the plurality of oligonucleotides in
step (b)(ii) are used as the
input for the next iteration of step (a)(i). The unenriched oligonucleotide
library may possess great
diversity. For example, the unenriched oligonucleotide library may comprise at
least 2, 3, 4, 5, 6, 7, 8, 9,
10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 40, 45, 50, 55, 60, 65,
70, 75, 80, 85, 90, 95, 100, 125,
150, 175, 200, 300, 400, 500, 600, 700, 800, 900, 1000, 2000, 3000, 4000,
5000, 6000, 7000, 8000, 9000,
10000, 20000, 30000, 40000, 50000, 60000, 70000, 80000, 90000, 100000, 200000,
300000, 400000,
500000, 106, 107, 108, 109, 1010, 1011, 1012,
10", 1 -0 14,
10", r16,
V 1017, or at least 1018 different
oligonucleotide sequences. In an embodiment, the unenriched oligonucleotide
library comprises the naive
F-Trim library as described herein.
[0015] In some embodiments of the enrichment methods of the invention, the at
least one sample and/or
at least one additional sample comprise fixed tissue. The fixed tissue may
comprise formalin fixed
paraffin embedded (FFPE) tissue. In embodiment, the FFPE tissue comprises at
least one of a fixed tissue,
unstained slide, bone marrow core or clot, biopsy sample, surgical sample,
core needle biopsy, malignant
fluid, and fine needle aspirate (FNA). The FFPE tissue can be fixed on a
substrate. For example, the
substrate can be a glass slide or membrane.
[0016] In some embodiment, the at least one sample and/or the at least one
additional sample are fixed on
different substrates. Alternately, the at least one sample and/or the at least
one additional sample is fixed
on a single substrate. In some embodiments, the at least one sample and/or the
at least one additional
sample are lysed, scraped from a substrate, or subjected to microdissection.
Lysed samples can be arrayed
on a substrate. In some embodiments, the substrate comprises a membrane. For
example, the membrane
can be a nitrocellulose membrane.
-3-
CA 03018066 2018-09-17
WO 2017/161357 PCT/US2017/023108
[0017] In various embodiments of the enrichment methods of the invention, the
at least one sample and
the at least one additional sample differ in a phenotype of interest. The at
least one sample and the at least
one additional sample can be from different sections of a same substrate. As a
non-limiting example, the
samples may comprise cancer tissue and normal adjacent tissue from a fixed
tissue sample. In such cases,
the at least one sample and the at least one additional sample may be scraped
or microdissected from the
same substrate to facilitate enrichment.
[0018] The oligonucleotide library can be enriched for analysis of any desired
phenotype. In
embodiments, the phenotype comprises a tissue, anatomical origin, medical
condition, disease, disorder,
or any combination thereof For example, the tissue can be muscle, epithelial,
connective and nervous
tissue, or any combination thereof For example, the anatomical origin can be
the stomach, liver, small
intestine, large intestine, rectum, anus, lungs, nose, bronchi, kidneys,
urinary bladder, urethra, pituitary
gland, pineal gland, adrenal gland, thyroid, pancreas, parathyroid, prostate,
heart, blood vessels, lymph
node, bone marrow, thymus, spleen, skin, tongue, nose, eyes, ears, teeth,
uterus, vagina, testis, penis,
ovaries, breast, mammary glands, brain, spinal cord, nerve, bone, ligament,
tendon, or any combination
thereof.
[0019] In various embodiments of the enrichment methods of the invention, the
method further
comprises determining a target of the enriched members of the oligonucleotide
library. Techniques for
such determining are provided herein.
[0020] In an aspect, the invention provides a method of characterizing a
phenotype in a sample
comprising: a) contacting the sample with at least one oligonucleotide or
plurality of oligonucleotides; and
b) identifying a presence or level of a complex formed between the at least
one oligonucleotide or
plurality of oligonucleotides and the sample, wherein the presence or level is
used to characterize the
phenotype. In a related aspect, the invention provides a method of visualizing
a sample comprising: a)
contacting the sample with at least one oligonucleotide or plurality of
oligonucleotides; b) removing the at
least one oligonucleotide or members of the plurality of oligonucleotides that
do not bind the sample; and
c) visualizing the at least one oligonucleotide or plurality of
oligonucleotides that bound to the sample.
The visualization can be used to characterize a phenotype.
[0021] The sample to be characterized can be any useful sample, including
without limitation a tissue
sample, bodily fluid, cell, cell culture, microvesicle, or any combination
thereof. In some embodiments,
the tissue sample comprises fixed tissue. The fixed tissue can be, e.g.,
formalin fixed paraffin embedded
(FFPE) tissue. In various embodiments, the FFPE sample comprises at least one
of a fixed tissue,
unstained slide, bone marrow core or clot, biopsy sample, surgical sample,
core needle biopsy, malignant
fluid, and fine needle aspirate (FNA).
[0022] Identifying a presence or level may comprise any useful technique,
including without limitation
nucleic acid sequencing, amplification, hybridization, gel electrophoresis,
chromatography, or
visualization. In some embodiments, the identifying by hybridization comprises
contacting the sample
with at least one labeled probe that is configured to hybridize with at least
one oligonucleotide or plurality
of oligonucleotides. The at least one labeled probe can be directly or
indirectly attached to a label. The
-4-
CA 03018066 2018-09-17
WO 2017/161357 PCT/US2017/023108
label can be, e.g., a fluorescent, radioactive or magnetic label. An indirect
label can be, e.g., biotin. In
some embodiments, the sequencing comprises next generation sequencing, dye
termination sequencing,
and/or pyrosequencing of the at least one oligonucleotide or plurality of
oligonucleotides. The
visualization may be that of a signal linked directly or indirectly to the at
least one oligonucleotide or
plurality of oligonucleotides. The signal can be any useful signal, e.g., a
fluorescent signal or an
enzymatic signal. In some embodiments, the enzymatic signal is produced by at
least one of a luciferase,
firefly luciferase, bacterial luciferase, luciferin, malate dehydrogenase,
urease, peroxidase, horseradish
peroxidase (HRP), alkaline phosphatase (AP), p-galactosidase, glucoamylase,
lysozyme, a saccharide
oxidase, glucose oxidase, galactose oxidase, glucose-6-phosphate
dehydrogenase, a heterocyclic oxidase,
uricase, xanthine oxidase, lactoperoxidase, and microperoxidase. Visualization
may comprise use of light
microscopy or fluorescent microscopy.
[0023] In the methods of the invention directed to characterizing or
visualizing a sample, the target of at
least one of the at least one oligonucleotide or plurality of oligonucleotides
may be known. For example,
an oligonucleotide may bind a known protein target. In some embodiments, the
target of at least one the at
least one oligonucleotide or plurality of oligonucleotides is unknown. For
example, the at least one
oligonucleotide or plurality of oligonucleotides may themselves provide a
biosignature or other useful
result that does not necessarily require knowledge of the antigens bound by
some or all of the
oligonucleotides.
[0024] In the methods of characterizing or visualizing a sample, the at least
one oligonucleotide or
plurality of oligonucleotides can be as provided above. The at least one
oligonucleotide or plurality of
oligonucleotides may have been determined using the enrichment methods of the
invention provided
herein.
[0025] For example, the at least one oligonucleotide or plurality of
oligonucleotides may comprise
nucleic acids may have a sequence or a portion thereof that is at least 50,
55, 60, 65, 70, 75, 80, 85, 90, 95,
96, 97, 98, 99 or 100 percent homologous to an oligonucleotide sequence
according to at least 1, 2, 3, 4, 5,
6, 7, 8, 9, 10, 12, 15, 20 or all of SEQ ID NOs. 2922-2926, 2929-2947 and 2950-
2952. In such cases, the
phenotype may be, e.g., lung cancer or prostate cancer.
[0026] In another example, the at least one oligonucleotide or plurality of
oligonucleotides may comprise
nucleic acids having a sequence or a portion thereof that is at least 50, 55,
60, 65, 70, 75, 80, 85, 90, 95,
96, 97, 98, 99 or 100 percent homologous to an oligonucleotide sequence
according to at least 1, 2, 3, 4, 5,
6, 7, 8, 9, 10, 12, 15, 20 or all of SEQ ID NOs. 2953-2961 and 2971-2979. In
such cases, the phenotype
may be, e.g., prostate cancer.
[0027] In yet another example, the at least one oligonucleotide or plurality
of oligonucleotides may
comprise nucleic acids having a sequence or a portion thereof that is at least
50, 55, 60, 65, 70, 75, 80, 85,
90, 95, 96, 97, 98, 99 or 100 percent homologous to an oligonucleotide
sequence according to at least 1, 2,
3, 4, 5, 6, 7, 8, 9, 10, 12, 15, 20, 25, 30, 35, 40, 50 or all of SEQ ID NOs.
3039-3061. In such cases, the
phenotype may be, e.g., HER2 status (+/-).
-5-
CA 03018066 2018-09-17
WO 2017/161357 PCT/US2017/023108
100281 In still another example, the at least one oligonucleotide or plurality
of oligonucleotides may
comprise nucleic acids having a sequence or a portion thereof that is at least
50, 55, 60, 65, 70, 75, 80, 85,
90, 95, 96, 97, 98, 99 or 100 percent homologous to an oligonucleotide
sequence according to at least 1, 2,
3, 4, 5, 6, 7, 8, 9, 10, 12, 15, 20, 25, 30, 35, 40, 50, 60, 70, 80, 90, 100,
200, 300, 400, 500, 600, 700, 800,
900, 1000, 2000, 3000, 4000, 5000, 6000, 7000, 8000, 9000, 10000, 20000,
30000, 40000, 50000, 60000,
70000, 80000, 90000, 100000, 150,000 or all of SEQ ID NOs. 3062-103061 and
103062-203061. In such
cases, the phenotype may be, e.g., response to anti-HER2 therapy, wherein
optionally the anti-HER2
therapy comprises traztuzamab.
100291 In an example, the at least one oligonucleotide or plurality of
oligonucleotides may comprise
nucleic acids having a sequence or a portion thereof that is at least 50, 55,
60, 65, 70, 75, 80, 85, 90, 95,
96, 97, 98, 99 or 100 percent homologous to an oligonucleotide sequence
according to at least 1, 2, 3, 4, 5,
6, 7, 8, 9, 10, 12, 15, 20, 25, 30, 35, 40, 50, 60, 70, 80, 90, 100, 200, 300,
400, 500, 600, 700, 800, 900,
1000, 2000, 3000, 4000 or all of SEQ ID NOs. 203064-203067 and 203076-206478.
In such cases, the
phenotype may be, e.g., response to at least one of FOLFOX and bevazicumab.
[0030] In another example, the at least one oligonucleotide or plurality of
oligonucleotides may comprise
nucleic acids having a sequence or a portion thereof that is at least 50, 55,
60, 65, 70, 75, 80, 85, 90, 95,
96, 97, 98, 99 or 100 percent homologous to an oligonucleotide sequence
according to at least 1, 2, 3, 4, 5,
6, 7, 8, 9, 10, 12, 15 or all of SEQ ID NOs. 206491-206506. In such cases, the
phenotype may be, e.g., a
tissue identity, including without limitation whether the tissue comprises
breast, colon, kidney, lung or
pancreatic tissue.
[0031] In the methods of the invention, including enriching an oligonucleotide
library, characterizing a
sample or visualizing a sample, the phenotype can be a biomarker status. In
some embodiments, the
biomarker is selected from Table 4. In some embodiments, the biomarker status
comprises at least one of
HER2 positive, HER2 negative, EGFR positive, EGFR negative, TUBB3 positive, or
TUBB3 negative. In
some embodiments, the biomarker status comprises expression, copy number,
mutation, insertion,
deletion or other alteration of at least one of ALK, AR, ER, ERCC1, Her2/Neu,
MGMT, MLH1, MSH2,
MSH6, PD-1, PD-L1, PD-Li (22c3), PMS2, PR, PTEN, RRM1, TLE3, TOP2A, TOP01,
TrkA, TrkB,
TrkC, TS, and TUBB3. In various embodiments, the biomarker status comprises
the presence or absence
of at least one of EGFR vIII or MET Exon 14 Skipping. In embodiments, the
biomarker status comprises
expression, copy number, fusion, mutation, insertion, deletion or other
alteration of at least one of ALK,
BRAF, NTRK1, NTRK2, NTRK3, RET, ROS1, and RSP03. In embodiments, the biomarker
status
comprises expression, copy number, fusion, mutation, insertion, deletion or
other alteration of at least one
of ABL2, ACSL3, ACSL6, AFF1, AFF3, AFF4, AKAP9, AKT2, AKT3, ALDH2, ALK, APC,
ARFRP1,
ARHGAP26, ARHGEF12, ARID1A, ARID2, ARNT, ASPSCR1, ASXL1, ATF1, ATIC, ATM,
ATP1A1,
ATR, AURKA, AURKB, AXIN1, AXL, BAP1, BARD1, BCL10, BCL11A, BCL2L11, BCL3,
BCL6,
BCL7A, BCL9, BCR, BIRC3, BLM, BMPR1A, BRAF, BRCA1, BRCA2, BRIP1, BUB1B,
Cllorf30
(EMSY), C2orf44, CACNA1D, CALR, CAMTA1, CANT1, CARD11, CARS, CASC5, CASP8,
CBFA2T3, CBFB, CBL, CBLB, CCDC6, CCNB1IP1, CCND1, CCND2, CCND3, CCNE1, CD274
-6-
CA 03018066 2018-09-17
WO 2017/161357 PCT/US2017/023108
(PDL1), CD74, CD79A, CDC73, CDH11, CDK4, CDK6, CDK8, CDKN1B, CDKN2A, CDX2,
CHEK1,
CHEK2, CHIC2, CHN1, CIC, CIITA, CLP1, CLTC, CLTCL1, CNBP, CNTRL, COPB1, CREB1,
CREB3L1, CREB3L2, CREBBP, CRKL, CRTC1, CRTC3, CSF1R, CSF3R, CTCF, CTLA4,
CTNNA1,
CTNNB1, CYLD, CYP2D6, DAXX, DDR2, DDX10, DDX5, DDX6, DEK, DICER1, DOT1L, EBF1,
ECT2L, EGFR, ELK4, ELL, EML4, EP300, EPHA3, EPHA5, EPHB1, EPS15, ERBB2 (HER2),
ERBB3
(HER3), ERBB4 (HER4), ERC1, ERCC2, ERCC3, ERCC4, ERCC5, ERG, ESR1, ETV1, ETV5,
ETV6,
EWSR1, EXT1, EXT2, EZH2, EZR, FANCA, FANCC, FANCD2, FANCE, FANCG, FANCL, FAS,
FBX011, FBXW7, FCRL4, FGF10, FGF14, FGF19, FGF23, FGF3, FGF4, FGF6, FGFR1,
FGFR1OP,
FGFR2, FGFR3, FGFR4, FH, FHIT, FIP1L1, FLCN, FLI1, FLT1, FLT3, FLT4, FNBP1,
FOXA1,
FOX01, FOXP1, FUBP1, FUS, GAS7, GATA3, GID4 (C17orf39), GMPS, GNA13, GNAQ,
GNAS,
GOLGA5, GOPC, GPHN, GPR124, GRIN2A, GSK3B, H3F3A, H3F3B, HERPUD1, HGF, HIP1,
HMGA1, HIMGA2, HNRNPA2B1, HOOK3, HSP9OAA1, HSP90AB1, IDH1, IDH2, IGF1R, IKZFl,
IL2,
IL21R, IL6ST, IL7R, IRF4, ITK, JAK1, JAK2, JAK3, JAZFl, KDM5A, KDR (VEGFR2),
KEAP1,
KIAA1549, KIF5B, KIT, KLHL6, KMT2A (MLL), KMT2C (MLL3), KMT2D (MLL2), KRAS,
KTN1,
LCK, LCP1, LGR5, LHFP, LIFR, LPP, LRIG3, LRP1B, LYL1, MAF, MALT1, MAML2,
MAP2K1,
MAP2K2, MAP2K4, MAP3K1, MCL1, MDM2, MDM4, MDS2, MEF2B, MEN1, MET (cMET), MITF,
MLF1, MLH1 (NGS), MLLT1, MLLT10, MLLT3, MLLT4, MLLT6, MNX1, MRE11A, MSH2
(NGS),
MSH6 (NGS), MSI2, MTOR, MYB, MYC, MYCN, MYD88, MYH11, MYH9, NACA, NCKIPSD,
NCOA1, NCOA2, NCOA4, NF1, NF2, NFE2L2, NFIB, NFKB2, NFKBIA, NIN, NOTCH2, NPM1,
NR4A3, NSD1, NT5C2, NTRK1, NTRK2, NTRK3, NUP214, NUP93, NUP98, NUTM1, PALB2,
PAX3,
PAX5, PAX7, PBRM1, PBX1, PCM1, PCSK7, PDCD1 (PD1), PDCD1LG2 (PDL2), PDGFB,
PDGFRA,
PDGFRB, PDK1, PERI, PICALM, PIK3CA, PIK3R1, PIK3R2, PIM1, PML, PMS2 (NGS),
POLE,
POT1, POU2AF1, PPARG, PRCC, PRDM1, PRDM16, PRKAR1A, PRRX1, PSIP1, PTCH1, PTEN
(NGS), PTPN11, PTPRC, RABEP1, RAC1, RAD50, RAD51, RAD51B, RAF1, RALGDS,
RANBP17,
RAP1GDS1, RARA, RB1, RBM15, REL, RET, RICTOR, RMI2, RNF43, ROS1, RPL22, RPL5,
RPN1,
RPTOR, RUNX1, RUNX1T1, SBDS, SDC4, SDHAF2, SDHB, SDHC, SDHD, SEPT9, SET,
SETBP1,
SETD2, SF3B1, SH2B3, SH3GL1, SLC34A2, SMAD2, SMAD4, SMARCB1, SMARCE1, SMO,
SNX29, SOX10, SPECC1, SPEN, SRGAP3, SRSF2, SRSF3, SS18, SS18L1, STAT3, STAT4,
STAT5B,
STIL, STK11, SUFU, SUZ12, SYK, TAF15, TCF12, TCF3, TCF7L2, TETI, TET2, TFEB,
TFG, TFRC,
TGFBR2, TLX1, TNFAIP3, TNFRSF14, TNFRSF17, TOP1, TP53, TPM3, TPM4, TPR, 1RAF7,
TRIM26, TRIM27, TRIM33, TRIP11, TRRAP, TSC1, TSC2, TSHR, TTL, U2AF1, USP6,
VEGFA,
VEGFB, VTI1A, WHSC1, WHSC1L1, WIF1, WISP3, WRN, WT1, WWTR1, XPA, XPC, XP01,
YWHAE, ZMYM2, ZNF217, ZNF331, ZNF384, ZNF521, and ZNF703. The biomarker status
may
comprise expression, copy number, fusion, mutation, insertion, deletion or
other alteration of at least one
of ABIl, ABL1, ACKR3, AKT1, AMER1 (FAM123B), AR, ARAF, ATP2B3, ATRX, BCL11B,
BCL2,
BCL2L2, BCOR, BCORL1, BRD3, BRD4, BTG1, BTK, C15orf65, CBLC, CD79B, CDH1,
CDK12,
CDKN2B, CDKN2C, CEBPA, CHCHD7, CNOT3, COL 1A1, COX6C, CRLF2, DDB2, DDIT3,
DNM2,
DNMT3A, EIF4A2, ELF4, ELN, ERCC1 (NGS), ETV4, FAM46C, FANCF, FEV, FOXL2,
FOX03,
-7-
CA 03018066 2018-09-17
WO 2017/161357 PCT/US2017/023108
FOX04, FSTL3, GATA1, GATA2, GNAll, GPC3, HEY1, HIST1H3B, HIST1H4I, ULF,
HMGN2P46,
HNF1A, HOXA11, HOXA13, HOXA9, HOXC11, HOXC13, HOXD11, HOXD13, HRAS, IKBKE,
INHBA, IRS2, JUN, KAT6A (MYST3), KAT6B, KCNJ5, KDM5C, KDM6A, KDSR, KLF4, KLK2,
LASP1, LM01, LM02, MAFB, MAX, MECOM, MED12, MKL1, MLLT11, MN1, MPL, MSN,
MTCP1, MUC1, MUTYH, MYCL (MYCL1), NBN, NDRG1, NKX2-1, NONO, NOTCH1, NRAS,
NUMA1, NUTM2B, OLIG2, OMD, P2RY8, PAFAH1B2, PAK3, PATZ1, PAX8, PDE4DIP, PHF6,
PHOX2B, PIK3CG, PLAG1, PMS1, POU5F1, PPP2R1A, PRF1, PRKDC, RAD21, RECQL4,
RHOH,
RNF213, RPL10, SEPT5, SEPT6, SFPQ, SLC45A3, SMARCA4, SOCS1, SOX2, SPOP, SRC,
SSX1,
STAG2, TALI, TAL2, TBL1XR1, TCEA1, TCL1A, TERT, TFE3, TFPT, THRAP3, TLX3,
TMPRSS2,
UBR5, VHL, WAS, ZBTB16, and ZRSR2.
[0032] In the methods of the invention, including enriching an oligonucleotide
library, characterizing a
sample or visualizing a sample, the phenotype can be a phenotype comprises a
disease or disorder. The
methods can be employed to assist in providing a diagnosis, prognosis and/or
theranosis for the disease or
disorder. For example, the enriching may be performed using sample such that
the enriched library can be
used to assist in providing a diagnosis, prognosis and/or theranosis for the
disease or disorder. Similarly,
the characterizing may comprise assisting in providing a diagnosis, prognosis
and/or theranosis for the
disease or disorder. The visualization may also comprise assisting in
providing a diagnosis, prognosis
and/or theranosis for the disease or disorder. In some embodiments, the
theranosis comprises predicting a
treatment efficacy or lack thereof, classifying a patient as a responder or
non-responder to treatment, or
monitoring a treatment efficacy. The theranosis can be directed to any
appropriate treatment, e.g., the
treatment may comprise at least one of chemotherapy, immunotherapy, targeted
cancer therapy, a
monoclonal antibody, an anti-HER2 antibody, trastuzumab, an anti-VEGF
antibody, bevacizumab, and/or
platinum / taxane therapy. In some embodiments, the treatment comprises at
least one of afatinib, afatinib
+ cetuximab, alectinib, aspirin, atezolizumab, bicalutamide, cabozantinib,
capecitabine, carboplatin,
ceritinib, cetuximab, cisplatin, crizotinib, dabrafenib, dacarbazine,
doxorubicin, enzalutamide, epirubicin,
erlotinib, everolimus, exemestane + everolimus, fluorouracil, fulvestrant,
gefitinib, gemcitabine, hormone
therapies, irinotecan, lapatinib, liposomal-doxorubicin, matinib, mitomycin-c,
nab-paclitaxel, nivolumab,
olaparib, osimertinib, oxaliplatin, palbociclib combination therapy,
paclitaxel, palbociclib, panitumumab,
pembrolizumab, pemetrexed, pertuzumab, sunitinib, T-DM1, temozolomide
docetaxel, temsirolimus,
topotecan, trametinib, trastuzumab, vandetanib, and vemurafenib. The hormone
therapy can be one or
more of tamoxifen, toremifene, fulvestrant, letrozole, anastrozole,
exemestane, megestrol acetate,
leuprolide, goserelin, bicalutamide, flutamide, abiraterone, enzalutamide,
triptorelin, abarelix, and
degarelix.
[0033] In the methods of the invention directed to characterizing a sample,
the characterizing may
comprise comparing the presence or level to a reference. In some embodiments,
the reference comprises a
presence or level determined in a sample from an individual without a disease
or disorder, or from an
individual with a different state of a disease or disorder. The presence or
level can be that of a visual level,
such as an IHC score, determined by the visualizing. As a non-limiting
example, the comparison to the
-8-
CA 03018066 2018-09-17
WO 2017/161357 PCT/US2017/023108
reference of at least one oligonucleotide or plurality of oligonucleotides
provided by the invention
indicates that the sample comprises a cancer sample or a non-cancer/normal
sample.
[0034] In some embodiments of the methods of the invention, one or more sample
comprises a bodily
fluid. The bodily fluid can be any useful bodily fluid, including without
limitation peripheral blood, sera,
plasma, ascites, urine, cerebrospinal fluid (CSF), sputum, saliva, bone
marrow, synovial fluid, aqueous
humor, amniotic fluid, cerumen, breast milk, broncheoalveolar lavage fluid,
semen, prostatic fluid,
cowper's fluid or pre-ejaculatory fluid, female ejaculate, sweat, fecal
matter, hair oil, tears, cyst fluid,
pleural and peritoneal fluid, pericardial fluid, lymph, chyme, chyle, bile,
interstitial fluid, menses, pus,
sebum, vomit, vaginal secretions, mucosal secretion, stool water, pancreatic
juice, lavage fluids from
sinus cavities, bronchopulmonary aspirates, blastocyl cavity fluid, or
umbilical cord blood.
[0035] In the methods of the invention, including characterizing a sample or
visualizing a sample, the
sample can be from a subject suspected of having or being predisposed to a
medical condition, disease, or
disorder.
[0036] In the methods of the invention, including enriching an oligonucleotide
library, characterizing a
sample or visualizing a sample, the medical condition, the disease or disorder
may be a cancer, a
premalignant condition, an inflammatory disease, an immune disease, an
autoimmune disease or disorder,
a cardiovascular disease or disorder, neurological disease or disorder,
infectious disease or pain. In some
embodiments, the cancer comprises comprises an acute lymphoblastic leukemia;
acute myeloid leukemia;
adrenocortical carcinoma; AIDS-related cancers; AIDS-related lymphoma; anal
cancer; appendix cancer;
astrocytomas; atypical teratoid/rhabdoid tumor; basal cell carcinoma; bladder
cancer; brain stem glioma;
brain tumor (including brain stem glioma, central nervous system atypical
teratoid/rhabdoid tumor, central
nervous system embryonal tumors, astrocytomas, craniopharyngioma,
ependymoblastoma, ependymoma,
medulloblastoma, medulloepithelioma, pineal parenchymal tumors of intermediate
differentiation,
supratentorial primitive neuroectodermal tumors and pineoblastoma); breast
cancer; bronchial tumors;
Burkitt lymphoma; cancer of unknown primary site; carcinoid tumor; carcinoma
of unknown primary site;
central nervous system atypical teratoid/rhabdoid tumor; central nervous
system embryonal tumors;
cervical cancer; childhood cancers; chordoma; chronic lymphocytic leukemia;
chronic myelogenous
leukemia; chronic myeloproliferative disorders; colon cancer; colorectal
cancer; craniopharyngioma;
cutaneous T-cell lymphoma; endocrine pancreas islet cell tumors; endometrial
cancer;
ependymoblastoma; ependymoma; esophageal cancer; esthesioneuroblastoma; Ewing
sarcoma;
extracranial germ cell tumor; extragonadal germ cell tumor; extrahepatic bile
duct cancer; gallbladder
cancer; gastric (stomach) cancer; gastrointestinal carcinoid tumor;
gastrointestinal stromal cell tumor;
gastrointestinal stromal tumor (GIST); gestational trophoblastic tumor;
glioma; hairy cell leukemia; head
and neck cancer; heart cancer; Hodgkin lymphoma; hypopharyngeal cancer;
intraocular melanoma; islet
cell tumors; Kaposi sarcoma; kidney cancer; Langerhans cell histiocytosis;
laryngeal cancer; lip cancer;
liver cancer; lung cancer; malignant fibrous histiocytoma bone cancer;
medulloblastoma;
medulloepithelioma; melanoma; Merkel cell carcinoma; Merkel cell skin
carcinoma; mesothelioma;
metastatic squamous neck cancer with occult primary; mouth cancer; multiple
endocrine neoplasia
-9-
CA 03018066 2018-09-17
WO 2017/161357 PCT/US2017/023108
syndromes; multiple myeloma; multiple myeloma/plasma cell neoplasm; mycosis
fungoides;
myelodysplastic syndromes; myeloproliferative neoplasms; nasal cavity cancer;
nasopharyngeal cancer;
neuroblastoma; Non-Hodgkin lymphoma; nonmelanoma skin cancer; non-small cell
lung cancer; oral
cancer; oral cavity cancer; oropharyngeal cancer; osteosarcoma; other brain
and spinal cord tumors;
ovarian cancer; ovarian epithelial cancer; ovarian germ cell tumor; ovarian
low malignant potential tumor;
pancreatic cancer; papillomatosis; paranasal sinus cancer; parathyroid cancer;
pelvic cancer; penile
cancer; pharyngeal cancer; pineal parenchymal tumors of intermediate
differentiation; pineoblastoma;
pituitary tumor; plasma cell neoplasm/multiple myeloma; pleuropulmonary
blastoma; primary central
nervous system (CNS) lymphoma; primary hepatocellular liver cancer; prostate
cancer; rectal cancer;
renal cancer; renal cell (kidney) cancer; renal cell cancer; respiratory tract
cancer; retinoblastoma;
rhabdomyosarcoma; salivary gland cancer; Sezary syndrome; small cell lung
cancer; small intestine
cancer; soft tissue sarcoma; squamous cell carcinoma; squamous neck cancer;
stomach (gastric) cancer;
supratentorial primitive neuroectodermal tumors; T-cell lymphoma; testicular
cancer; throat cancer;
thymic carcinoma; thymoma; thyroid cancer; transitional cell cancer;
transitional cell cancer of the renal
pelvis and ureter; trophoblastic tumor; ureter cancer; urethral cancer;
uterine cancer; uterine sarcoma;
vaginal cancer; vulvar cancer; Waldenstrom macroglobulinemia; or Wilm's tumor.
In some embodiments,
the premalignant condition comprises Barrett's Esophagus. In some embodiments,
the autoimmune
disease comprises inflammatory bowel disease (IBD), Crohn's disease (CD),
ulcerative colitis (UC),
pelvic inflammation, vasculitis, psoriasis, diabetes, autoimmune hepatitis,
multiple sclerosis, myasthenia
gravis, Type I diabetes, rheumatoid arthritis, psoriasis, systemic lupus
erythematosis (SLE), Hashimoto's
Thyroiditis, Grave's disease, Ankylosing Spondylitis Sjogrens Disease, CREST
syndrome, Scleroderma,
Rheumatic Disease, organ rejection, Primary Sclerosing Cholangitis, or sepsis.
In some embodiments, the
cardiovascular disease comprises atherosclerosis, congestive heart failure,
vulnerable plaque, stroke,
ischemia, high blood pressure, stenosis, vessel occlusion or a thrombotic
event. In some embodiments, the
neurological disease comprises Multiple Sclerosis (MS), Parkinson's Disease
(PD), Alzheimer's Disease
(AD), schizophrenia, bipolar disorder, depression, autism, Prion Disease,
Pick's disease, dementia,
Huntington disease (HD), Down's syndrome, cerebrovascular disease, Rasmussen's
encephalitis, viral
meningitis, neurospsychiatric systemic lupus erythematosus (NPSLE),
amyotrophic lateral sclerosis,
Creutzfeldt-Jacob disease, Gerstmann-Straussler-Scheinker disease,
transmissible spongiform
encephalopathy, ischemic reperfusion damage (e.g. stroke), brain trauma,
microbial infection, or chronic
fatigue syndrome. In some embodiments, the pain comprises fibromyalgia,
chronic neuropathic pain, or
peripheral neuropathic pain. In some embodiments, the infectious disease
comprises a bacterial infection,
viral infection, yeast infection, Whipple's Disease, Prion Disease, cirrhosis,
methicillin-resistant
staphylococcus aureus, HIV, HCV, hepatitis, syphilis, meningitis, malaria,
tuberculosis, influenza.
[0037] In an aspect, the invention provides a kit comprising at least one
reagent for carrying out the
methods provided by the invention, including enriching an oligonucleotide
library, characterizing a
sample or visualizing a sample. In a related aspect, the invention provides
use of at least one reagent for
carrying out the methods provided by the invention, including enriching an
oligonucleotide library,
-10-
CA 03018066 2018-09-17
WO 2017/161357 PCT/US2017/023108
characterizing a sample or visualizing a sample. In some embodiments, the at
least one reagent comprises
an oligonucleotide or a plurality of oligonucleotides provided herein.
Additional useful reagents are also
provided herein. See, e.g., the protocols provided in the Examples.
[0038] In an aspect, the invention provides a method of imaging at least one
cell or tissue, comprising
contacting the at least one cell or tissue with at least one oligonucleotide
or plurality of oligonucleotides
provided herein, and detecting the at least one oligonucleotide or the
plurality of oligonucleotides in
contact with at least one cell or tissue.
[0039] For example, the at least one oligonucleotide or plurality of
oligonucleotides may comprise
nucleic acids may have a sequence or a portion thereof that is at least 50,
55, 60, 65, 70, 75, 80, 85, 90, 95,
96, 97, 98, 99 or 100 percent homologous to an oligonucleotide sequence
according to at least 1, 2, 3, 4, 5,
6, 7, 8, 9, 10, 12, 15, 20 or all of SEQ ID NOs. 2922-2926, 2929-2947 and 2950-
2952. In such cases, the
imaging may be, e.g., directed to lung or prostate tissue.
[0040] In another example, the at least one oligonucleotide or plurality of
oligonucleotides may comprise
nucleic acids having a sequence or a portion thereof that is at least 50, 55,
60, 65, 70, 75, 80, 85, 90, 95,
96, 97, 98, 99 or 100 percent homologous to an oligonucleotide sequence
according to at least 1, 2, 3, 4, 5,
6, 7, 8, 9, 10, 12, 15, 20 or all of SEQ ID NOs. 2953-2961 and 2971-2979. In
such cases, the phenotype
may be, e.g., prostate cancer.
[0041] In yet another example, the at least one oligonucleotide or plurality
of oligonucleotides may
comprise nucleic acids having a sequence or a portion thereof that is at least
50, 55, 60, 65, 70, 75, 80, 85,
90, 95, 96, 97, 98, 99 or 100 percent homologous to an oligonucleotide
sequence according to at least 1, 2,
3, 4, 5, 6, 7, 8, 9, 10, 12, 15, 20, 25, 30, 35, 40, 50 or all of SEQ ID NOs.
3039-3061. In such cases, the
imaging may be, e.g., directed to HER2 status of a cell or tissue.
[0042] In still another example, the at least one oligonucleotide or plurality
of oligonucleotides may
comprise nucleic acids having a sequence or a portion thereof that is at least
50, 55, 60, 65, 70, 75, 80, 85,
90, 95, 96, 97, 98, 99 or 100 percent homologous to an oligonucleotide
sequence according to at least 1, 2,
3, 4, 5, 6, 7, 8, 9, 10, 12, 15, 20, 25, 30, 35, 40, 50, 60, 70, 80, 90, 100,
200, 300, 400, 500, 600, 700, 800,
900, 1000, 2000, 3000, 4000, 5000, 6000, 7000, 8000, 9000, 10000, 20000,
30000, 40000, 50000, 60000,
70000, 80000, 90000, 100000, 150,000 or all of SEQ ID NOs. 3062-103061 and
103062-203061. In such
cases, the imaging may be, e.g., directed to a HER2 status of a cell or
tissue.
[0043] In an example, the at least one oligonucleotide or plurality of
oligonucleotides may comprise
nucleic acids having a sequence or a portion thereof that is at least 50, 55,
60, 65, 70, 75, 80, 85, 90, 95,
96, 97, 98, 99 or 100 percent homologous to an oligonucleotide sequence
according to at least 1, 2, 3, 4, 5,
6, 7, 8, 9, 10, 12, 15, 20, 25, 30, 35, 40, 50, 60, 70, 80, 90, 100, 200, 300,
400, 500, 600, 700, 800, 900,
1000, 2000, 3000, 4000 or all of SEQ ID NOs. 203064-203067 and 203076-206478.
In such cases, the
imaging may be, e.g., directed to colorectal cells or tissue.
[0044] In another example, the at least one oligonucleotide or plurality of
oligonucleotides may comprise
nucleic acids having a sequence or a portion thereof that is at least 50, 55,
60, 65, 70, 75, 80, 85, 90, 95,
96, 97, 98, 99 or 100 percent homologous to an oligonucleotide sequence
according to at least 1, 2, 3, 4, 5,
-11-
CA 03018066 2018-09-17
WO 2017/161357 PCT/US2017/023108
6, 7, 8, 9, 10, 12, 15 oral! of SEQ ID NOs. 206491-206506. In such cases, the
imaging may be, e.g.,
directed to a tissue, including without limitation breast, colon, kidney, lung
or pancreatic tissue.
[0045] In the imaging methods provided by the invention, the at least one
oligonucleotide or the plurality
of oligonucleotides can carry various useful chemical structures or
modifications such as described herein.
[0046] In the imaging methods provided by the invention, the at least one
oligonucleotide or the plurality
of oligonucleotides can be administered to a subject prior to the detecting.
Such method may allow
imaging of at least one cell or tissue in the subject. In some embodiments,
the at least one cell or tissue
comprises neoplastic, malignant, tumor, hyperplastic, or dysplastic cells. In
some embodiments, the at
least one cell or tissue comprises at least one of lymphoma, leukemia, renal
carcinoma, sarcoma,
hemangiopericytoma, melanoma, abdominal cancer, gastric cancer, colon cancer,
cervical cancer, prostate
cancer, pancreatic cancer, breast cancer, or non-small cell lung cancer cells.
In some embodiments, the at
least one cell or tissue comprises a medical condition, disease or disorder.
[0047] In an aspect, the invention provides a pharmaceutical composition
comprising a construct
comprising a therapeutically effective amount of the at least one
oligonucleotide or the plurality of
oligonucleotides as provided herein, or a salt thereof, and a pharmaceutically
acceptable carrier, diluent,
or both. In some embodiments, the at least one oligonucleotide or the
plurality of oligonucleotides
associates with at least one protein listed in Table 28 herein.
[0048] For example, the at least one oligonucleotide or plurality of
oligonucleotides may comprise
nucleic acids having a sequence or a portion thereof that is at least 50, 55,
60, 65, 70, 75, 80, 85, 90, 95,
96, 97, 98, 99 or 100 percent homologous to an oligonucleotide sequence
according to at least 1, 2, 3, 4, 5,
6, 7, 8, 9, 10, 12, 15,20 or all of SEQ ID NOs. 2922-2926, 2929-2947 and 2950-
2952. Such
pharmaceutical composition may be useful for therapy related to a cancer,
wherein optionally the cancer
comprises lung cancer or prostate cancer.
[0049] In another example, the at least one oligonucleotide or plurality of
oligonucleotides may comprise
nucleic acids having a sequence or a portion thereof that is at least 50, 55,
60, 65, 70, 75, 80, 85, 90, 95,
96, 97, 98, 99 or 100 percent homologous to an oligonucleotide sequence
according to at least 1, 2, 3, 4, 5,
6, 7, 8, 9, 10, 12, 15,20 or all of SEQ ID NOs. 2953-2961 and 2971-2979. Such
pharmaceutical
composition may be useful for therapy related to a cancer, wherein optionally
the cancer comprises
prostate cancer.
[0050] In still another example, the at least one oligonucleotide or plurality
of oligonucleotides may
comprise nucleic acids having a sequence or a portion thereof that is at least
50, 55, 60, 65, 70, 75, 80, 85,
90, 95, 96, 97, 98, 99 or 100 percent homologous to an oligonucleotide
sequence according to at least 1, 2,
3, 4, 5, 6, 7, 8, 9, 10, 12, 15, 20, 25, 30, 35, 40, 50 or all of SEQ ID NOs.
3039-3061. Such pharmaceutical
composition may be useful for therapy related to a cancer, wherein optionally
the cancer comprises breast
cancer.
[0051] In yet another example, the at least one oligonucleotide or plurality
of oligonucleotides may
comprise nucleic acids having a sequence or a portion thereof that is at least
50, 55, 60, 65, 70, 75, 80, 85,
90, 95, 96, 97, 98, 99 or 100 percent homologous to an oligonucleotide
sequence according to at least 1, 2,
-12-
CA 03018066 2018-09-17
WO 2017/161357 PCT/US2017/023108
3, 4, 5, 6, 7, 8, 9, 10, 12, 15, 20, 25, 30, 35, 40, 50, 60, 70, 80, 90, 100,
200, 300, 400, 500, 600, 700, 800,
900, 1000, 2000, 3000, 4000, 5000, 6000, 7000, 8000, 9000, 10000, 20000,
30000, 40000, 50000, 60000,
70000, 80000, 90000, 100000, 150,000 or all of SEQ ID NOs. 3062-103061 and
103062-203061. Such
pharmaceutical composition may be useful for therapy related to a cancer,
wherein optionally the cancer
comprises breast cancer.
[0052] In an example, the at least one oligonucleotide or plurality of
oligonucleotides may comprise
nucleic acids having a sequence or a portion thereof that is at least 50, 55,
60, 65, 70, 75, 80, 85, 90, 95,
96, 97, 98, 99 or 100 percent homologous to an oligonucleotide sequence
according to at least 1, 2, 3, 4, 5,
6, 7, 8, 9, 10, 12, 15, 20, 25, 30, 35, 40, 50, 60, 70, 80, 90, 100, 200, 300,
400, 500, 600, 700, 800, 900,
1000, 2000, 3000, 4000 or all of SEQ ID NOs. 203064-203067 and 203076-206478.
Such pharmaceutical
composition may be useful for therapy related to a cancer, wherein optionally
the cancer comprises
colorectal cancer.
[0053] In yet another example, the at least one oligonucleotide or plurality
of oligonucleotides may
comprise nucleic acids having a sequence or a portion thereof that is at least
50, 55, 60, 65, 70, 75, 80, 85,
90, 95, 96, 97, 98, 99 or 100 percent homologous to an oligonucleotide
sequence according to at least 1, 2,
3, 4, 5, 6, 7, 8, 9, 10, 12, 15 or all of SEQ ID NOs. 206491-206506. Such
pharmaceutical composition
may be useful for therapy related to a cancer, wherein optionally the cancer
comprises a cancer of the
breast, colon, kidney, lung or pancreas.
[0054] The at least one oligonucleotide or the plurality of oligonucleotides
within the pharmaceutical
composition can have any useful desired chemical modification. In an
embodiment, the at least one
oligonucleotide or the plurality of oligonucleotides is attached to a toxin or
chemotherapeutic agent. The
at least one oligonucleotide or the plurality of oligonucleotides may be
comprised within a multipartite
construct. The at least one oligonucleotide or the plurality of
oligonucleotides can be attached to a
liposome or nanoparticle. In some embodiments, the liposome or nanoparticle
comprises a toxin or
chemotherapeutic agent.
[0055] In a related aspect, the invention provides a method of treating or
ameliorating a disease or
disorder in a subject in need thereof, comprising administering the
pharmaceutical composition of the
invention to the subject. In another related aspect, the invention provides a
method of inducing
cytotoxicity in a subject, comprising administering the pharmaceutical
composition of the invention to the
subject. Any useful means of administering can be used, including without
limitation at least one of
intradermal, intramuscular, intraperitoneal, intravenous, subcutaneous,
intranasal, epidural, oral,
sublingual, intracerebral, intravaginal, transdermal, rectal, by inhalation,
topical administration, or any
combination thereof.
BRIEF DESCRIPTION OF THE DRAWINGS
[0056] FIGs. 1A-1B illustrate methods of assessing biomarkers such as cellular
or microvesicle surface
antigens. FIG. 1A is a schematic of a planar substrate coated with a capture
agent, such as an aptamer or
antibody, which captures cells or microvesicles expressing the target antigen
of the capture agent. The
capture agent may bind a protein expressed on the surface of the diseased cell
or vesicle. The detection
-13-
CA 03018066 2018-09-17
WO 2017/161357 PCT/US2017/023108
agent, which may also be an aptamer or antibody, carries a detectable label,
here a fluorescent signal. The
detection agent binds to the captured cell or microvesicle and provides a
detectable signal via its
fluorescent label. The detection agent can detect an antigen that is generally
associated a cell-of-origin or
a disease, e.g., a cancer. FIG. 1B is a schematic of a particle bead
conjugated with a capture agent, which
captures cells or microvesicles expressing the target antigen of the capture
agent. The capture agent may
bind a protein expressed on the surface of the diseased cell or vesicle. The
detection agent, which may
also be an aptamer or antibody, carries a detectable label, here a fluorescent
signal. The detection agent
binds to the captured cell or microvesicle and provides a detectable signal
via its fluorescent label. The
detection agent can detect an antigen that is generally associated with a cell-
of-origin or a disease, e.g., a
cancer.
[0057] FIGs. 2A-B illustrates a non-limiting example of an aptamer nucleotide
sequence and its
secondary structure. FIG. 2A illustrates a secondary structure of a 32-mer
oligonucleotide, Aptamer 4,
with sequence 5'-CCCCCCGAATCACATGACTTGGGCGGGGGTCG (SEQ ID NO. 1). In the
figure, the
sequence is shown with 6 thymine nucleotides added to the end, which can act
as a spacer to attach a
biotin molecule. This particular oligo has a high binding affinity to the
target, EpCAM. Additional
candidate EpCAM binders are identified by modeling the entire database of
sequenced oligos to the
secondary structure of this oligo. FIG. 2B illustrates another 32-mer oligo
with sequence 5'-
ACCGGATAGCGGTTGGAGGCGTGCTCCACTCG (SEQ ID NO. 2) that has a different secondary
structure
than the aptamer in FIG. 2A. This aptamer is also shown with a 6-thymine tail.
[0058] FIG. 3 illustrates a process for producing a target-specific set of
aptamers using a cell subtraction
method, wherein the target is a biomarker associated with a specific disease.
In Step 1, a random pool of
oligonucleotides are contacted with a biological sample from a normal patient.
In Step 2, the oligos that
did not bind in Step 1 are added to a biological sample isolated from diseased
patients. The bound oligos
from this step are then eluted, captured via their biotin linkage and then
combined again with normal
biological sample. The unbound oligos are then added again to disease-derived
biological sample and
isolated. This process can be repeated iteratively. The final eluted aptamers
are tested against patient
samples to measure the sensitivity and specificity of the set. Biological
samples can include blood,
including plasma or serum, or other components of the circulatory system, such
as microvesicles.
[0059] FIG. 4 comprises a schematic for identifying a target of a selected
aptamer, such as an aptamer
selected by the process of the invention. The figure shows a binding agent
402, here an aptamer for
purposes of illustration, tethered to a substrate 401. The binding agent 402
can be covalently attached to
substrate 401. The binding agent 402 may also be non-covalently attached. For
example, binding agent
402 can comprise a label which can be attracted to the substrate, such as a
biotin group which can form a
complex with an avidin/streptavidin molecule that is covalently attached to
the substrate. The binding
agent 402 binds to a surface antigen 403 of microvesicle 404. In the step
signified by arrow (i), the
microvesicle is disrupted while leaving the complex between the binding agent
402 and surface antigen
403 intact. Disrupted microvesicle 405 is removed, e.g., via washing or buffer
exchange, in the step
-14-
CA 03018066 2018-09-17
WO 2017/161357 PCT/US2017/023108
signified by arrow (ii). In the step signified by arrow (iii), the surface
antigen 403 is released from the
binding agent 402. The surface antigen 403 can be analyzed to determine its
identity.
[0060] FIGs. 5A-5G illustrate using an oligonucleotide probe library to
differentiate cancer and non-
cancer samples.
[0061] FIG. 6 shows protein targets of oligonucleotide probes run on a silver
stained SDS-PAGE gel.
[0062] FIGs. 7A-B illustrate a model generated using a training (FIG. 7A) and
test (FIG. 7B) set from a
round of cross validation. The AUC for the test set was 0.803. Another
exemplary round of cross-
validation is shown in FIGs. 7C-D with training (FIG. 7C) and test (FIG. 7D)
sets. The AUC for the test
set was 0.678.
[0063] FIG. 8 illustrates multipart oligonucleotide constructs.
[0064] FIGs. 18A-C illustrate SUPRA (SsDNA by Unequal length PRimer Asymmetric
PCR), a
protocol for single stranded DNA (ssDNA) oligonucleotide library preparation.
[0065] FIGs. 10A-C illustrate use of aptamers in methods of characterizing a
phenotype. FIG. 10A is a
schematic 1000 showing an assay configuration that can be used to detect
and/or quantify a target of
interest. In the figure, capture aptamer 1002 is attached to substrate 1001.
Target of interest 1003 is bound
by capture aptamer 1002. Detection aptamer 1004 is also bound to target of
interest 1003. Detection
aptamer 1004 carries label 1005 which can be detected to identify target
captured to substrate 1001 via
capture aptamer 1002. FIG. 10B is a schematic 1010 showing use of an aptamer
pool to characterize a
phenotype. A pool of aptamers to a target of interest is provided 1011. The
pool is contacted with a test
sample to be characterized 1012. The mixture is washed to remove unbound
aptamers. The remaining
aptamers are disassociated and collected 1013. The collected aptamers are
identified 1014 and the identity
of the retained aptamers is used to characterize the phenotype 1015. FIG. 10C
is a schematic 1020
showing an implementation of the method in FIG. 10B. A pool of aptamers
identified as binding a
microvesicle population is provided 1019. The input sample comprises
microvesicles that are isolated
from a test sample 1020. The pool is contacted with the isolated microvesicles
to be characterized 1023.
The mixture is washed to remove unbound aptamers and the remaining aptamers
are disassociated and
collected 1025. The collected aptamers are identified and the identity of the
retained aptamers is used to
characterize the phenotype 1026.
[0066] FIGs. 11A-I illustrate development and use of an oligonucleotide probe
library to distinguish
biological sample types.
[0067] FIGs. 12A-C illustrate enriching a naïve oligonucleotide library with
balanced design for
oligonucleotides that differentiate between breast cancer and non-cancer
microvesicles derived from
plasma samples.
[0068] FIG. 13 shows a schematic for enriching an oligonucleotide library
against cell lines.
[0069] FIGs. 14A-C show oligonucleotide probes that recognize microvesicles
(exosomes) shed by
prostate cancer cell lines.
[0070] FIGs. 15A-E show identification of oligonucleotide probes that
recognize HER2+ cancer
samples.
-15-
CA 03018066 2018-09-17
WO 2017/161357 PCT/US2017/023108
[0071] FIGs. 16A-F show oligonucleotide probes that distinguish trastuzamab
responder breast cancer
samples.
[0072] FIGs. 17A-P show oligonucleotide probes that distinguish trastuzamab
responder breast cancer
tissue samples.
[0073] FIGs. 18A-G show development of oligonucleotide probes that predict the
response to a
combinational therapy with FOLFOX / bevacizumab in individuals diagnosed with
colorectal cancer.
[0074] FIGs. 19A-K show background optimization of oligonucleotide probe
staining of fixed tissue
samples.
[0075] FIGs. 20A-D show oligonucleotide probes that distinguish tubulin 3
(TUBB3) positive and
negative pancreatic cancer tissue samples.
[0076] FIGs. 21A-B show development of oligonucleotide probes that predict the
response to platinum /
taxane therapy in individuals diagnosed with ovarian cancer.
[0077] FIGs. 22A-B show enrichment and staining of an oligonucleotide probe
library against kidney
tissue anti-digoxigenin (DIG) antibody detection.
[0078] FIGs. 23A-D illustrate oligonucleotide probe library enrichment using
lysates from fixed tissue
samples.
[0079] FIGs. 24A-B illustrate oligonucleotide probe library enrichment using
scraped tissue from cancer
and non-cancer regions from fixed tissue samples.
[0080] FIGs. 25A-B illustrate oligonucleotide probe library enrichment using
microdissection of fixed
tissue samples.
[0081] FIGs. 26A-B illustrate therapeutic agents whose benefit or lack of
benefit for treating a cancer
may depend on a biomarker status.
DETAILED DESCRIPTION OF THE INVENTION
[0082] The details of one or more embodiments of the invention are set forth
in the accompanying
description below. Although any methods and materials similar or equivalent to
those described herein
can be used in the practice or testing of the present invention, the preferred
methods and materials are now
described. Other features, objects, and advantages of the invention will be
apparent from the description.
In the specification, the singular forms also include the plural unless the
context clearly dictates otherwise.
Unless defined otherwise, all technical and scientific terms used herein have
the same meaning as
commonly understood by one of ordinary skill in the art to which this
invention belongs. In the case of
conflict, the present Specification will control.
[0083] Disclosed herein are compositions and methods that can be used to
characterize a phenotype, or
assess, a biological sample. The compositions and methods of the invention
comprise the use of
oligonucleotide probes (aptamers) that bind biological entities of interest,
including without limitation
tissues, cell, microvesicles, or fragments thereof. The antigens recognized by
the oligonucleotide aptamers
may comprise proteins or polypeptides or any other useful biological
components such as nucleic acids,
lipids and/or carbohydrates. In general, the oligonucleotides disclosed are
synthetic nucleic acid
-16-
CA 03018066 2018-09-17
WO 2017/161357 PCT/US2017/023108
molecules, including DNA and RNA, and variations thereof Unless otherwise
specified, the
oligonucleotide probes can be synthesized in DNA or RNA format or as hybrid
molecules as desired. The
methods disclosed herein comprise diagnostic, prognostic and theranostic
processes and techniques using
one or more aptamer of the invention. Alternatively, an oligonucleotide probe
of the invention can also be
used as a binding agent to capture, isolate, or enrich, a cell, cell fragment,
microvesicle or any other
fragment or complex that comprises the antigen or functional fragments
thereof.
[0084] The compositions and methods of the invention also comprise individual
oligonucleotides that can
be used to assess biological samples. The invention further discloses
compositions and methods of
oligonucleotide pools that can be used to detect a biosignature in a sample.
[0085] Oligonucleotide probes and sequences disclosed in the compositions and
methods of the invention
may be identified herein in the form of DNA or RNA. Unless otherwise
specified, one of skill in the art
will appreciate that an oligonucleotide may generally be synthesized as either
form of nucleic acid and
carry various chemical modifications and remain within the scope of the
invention. The term aptamer may
be used in the art to refer to a single oligonucleotide that binds
specifically to a target of interest through
mechanisms other than Watson crick base pairing, similar to binding of a
monoclonal antibody to a
particular antigen. Within the scope of this disclosure and unless stated
explicitly or otherwise implicit in
context, the terms aptamer, oligonucleotide and oligonucleotide probe, and
variations thereof, may be
used interchangeably to refer to an oligonucleotide capable of distinguishing
biological entities of interest
(e.g, tissues, cells, microvesicles, biomarkers) whether or not the specific
entity has been identified or
whether the precise mode of binding has been determined.
[0086] An oligonucleotide probe or plurality of such probes of the invention
can also be used to provide
in vitro or in vivo detection or imaging and to provide diagnostic readouts,
including for diagnostic,
prognostic or theranostic purposes.
[0087] Separately, an oligonucleotide probe of the invention can also be used
for treatment or as a
therapeutic to specifically target a cell, tissue, organ or the like. As the
invention provides methods to
identify oligonucleotide probes that bind to specific tissues, cells,
microvesicles or other biological
entities of interest, the oligonucleotide probes of the invention target such
entities and are inherently drug
candidates, agents that can be used for targeted drug delivery, or both.
Phenotypes
[0088] Disclosed herein are products and processes for characterizing a
phenotype using the methods and
compositions of the invention. The term "phenotype" as used herein can mean
any trait or characteristic
that can be identified using in part or in whole the compositions and/or
methods of the invention. For
example, a phenotype can be a diagnostic, prognostic or theranostic
determination based on a
characterized biomarker profile for a sample obtained from a subject. A
phenotype can be any observable
characteristic or trait of, such as a disease or condition, a stage of a
disease or condition, susceptibility to a
disease or condition, prognosis of a disease stage or condition, a
physiological state, or response /
potential response to therapeutics. A phenotype can result from a subject's
genetic makeup as well as the
-17-
CA 03018066 2018-09-17
WO 2017/161357 PCT/US2017/023108
influence of environmental factors and the interactions between the two, as
well as from epigenetic
modifications to nucleic acid sequences.
[0089] A phenotype in a subject can be characterized by obtaining a biological
sample from a subject and
analyzing the sample using the compositions and/or methods of the invention.
For example, characterizing
a phenotype for a subject or individual can include detecting a disease or
condition (including pre-
symptomatic early stage detecting), determining a prognosis, diagnosis, or
theranosis of a disease or
condition, or determining the stage or progression of a disease or condition.
Characterizing a phenotype
can include identifying appropriate treatments or treatment efficacy for
specific diseases, conditions,
disease stages and condition stages, predictions and likelihood analysis of
disease progression, particularly
disease recurrence, metastatic spread or disease relapse. A phenotype can also
be a clinically distinct type
or subtype of a condition or disease, such as a cancer or tumor. Phenotype
determination can also be a
determination of a physiological condition, or an assessment of organ distress
or organ rejection, such as
post-transplantation. The compositions and methods described herein allow
assessment of a subject on an
individual basis, which can provide benefits of more efficient and economical
decisions in treatment.
[0090] In an aspect, the invention relates to the analysis of tissues,
microvesicles, and circulating
biomarkers to provide a diagnosis, prognosis, and/or theranosis of a disease
or condition. Theranostics
includes diagnostic testing that provides the ability to affect therapy or
treatment of a disease or disease
state. Theranostics testing provides a theranosis in a similar manner that
diagnostics or prognostic testing
provides a diagnosis or prognosis, respectively. As used herein, theranostics
encompasses any desired
form of therapy related testing, including predictive medicine, personalized
medicine, precision medicine,
integrated medicine, pharmacodiagnostics and Dx/Rx partnering. Therapy related
tests can be used to
predict and assess drug response in individual subjects, i.e., to provide
personalized medicine. Predicting a
drug response can be determining whether a subject is a likely responder or a
likely non-responder to a
candidate therapeutic agent, e.g., before the subject has been exposed or
otherwise treated with the
treatment. Assessing a drug response can be monitoring a response to a drug,
e.g., monitoring the
subject's improvement or lack thereof over a time course after initiating the
treatment. Therapy related
tests are useful to select a subject for treatment who is particularly likely
to benefit from the treatment or
to provide an early and objective indication of treatment efficacy in an
individual subject. Thus, analysis
using the compositions and methods of the invention may indicate that
treatment should be altered to
select a more promising treatment, thereby avoiding the great expense of
delaying beneficial treatment
and avoiding the financial and morbidity costs of administering an ineffective
drug(s).
[0091] In assessing a phenotype, a biosignature can be analyzed in the subject
and compared against that
of previous subjects that were known to respond or not to a treatment. The
biosignature may comprise
certain biomarkers or may comprise certain detection agents, such as the
oligonucleotide probes as
provided herein. If the biosignature in the subject more closely aligns with
that of previous subjects that
were known to respond to the treatment, the subject can be characterized, or
predicted, as a responder to
the treatment. Similarly, if the biomarker profile in the subject more closely
aligns with that of previous
subjects that did not respond to the treatment, the subject can be
characterized, or predicted as a non-
-18-
CA 03018066 2018-09-17
WO 2017/161357 PCT/US2017/023108
responder to the treatment. The treatment can be for any appropriate disease,
disorder or other condition,
including without limitation those disclosed herein.
[0092] In some embodiments, the phenotype comprises a medical condition
including without limitation
a disease or disorder listed in Table 1. For example, the phenotype can
comprise detecting the presence of
or likelihood of developing a tumor, neoplasm, or cancer, or characterizing
the tumor, neoplasm, or cancer
(e.g., stage, grade, aggressiveness, likelihood of metastatis or recurrence,
etc). Cancers that can be
detected or assessed by methods or compositions described herein include, but
are not limited to, breast
cancer, ovarian cancer, lung cancer, colon cancer, hyperplastic polyp,
adenoma, colorectal cancer, high
grade dysplasia, low grade dysplasia, prostatic hyperplasia, prostate cancer,
melanoma, pancreatic cancer,
brain cancer (such as a glioblastoma), hematological malignancy,
hepatocellular carcinoma, cervical
cancer, endometrial cancer, head and neck cancer, esophageal cancer,
gastrointestinal stromal tumor
(GIST), renal cell carcinoma (RCC) or gastric cancer. The colorectal cancer
can be CRC Dukes B or
Dukes C-D. The hematological malignancy can be B-Cell Chronic Lymphocytic
Leukemia, B-Cell
Lymphoma-DLBCL, B-Cell Lymphoma-DLBCL-germinal center-like, B-Cell Lymphoma-
DLBCL-
activated B-cell-like, and Burkitt's lymphoma.
[0093] The phenotype can be a premalignant condition, such as actinic
keratosis, atrophic gastritis,
leukoplakia, erythroplasia, Lymphomatoid Granulomatosis, preleukemia,
fibrosis, cervical dysplasia,
uterine cervical dysplasia, xeroderma pigmentosum, Barrett's Esophagus,
colorectal polyp, or other
abnormal tissue growth or lesion that is likely to develop into a malignant
tumor. Transformative viral
infections such as HIV and HPV also present phenotypes that can be assessed
according to the invention.
[0094] A cancer characterized by the compositions and methods of the invention
can comprise, without
limitation, a carcinoma, a sarcoma, a lymphoma or leukemia, a germ cell tumor,
a blastoma, or other
cancers. Carcinomas include without limitation epithelial neoplasms, squamous
cell neoplasms squamous
cell carcinoma, basal cell neoplasms basal cell carcinoma, transitional cell
papillomas and carcinomas,
adenomas and adenocarcinomas (glands), adenoma, adenocarcinoma, linitis
plastica insulinoma,
glucagonoma, gastrinoma, vipoma, cholangiocarcinoma, hepatocellular carcinoma,
adenoid cystic
carcinoma, carcinoid tumor of appendix, prolactinoma, oncocytoma, hurthle cell
adenoma, renal cell
carcinoma, grawitz tumor, multiple endocrine adenomas, endometrioid adenoma,
adnexal and skin
appendage neoplasms, mucoepidermoid neoplasms, cystic, mucinous and serous
neoplasms, cystadenoma,
pseudomyxoma peritonei, ductal, lobular and medullary neoplasms, acinar cell
neoplasms, complex
epithelial neoplasms, warthin's tumor, thymoma, specialized gonadal neoplasms,
sex cord stromal tumor,
thecoma, granulosa cell tumor, arrhenoblastoma, sertoli leydig cell tumor,
glomus tumors, paraganglioma,
pheochromocytoma, glomus tumor, nevi and melanomas, melanocytic nevus,
malignant melanoma,
melanoma, nodular melanoma, dysplastic nevus, lentigo maligna melanoma,
superficial spreading
melanoma, and malignant acral lentiginous melanoma. Sarcoma includes without
limitation Askin's
tumor, botryodies, chondrosarcoma, Ewing's sarcoma, malignant hemangio
endothelioma, malignant
schwannoma, osteosarcoma, soft tissue sarcomas including: alveolar soft part
sarcoma, angiosarcoma,
cystosarcoma phyllodes, dermatofibrosarcoma, desmoid tumor, desmoplastic small
round cell tumor,
-19-
CA 03018066 2018-09-17
WO 2017/161357 PCT/US2017/023108
epithelioid sarcoma, extraskeletal chondrosarcoma, extraskeletal osteosarcoma,
fibrosarcoma,
hemangiopericytoma, hemangiosarcoma, kaposi's sarcoma, leiomyosarcoma,
liposarcoma,
lymphangiosarcoma, lymphosarcoma, malignant fibrous histiocytoma,
neurofibrosarcoma,
rhabdomyosarcoma, and synovialsarcoma. Lymphoma and leukemia include without
limitation chronic
lymphocytic leukemia/small lymphocytic lymphoma, B-cell prolymphocytic
leukemia,
lymphoplasmacytic lymphoma (such as waldenstrom macroglobulinemia), splenic
marginal zone
lymphoma, plasma cell myeloma, plasmacytoma, monoclonal immunoglobulin
deposition diseases, heavy
chain diseases, extranodal marginal zone B cell lymphoma, also called malt
lymphoma, nodal marginal
zone B cell lymphoma (nmzl), follicular lymphoma, mantle cell lymphoma,
diffuse large B cell
lymphoma, mediastinal (thymic) large B cell lymphoma, intravascular large B
cell lymphoma, primary
effusion lymphoma, burkitt lymphoma/leukemia, T cell prolymphocytic leukemia,
T cell large granular
lymphocytic leukemia, aggressive NK cell leukemia, adult T cell
leukemia/lymphoma, extranodal NK/T
cell lymphoma, nasal type, enteropathy-type T cell lymphoma, hepatosplenic T
cell lymphoma, blastic
NK cell lymphoma, mycosis fungoides / sezary syndrome, primary cutaneous CD30-
positive T cell
lymphoproliferative disorders, primary cutaneous anaplastic large cell
lymphoma, lymphomatoid
papulosis, angioimmunoblastic T cell lymphoma, peripheral T cell lymphoma,
unspecified, anaplastic
large cell lymphoma, classical hodgkin lymphomas (nodular sclerosis, mixed
cellularity, lymphocyte-rich,
lymphocyte depleted or not depleted), and nodular lymphocyte-predominant
hodgkin lymphoma. Germ
cell tumors include without limitation germinoma, dysgerminoma, seminoma,
nongerminomatous germ
cell tumor, embryonal carcinoma, endodermal sinus turmor, choriocarcinoma,
teratoma, polyembryoma,
and gonadoblastoma. Blastoma includes without limitation nephroblastoma,
medulloblastoma, and
retinoblastoma. Other cancers include without limitation labial carcinoma,
larynx carcinoma,
hypopharynx carcinoma, tongue carcinoma, salivary gland carcinoma, gastric
carcinoma,
adenocarcinoma, thyroid cancer (medullary and papillary thyroid carcinoma),
renal carcinoma, kidney
parenchyma carcinoma, cervix carcinoma, uterine corpus carcinoma, endometrium
carcinoma, chorion
carcinoma, testis carcinoma, urinary carcinoma, melanoma, brain tumors such as
glioblastoma,
astrocytoma, meningioma, medulloblastoma and peripheral neuroectodermal
tumors, gall bladder
carcinoma, bronchial carcinoma, multiple myeloma, basalioma, teratoma,
retinoblastoma, choroidea
melanoma, seminoma, rhabdomyosarcoma, craniopharyngeoma, osteosarcoma,
chondrosarcoma,
myosarcoma, liposarcoma, fibrosarcoma, Ewing sarcoma, and plasmocytoma.
[0095] In a further embodiment, the cancer under analysis may be a lung cancer
including non-small cell
lung cancer and small cell lung cancer (including small cell carcinoma (oat
cell cancer), mixed small
cell/large cell carcinoma, and combined small cell carcinoma), colon cancer,
breast cancer, prostate
cancer, liver cancer, pancreas cancer, brain cancer, kidney cancer, ovarian
cancer, stomach cancer, skin
cancer, bone cancer, gastric cancer, breast cancer, pancreatic cancer, glioma,
glioblastoma, hepatocellular
carcinoma, papillary renal carcinoma, head and neck squamous cell carcinoma,
leukemia, lymphoma,
myeloma, or a solid tumor.
-20-
CA 03018066 2018-09-17
WO 2017/161357 PCT/US2017/023108
[0096] In embodiments, the cancer comprises an acute lymphoblastic leukemia;
acute myeloid leukemia;
adrenocortical carcinoma; AIDS-related cancers; AIDS-related lymphoma; anal
cancer; appendix cancer;
astrocytomas; atypical teratoid/rhabdoid tumor; basal cell carcinoma; bladder
cancer; brain stem glioma;
brain tumor (including brain stem glioma, central nervous system atypical
teratoid/rhabdoid tumor, central
nervous system embryonal tumors, astrocytomas, craniopharyngioma,
ependymoblastoma, ependymoma,
medulloblastoma, medulloepithelioma, pineal parenchymal tumors of intermediate
differentiation,
supratentorial primitive neuroectodermal tumors and pineoblastoma); breast
cancer; bronchial tumors;
Burkitt lymphoma; cancer of unknown primary site; carcinoid tumor; carcinoma
of unknown primary site;
central nervous system atypical teratoid/rhabdoid tumor; central nervous
system embryonal tumors;
cervical cancer; childhood cancers; chordoma; chronic lymphocytic leukemia;
chronic myelogenous
leukemia; chronic myeloproliferative disorders; colon cancer; colorectal
cancer; craniopharyngioma;
cutaneous T-cell lymphoma; endocrine pancreas islet cell tumors; endometrial
cancer;
ependymoblastoma; ependymoma; esophageal cancer; esthesioneuroblastoma; Ewing
sarcoma;
extracranial germ cell tumor; extragonadal germ cell tumor; extrahepatic bile
duct cancer; gallbladder
cancer; gastric (stomach) cancer; gastrointestinal carcinoid tumor;
gastrointestinal stromal cell tumor;
gastrointestinal stromal tumor (GIST); gestational trophoblastic tumor;
glioma; hairy cell leukemia; head
and neck cancer; heart cancer; Hodgkin lymphoma; hypopharyngeal cancer;
intraocular melanoma; islet
cell tumors; Kaposi sarcoma; kidney cancer; Langerhans cell histiocytosis;
laryngeal cancer; lip cancer;
liver cancer; malignant fibrous histiocytoma bone cancer; medulloblastoma;
medulloepithelioma;
melanoma; Merkel cell carcinoma; Merkel cell skin carcinoma; mesothelioma;
metastatic squamous neck
cancer with occult primary; mouth cancer; multiple endocrine neoplasia
syndromes; multiple myeloma;
multiple myeloma/plasma cell neoplasm; mycosis fungoides; myelodysplastic
syndromes;
myeloproliferative neoplasms; nasal cavity cancer; nasopharyngeal cancer;
neuroblastoma; Non-Hodgkin
lymphoma; nonmelanoma skin cancer; non-small cell lung cancer; oral cancer;
oral cavity cancer;
oropharyngeal cancer; osteosarcoma; other brain and spinal cord tumors;
ovarian cancer; ovarian
epithelial cancer; ovarian germ cell tumor; ovarian low malignant potential
tumor; pancreatic cancer;
papillomatosis; paranasal sinus cancer; parathyroid cancer; pelvic cancer;
penile cancer; pharyngeal
cancer; pineal parenchymal tumors of intermediate differentiation;
pineoblastoma; pituitary tumor; plasma
cell neoplasm/multiple myeloma; pleuropulmonary blastoma; primary central
nervous system (CNS)
lymphoma; primary hepatocellular liver cancer; prostate cancer; rectal cancer;
renal cancer; renal cell
(kidney) cancer; renal cell cancer; respiratory tract cancer; retinoblastoma;
rhabdomyosarcoma; salivary
gland cancer; Sezary syndrome; small cell lung cancer; small intestine cancer;
soft tissue sarcoma;
squamous cell carcinoma; squamous neck cancer; stomach (gastric) cancer;
supratentorial primitive
neuroectodermal tumors; T-cell lymphoma; testicular cancer; throat cancer;
thymic carcinoma; thymoma;
thyroid cancer; transitional cell cancer; transitional cell cancer of the
renal pelvis and ureter; trophoblastic
tumor; ureter cancer; urethral cancer; uterine cancer; uterine sarcoma;
vaginal cancer; vulvar cancer;
Waldenstrom macroglobulinemia; or Wilm's tumor. The methods of the invention
can be used to
-21-
CA 03018066 2018-09-17
WO 2017/161357 PCT/US2017/023108
characterize these and other cancers. Thus, characterizing a phenotype can be
providing a diagnosis,
prognosis or theranosis of one of the cancers disclosed herein.
[0097] In some embodiments, the cancer comprises an acute myeloid leukemia
(AML), breast
carcinoma, cholangiocarcinoma, colorectal adenocarcinoma, extrahepatic bile
duct adenocarcinoma,
female genital tract malignancy, gastric adenocarcinoma, gastroesophageal
adenocarcinoma,
gastrointestinal stromal tumors (GIST), glioblastoma, head and neck squamous
carcinoma, leukemia, liver
hepatocellular carcinoma, low grade glioma, lung bronchioloalveolar carcinoma
(BAC), lung non-small
cell lung cancer (NSCLC), lung small cell cancer (SCLC), lymphoma, male
genital tract malignancy,
malignant solitary fibrous tumor of the pleura (MSFT), melanoma, multiple
myeloma, neuroendocrine
tumor, nodal diffuse large B-cell lymphoma, non epithelial ovarian cancer (non-
EOC), ovarian surface
epithelial carcinoma, pancreatic adenocarcinoma, pituitary carcinomas,
oligodendroglioma, prostatic
adenocarcinoma, retroperitoneal or peritoneal carcinoma, retroperitoneal or
peritoneal sarcoma, small
intestinal malignancy, soft tissue tumor, thymic carcinoma, thyroid carcinoma,
or uveal melanoma. The
methods of the invention can be used to characterize these and other cancers.
Thus, characterizing a
phenotype can be providing a diagnosis, prognosis or theranosis of one of the
cancers disclosed herein.
[0098] The phenotype can also be an inflammatory disease, immune disease, or
autoimmune disease. For
example, the disease may be inflammatory bowel disease (IBD), Crohn's disease
(CD), ulcerative colitis
(UC), pelvic inflammation, vasculitis, psoriasis, diabetes, autoimmune
hepatitis, Multiple Sclerosis,
Myasthenia Gravis, Type I diabetes, Rheumatoid Arthritis, Psoriasis, Systemic
Lupus Erythematosis
(SLE), Hashimoto's Thyroiditis, Grave's disease, Ankylosing Spondylitis
Sjogrens Disease, CREST
syndrome, Scleroderma, Rheumatic Disease, organ rejection, Primary Sclerosing
Cholangitis, or sepsis.
[0099] The phenotype can also comprise a cardiovascular disease, such as
atherosclerosis, congestive
heart failure, vulnerable plaque, stroke, or ischemia. The cardiovascular
disease or condition can be high
blood pressure, stenosis, vessel occlusion or a thrombotic event.
[00100] The phenotype can also comprise a neurological disease, such as
Multiple Sclerosis (MS),
Parkinson's Disease (PD), Alzheimer's Disease (AD), schizophrenia, bipolar
disorder, depression, autism,
Prion Disease, Pick's disease, dementia, Huntington disease (HD), Down's
syndrome, cerebrovascular
disease, Rasmussen's encephalitis, viral meningitis, neurospsychiatric
systemic lupus erythematosus
(NPSLE), amyotrophic lateral sclerosis, Creutzfeldt-Jacob disease, Gerstmann-
Straussler-Scheinker
disease, transmissible spongiform encephalopathy, ischemic reperfusion damage
(e.g. stroke), brain
trauma, microbial infection, or chronic fatigue syndrome. The phenotype may
also be a condition such as
fibromyalgia, chronic neuropathic pain, or peripheral neuropathic pain.
[00101] The phenotype may also comprise an infectious disease, such as a
bacterial, viral or yeast
infection. For example, the disease or condition may be Whipple's Disease,
Prion Disease, cirrhosis,
methicillin-resistant staphylococcus aureus, HIV, hepatitis, syphilis,
meningitis, malaria, tuberculosis, or
influenza. Viral proteins, such as HIV or HCV-like particles can be assessed
in a vesicle, to characterize a
viral condition.
-22-
CA 03018066 2018-09-17
WO 2017/161357 PCT/US2017/023108
[00102] The phenotype can also comprise a perinatal or pregnancy related
condition (e.g. preeclampsia or
preterm birth), metabolic disease or condition, such as a metabolic disease or
condition associated with
iron metabolism. For example, hepcidin can be assayed in a vesicle to
characterize an iron deficiency. The
metabolic disease or condition can also be diabetes, inflammation, or a
perinatal condition.
[00103] The compositions and methods of the invention can be used to
characterize these and other
diseases and disorders. Thus, characterizing a phenotype can be providing a
diagnosis, prognosis or
theranosis of a medical condition, disease or disorder, including without
limitation one of the diseases and
disorders disclosed herein.
Subject
[00104] One or more phenotypes of a subject can be determined by analyzing a
biological sample
obtained from the subject. A subject or patient can include, but is not
limited to, mammals such as bovine,
avian, canine, equine, feline, ovine, porcine, or primate animals (including
humans and non-human
primates). A subject can also include a mammal of importance due to being
endangered, such as a
Siberian tiger; or economic importance, such as an animal raised on a farm for
consumption by humans,
or an animal of social importance to humans, such as an animal kept as a pet
or in a zoo. Examples of
such animals include, but are not limited to, carnivores such as cats and
dogs; swine including pigs, hogs
and wild boars; ruminants or ungulates such as cattle, oxen, sheep, giraffes,
deer, goats, bison, camels or
horses. Also included are birds that are endangered or kept in zoos, as well
as fowl and more particularly
domesticated fowl, e.g., poultry, such as turkeys and chickens, ducks, geese,
guinea fowl. Also included
are domesticated swine and horses (including race horses). In addition, any
animal species connected to
commercial activities are also included such as those animals connected to
agriculture and aquaculture
and other activities in which disease monitoring, diagnosis, and therapy
selection are routine practice in
husbandry for economic productivity and/or safety of the food chain.
[00105] The subject can have a pre-existing disease or condition, including
without limitation cancer.
Alternatively, the subject may not have any known pre-existing condition. The
subject may also be non-
responsive to an existing or past treatment, such as a treatment for cancer.
Samples
[00106] A sample used and/or assessed via the compositions and methods of the
invention includes any
relevant biological sample that can be used to characterize a phenotype of
interest, including without
limitation sections of tissues such as biopsy or tissue removed during
surgical or other procedures, bodily
fluids, autopsy samples, frozen sections taken for histological purposes, and
cell cultures. Such samples
include blood and blood fractions or products (e.g., serum, buffy coat,
plasma, platelets, red blood cells,
and the like), sputum, malignant effusion, cheek cells tissue, cultured cells
(e.g., primary cultures,
explants, and transformed cells), stool, urine, other biological or bodily
fluids (e.g., prostatic fluid, gastric
fluid, intestinal fluid, renal fluid, lung fluid, cerebrospinal fluid, and the
like), etc. The sample can
comprise biological material that is a fresh frozen & formalin fixed paraffin
embedded (FFPE) block,
formalin-fixed paraffin embedded, or is within an RNA preservative + formalin
fixative. More than one
sample of more than one type can be used for each patient.
-23-
CA 03018066 2018-09-17
WO 2017/161357 PCT/US2017/023108
[00107] The sample used in the methods described herein can be a formalin
fixed paraffin embedded
(FFPE) sample. The FFPE sample can be one or more of fixed tissue, unstained
slides, bone marrow core
or clot, core needle biopsy, malignant fluids and fine needle aspirate (FNA).
In an embodiment, the fixed
tissue comprises a tumor containing formalin fixed paraffin embedded (FFPE)
block from a surgery or
biopsy. In another embodiment, the unstained slides comprise unstained,
charged, unbaked slides from a
paraffin block. In another embodiment, bone marrow core or clot comprises a
decalcified core. A formalin
fixed core and/or clot can be paraffin-embedded. In still another embodiment,
the core needle biopsy
comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more, e.g., 3-6, paraffin embedded
biopsy samples. An 18 gauge
needle biopsy can be used. The malignant fluid can comprise a sufficient
volume of fresh pleural/ascitic
fluid to produce a 5x5x2mm cell pellet. The fluid can be formalin fixed in a
paraffin block. In an
embodiment, the core needle biopsy comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or
more, e.g., 4-6, paraffin
embedded aspirates.
[00108] A sample may be processed according to techniques understood by those
in the art. A sample can
be without limitation fresh, frozen or fixed cells or tissue. In some
embodiments, a sample comprises
formalin-fixed paraffin-embedded (FFPE) tissue, fresh tissue or fresh frozen
(FF) tissue. A sample can
comprise cultured cells, including primary or immortalized cell lines derived
from a subject sample. A
sample can also refer to an extract from a sample from a subject. For example,
a sample can comprise
DNA, RNA or protein extracted from a tissue or a bodily fluid. Many techniques
and commercial kits are
available for such purposes. The fresh sample from the individual can be
treated with an agent to preserve
RNA prior to further processing, e.g., cell lysis and extraction. Samples can
include frozen samples
collected for other purposes. Samples can be associated with relevant
information such as age, gender, and
clinical symptoms present in the subject; source of the sample; and methods of
collection and storage of
the sample. A sample is typically obtained from a subject, e.g., a human
subject.
[00109] A biopsy comprises the process of removing a tissue sample for
diagnostic or prognostic
evaluation, and to the tissue specimen itself Any biopsy technique known in
the art can be applied to the
molecular profiling methods of the present invention. The biopsy technique
applied can depend on the
tissue type to be evaluated (e.g., colon, prostate, kidney, bladder, lymph
node, liver, bone marrow, blood
cell, lung, breast, etc.), the size and type of the tumor (e.g., solid or
suspended, blood or ascites), among
other factors. Representative biopsy techniques include, but are not limited
to, excisional biopsy,
incisional biopsy, needle biopsy, surgical biopsy, and bone marrow biopsy. An
"excisional biopsy" refers
to the removal of an entire tumor mass with a small margin of normal tissue
surrounding it. An "incisional
biopsy" refers to the removal of a wedge of tissue that includes a cross-
sectional diameter of the tumor.
The invention can make use a "core-needle biopsy" of the tumor mass, or a
"fine-needle aspiration
biopsy" which generally obtains a suspension of cells from within the tumor
mass. Biopsy techniques are
discussed, for example, in Harrison's Principles of Internal Medicine, Kasper,
et al., eds., 16th ed., 2005,
Chapter 70, and throughout Part V.
[00110] Standard molecular biology techniques known in the art and not
specifically described are
generally followed as in Sambrook et al., Molecular Cloning: A Laboratory
Manual, Cold Spring Harbor
-24-
CA 03018066 2018-09-17
WO 2017/161357 PCT/US2017/023108
Laboratory Press, New York (1989), and as in Ausubel etal., Current Protocols
in Molecular Biology,
John Wiley and Sons, Baltimore, Md. (1989) and as in Perbal, A Practical Guide
to Molecular Cloning,
John Wiley & Sons, New York (1988), and as in Watson et al., Recombinant DNA,
Scientific American
Books, New York and in Birren et al (eds) Genome Analysis: A Laboratory Manual
Series, Vols. 1-4
Cold Spring Harbor Laboratory Press, New York (1998) and methodology as set
forth in U.S. Pat. Nos.
4,666,828; 4,683,202; 4,801,531; 5,192,659 and 5,272,057 and incorporated
herein by reference.
Polymerase chain reaction (PCR) can be carried out generally as in PCR
Protocols: A Guide to Methods
and Applications, Academic Press, San Diego, Calif. (1990).
[00111] The biological sample assessed using the compositions and methods of
the invention can be any
useful bodily or biological fluid, including but not limited to peripheral
blood, sera, plasma, ascites, urine,
cerebrospinal fluid (C SF), sputum, saliva, bone marrow, synovial fluid,
aqueous humor, amniotic fluid,
cerumen, breast milk, broncheoalveolar lavage fluid, semen (including
prostatic fluid), Cowper's fluid or
pre-ejaculatory fluid, female ejaculate, sweat, fecal matter, hair, tears,
cyst fluid, pleural and peritoneal
fluid, pericardial fluid, lymph, chyme, chyle, bile, interstitial fluid,
menses, pus, sebum, vomit, vaginal
secretions, mucosal secretion, stool water, pancreatic juice, lavage fluids
from sinus cavities,
bronchopulmonary aspirates or other lavage fluids, cells, cell culture, or a
cell culture supernatant. A
biological sample may also include the blastocyl cavity, umbilical cord blood,
or maternal circulation
which may be of fetal or maternal origin. The biological sample may also be a
cell culture, tissue sample
or biopsy from which microvesicles, circulating tumor cells (CTCs), and other
circulating biomarkers may
be obtained. For example, cells of interest can be cultured and microvesicles
isolated from the culture. In
various embodiments, biomarkers or more particularly biosignatures disclosed
herein can be assessed
directly from such biological samples (e.g., identification of presence or
levels of nucleic acid or
polypeptide biomarkers or functional fragments thereof) using various methods,
such as extraction of
nucleic acid molecules from blood, plasma, serum or any of the foregoing
biological samples, use of
protein or antibody arrays to identify polypeptide (or functional fragment)
biomarker(s), as well as other
array, sequencing, PCR and proteomic techniques known in the art for
identification and assessment of
nucleic acid and polypeptide molecules. In addition, one or more components
present in such samples can
be first isolated or enriched and further processed to assess the presence or
levels of selected biomarkers,
to assess a given biosignature (e.g., isolated microvesicles prior to
profiling for protein and/or nucleic acid
biomarkers).
[00112] Table 1 presents a non-limiting listing of diseases, conditions, or
biological states and
corresponding biological samples that may be used for analysis according to
the methods of the invention.
Table 1: Examples of Biological Samples for Various Diseases,
Conditions, or Biological States
Illustrative Disease, Condition or Biological
State Illustrative Biological Samples
Cancers/neoplasms affecting the following tissue Tumor, blood, serum,
plasma, cerebrospinal fluid
types/bodily systems: breast, lung, ovarian, colon, (CSF), urine, sputum,
ascites, synovial fluid,
rectal, prostate, pancreatic, brain, bone, connective semen, nipple
aspirates, saliva, bronchoalveolar
tissue, glands, skin, lymph, nervous system, lavage fluid, tears,
oropharyngeal washes, feces,
-25-
CA 03018066 2018-09-17
WO 2017/161357 PCT/US2017/023108
endocrine, germ cell, genitourinary, peritoneal fluids, pleural effusion,
sweat, tears,
hematologic/blood, bone marrow, muscle, eye, aqueous humor, pericardial
fluid, lymph, chyme,
esophageal, fat tissue, thyroid, pituitary, spinal chyle, bile, stool
water, amniotic fluid, breast milk,
cord, bile duct, heart, gall bladder, bladder, testes, pancreatic juice,
cerumen, Cowper's fluid or pre-
cervical, endometrial, renal, ovarian, ejaculatory fluid, female ejaculate,
interstitial fluid,
digestive/gastrointestinal, stomach, head and neck, menses, mucus, pus,
sebum, vaginal lubrication,
liver, leukemia, respiratory/thorasic, cancers of vomit
unknown primary (CUP)
Neurodegenerative/neurological disorders: Blood, serum, plasma, CSF, urine
Parkinson's disease, Alzheimer's Disease and
multiple sclerosis, Schizophrenia, and bipolar
disorder, spasticity disorders, epilepsy
Cardiovascular Disease: atherosclerosis, Blood, serum, plasma, CSF, urine
cardiomyopathy, endocarditis, vunerable plaques,
infection
Stroke: ischemic, intracerebral hemorrhage, Blood, serum, plasma, CSF,
urine
subarachnoid hemorrhage, transient ischemic
attacks (TIA)
Pain disorders: peripheral neuropathic pain and Blood, serum, plasma, CSF,
urine
chronic neuropathic pain, and fibromyalgia,
Autoimmune disease: systemic and localized Blood, serum, plasma, CSF,
urine, synovial fluid
diseases, rheumatic disease, Lupus, Sjogren's
syndrome
Digestive system abnormalities: Barrett's Blood, serum, plasma, CSF, urine
esophagus, irritable bowel syndrome, ulcerative
colitis, Crohn's disease, Diverticulosis and
Diverticulitis, Celiac Disease
Endocrine disorders: diabetes mellitus, various Blood, serum, plasma, CSF,
urine
forms of Thyroiditis, adrenal disorders, pituitary
disorders
Diseases and disorders of the skin: psoriasis Blood, serum, plasma, CSF,
urine, synovial fluid,
tears
Urological disorders: benign prostatic hypertrophy Blood, serum, plasma, urine
(BPH), polycystic kidney disease, interstitial
cystitis
Hepatic disease/injury: Cirrhosis, induced Blood, serum, plasma, urine
hepatotoxicity (due to exposure to natural or
synthetic chemical sources)
Kidney disease/injury: acute, sub-acute, chronic Blood, serum, plasma,
urine
conditions, Podocyte injury, focal segmental
glomerulosclerosis
Endometriosis Blood, serum, plasma, urine, vaginal
fluids
Osteoporosis Blood, serum, plasma, urine, synovial
fluid
Pancreatitis Blood, serum, plasma, urine, pancreatic
juice
Asthma Blood, serum, plasma, urine, sputum,
bronchiolar lavage
fluid
Allergies Blood, serum, plasma, urine, sputum,
bronchiolar lavage
fluid
Prion-related diseases Blood, serum, plasma, CSF, urine
Viral Infections: HIV/AIDS Blood, serum, plasma, urine
Sepsis Blood, serum, plasma, urine, tears, nasal
lavage
Organ rejection/transplantation Blood, serum, plasma, urine, various
lavage fluids
Differentiating conditions: adenoma versus Blood, serum, plasma, urine,
sputum, feces, colonic
hyperplastic polyp, irritable bowel syndrome (IBS) lavage fluid
versus normal, classifying Dukes stages A, B, C,
and/or D of colon cancer, adenoma with low-grade
-26-
CA 03018066 2018-09-17
WO 2017/161357 PCT/US2017/023108
hyperplasia versus high-grade hyperplasia,
adenoma versus normal, colorectal cancer versus
normal, IBS versus, ulcerative colitis (UC) versus
Crohn's disease (CD),
Pregnancy related physiological states, conditions, or Maternal serum,
plasma, amniotic fluid, cord blood
affiliated diseases: genetic risk, adverse pregnancy
outcomes
[00113] The methods of the invention can be used to characterize a phenotype
using a blood sample or
blood derivative. Blood derivatives include plasma and serum. Blood plasma is
the liquid component of
whole blood, and makes up approximately 55% of the total blood volume. It is
composed primarily of
water with small amounts of minerals, salts, ions, nutrients, and proteins in
solution. In whole blood, red
blood cells, leukocytes, and platelets are suspended within the plasma. Blood
serum refers to blood
plasma without fibrinogen or other clotting factors (i.e., whole blood minus
both the cells and the clotting
factors).
[00114] The biological sample may be obtained through a third party, such as a
party not performing the
analysis of the sample. For example, the sample may be obtained through a
clinician, physician, or other
health care manager of a subject from which the sample is derived.
Alternatively, the biological sample
may obtained by the same party analyzing the sample. In addition, biological
samples be assayed, are
archived (e.g., frozen) or ortherwise stored in under preservative conditions.
[00115] In various embodiments, the biological sample comprises a microvesicle
or cell membrane
fragment that is derived from a cell of origin and available extracellularly
in a subject's biological fluid or
extracellular milieu. Methods of the invention may include assessing one or
more such microvesicles,
including assessing populations thereof A vesicle or microvesicle, as used
herein, is a membrane vesicle
that is shed from cells. Vesicles or membrane vesicles include without
limitation: circulating
microvesicles (cMVs), microvesicle, exosome, nanovesicle, dexosome, bleb,
blebby, prostasome,
microparticle, intralumenal vesicle, membrane fragment, intralumenal endosomal
vesicle, endosomal-like
vesicle, exocytosis vehicle, endosome vesicle, endosomal vesicle, apoptotic
body, multivesicular body,
secretory vesicle, phospholipid vesicle, liposomal vesicle, argosome,
texasome, secresome, tolerosome,
melanosome, oncosome, or exocytosed vehicle. Furthermore, although vesicles
may be produced by
different cellular processes, the methods of the invention are not limited to
or reliant on any one
mechanism, insofar as such vesicles are present in a biological sample and are
capable of being
characterized by the methods disclosed herein. Unless otherwise specified,
methods that make use of a
species of vesicle can be applied to other types of vesicles. Vesicles
comprise spherical structures with a
lipid bilayer similar to cell membranes which surrounds an inner compartment
which can contain soluble
components, sometimes referred to as the payload. In some embodiments, the
methods of the invention
make use of exosomes, which are small secreted vesicles of about 40-100 nm in
diameter. For a review of
membrane vesicles, including types and characterizations, see Thery et al.,
Nat Rev Immunol. 2009
Aug;9(8):.581-93. Some properties of different types of vesicles include those
in Table 2:
Table 2: Vesicle Properties
Feature Exosomes Microvesicle Ectosomes Membrane Exosome- Apoptotic
-27-
CA 03018066 2018-09-17
WO 2017/161357 PCT/US2017/023108
particles like vesicles
vesicles
Size 50-100 nm 100-1,000 50-200 nm 50-80 nm 20-50 nm 50-
500 nm
nm
Density in 1.13-1.19 g/ml 1.04-1.07 1.1 g/ml 1.16-
1.28
sucrose g/ml g/ml
EM Cup shape Irregular Bilamellar Round Irregular
Heterogeneou
appearance shape, round shape
electron structures
dense
Sedimentatio 100,000 g 10,000 g 160,000- 100,000- 175,000 g
1,200 g,
200,000 g 200,000 g 10,000 g,
100,000 g
Lipid Enriched in Expose PPS Enriched in No lipid
composition cholesterol, cholesterol rafts
sphingomyelin and
and ceramide; diacylglycerol;
contains lipid expose PPS
rafts; expose
PPS
Major protein Tetraspanins Integrins, CR1 and CD133; no
TNFRI Histones
markers (e.g., CD63, selectins and proteolytic CD63
CD9), Alix, CD40 ligand enzymes; no
TSG101 CD63
Intracellular Internal Plasma Plasma Plasma
origin compartments membrane membrane membrane
(endosomes)
Abbreviations: phosphatidylserine (PPS); electron microscopy (EM)
[00116] Vesicles include shed membrane bound particles, or "microparticles,"
that are derived from either
the plasma membrane or an internal membrane. Vesicles can be released into the
extracellular
environment from cells. Cells releasing vesicles include without limitation
cells that originate from, or are
derived from, the ectoderm, endoderm, or mesoderm. The cells may have
undergone genetic,
environmental, and/or any other variations or alterations. For example, the
cell can be tumor cells. A
vesicle can reflect any changes in the source cell, and thereby reflect
changes in the originating cells, e.g.,
cells having various genetic mutations. In one mechanism, a vesicle is
generated intracellularly when a
segment of the cell membrane spontaneously invaginates and is ultimately
exocytosed (see for example,
Keller et al., Immunol. Lett. 107 (2): 102-8 (2006)). Vesicles also include
cell-derived structures bounded
by a lipid bilayer membrane arising from both herniated evagination (blebbing)
separation and sealing of
portions of the plasma membrane or from the export of any intracellular
membrane-bounded vesicular
structure containing various membrane-associated proteins of tumor origin,
including surface-bound
molecules derived from the host circulation that bind selectively to the tumor-
derived proteins together
with molecules contained in the vesicle lumen, including but not limited to
tumor-derived microRNAs or
intracellular proteins. Blebs and blebbing are further described in Charras et
al., Nature Reviews
Molecular and Cell Biology, Vol. 9, No. 11, p. 730-736 (2008). A vesicle shed
into circulation or bodily
fluids from tumor cells may be referred to as a "circulating tumor-derived
vesicle." When such vesicle is
an exosome, it may be referred to as a circulating-tumor derived exosome
(CTE). In some instances, a
vesicle can be derived from a specific cell of origin. CTE, as with a cell-of-
origin specific vesicle,
typically have one or more unique biomarkers that permit isolation of the CTE
or cell-of-origin specific
-28-
CA 03018066 2018-09-17
WO 2017/161357 PCT/US2017/023108
vesicle, e.g., from a bodily fluid and sometimes in a specific manner. For
example, a cell or tissue specific
markers are used to identify the cell of origin. Examples of such cell or
tissue specific markers are
disclosed herein and can further be accessed in the Tissue-specific Gene
Expression and Regulation
(TiGER) Database, available at bioinfo.wilmerjhu.edu/tiged; Liu et al. (2008)
TiGER: a database for
tissue-specific gene expression and regulation. BMC Bioinformatics. 9:271;
TissueDistributionDBs,
available at genome.dkfz-heidelberg.de/menu/tissue_db/index.html.
[00117] A vesicle can have a diameter of greater than about 10 nm, 20 nm, or
30 nm. A vesicle can have a
diameter of greater than 40 nm, 50 nm, 100 nm, 200 nm, 500 nm, 1000 nm, 1500
nm, 2000 nm or greater
than 10,000 nm. A vesicle can have a diameter of about 20-2000 nm, about 20-
1500 nm, about 30-1000
nm, about 30-800 nm, about 30-200 nm, or about 30-100 nm. In some embodiments,
the vesicle has a
diameter of less than 10,000 nm, 2000 nm, 1500 nm, 1000 nm, 800 nm, 500 nm,
200 nm, 100 nm, 50 nm,
40 nm, 30 nm, 20 nm or less than 10 nm. As used herein the term "about" in
reference to a numerical
value means that variations of 10% above or below the numerical value are
within the range ascribed to
the specified value. Typical sizes for various types of vesicles are shown in
Table 2. Vesicles can be
assessed to measure the diameter of a single vesicle or any number of
vesicles. For example, the range of
diameters of a vesicle population or an average diameter of a vesicle
population can be determined.
Vesicle diameter can be assessed using methods known in the art, e.g., imaging
technologies such as
electron microscopy. In an embodiment, a diameter of one or more vesicles is
determined using optical
particle detection. See, e.g., U.S. Patent 7,751,053, entitled "Optical
Detection and Analysis of Particles"
and issued July 6, 2010; and U.S. Patent 7,399,600, entitled "Optical
Detection and Analysis of Particles"
and issued July 15, 2010.
[00118] In some embodiments, the methods of the invention comprise assessing
vesicles directly such as
in a biological sample without prior isolation, purification, or concentration
from the biological sample.
For example, the amount of vesicles in the sample can by itself provide a
biosignature that provides a
diagnostic, prognostic or theranostic determination. Alternatively, the
vesicle in the sample may be
isolated, captured, purified, or concentrated from a sample prior to analysis.
As noted, isolation, capture or
purification as used herein comprises partial isolation, partial capture or
partial purification apart from
other components in the sample. Vesicle isolation can be performed using
various techniques as described
herein, e.g., chromatography, filtration, centrifugation, flow cytometry,
affinity capture (e.g., to a planar
surface or bead), and/or using microfluidics. FIGs. 10B-C present an overview
of a method of the
invention for assessing microvesicles using an aptamer pool.
[00119] Vesicles such as exosomes can be assessed to provide a phenotypic
characterization by comparing
vesicle characteristics to a reference. In some embodiments, surface antigens
on a vesicle are assessed.
The surface antigens can provide an indication of the anatomical origin and/or
cellular of the vesicles and
other phenotypic information, e.g., tumor status. For example, wherein
vesicles found in a patient sample,
e.g., a bodily fluid such as blood, serum or plasma, are assessed for surface
antigens indicative of
colorectal origin and the presence of cancer. The surface antigens may
comprise any informative
biological entity that can be detected on the vesicle membrane surface,
including without limitation
-29-
CA 03018066 2018-09-17
WO 2017/161357 PCT/US2017/023108
surface proteins, lipids, carbohydrates, and other membrane components. For
example, positive detection
of colon derived vesicles expressing tumor antigens can indicate that the
patient has colorectal cancer. As
such, methods of the invention can be used to characterize any disease or
condition associated with an
anatomical or cellular origin, by assessing, for example, disease-specific and
cell-specific biomarkers of
one or more vesicles obtained from a subject.
[00120] In another embodiment, the methods of the invention comprise assessing
one or more vesicle
payload to provide a phenotypic characterization. The payload with a vesicle
comprises any informative
biological entity that can be detected as encapsulated within the vesicle,
including without limitation
proteins and nucleic acids, e.g., genomic or cDNA, mRNA, or functional
fragments thereof, as well as
microRNAs (miRs). In addition, methods of the invention are directed to
detecting vesicle surface
antigens (in addition or exclusive to vesicle payload) to provide a phenotypic
characterization. For
example, vesicles can be characterized by using binding agents (e.g.,
antibodies or aptamers) that are
specific to vesicle surface antigens, and the bound vesicles can be further
assessed to identify one or more
payload components disclosed therein. As described herein, the levels of
vesicles with surface antigens of
interest or with payload of interest can be compared to a reference to
characterize a phenotype. For
example, overexpression in a sample of cancer-related surface antigens or
vesicle payload, e.g., a tumor
associated mRNA or microRNA, as compared to a reference, can indicate the
presence of cancer in the
sample. The biomarkers assessed can be present or absent, increased or reduced
based on the selection of
the desired target sample and comparison of the target sample to the desired
reference sample. Non-
limiting examples of target samples include: disease; treated/not-treated;
different time points, such as a in
a longitudinal study; and non-limiting examples of reference sample: non-
disease; normal; different time
points; and sensitive or resistant to candidate treatment(s).
Diagnostic Methods
[00121] The aptamers of the invention can be used in various methods to assess
presence or level of
biomarkers in a biological sample, e.g., biological entities of interest such
as proteins, nucleic acids, or
microvesicles. The biological entities can be part of larger entities, such as
complexes, cells or tissue, or
can be circulating in bodily fluids. The aptamers may be used to assess
presence or level of the target
molecule/s. Therefore, in various embodiments of the invention directed to
diagnostics, prognostics or
theranostics, one or more aptamers of the invention are configured in a ligand-
target based assay, where
one or more aptamer of the invention is contacted with a selected biological
sample, where the or more
aptamer associates with or binds to its target molecules. Aptamers of the
invention are used to identify
candidate biosignatures based on the biological samples assessed and
biomarkers detected. In some
embodiments, aptamer or oligonucleotide probes, or libraries thereof, may
themselves provide a
biosignature for a particular condition or disease. A biosignature refers to a
biomarker profile of a
biological sample comprising a presence, level or other characteristic that
can be assessed (including
without limitation a sequence, mutation, rearrangement, translocation,
deletion, epigenetic modification,
methylation, post-translational modification, allele, activity, complex
partners, stability, half life, and the
like) of one or more biomarker of interest. Biosignatures can be used to
evaluate diagnostic and/or
-30-
CA 03018066 2018-09-17
WO 2017/161357 PCT/US2017/023108
prognostic criteria such as presence of disease, disease staging, disease
monitoring, disease stratification,
or surveillance for detection, metastasis or recurrence or progression of
disease. For example, methods of
the invention using aptamers against microvesicle surface antigen are useful
for correlating a biosignature
comprising microvesicle antigens to a selected condition or disease. As
another example, methods of the
invention using aptamers against tissue are useful for correlating a
biosignature comprising tissue antigens
to a selected condition or disease. A biosignature can also be used clinically
in making decisions
concerning treatment modalities including therapeutic intervention. A
biosignature can further be used
clinically to make treatment decisions, including whether to perform surgery
or what treatment standards
should be used along with surgery (e.g., either pre-surgery or post-surgery).
As an illustrative example, a
biosignature of circulating biomarkers or biomarkers displayed on fixed tissue
may indicate an aggressive
form of cancer and may call for a more aggressive surgical procedure and/or
more aggressive therapeutic
regimen to treat the patient.
[00122] Characterizing a phenotype, such as providing a diagnosis, prognosis
or theranosis, may comprise
comparing a biosignature to a reference. For example, the level of a biomarker
in a diseased state may be
elevated or reduced as compared to a reference control without the disease, or
with a different state of the
disease. An oligonucleotide probe library according to the invention may be
engineered to detect a certain
phenotype and not another phenotype. As a non-limiting example, the
oligonucleotide probe library may
stain a cancer tissue using an immunoassay but not a non-cancer reference
tissue. Alternately, the
oligonucleotide probe library may stain a cancer tissue using an immunoassay
at a detectable higher level
than a non-cancer reference tissue. One of skill will appreciate that one may
engineer an oligonucleotide
probe library to stain a non-cancer tissue using an immunoassay at a
detectable higher level than cancer
tissue as well.
[00123] A biosignature can be used in any methods disclosed herein, e.g., to
assess whether a subject is
afflicted with disease, is at risk for developing disease or to assess the
stage or progression of the disease.
For example, a biosignature can be used to assess whether a subject has
prostate cancer, colon cancer, or
other cancer as described herein. See, e.g., section labeled "Phenotypes."
Furthermore, a biosignature can
be used to determine a stage of a disease or condition, such as cancer.
[00124] A biosignature/biomarker profile comprising a microvesicle can include
assessment of payload
within the microvesicle. For example, one or more aptamer of the invention can
be used to capture a
microvesicle population, thereby providing readout of microvesicle antigens,
and then the payload content
within the captured microvesicles can be assessed, thereby providing further
biomarker readout of the
payload content.
[00125] A biosignature for characterizing a phenotype may comprise any number
of useful criteria. The
term "phenotype" as used herein can mean any trait or characteristic that is
attributed to a biosignature /
biomarker profile. A phenotype can be detected or identified in part or in
whole using the compositions
and/or methods of the invention. In some embodiments, at least one criterion
is used for each biomarker.
In some embodiments, at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 30, 40,
50, 60, 70, 80, 90 or at least 100
criteria are used. For example, for the characterizing of a cancer, a number
of different criteria can be used
-31-
CA 03018066 2018-09-17
WO 2017/161357 PCT/US2017/023108
when the subject is diagnosed with a cancer: 1) if the amount of a biomarker
in a sample from a subject is
higher than a reference value; 2) if the amount of a biomarker within specific
cell types or specific
microvesicles (e.g., microvesicles derived from a specific tissue or organ) is
higher than a reference value;
or 3) if the amount of a biomarker within a cell, tissue or microvesicle with
one or more cancer specific
biomarkers is higher than a reference value. Similar rules can apply if the
amount of the biomarkers is less
than or the same as the reference. The method can further include a quality
control measure, such that the
results are provided for the subject if the samples meet the quality control
measure. In some embodiments,
if the criteria are met but the quality control is questionable, the subject
is reassessed.
[00126] A biosignature can be used in therapy related diagnostics to provide
tests useful to diagnose a
disease or choose the correct treatment regimen, such as provide a theranosis.
Theranostics includes
diagnostic testing that provides the ability to affect therapy or treatment of
a diseased state. Theranostics
testing provides a theranosis in a similar manner that diagnostics or
prognostic testing provides a
diagnosis or prognosis, respectively. As used herein, theranostics encompasses
any desired form of
therapy related testing, including predictive medicine, personalized medicine,
integrated medicine,
pharmacodiagnostics and Dx/Rx partnering. Therapy related tests can be used to
predict and assess drug
response in individual subjects, i.e., to provide personalized medicine.
Predicting a drug response can be
determining whether a subject is a likely responder or a likely non-responder
to a candidate therapeutic
agent, e.g., before the subject has been exposed or otherwise treated with the
treatment. Assessing a drug
response can be monitoring a response to a drug, e.g., monitoring the
subject's improvement or lack
thereof over a time course after initiating the treatment. Therapy related
tests are useful to select a subject
for treatment who is particularly likely to benefit from the treatment or to
provide an early and objective
indication of treatment efficacy in an individual subject. Thus, a
biosignature as disclosed herein may
indicate that treatment should be altered to select a more promising
treatment, thereby avoiding the great
expense of delaying beneficial treatment and avoiding the financial and
morbidity costs of administering
an ineffective drug(s).
[00127] The compositions and methods of the invention can be used to identify
or detect a biosignature
associated with a variety of diseases and disorders, which include, but are
not limited to cardiovascular
disease, cancer, infectious diseases, sepsis, neurological diseases, central
nervous system related diseases,
endovascular related diseases, and autoimmune related diseases. Therapy
related diagnostics also aid in
the prediction of drug toxicity, drug resistance or drug response. Therapy
related tests may be developed
in any suitable diagnostic testing format, which include, but are not limited
to, e.g., immunohistochemical
tests, clinical chemistry, immunoassay, cell-based technologies, nucleic acid
tests or body imaging
methods. Therapy related tests can further include but are not limited to,
testing that aids in the
determination of therapy, testing that monitors for therapeutic toxicity, or
response to therapy testing.
Thus, a biosignature can be used to predict or monitor a subject's response to
a treatment. A biosignature
can be determined at different time points for a subject after initiating,
removing, or altering a particular
treatment.
-32-
CA 03018066 2018-09-17
WO 2017/161357 PCT/US2017/023108
[00128] In some embodiments, the compositions and methods of the invention
provide for a determination
or prediction as to whether a subject is responding to a treatment is made
based on a change in the amount
of one or more components of a biosignature (e.g., biomarkers of interest), an
amount of one or more
components of a particular biosignature, or the biosignature detected for the
components. In another
embodiment, a subject's condition is monitored by determining a biosignature
at different time points.
The progression, regression, or recurrence of a condition is determined.
Response to therapy can also be
measured over a time course. Thus, the invention provides a method of
monitoring a status of a disease or
other medical condition in a subject, comprising isolating or detecting a
biosignature from a biological
sample from the subject, detecting the overall amount of the components of a
particular biosignature, or
detecting the biosignature of one or more components (such as the presence,
absence, or expression level
of a biomarker). The biosignatures are used to monitor the status of the
disease or condition.
[00129] One or more novel biosignatures can also be identified by the methods
of the invention. For
example, one or more vesicles can be isolated from a subject that responds to
a drug treatment or
treatment regimen and compared to a reference, such as another subject that
does not respond to the drug
treatment or treatment regimen. Differences between the biosignatures can be
determined and used to
identify other subjects as responders or non-responders to a particular drug
or treatment regimen.
[00130] In some embodiments, a biosignature is used to determine whether a
particular disease or
condition is resistant to a drug, in which case a physician need not waste
valuable time with such drug
treatment. To obtain early validation of a drug choice or treatment regimen, a
biosignature is determined
for a sample obtained from a subject. The biosignature is used to assess
whether the particular subject's
disease has the biomarker associated with drug resistance. Such a
determination enables doctors to devote
critical time as well as the patient's financial resources to effective
treatments.
[00131] Biosignatures can be used in the theranosis of diseases such as
cancer, e.g., identifying whether a
subject suffering from a disease is a likely responder or non-responder to a
particular treatment. The
subject methods can be used to theranose cancers including without limitation
those listed herein, e.g., in
the "Phenotypes" section herein. These include without limitation lung cancer,
non-small cell lung cancer
small cell lung cancer (including small cell carcinoma (oat cell cancer),
mixed small cell/large cell
carcinoma, and combined small cell carcinoma), colon cancer, breast cancer,
prostate cancer, liver cancer,
pancreatic cancer, brain cancer, kidney cancer, ovarian cancer, stomach
cancer, melanoma, bone cancer,
gastric cancer, breast cancer, glioma, glioblastoma, hepatocellular carcinoma,
papillary renal carcinoma,
head and neck squamous cell carcinoma, leukemia, lymphoma, myeloma, or other
solid tumors.
[00132] A biosignature of circulating biomarkers, including markers associated
with a component present
in a biological sample (e.g., cell, cell-fragment, cell-derived microvesicle),
in a sample from a subject
suffering from a cancer can be used select a candidate treatment for the
subject. The biosignature can be
determined according to the methods of the invention presented herein. In some
embodiments, the
candidate treatment comprises a standard of care for the cancer. The treatment
can be a cancer treatment
such as radiation, surgery_ chemotherapy or a combination thereof The cancer
treatment can be a
therapeutic such as anti-cancer agents and chemotherapeutic regimens. Further
drug associations and rules
-33-
CA 03018066 2018-09-17
WO 2017/161357 PCT/US2017/023108
that are used in embodiments of the invention are found in PCT/US2007/69286,
filed May 18, 2007;
PCT/US2009/60630, filed October 14, 2009; PCT/ 2010/000407, filed February 11,
2010;
PCT/US12/41393, filed June 7, 2012; PCT/US2013/073184, filed December 4, 2013;
PCT/US2010/54366, filed October 27, 2010; PCT/US11/67527, filed December 28,
2011;
PCT/US15/13618, filed January 29, 2015; and PCT/US16/20657, filed March 3,
2016; each of which
applications is incorporated herein by reference in its entirety.
Biomarkers
[00133] The methods and compositions of the invention can be used in assays to
detect the presence or
level of one or more biomarker of interest. Given the adaptable nature of the
invention, the biomarker can
be any useful biomarker including those disclosed herein or in the literature,
or to be discovered. In an
embodiment, the biomarker comprises a protein or polypeptide. As used herein,
"protein," "polypeptide"
and "peptide" are used interchangeably unless stated otherwise. The biomarker
can be a nucleic acid,
including DNA, RNA, and various subspecies of any thereof as disclosed herein
or known in the art. The
biomarker can comprise a lipid. The biomarker can comprise a carbohydrate. The
biomarker can also be a
complex, e.g., a complex comprising protein, nucleic acids, lipids and/or
carbohydrates. In some
embodiments, the biomarker comprises a microvesicle. In an embodiment, the
invention provides a
method wherein a pool of aptamers is used to assess the presence and/or level
of a population of
microvesicles of interest without knowing the precise microvesicle antigen
targeted by each member of
the pool. See, e.g., FIGs. 10B-C. In other cases, biomarkers associated with
microvesicles are assessed
according to the methods of the invention. See, e.g., FIG. 10A. The
oligonucleotide pools of the invention
can also used to assess cells and tissue whether or not the target biomarkers
of the individual
oligonucleotide aptamers are known. The invention further includes determining
the targets of such
oligonucleotide aptamer pools and members thereof. See Examples 19-31.
[00134] A biosignature may comprise one type of biomarker or multiple types of
biomarkers. As a non-
limiting example, a biosignature can comprise multiple proteins, multiple
nucleic acids, multiple lipids,
multiple carbohydrates, multiple biomarker complexes, multiple microvesicles,
or a combination of any
thereof. For example, the biosignature may comprise one or more microvesicle,
one or more protein, and
one or more microRNA, wherein the one or more protein and/or one or more
microRNA is optionally in
association with the microvesicle as a surface antigen and/or payload, as
appropriate. As another example,
the biosignature may be an oligonucleotide pool signature, and the members of
the oligonucleotide pool
can associate with various biomarker or multiple types of biomarkers.
[00135] In some embodiments, microvesicles are detected using vesicle surface
antigens. A commonly
expressed vesicle surface antigen can be referred to as a "housekeeping
protein," or general vesicle
biomarker. The biomarker can be CD63, CD9, CD81, CD82, CD37, CD53, Rab-5b,
Annexin V or MFG-
E8. Tetraspanins, a family of membrane proteins with four transmembrane
domains, can be used as
general vesicle biomarkers. The tetraspanins include CD151, CD53, CD37, CD82,
CD81, CD9 and CD63.
There have been over 30 tetraspanins identified in mammals, including the
TSPAN1 (TSP-1), TSPAN2
(TSP-2), TSPAN3 (TSP-3), TSPAN4 (TSP-4, NAG-2), TSPAN5 (TSP-5), TSPAN6 (TSP-
6), TSPAN7
-34-
CA 03018066 2018-09-17
WO 2017/161357 PCT/US2017/023108
(CD231, TALLA-1, A15), TSPAN8 (C0-029), TSPAN9 (NET-5), TSPAN10 (Oculospanin),
TSPAN11
(CD151-like), TSPAN12 (NET-2), TSPAN13 (NET-6), TSPAN14, TSPAN15 (NET-7),
TSPAN16
(TM4-B), TSPAN17, TSPAN18, TSPAN19, TSPAN20 (UP lb, UPK1B), TSPAN21 (UPla,
UPK1A),
TSPAN22 (RDS, PRPH2), TSPAN23 (ROM1), TSPAN24 (CD151), TSPAN25 (CD53), TSPAN26
(CD37), TSPAN27 (CD82), TSPAN28 (CD81), TSPAN29 (CD9), TSPAN30 (CD63), TSPAN31
(SAS),
TSPAN32 (TSSC6), TSPAN33, and TSPAN34. Other commonly observed vesicle markers
include those
listed in Table 3. One or more of these proteins can be useful biomarkers for
the characterizing a
phenotype using the subject methods and compositions.
Table 3: Proteins Observed in Microvesicles from Multiple Cell Types
Class Protein
Antigen Presentation MEC class I, MHC class II, Integrins, Alpha 4 beta 1,
Alpha M beta 2,
Beta 2
Immunoglobulin family ICAM1/CD54, P-selection
Cell-surface peptidases Dipeptidylpeptidase IV/CD26, Aminopeptidase n/CD13
Tetraspanins CD151, CD53, CD37, CD82, CD81, CD9 and CD63
Heat-shock proteins Hsp70, Hsp84/90
Cytoskeletal proteins Actin, Actin-binding proteins, Tubulin
Membrane transport Annexin I, Annexin II, Annexin IV, Annexin V, Annexin
VI,
and fusion RAB7/RAP1B/RADGDI
Signal transduction Gi2alpha/14-3-3, CBL/LCK
Abundant membrane CD63, GAPDH, CD9, CD81, ANXA2, EN01, SDCBP, MSN, MFGE8,
proteins EZR, GK, ANXA1, LAMP2, DPP4, TSG101, HSPA1A, GDI2, CLTC,
LAMP1, Cd86, ANPEP, TFRC, SLC3A2, RDX, RAP1B, RAB5C,
RAB5B, MYH9, ICAM1, FN1, RAB11B, PIGR, LGALS3, ITGB1,
EHD1, CLIC1, ATP1A1, ARF1, RAP1A, P4HB, MUC1, KRT10, HLA-
A, FLOT1, CD59, C1orf58, BASP1, TACSTD1, STOM
Other Transmembrane Cadherins: CDH1, CDH2, CDH12, CDH3, Deomoglein, DSG1,
DSG2,
Proteins DSG3, DSG4, Desmocollin, DSC1, DSC2, DSC3, Protocadherins,
PCDH1, PCDH10, PCDH1 lx, PCDHlly, PCDH12, FAT, FAT2, FAT4,
PCDH15, PCDH17, PCDH18, PCDH19; PCDH20; PCDH7, PCDH8,
PCDH9, PCDHAl, PCDHA10, PCDHAll, PCDHAl2, PCDHA13,
PCDHA2, PCDHA3, PCDHA4, PCDHA5, PCDHA6, PCDHA7,
PCDHA8, PCDHA9, PCDHAC1, PCDHAC2, PCDHB1, PCDHB10,
PCDHB11, PCDHB12, PCDHB13, PCDHB14, PCDHB15, PCDHB16,
PCDHB17, PCDHB18, PCDHB2, PCDHB3, PCDHB4, PCDHB5,
PCDHB6, PCDHB7, PCDHB8, PCDHB9, PCDHGA1, PCDHGA10,
PCDHGAll, PCDHGA12, PCDHGA2; PCDHGA3, PCDHGA4,
PCDHGA5, PCDHGA6, PCDHGA7, PCDHGA8, PCDHGA9,
PCDHGB1, PCDHGB2, PCDHGB3, PCDHGB4, PCDHGB5,
PCDHGB6, PCDHGB7, PCDHGC3, PCDHGC4, PCDHGC5, CDH9
(cadherin 9, type 2 (Ti-cadherin)), CDH10 (cadherin 10, type 2 (T2-
cadherin)), CDH5 (VE-cadherin (vascular endothelial)), CDH6 (K-
cadherin (kidney)), CDH7 (cadherin 7, type 2), CDH8 (cadherin 8, type
2), CDH11 (0B-cadherin (osteoblast)), CDH13 (T-cadherin - H-cadherin
(heart)), CDH15 (M-cadherin (myotubule)), CDH16 (KSP-cadherin),
CDH17 (LI cadherin (liver-intestine)), CDH18 (cadherin 18, type 2),
CDH19 (cadherin 19, type 2), CDH20 (cadherin 20, type 2), CDH23
(cadherin 23, (neurosensory epithelium)), CDH10, CDH11, CDH13,
CDH15, CDH16, CDH17, CDH18, CDH19, CDH22, CDH23, CDH24,
CDH26, CDH28, CDH4, CDH5, CDH6, CDH7, CDH8, CDH9,
CELSR1, CELSR2, CELSR3, CLSTN1, CLSTN2, CLSTN3, DCHS1,
DCHS2, L0C389118, PCLKC, RESDA1, RET
-35-
CA 03018066 2018-09-17
WO 2017/161357 PCT/US2017/023108
[00136] Any of the types of biomarkers described herein can be used and/or
assessed via the subject
methods and compositions. Exemplary biomarkers include without limitation
those in Table 4. The
markers can be detected as protein, RNA or DNA as appropriate, which can be
circulating freely or in a
complex with other biological molecules. As desired, the markers in Table 4
can also be used to detect
tumor tissue or for capture and/or detection of vesicles for characterizing
phenotypes as disclosed herein.
In some cases, multiple capture and/or detectors are used to enhance the
characterization. The markers can
be detected as vesicle surface antigens and/or vesicle payload. The
"Illustrative Class" indicates
indications for which the markers are known markers. Those of skill will
appreciate that the markers can
also be used in alternate settings in certain instances. For example, a marker
which can be used to
characterize one type of disease may also be used to characterize another
disease as appropriate. Consider
a non-limiting example of a tumor marker which can be used as a biomarker for
tumors from various
lineages. The biomarker references in Tables 3 and 4, or through the
specification, are those commonly
used in the art. Gene aliases and descriptions can be found using a variety of
online databases, including
Gene Cards (www.genecards.org), HUGO Gene Nomenclature (www.genenames.org),
Entrez Gene
(www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=gene), UniProtKB/Swiss-Prot
(www.uniprot.org),
UniProtKB/TrEMBL (www.uniprot.org), OMIM
(www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=0MIM),
GeneLoc (genecards.weizmann.ac.il/geneloc/), and Ensembl (www.ensembl.org).
Generally, gene
symbols and names below correspond to those approved by HUGO, and protein
names are those
recommended by UniProtKB/Swiss-Prot. Common alternatives are provided as well.
Where a protein
name indicates a precursor, the mature protein is also implied. Throughout the
application, gene and
protein symbols may be used interchangeably and the meaning can be derived
from context as necessary.
Table 4: Illustrative Biomarkers
Illustrative Biomarkers
Class
Drug associated ABCC1, ABCG2, ACE2, ADA, ADH1C, ADH4, AGT, AR, AREG, ASNS,
BCL2,
targets and BCRP, BDCA1, beta III tubulin, BIRC5, B-RAF, BRCA1, BRCA2, CA2,
caveolin,
prognostic CD20, CD25, CD33, CD52, CDA, CDKN2A, CDKN1A, CDKN1B, CDK2,
markers CDW52, CES2, CK 14, CK 17, CK 5/6, c-KIT, c-Met, c-Myc, COX-2,
Cyclin D1,
DCK, DHFR, DNMT1, DNMT3A, DNMT3B, E-Cadherin, ECGF1, EGFR, EML4-
ALK fusion, EPHA2, Epiregulin, ER, ERBR2, ERCC1, ERCC3, EREG, ESR1,
FLT1, folate receptor, FOLR1, FOLR2, FSHB, FSHPRH1, FSHR, FYN, GART,
GNAll, GNAQ, GNRH1, GNRHR1, GSTP1, HCK, HDAC1, hENT-1, Her2/Neu,
HGF, HIF1A, HIG1, HSP90, HSP9OAA1, HSPCA, IGF-1R, IGFRBP, IGFRBP3,
IGFRBP4, IGFRBP5, IL13RA1, IL2RA, KDR, Ki67, KIT, K-RAS, LCK, LTB,
Lymphotoxin Beta Receptor, LYN, MET, MGMT, MLH1, MMR, MRP1, MS4A1,
MSH2, MSH5, Myc, NFKB1, NFKB2, NFKBIA, NRAS, ODC1, OGFR, p16, p21,
p27, p53, p95, PARP-1, PDGFC, PDGFR, PDGFRA, PDGFRB, PGP, PGR, PI3K,
POLA, POLA1, PPARG, PPARGC1, PR, PTEN, PTGS2, PTPN12, RAF1, RARA,
ROS1, RRM1, RRM2, RRM2B, RXRB, RXRG, SIK2, SPARC, SRC, SSTR1,
SSTR2, SSTR3, SSTR4, SSTR5, Survivin, TK1, TLE3, TNF, TOP1, TOP2A,
TOP2B, TS, TUBB3, TXN, TXNRD1, TYMS, VDR, VEGF, VEGFA, VEGFC,
VHL, YES1, ZAP70
Drug associated ABL1, STK11, FGFR2, ERBB4, SMARCB1, CDKN2A, CTNNB1, FGFR1,
FLT3,
targets and NOTCH1, NPM1, SRC, SMAD4, FBX-W7, PTEN, TP53, AKT1, ALK, APC,
prognostic CDH1, C-Met, HRAS, IDH1, JAK2, MPL, PDGFRA, SMO, VHL, ATM,
CSF1R,
-36-
CA 03018066 2018-09-17
WO 2017/161357 PCT/US2017/023108
markers FGFR3, GNAS, ERBB2, HNF1A, JAK3, KDR, MLH1, PTPN11, RB1, RET, c-
Kit,
EGFR, PIK3CA, NRAS, GNAll, GNAQ, KRAS, BRAF
Drug associated ALK, AR, BRAF, cKIT, cMET, EGFR, ER, ERCC1, GNAll, HER2, IDH1,
KRAS,
targets and MGMT, MGMT promoter methylation, NRAS, PDGFRA, Pgp, PIK3CA, PR,
prognostic PTEN, ROS1, RRM1, SPARC, TLE3, TOP2A, TOP01, TS, TUBB3, VHL
markers
Drug associated ABL1, AKT1, ALK, APC, AR, ATM, BRAF, BRAF, BRCA1, BRCA2, CDH1,
targets cKIT, cMET, CSF1R, CTNNB1, EGFR, EGFR (H-score), EGFRvIII, ER,
ERBB2
(HER2), ERBB4, ERCC1, FBXW7, FGFR1, FGFR2, FLT3, GNAll, GNAQ,
GNAS, HER2, HNF1A, HRAS, IDH1, IDH2, JAK2, JAK3, KDR (VEGFR2),
KRAS, MGMT, MGMT Promoter Methylation, microsatellite instability (MSI),
MLH1, MPL, MSH2, MSH6, NOTCH1, NPM1, NRAS, PD-1, PDGFRA, PD-L1,
Pgp, PIK3CA, PMS2, PR, PTEN, PTPN11, RB1, RET, ROS1, RRM1, SMAD4,
SMARCB1, SMO, SPARC, STK11, TLE3, TOP2A, TOP01, TP53, TS, TUBB3,
VHL
Drug associated 1p19q co-deletion, ABL1, AKT1, ALK, APC, AR, ARAF, ATM, BAP1,
BRAF,
targets BRCA1, BRCA2, CDH1, CHEK1, CHEK2, cKIT, cMET, CSF1R, CTNNB1,
DDR2, EGFR, EGFRvIII, ER, ERBB2 (HER2), ERBB3, ERBB4, ERCC1, FBXW7,
FGFR1, FGFR2, FLT3, GNAll, GNAQ, GNAS, H3K36me3, HER2, HNF1A,
HRAS, IDH1, IDH2, JAK2, JAK3, KDR (VEGFR2), KRAS, MDMT, MGMT,
MGMT Methylation, Mierosatellite instability, 1\'ILH1, MPL, MSH2, MSH6, NF1,
NOTCH1, NPM1, NRAS, NY-ESO-1, PD-1, PDGFRA, PD-L1, Pgp, PIK3CA,
PMS2, PR, PTEN, PTPN11, RAF1, RBI, RET, ROS1, ROS1, RRM1, SMAD4,
SMARCB1, SMO, SPARC, STK11, TLE3, TOP2A, TOP01, TP53, TRKA, TS,
TUBB3, VHL, WT1
Drug associated ABL1, AKT1, ALK, APC, AR, ATM, BRAF, BRAF, BRCA1, BRCA2, CDH1,
targets cKIT, cMET, CSF1R, CTNNB1, EGFR, EGFR (H-score), EGFRvIII, ER,
ERBB2
(HER2), ERBB4, ERCC1, FBXW7, FGFR1, FGFR2, FLT3, GNAll, GNAQ,
GNAS, HER2, HNF1A, HRAS, IDH1, IDH2, JAK2, JAK3, KDR (VEGFR2),
KRAS, MGMT, MGMT Promoter Methylation, microsatellite instability (MSI),
MLH1, MPL, MSH2, MSH6, NOTCH1, NPM1, NRAS, PD-1, PDGFRA, PD-L1,
Pgp, PIK3CA, PMS2, PR, PTEN, PTPN11, RB1, RET, ROS1, RRM1, SMAD4,
SMARCB1, SMO, SPARC, STK11, TLE3, TOP2A, TOP01, TP53, TS, TUBB3,
VHL
Drug associated 1p19q, ALK, ALK (2p23), Androgen Receptor, BRCA, cMET, EGFR,
EGFR,
targets EGFRvIII, ER, ERCC1, Her2, Her2/Neu, MGMT, MGMT Promoter
Methylation,
microsatellite instability (MSI), MLH1, MSH2, MSH6, PD-1, PD-L1, PMS2, PR,
PTEN, ROS1, RRM1, TLE3, TOP2A, TOP2A, TOP01, TS, TUBB3
Drug associated TOP2A, Chromosome 17 alteration, PBRM1 (PB1/BAF180), BAP1,
SETD2 (ANTI-
targets HISTONE H3), MDM2, Chromosome 12 alteration, ALK, CTLA4, CD3, NY-
ESO-
1, MAGE-A, TP, EGFR
5-aminosalicyclic a-protocadherin, KLF4, CEBPa
acid (5-ASA)
efficacy
Cancer treatment AR, AREG (Amphiregulin), BRAF, BRCA1, cKIT, cMET, EGFR, EGFR
associated w/T790M, EML4-ALK, ER, ERBB3, ERBB4, ERCC1, EREG, GNAll, GNAQ,
markers hENT-1, Her2, Her2 Exon 20 insert, IGF1R, Ki67, KRAS, MGMT, MGMT
methylation, MSH2, MSI, NRAS, PGP (MDR1), PIK3CA, PR, PTEN, ROS1, ROS1
translocation, RRM1, SPARC, TLE3, TOP01, TOPO2A, TS, TUBB3, VEGFR2
Cancer treatment AR, AREG, BRAF, BRCA1, cKIT, cMET, EGFR, EGFR w/T790M, EML4-
ALK,
associated ER, ERBB3, ERBB4, ERCC1, EREG, GNAll, GNAQ, Her2, Her2 Exon 20
insert,
markers IGFR1, Ki67, KRAS, MGMT-Me, MSH2, MSI, NRAS, PGP (MDR-1), PIK3CA,
PR, PTEN, ROS1 translocation, RRM1, SPARC, TLE3, TOP01, TOPO2A, TS,
TUBB3, VEGFR2
Colon cancer AREG, BRAF, EGFR, EML4-ALK, ERCC1, EREG, KRAS, MSI, NRAS,
PIK3CA,
treatment PTEN, TS, VEGFR2
associated
-37-
CA 03018066 2018-09-17
WO 2017/161357 PCT/US2017/023108
markers
Colon cancer AREG, BRAF, EGFR, EML4-ALK, ERCC1, EREG, KRAS, MSI, NRAS,
PIK3CA,
treatment PTEN, TS, VEGFR2
associated
markers
Melanoma BRAF, cKIT, ERBB3, ERBB4, ERCC1, GNAll, GNAQ, MGMT, MGMT
treatment methylation, NRAS, PIK3CA, TUBB3, VEGFR2
associated
markers
Melanoma BRAF, cKIT, ERBB3, ERBB4, ERCC1, GNAll, GNAQ, MGMT-Me, NRAS,
treatment PIK3CA, TUBB3, VEGFR2
associated
markers
Ovarian cancer BRCA1, cMET, EML4-ALK, ER, ERBB3, ERCC1, hENT-1, HER2, IGF1R,
treatment PGP(MDR1), PIK3CA, PR, PTEN, RRM1, TLE3, TOP01, TOPO2A, TS
associated
markers
Ovarian cancer BRCA1, cMET, EML4-ALK (translocation), ER, ERBB3, ERCC1, HER2,
PIK3CA,
treatment PR, PTEN, RRM1, TLE3, TS
associated
markers
Breast cancer BRAF, BRCA1, EGFR, EGFR T790M, EML4-ALK, ER, ERBB3, ERCC1,
HER2,
treatment Ki67, PGP (MDR1), PIK3CA, PR, PTEN, ROS1, ROS1 translocation,
RRM1,
associated TLE3, TOP01, TOPO2A, TS
markers
Breast cancer BRAF, BRCA1, EGFR w/T790M, EML4-ALK, ER, ERBB3, ERCC1, HER2,
Ki67,
treatment KRAS, PIK3CA, PR, PTEN, ROS1 translocation, RRM1, TLE3, TOP01,
TOPO2A,
associated TS
markers
NSCLC cancer BRAF, BRCA1, cMET, EGFR, EGFR w/T790M, EML4-ALK, ERCC1, Her2 Exon
treatment 20 insert, KRAS, MSH2, PIK3CA, PTEN, ROS1 (trans), RRM1, TLE3,
TS,
associated VEGFR2
markers
NSCLC cancer BRAF, cMET, EGFR, EGFR w/T790M, EML4-ALK, ERCC1, Her2 Exon 20
insert,
treatment KRAS, MSH2, PIK3CA, PTEN, ROS1 translocation, RRM1, TLE3, TS
associated
markers
Mutated in AKT1, ALK, APC, ATM, BRAF, CDH1, CDKN2A, c-Kit, C-Met, CSF1R,
cancers CTNNB1, EGFR, ERBB2, ERBB4, FBMV7, FGFR1, FGFR2, FGFR3, FLT3,
GNAll, GNAQ, GNAS, HNF1A, HRAS, IDH1, JAK2, JAK3, KDR, KRAS,
MLH1, MPL, NOTCH1, NPM1, NRAS, PDGFRA, PIK3CA, PTEN, PTPN11, RB1,
RET, SMAD4, SMARCB1, SMO, SRC, STK11, TP53, VHL
Mutated in ALK, BRAF, BRCA1, BRCA2, EGFR, ERRB2, GNAll, GNAQ, IDH1, IDH2,
cancers KIT, KRAS, MET, NRAS, PDGFRA, PIK3CA, PTEN, RET, SRC, TP53
Mutated in AKT1, HRAS, GNAS, MEK1, MEK2, ERK1, ERK2, ERBB3, CDKN2A, PDGFRB,
cancers IFG1R, FGFR1, FGFR2, FGFR3, ERBB4, SMO, DDR2, GRB1, PTCH, SHH,
PD1,
UGT1A1, BIM, ESR1, MLL, AR, CDK4, SMAD4
Mutated in ABL, APC, ATM, CDH1, CSFR1, CTNNB1, FBX1V7, FLT3, HNF1A, JAK2,
cancers JAK3, KDR, MLH1, MPL, NOTCH1, NPM1, PTPN11, RB1, SMARCB1, STK11,
VHL
Mutated in ABL1, AKT1, AKT2, AKT3, ALK, APC, AR, ARAF, ARFRP1, ARID1A,
ARID2,
cancers ASXL1, ATM, ATR, ATRX, AURKA, AURKB, AXL, BAP1, BARD1, BCL2,
BCL2L2, BCL6, BCOR, BCORL1, BLM, BRAF, BRCA1, BRCA2, BRIP1, BTK,
CARD11, CBFB, CBL, CCND1, CCND2, CCND3, CCNE1, CD79A, CD79B,
CDC73, CDH1, CDK12, CDK4, CDK6, CDK8, CDKN1B, CDKN2A, CDKN2B,
CDKN2C, CEBPA, CHEK1, CHEK2, CIC, CREBBP, CRKL, CRLF2, CSF1R,
CTCF, CTNNA1, CTNNB1, DAXX, DDR2, DNMT3A, DOT1L, EGFR, EMSY
-38-
CA 03018066 2018-09-17
WO 2017/161357 PCT/US2017/023108
(Cllorf30), EP300, EPHA3, EPHA5, EPHB1, ERBB2, ERBB3, ERBB4, ERG,
ESR1, EZH2, FAM123B (WTX), FAM46C, FANCA, FANCC, FANCD2, FANCE,
FANCF, FANCG, FANCL, FBXW7, FGF10, FGF14, FGF19, FGF23, FGF3, FGF4,
FGF6, FGFR1, FGFR2, FGFR3, FGFR4, FLT1, FLT3, FLT4, FOXL2, GATA1,
GATA2, GATA3, GID4 (C17orf39), GNAll, GNA13, GNAQ, GNAS, GPR124,
GRIN2A, GSK3B, HGF, HRAS, IDH1, IDH2, IGF1R, IKBKE, IKZFl, IL7R,
INHBA, IRF4, IRS2, JAK1, JAK2, JAK3, JUN, KAT6A (MYST3), KDM5A,
KDM5C, KDM6A, KDR, KEAP1, KIT, KLHL6, KRAS, LRP1B, MAP2K1,
MAP2K2, MAP2K4, MAP3K1, MCL1, MDM2, MDM4, MED12, MEF2B, MEN1,
MET, MITF, MLH1, MLL, MLL2, MPL, MRE11A, MSH2, MSH6, MTOR,
MUTYH, MYC, MYCL1, MYCN, MYD88, NF1, NF2, NFE2L2, NFKBIA, NKX2-
1, NOTCH1, NOTCH2, NPM1, NRAS, NTRK1, NTRK2, NTRK3, NUP93, PAK3,
PALB2, PAX5, PBRM1, PDGFRA, PDGFRB, PDK1, PIK3CA, PIK3CG, PIK3R1,
PIK3R2, PPP2R1A, PRDM1, PRKAR1A, PRKDC, PTCH1, PTEN, PTPN11,
RAD50, RAD51, RAF1, RARA, RB1, RET, RICTOR, RNF43, RPTOR, RUNX1,
SETD2, SF3B1, SMAD2, SMAD4, SMARCA4, SMARCB1, SMO, SOCS1,
SOX10, SOX2, SPEN, SPOP, SRC, STAG2, STAT4, STK11, SUFU, TET2,
TGFBR2, TNFAIP3, TNFRSF14, TOP1, TP53, TSC1, TSC2, TSHR, VHL, WISP3,
WT1, XP01, ZNF217, ZNF703
Gene ALK, BCR, BCL2, BRAF, EGFR, ETV1, ETV4, ETV5, ETV6, EWSR1, MLL,
rearrangement in MYC, NTRK1, PDGFRA, RAF1, RARA, RET, ROS1, TMPRSS2
cancer
Cancer Related ABL1, ACE2, ADA, ADH1C, ADH4, AGT, AKT1, AKT2, AKT3, ALK, APC,
AR,
ARAF, AREG, ARFRP1, ARID 1A, ARID2, ASNS, ASXL1, ATM, ATR, ATRX,
AURKA, AURKB, AXL, BAP1, BARD1, BCL2, BCL2L2, BCL6, BCOR,
BCORL1, BCR, BIRC5 (survivin), BLM, BRAF, BRCA1, BRCA2, BRIP1, BTK,
CA2, CARD11, CAV, CBFB, CBL, CCND1, CCND2, CCND3, CCNE1, CD33,
CD52 (CDW52), CD79A, CD79B, CDC73, CDH1, CDK12, CDK2, CDK4, CDK6,
CDK8, CDKN1B, CDKN2A, CDKN2B, CDKN2C, CEBPA, CES2, CHEK1,
CHEK2, CIC, CREBBP, CRKL, CRLF2, CSF1R, CTCF, CTNNA1, CTNNB1,
DAXX, DCK, DDR2, DHFR, DNMT1, DNMT3A, DNMT3B, DOT1L, EGFR,
EMSY (Cllorf30), EP300, EPHA2, EPHA3, EPHA5, EPHB1, ERBB2, ERBB3,
ERBB4, ERBR2 (typo?), ERCC3, EREG, ERG, ESR1, ETV1, ETV4, ETV5, ETV6,
EWSR1, EZH2, FAM123B (WTX), FAM46C, FANCA, FANCC, FANCD2,
FANCE, FANCF, FANCG, FANCL, FBXW7, FGF10, FGF14, FGF19, FGF23,
FGF3, FGF4, FGF6, FGFR1, FGFR2, FGFR3, FGFR4, FLT1, FLT3, FLT4, FOLR1,
FOLR2, FOXL2, FSHB, FSHPRH1, FSHR, GART, GATA1, GATA2, GATA3,
GID4 (C17orf39), GNAll, GNA13, GNAQ, GNAS, GNRH1, GNRHR1, GPR124,
GRIN2A, GSK3B, GSTP1, HDAC1, HGF, HIG1, FINF1A, HRAS, HSPCA
(HSP90), IDH1, IDH2, IGF1R, IKBKE, IKZFl, IL13RA1, IL2, IL2RA (CD25),
IL7R, INHBA, IRF4, IRS2, JAK1, JAK2, JAK3, JUN, KAT6A (MYST3), KDM5A,
KDM5C, KDM6A, KDR (VEGFR2), KEAP1, KIT, KLHL6, KRAS, LCK, LRP1B,
LTB, LTBR, MAP2K1, MAP2K2, MAP2K4, MAP3K1, MAPK, MCL1, MDM2,
MDM4, MED12, MEF2B, MEN1, MET, MGMT, MITF, MLH1, MLL, MLL2,
MPL, MRE11A, MS4A1 (CD20), MSH2, MSH6, MTAP, MTOR, MUTYH, MYC,
MYCL1, MYCN, MYD88, NF1, NF2, NFE2L2, NFKB1, NFKB2, NFKBIA, NGF,
NKX2-1, NOTCH1, NOTCH2, NPM1, NRAS, NTRK1, NTRK2, NTRK3, NUP93,
ODC1, OGFR, PAK3, PALB2, PAX5, PBRM1, PDGFC, PDGFRA, PDGFRB,
PDK1, PGP, PGR (PR), PIK3CA, PIK3CG, PIK3R1, PIK3R2, POLA, PPARG,
PPARGC1, PPP2R1A, PRDM1, PRKAR1A, PRKDC, PTCH1, PTEN, PTPN11,
RAD50, RAD51, RAF1, RARA, RBI, RET, RICTOR, RNF43, ROS1, RPTOR,
RRM1, RRM2, RRM2B, RUNX1, RXR, RXRB, RXRG, SETD2, SF3B1, SMAD2,
SMAD4, SMARCA4, SMARCB1, SMO, SOCS1, SOX10, SOX2, SPARC, SPEN,
SPOP, SRC, SST, SSTR1, SSTR2, SSTR3, SSTR4, SSTR5, STAG2, STAT4,
STK11, SUFU, TET2, TGFBR2, TK1, TLE3, TMPRSS2, TNF, TNFAIP3,
TNFRSF14, TOP1, TOP2, TOP2A, TOP2B, TP53, TS, TSC1, TSC2, TSHR,
TUBB3, TXN, TYMP, VDR, VEGF (VEGFA), VEGFC, VHL, WISP3, WT1, XDH,
-39-
CA 03018066 2018-09-17
WO 2017/161357 PCT/US2017/023108
XP01, YES1, ZAP70, ZNF217, ZNF703
Cancer Related 5T4, ABIl, ABL1, ABL2, ACKR3, ACSL3, ACSL6, ACVR1B, ACVR2A,
AFF1,
AFF3, AFF4, AKAP9, AKT1, AKT2, AKT3, ALDH2, ALK, AMER1,
ANG1/ANGPT1/TM7SF2, ANG2/ANGPT2NPS51, APC, AR, ARAF, ARFRP1,
ARHGAP26, ARHGEF12, ARID1A, ARID1B, ARID2, ARNT, ASPSCR1, ASXL1,
ATF1, ATIC, ATM, ATP 1A1, ATP2B3, ATR, ATRX, AURKA, AURKB, AXIN1,
AXL, BAP1, BARD1, BBC3, BCL10, BCL11A, BCL11B, BCL2, BCL2L1,
BCL2L11, BCL2L2, BCL3, BCL6, BCL7A, BCL9, BCOR, BCORL1, BCR,
BIRC3, BLM, BMPR1A, BRAF, BRCA1, BRCA2, BRD3, BRD4, BRIP1, BTG1,
BTK, BUB1B, c-KIT, Cl lorf30, cl5orf21, C15orf65, C2orf44, CA6, CACNA1D,
CALR, CAMTA1, CANT1, CARD11, CARS, CASC5, CASP8, CBFA2T3, CBFB,
CBL, CBLB, CBLC, CCDC6, CCNB lIP1, CCND1, CCND2, CCND3, CCNE1,
CD110, CD123, CD137, CD19, CD20, CD274, CD27L, CD38, CD4, CD74,
CD79A, CD79B, CDC73, CDH1, CDH11, CDK12, CDK4, CDK6, CDK7, CDK8,
CDK9, CDKN1A, CDKN1B, CDKN2A, CDKN2B, CDKN2C, CDX2, CEBPA,
CHCHD7, CHD2, CHD4, CHEK1, CHEK2, CHIC2, Chkl, CHN1, CIC, CIITA,
CLP1, CLTC, CLTCL1, CNBP, CNOT3, CNTRL, COL1A1, COPB1, CoREST,
COX6C, CRAF, CREB1, CREB3L1, CREB3L2, CREBBP, CRKL, CRLF2,
CRTC1, CRTC3, CSF1R, CSF3R, CTCF, CTLA4, CTNNA1, CTNNB1, CUL3,
CXCR4, CYLD, CYP17A1, CYP2D6, DAXX, DDB2, DDIT3, DDR1, DDR2,
DDX10, DDX5, DDX6, DEK, DICER1, DLL-4, DNAPK, DNM2, DNMT3A,
DOT1L, EBF1, ECT2L, EGFR, EIF4A2, ELF4, ELK4, ELL, ELN, EML4, EP300,
EPHA3, EPHA5, EPHA7, EPHA8, EPHB1, EPHB2, EPS15, ERBB2, ERBB3,
ERBB4, ERC1, ERCC1, ERCC2, ERCC3, ERCC4, ERCC5, ERG, ERRFIl, ESR1,
ETBR, ETV1, ETV4, ETV5, ETV6, EWSR1, EXT1, EXT2, EZH2, EZR, FAK,
FAM46C, FANCA, FANCC, FANCD2, FANCE, FANCF, FANCG, FANCL, FAS,
FAT1, FBX011, FBXW7, FCRL4, FEY, FGF10, FGF14, FGF19, FGF2, FGF23,
FGF3, FGF4, FGF6, FGFR1, FGFR1OP, FGFR2, FGFR3, FGFR4, FH, FHIT,
FIP1L1, FKBP12, FLCN, FLI1, FLT1, FLT3, FLT4, FNBP1, FOXA1, FOXL2,
FOX01, FOX03, FOX04, FOXP1, FRS2, FSTL3, FUBP1, FUS, GABRA6, GAS7,
GATA1, GATA2, GATA3, GATA4, GATA6, GID4, GITR, GLI1, GMPS, GNAll,
GNA13, GNAQ, GNAS, GNRH1, GOLGA5, GOPC, GPC3, GPHN, GPR124,
GRIN2A, GRM3, GSK3B, GUCY2C, H3F3A, H3F3B, HCK, HERPUD1, HEY1,
HGF, HIP1, HIST1H3B, HIST1H4I, HLF, HMGA1, HMGA2, HMT, HNF1A,
HNRNPA2B1, HOOK3, HOXA11, HOXA13, HOXA9, HOXC11, H0XC13,
HOXD11, H0XD13, HRAS, H5D3B1, HSP9OAA1, H5P90AB1, LAP, IDH1, IDH2,
IGF1R, IGF2, IKBKE, IKZFl, IL2, IL21R, IL6, IL6ST, IL7R, INHBA, INPP4B,
IRF2, IRF4, IRS2, ITGAV, ITGB1, ITK, JAK1, JAK2, JAK3, JAZFl, JUN,
KAT6A, KAT6B, KCNJ5, KDM5A, KDM5C, KDM6A, KDR, KDSR, KEAP1,
KEL, KIAA1549, KIF5B, KIR3DL1, KLF4, KLHL6, KLK2, KMT2A, KMT2C,
KMT2D, KRAS, KTN1, LASP1, LCK, LCP1, LGALS3, LGR5, LHFP, LIFR,
LM01, LM02, LOXL2, LPP, LRIG3, LRP1B, LSD1, LYL1, LYN, LZTR1, MAF,
MAFB, MAGI2, MALT1, MAML2, MAP2K1, MAP2K2, MAP2K4, MAP3K1,
MAPK1, MAPK11, MAX, MCL1, MDM2, MDM4, MDS2, MECOM, MED12,
MEF2B, MEK1, MEK2, MEN1, MET, MITF, MKL1, MLF1, MLH1, MLLT1,
MLLT10, MLLT11, MLLT3, MLLT4, MLLT6, MMP9, MN1, MNX1, MPL, MPS1,
MRE11A, MS4A1, MSH2, MSH6, M5I2, MSN, MST1R, MTCP1, MTOR, MUC1,
MUC16, MUTYH, MYB, MYC, MYCL, MYCN, MYD88, MYH11, MYH9,
NACA, NAE1, NBN, NCKIPSD, NCOA1, NCOA2, NCOA4, NDRG1, NF1, NF2,
NFE2L2, NFIB, NFKB2, NFKBIA, NIN, NKX2-1, NONO, NOTCH1, NOTCH2,
NOTCH3, NPM1, NR4A3, NRAS, NSD1, NT5C2, NTRK1, NTRK2, NTRK3,
NUMA1, NUP214, NUP93, NUP98, NUTM1, NUTM2B, OLIG2, OMD, P2RY8,
PAFAH1B2, PAK3, PALB2, PARK2, PARP1, PATZ1, PAX3, PAX5, PAX7,
PAX8, PBRM1, PBX1, PCM1, PCSK7, PDCD1, PDCD1LG2, PDE4DIP, PDGFB,
PDGFRA, PDGFRB, PDK1, PERI, PHF6, PHOX2B, PICALM, PIK3C2B,
PIK3CA, PIK3CB, PIK3CD, PIK3CG, PIK3R1, PIK3R2, PIM1, PKC, PLAG1,
PLCG2, PML, PMS1, PMS2, POLD1, POLE, POT1, POU2AF1, P0U5F1, PPARG,
-40-
CA 03018066 2018-09-17
WO 2017/161357 PCT/US2017/023108
PPP2R1A, PRCC, PRDM1, PRDM16, PREX2, PRF1, PRKAR1A, PRKCI, PRKDC,
PRLR, PRRX1, PRSS8, PSIP1, PTCH1, PTEN, PTK2, PTPN11, PTPRC, PTPRD,
QKI, RABEP1, RAC1, RAD21, RAD50, RAD51, RAD51B, RAF1, RALGDS,
RANBP17, RANBP2, RANKL, RAP1GDS1, RARA, RB1, RBM10, RBM15,
RECQL4, REL, RET, RHOH, RICTOR, RMI2, RNF213, RNF43, ROS1, RPL10,
RPL20, RPL5, RPN1, RPS6KB1, RPTOR, RUNX1, RUNx1T1, SBDS, SDC4,
SDHA, SDHAF2, SDHB, SDHC, SDHD, SEPT5, SEPT6, SEPT9, SET, SETBP1,
SETD2, SF3B1, SFPQ, SH2B3, SH3GL1, SLAMF7, SLC34A2, SLC45A3, SLIT2,
SMAD2, SMAD3, SMAD4, SMARCA4, SMARCB1, SMARCE1, SMO, SNCAIP,
5NX29, SOCS1, SOX10, SOX2, SOX9, SPECC1, SPEN, SPOP, SPTA1, SRC,
SRGAP3, SRSF2, SRSF3, SS18, SS18L1, SSX1, SSX2, SSX4, STAG2, STAT3,
STAT4, STAT5B, STEAP1, STIL, STK11, SUFU, SUZ12, SYK, TAF1, TAF15,
TALI, TAL2, TBL1XR1, TBX3, TCEA1, TCF12, TCF3, TCF7L2, TCL1A, TERC,
TERT, TETI, TET2, TFE3, TFEB, TFG, TFPT, TFRC, TGFB1, TGFBR2,
THRAP3, TIE2, TLX1, TLX3, TMPRSS2, TNFAIP3, TNFRSF14, TNFRSF17,
TOP1, TOP2A, TP53, TPM3, TPM4, TPR, TRAF7, TRIM26, TRIM27, TRIM33,
TRIP11, TRRAP, TSC1, TSC2, TSHR, TTL, U2AF1, UBA1, UBR5, USP6,
VEGFA, VEGFB, VEGFR, VHL, VTI1A, WAS, WEE1, WHSC1, WHSC1L1,
WIF1, WISP3, WNT11, WNT2B, WNT3, WNT3A, WNT4, WNT5A, WNT6,
WNT7B, WRN, WT1, WWTRE XPA, XPC, XP01, YWHAE, ZAK, ZBTB16,
ZBTB2, ZMYM2, ZNF217, ZNF331, ZNF384, ZNF521, ZNF703, ZRSR2
Cancer Related ABL2, ACSL3, ACSL6, AFF1, AFF3, AFF4, AKAP9, AKT3, ALDH2, APC,
ARFRP1, ARHGAP26, ARHGEF12, ARID2, ARNT, ASPSCR1, ASXL1, ATF1,
ATIC, ATM, ATP1A1, ATR, AURKA, AXIN1, AXL, BAP1, BARD1, BCL10,
BCL11A, BCL2L11, BCL3, BCL6, BCL7A, BCL9, BCR, BIRC3, BLM, BMPR1A,
BRAF, BRCA1, BRCA2, BRIP1, BUB1B, Cllorf30, C2orf44, CACNA1D, CALR,
CAMTA1, CANT1, CARD11, CARS, CASC5, CASP8, CBFA2T3, CBFB, CBL,
CBLB, CCDC6, CCNB lIP1, CCND2, CD274, CD74, CD79A, CDC73, CDH11,
CDKN1B, CDX2, CHEK1, CHEK2, CHIC2, CHN1, CIC, CIITA, CLP1, CLTC,
CLTCL1, CNBP, CNTRL, COPB1, CREB1, CREB3L1, CREB3L2, CRTC1,
CRTC3, CSF1R, CSF3R, CTCF, CTLA4, CTNNA1, CTNNB1, CYLD, CYP2D6,
DAXX, DDR2, DDX10, DDX5, DDX6, DEK, DICER1, DOT1L, EBF1, ECT2L,
ELK4, ELL, EML4, EPHA3, EPHA5, EPHB1, EPS15, ERBB3, ERBB4, ERC1,
ERCC2, ERCC3, ERCC4, ERCC5, ERG, ESR1, ETV1, ETV5, ETV6, EWSR1,
EXT1, EXT2, EZR, FANCA, FANCC, FANCD2, FANCE, FANCG, FANCL, FAS,
FBX011, FBXW7, FCRL4, FGF14, FGF19, FGF23, FGF6, FGFR1OP, FGFR4, FH,
FHIT, FIP1L1, FLCN, FLI1, FLT1, FLT3, FLT4, FNBP1, FOXA1, FOX01,
FOXP1, FUBP1, FUS, GAS7, GID4, GMPS, GNA13, GNAQ, GNAS, GOLGA5,
GOPC, GPHN, GPR124, GRIN2A, GSK3B, H3F3A, H3F3B, HERPUD1, HGF,
HIP1, HMGA1, HMGA2, HNRNPA2B1, HOOK3, HSP90AA1, HSP90AB1, IDH1,
IDH2, IGF1R, IKZFE IL2, IL21R, IL6ST, IL7R, IRF4, ITK, JAKE JAK2, JAK3,
JAZFl, KDM5A, KEAP1, KIAA1549, KIF5B, KIT, KLHL6, KMT2A, KMT2C,
KMT2D, KRAS, KTN1, LCK, LCP1, LGR5, LHFP, LIFR, LPP, LRIG3, LRP1B,
LYL1, MAF, MALT1, MAML2, MAP2K2, MAP2K4, MAP3K1, MDM4, MDS2,
MEF2B, MEN1, MITF, MLF1, MLH1, MLLT1, MLLT10, MLLT3, MLLT4,
MLLT6, MNX1, MRE11A, MSH2, MSH6, MSI2, MTOR, MYB, MYCN, MYD88,
MYH11, MYH9, NACA, NCKIPSD, NCOA1, NCOA2, NCOA4, NF1, NFE2L2,
NFIB, NFKB2, NIN, NOTCH2, NPM1, NR4A3, NSD1, NT5C2, NTRK2, NTRK3,
NUP214, NUP93, NUP98, NUTM1, PALB2, PAX3, PAX5, PAX7, PBRM1, PBX1,
PCM1, PCSK7, PDCD1, PDCD1LG2, PDGFB, PDGFRA, PDGFRB, PDK1, PERE
PICALM, PIK3CA, PIK3R1, PIK3R2, PIM1, PML, PMS2, POLE, POT1,
POU2AF1, PPARG, PRCC, PRDM1, PRDM16, PRKAR1A, PRRX1, PSIP1,
PTCH1, PTEN, PTPN11, PTPRC, RABEP1, RAC1, RAD50, RAD51, RAD51B,
RAF1, RALGDS, RANBP17, RAP1GDS1, RARA, RBM15, REL, RET, RMI2,
RNF43, RPL20, RPL5, RPN1, RPTOR, RUNX1, RUNX1T1, SBDS, SDC4,
SDHAF2, SDHB, SDHC, SDHD, 8-Sep, SET, SETBP1, SETD2, SF3B1, SH2B3,
SH3GL1, SLC34A2, SMAD2, SMAD4, SMARCB1, SMARCE1, SMO, SNX29,
-41-
CA 03018066 2018-09-17
WO 2017/161357 PCT/US2017/023108
SOX10, SPECC1, SPEN, SRGAP3, SRSF2, SRSF3, SS18, SS18L1, STAT3,
STAT4, STAT5B, STIL, STK11, SUFU, SUZ12, SYK, TAF15, TCF12, TCF3,
TCF7L2, TETI, TET2, TFEB, TFG, TFRC, TGFBR2, TLX1, TNFAIP3,
TNFRSF14, TNFRSF17, TP53, TPM3, TPM4, TPR, TRAF7, TRIM26, TRIM27,
TRIM33, TRIP11, TRRAP, TSC1, TSC2, TSHR, TTL, U2AF1, USP6, VEGFA,
VEGFB, VTI1A, WHSC1, WHSC1L1, WIF1, WISP3, WRN, WWTR1, XPA, XPC,
XP01, YWHAE, Z1\/IYM2, ZNF217, ZNF331, ZNF384, ZNF521, ZNF703
Gene fusions and AKT3, ALK, ARHGAP26, AXL, BRAF, BRD3/4, EGFR, ERG, ESR1,
ETV1/4/5/6,
mutations in EWSR1, FGFR1, FGFR2, FGFR3, FGR, INSR, MAML2, MAST1/2, MET,
MSMB,
cancer MUSK, MYB, NOTCH1/2, NRG1, NTRK1/2/3, NUMBL, NUTM1, PDGFRA/B,
PIK3CA, PKN1, PPARG, PRKCA/B, RAF1, RELA, RET, ROS1, RSP02/3, TERT,
TFE3, TFEB, THADA, TMPRSS2
Gene fusions and ABL1 fusion to (ETV6, NUP214, RCSD1, RANBP2, SNX2, or ZMIZ1);
ABL2
mutations in fusion to (PAG1 or RCSD1): CSF1R fusion to (SSBP2): PDGFRB
fusion to (EBF1,
cancer SSBP2, TNIP1 or ZEB2); CRLF2 fusion to (P2RY8); JAK2 fusion to
(ATF7IP, BCR,
ETV6, PAX5, PPFIBP1, SSBP2, STRN3, TERF2, or TPR): EPOR fusion to (1GH or
IGK); IL2RB fusion to (MY149); NTRK3 fusion to (ETV6); PTK2B fusion to (KDM6A
or STAG2); TSLP fusion to (1QGAP2); TYK2 fusion to (MYB)
Cytohesions cytohesin-1 (CYTH1), cytohesin-2 (CYTH2; ARNO), cytohesin-3
(CYTH3; Grpl;
ARN03), cytohesin-4 (CYTH4)
Cancer/Angio Erb 2, Erb 3, Erb 4, UNC93a, B7H3, MUC1, MUC2, MUC16, MUC17,
5T4,
RAGE, VEGF A, VEGFR2, FLT1, DLL4, Epcam
Tissue (Breast) BIG H3, GCDFP-15, PR(B), GPR 30, CYFRA 21, BRCA 1, BRCA 2, ESR
1, ESR2
Tissue (Prostate) PSMA, PCSA, PSCA, PSA, TMPRSS2
Inflammation/Im MFG-E8, IFNAR, CD40, CD80, MICB, HLA-DRb, IL-17-Ra
mune
[00137] Examples of additional biomarkers that can be incorporated into the
methods and compositions of
the invention include without limitation those disclosed in International
Patent Application Nos.
PCT/US2009/62880, filed October 30, 2009; PCT/US2009/006095, filed November
12, 2009;
PCT/US2011/26750, filed March 1, 2011; PCT/US2011/031479, filed April 6, 2011;
PCT/US11/48327,
filed August 18, 2011; PCT/US2008/71235, filed July 25, 2008; PCT/US10/58461,
filed November 30,
2010; PCT/US2011/21160, filed January 13, 2011; PCT/US2013/030302, filed March
11,2013;
PCT/US12/25741, filed February 17, 2012; PCT/2008/76109, filed September 12,
2008;
PCT/US12/42519, filed June 14, 2012; PCT/US12/50030, filed August 8, 2012;
PCT/US12/49615, filed
August 3, 2012; PCT/US12/41387, filed June 7,2012; PCT/US2013/072019, filed
November 26, 2013;
PCT/US2014/039858, filed May 28, 2013; PCT/IB2013/003092, filed October 23,
2013;
PCT/US13/76611, filed December 19, 2013; PCT/US14/53306, filed August 28,
2014; and
PCT/US15/62184, filed November 23, 2015; PCT/US16/40157, filed June 29, 2016;
PCT/US16/44595,
filed July 28, 2016; and PCT/US16/21632, filed March 9, 2016; each of which
applications is
incorporated herein by reference in its entirety.
[00138] In various embodiments of the invention, the biomarkers or
biosignature used to detect or assess
any of the conditions or diseases disclosed herein can comprise one or more
biomarkers in one of several
different categories of markers, wherein the categories include without
limitation one or more of: 1)
disease specific biomarkers; 2) cell- or tissue-specific biomarkers; 3)
vesicle-specific markers (e.g.,
general vesicle biomarkers); 4) angiogenesis-specific biomarkers; and 5)
immunomodulatory biomarkers.
Examples of all such markers are disclosed herein and known to a person having
ordinary skill in the art.
-42-
CA 03018066 2018-09-17
WO 2017/161357 PCT/US2017/023108
Furthermore, a biomarker known in the art that is characterized to have a role
in a particular disease or
condition can be adapted for use as a target in compositions and methods of
the invention. In further
embodiments, such biomarkers of interest may be cellular or vesicular surface
markers, or a combination
of surface markers and soluble or payload markers (e.g., molecules enclosed by
a microvesicle). The
biomarkers assessed can be from a combination of sources. For example, a
disease or disorder may be
detected or characterized by assessing a combination of proteins, nucleic
acids, vesicles, circulating
biomarkers, biomarkers from a tissue sample, and the like. In addition, as
noted herein, the biological
sample assessed can be any biological fluid, or can comprise individual
components present within such
biological fluid (e.g., vesicles, nucleic acids, proteins, or complexes
thereof).
Biomarker Detection
[00139] The compositions and methods of the invention can be used to assess
any useful biomarkers in a
biological sample for charactering a phenotype associated with the sample.
Such biomarkers include all
sorts of biological entities such as proteins, nucleic acids, lipids,
carbohydrates, complexes of any thereof,
and microvesicles.
[00140] The aptamers of the invention can be used to provide a biosignature in
tissue or bodily fluids, e.g.,
by assessing various biomarkers therein. See, e.g., FIGs. 10B-C. The aptamers
of the invention can also
be used to assess levels or presence of their specific target molecule. See,
e.g., FIG. 10A. In addition,
aptamers of the invention are used to capture or isolated a component present
in a biological sample that
has the aptamer's target molecule present. For example, if a given surface
antigen is present on a cell, cell
fragment or cell-derived extracellular vesicle, a binding agent to the
biomarker, including without
limitation an aptamer provided by the invention, may be used to capture or
isolate the cell, cell fragment
or cell-derived extracellular vesicles. See, e.g., FIGs. 1A-B, 10A. Such
captured or isolated entities may
be further characterized to assess additional surface antigens or internal
"payload" molecules, e.g., nucleic
acid molecules, lipids, sugars, polypeptides or functional fragments thereof,
or anything else present in the
cellular milieu that may be used as a biomarker. Therefore, aptamers of the
invention are used not only to
assess one or more surface antigen of interest but are also used to separate a
component present in a
biological sample, where the components themselves can be comprised within the
biosignature.
[00141] The methods of the invention can comprise multiplex analysis of at
least 2, 3, 4, 5, 6, 7, 8, 9, 10,
11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 50, 75, 100, 200, 300, 400, 500,
600, 700, 800, 900, 1000, or
more different biomarkers. For example, an oligonucleotide pool may contain
any number of individual
aptamers that can target different biomarkers. As another example, an assay
can be performed with a
plurality of particles that are differentially labeled. There can be at least
2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13,
14, 15, 16, 17, 18, 19, 20, 25, 50, 75 or 100 differentially labeled
particles. The particles may be
externally labeled, such as with a tag, or they may be intrinsically labeled.
Each differentially labeled
particle can be coupled to a capture agent, such as a antibody or aptamer, and
can be used to capture its
target. The multiple capture agents can be selected to characterize a
phenotype of interest, including
capture agents against general vesicle biomarkers, cell-of-origin specific
biomarkers, and disease
biomarkers. One or more captured biomarkers can be detected by a plurality of
binding agents. The
-43-
CA 03018066 2018-09-17
WO 2017/161357 PCT/US2017/023108
binding agent can be directly labeled to facilitate detection. Alternatively,
the binding agent is labeled by a
secondary agent. For example, the binding agent may be an antibody or aptamer
for a biomarker, wherein
the binding agent is linked to biotin. A secondary agent comprises
streptavidin linked to a reporter and can
be added to detect the biomarker. In some embodiments, the captured vesicle is
assayed for at least 2, 3, 4,
5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 50, 75 or 100
different biomarkers. For example,
multiple detectors, i.e., detection of multiple biomarkers of a captured
vesicle or population of vesicles,
can increase the signal obtained, permitted increased sensitivity,
specificity, or both, and the use of
smaller amounts of samples. Detection can be with more than one biomarker,
including without limitation
more than one vesicle marker such as in any of Tables 3-4, and Tables 10-17.
[00142] An immunoassay based method (e.g., sandwich assay) can be used to
detect a biomarker of
interest. An example includes ELISA. A binding agent can be bound to a well.
For example, a binding
agent such as an aptamer or antibody to biomarker of interest can be attached
to a well. A captured
biomarker can be detected based on the methods described herein. FIG. 1A shows
an illustrative
schematic for a sandwich-type of immunoassay. The capture agent can be against
a cellular or vesicular
antigen of In the figure, the captured entities are detected using
fluorescently labeled binding agent
(detection agent) against antigens of interest. Multiple capture binding
agents can be used, e.g., in
distinguishable addresses on an array or different wells of an immunoassay
plate. The detection binding
agents can be against the same antigen as the capture binding agent, or can be
directed against other
markers. The capture binding agent can be any useful binding agent, e.g.,
tethered aptamers, antibodies or
lectins, and/or the detector antibodies can be similarly substituted, e.g.,
with detectable (e.g., labeled)
aptamers, antibodies, lectins or other binding proteins or entities.
[00143] In an embodiment, one or more capture agents to a general vesicle
biomarker, a cell-of-origin
marker, and/or a disease marker are used along with detection agents against
general vesicle biomarker,
such as tetraspanin molecules including without limitation one or more of CD9,
CD63 and CD81, or other
markers in Table 3 herein. Examples of microvesicle surface antigens are
disclosed herein, e.g. in Tables
3- 4 and 10-17. Further biomarkers and detection techniques are disclosed in
International Patent
Application Nos. PCT/US2009/62880, filed October 30, 2009; PCT/US2009/006095,
filed November 12,
2009; PCT/US2011/26750, filed March 1, 2011; PCT/US2011/031479, filed April 6,
2011;
PCT/US11/48327, filed August 18, 2011; PCT/US2008/71235, filed July 25, 2008;
PCT/US10/58461,
filed November 30, 2010; PCT/US2011/21160, filed January 13, 2011;
PCT/US2013/030302, filed March
11,2013; PCT/US12/25741, filed February 17, 2012; PCT/2008/76109, filed
September 12, 2008;
PCT/U512/42519, filed June 14, 2012; PCT/US12/50030, filed August 8, 2012;
PCT/U512/49615, filed
August 3, 2012; PCT/US12/41387, filed June 7,2012; PCT/U52013/072019, filed
November 26, 2013;
PCT/U52014/039858, filed May 28, 2013; PCT/IB2013/003092, filed October 23,
2013;
PCT/U513/76611, filed December 19, 2013; PCT/U514/53306, filed August 28,
2014; PCT/US15/62184,
filed November 23, 2015; PCT/US16/40157, filed June 29, 2016; PCT/U516/44595,
filed July 28, 2016;
and PCT/U516/21632, filed March 9, 2016; each of which applications is
incorporated herein by
reference in its entirety.
-44-
CA 03018066 2018-09-17
WO 2017/161357 PCT/US2017/023108
[00144] Techniques of detecting biomarkers or capturing sample components
using an aptamer of the
invention include the use of a planar substrate such as an array (e.g.,
biochip or microarray), with
molecules immobilized to the substrate as capture agents that facilitate the
detection of a particular
biosignature. The array can be provided as part of a kit for assaying one or
more biomarkers. Aptamers of
the invention can be included in an array for detection and diagnosis of
diseases including
presymptomatic diseases. In some embodiments, an array comprises a custom
array comprising
biomolecules selected to specifically identify biomarkers of interest.
Customized arrays can be modified
to detect biomarkers that increase statistical performance, e.g., additional
biomolecules that identifies a
biosignature which lead to improved cross-validated error rates in
multivariate prediction models (e.g.,
logistic regression, discriminant analysis, or regression tree models). In
some embodiments, customized
array(s) are constructed to study the biology of a disease, condition or
syndrome and profile biosignatures
in defined physiological states. Markers for inclusion on the customized array
be chosen based upon
statistical criteria, e.g., having a desired level of statistical significance
in differentiating between
phenotypes or physiological states. In some embodiments, standard significance
of p-value = 0.05 is
chosen to exclude or include biomolecules on the microarray. The p-values can
be corrected for multiple
comparisons. As an illustrative example, nucleic acids extracted from samples
from a subject with or
without a disease can be hybridized to a high density microarray that binds to
thousands of gene
sequences. Nucleic acids whose levels are significantly different between the
samples with or without the
disease can be selected as biomarkers to distinguish samples as having the
disease or not. A customized
array can be constructed to detect the selected biomarkers. In some
embodiments, customized arrays
comprise low density microarrays, which refer to arrays with lower number of
addressable binding agents,
e.g., tens or hundreds instead of thousands. Low density arrays can be formed
on a substrate. In some
embodiments, customizable low density arrays use PCR amplification in plate
wells, e.g., TaqMan0 Gene
Expression Assays (Applied Biosystems by Life Technologies Corporation,
Carlsbad, CA).
[00145] An aptamer of the invention or other useful binding agent may be
linked directly or indirectly to a
solid surface or substrate. A solid surface or substrate can be any physically
separable solid to which a
binding agent can be directly or indirectly attached including, but not
limited to, surfaces provided by
microarrays and wells, particles such as beads, columns, optical fibers,
wipes, glass and modified or
functionalized glass, quartz, mica, diazotized membranes (paper or nylon),
polyformaldehyde, cellulose,
cellulose acetate, paper, ceramics, metals, metalloids, semiconductive
materials, quantum dots, coated
beads or particles, other chromatographic materials, magnetic particles;
plastics (including acrylics,
polystyrene, copolymers of styrene or other materials, polypropylene,
polyethylene, polybutylene,
polyurethanes, Teflon material, etc.), polysaccharides, nylon or
nitrocellulose, resins, silica or silica-based
materials including silicon and modified silicon, carbon, metals, inorganic
glasses, plastics, ceramics,
conducting polymers (including polymers such as polypyrole and polyindole);
micro or nanostructured
surfaces such as nucleic acid tiling arrays, nanotube, nanowire, or
nanoparticulate decorated surfaces; or
porous surfaces or gels such as methacrylates, acrylamides, sugar polymers,
cellulose, silicates, or other
fibrous or stranded polymers. In addition, as is known the art, the substrate
may be coated using passive or
-45-
CA 03018066 2018-09-17
WO 2017/161357 PCT/US2017/023108
chemically-derivatized coatings with any number of materials, including
polymers, such as dextrans,
acrylamides, gelatins or agarose. Such coatings can facilitate the use of the
array with a biological sample.
[00146] An aptamer or other useful binding agent can be conjugated to a
detectable entity or label.
Appropriate labels include without limitation a magnetic label, a fluorescent
moiety, an enzyme, a
chemiluminescent probe, a metal particle, a non-metal colloidal particle, a
polymeric dye particle, a
pigment molecule, a pigment particle, an electrochemically active species,
semiconductor nanocrystal or
other nanoparticles including quantum dots or gold particles, fluorophores,
quantum dots, or radioactive
labels. Protein labels include green fluorescent protein (GFP) and variants
thereof (e.g., cyan fluorescent
protein and yellow fluorescent protein); and luminescent proteins such as
luciferase, as described below.
Radioactive labels include without limitation radioisotopes (radionuclides),
such as 3H, 14C, 18F, 32F,
35s, 64cu, 68Ga, 86-Y,
"Tc, 11J,123I, 1241, 1251, 1311, 133xe, 177Lu, 211
At or 213Bi. Fluorescent labels include
without limitation a rare earth chelate (e.g., europium chelate), rhodamine;
fluorescein types including
without limitation FITC, 5-carboxyfluorescein, 6-carboxy fluorescein; a
rhodamine type including without
limitation TAMRA; dansyl; Lissamine; cyanines; phycoerythrins; Texas Red; Cy3,
Cy5, dapoxyl, NBD,
Cascade Yellow, dansyl, PyMPO, pyrene, 7-diethylaminocoumarin-3-carboxylic
acid and other coumarin
derivatives, Marina BlueTM, Pacific BlueTM, Cascade BlueTM, 2-
anthracenesulfonyl, PyMPO, 3,4,9,10-
perylene-tetracarboxylic acid, 2,7-difluorofluorescein (Oregon GreenTM 488-X),
5-carboxyfluorescein,
Texas RedTm-X, Alexa Fluor 430, 5-carboxytetramethylrhodamine (5-TAMRA), 6-
carboxytetramethylrhodamine (6-TAMRA), BODIPY FL, bimane, and Alexa Fluor 350,
405, 488, 500,
514, 532, 546, 555, 568, 594, 610, 633, 647, 660, 680, 700, and 750, and
derivatives thereof, among many
others. See, e.g., "The Handbook--A Guide to Fluorescent Probes and Labeling
Technologies," Tenth
Edition, available on the internet at probes (dot) invitrogen (dot)
corn/handbook. The fluorescent label can
be one or more of FAM, dRHO, 5-FAM, 6FAM, dR6G, JOE, HEX, VIC, TET, dTAMRA,
TAMRA,
NED, dROX, PET, BHQ, Gold540 and LIZ.
[00147] Using conventional techniques, an aptamer can be directly or
indirectly labeled. In a non-limiting
example, the label is attached to the aptamer through biotin-
streptavidin/avidin chemistry. For example,
synthesize a biotinylated aptamer, which is then capable of binding a
streptavidin molecule that is itself
conjugated to a detectable label; non-limiting example is streptavidin,
phycoerythrin conjugated (SAPE)).
Methods for chemical coupling using multiple step procedures include
biotinylation, coupling of
trinitrophenol (TNP) or digoxigenin using for example succinimide esters of
these compounds.
Biotinylation can be accomplished by, for example, the use of D-biotinyl-N-
hydroxysuccinimide.
Succinimide groups react effectively with amino groups at pH values above 7,
and preferentially between
about pH 8.0 and about pH 8.5. The labeling may comprise a secondary labeling
system. As a non-
limiting example, the aptamer can be conjugated to biotin or digoxigenin.
Target bound aptamer can be
detected using streptavidin/avidin or anti-digoxigenin antibodies,
respectively.
[00148] Various enzyme-substrate labels may also be used in conjunction with a
composition or method
of the invention. Such enzyme-substrate labels are available commercially
(e.g., U.S. Pat. No. 4,275,149).
The enzyme generally catalyzes a chemical alteration of a chromogenic
substrate that can be measured
-46-
CA 03018066 2018-09-17
WO 2017/161357 PCT/US2017/023108
using various techniques. For example, the enzyme may catalyze a color change
in a substrate, which can
be measured spectrophotometrically. Alternatively, the enzyme may alter the
fluorescence or
chemiluminescence of the substrate. Examples of enzymatic labels include
luciferases (e.g., firefly
luciferase and bacterial luciferase; U.S. Pat. No. 4,737,456), luciferin, 2,3-
dihydrophthalazinediones,
malate dehydrogenase, urease, peroxidase such as horseradish peroxidase (HRP),
alkaline phosphatase
(AP), P-galactosidase, glucoamylase, lysozyme, saccharide oxidases (e.g.,
glucose oxidase, galactose
oxidase, and glucose-6-phosphate dehydrogenase), heterocyclic oxidases (such
as unease and xanthine
oxidase), lactoperoxidase, microperoxidase, and the like. Examples of enzyme-
substrate combinations
include, but are not limited to, horseradish peroxidase (HRP) with hydrogen
peroxidase as a substrate,
wherein the hydrogen peroxidase oxidizes a dye precursor (e.g., orthophenylene
diamine (OPD) or
3,3',5,5'-tetramethylbenzidine hydrochloride (TMB)); alkaline phosphatase (AP)
with para-nitrophenyl
phosphate as chromogenic substrate; and P-D-galactosidase (-D-Gal) with a
chromogenic substrate (e.g.,
p-nitrophenyl- P-D-galactosidase) or fluorogenic substrate 4-
methylumbelliferyl-3-D-galactosidase.
[00149] Aptamer(s) can be linked to a substrate such as a planar substrate. A
planar array generally
contains addressable locations (e.g., pads, addresses, or micro-locations) of
biomolecules in an array
format. The size of the array will depend on the composition and end use of
the array. Arrays can be made
containing from 2 different molecules to many thousands. Generally, the array
comprises from two to as
many as 100,000 or more molecules, depending on the end use of the array and
the method of
manufacture. A microarray for use with the invention comprises at least one
biomolecule that identifies or
captures a biomarker present in a biosignature of interest, e.g., a cell,
microRNA or other biomolecule or
vesicle that makes up the biosignature. In some arrays, multiple substrates
are used, either of different or
identical compositions. Accordingly, planar arrays may comprise a plurality of
smaller substrates.
[00150] The present invention can make use of many types of arrays for
detecting a biomarker, e.g., a
biomarker associated with a biosignature of interest. Useful arrays or
microarrays include without
limitation DNA microarrays, such as cDNA microarrays, oligonucleotide
microarrays and SNP
microarrays, microRNA arrays, protein microarrays, antibody microarrays,
tissue microarrays, cellular
microarrays (also called transfection microarrays), chemical compound
microarrays, and carbohydrate
arrays (glycoarrays). These arrays are described in more detail above. In some
embodiments, microarrays
comprise biochips that provide high-density immobilized arrays of recognition
molecules (e.g., aptamers
or antibodies), where biomarker binding is monitored indirectly (e.g., via
fluorescence).
[00151] An array or microarray that can be used to detect a biosignature
comprising one or more aptamers
of the invention can be made according to the methods described in U.S. Pat.
Nos. 6,329,209; 6,365,418;
6,406,921; 6,475,808; and 6,475,809, and U.S. Patent Application Ser. No.
10/884,269, each of which is
herein incorporated by reference in its entirety. Custom arrays to detect
specific can be made using the
methods described in these patents. Commercially available microarrays can
also be used to carry out the
methods of the invention, including without limitation those from Affymetrix
(Santa Clara, CA), Illumina
(San Diego, CA), Agilent (Santa Clara, CA), Exiqon (Denmark), or Invitrogen
(Carlsbad, CA). Custom
-47-
CA 03018066 2018-09-17
WO 2017/161357 PCT/US2017/023108
and/or commercial arrays include arrays for detection proteins, nucleic acids,
and other biological
molecules and entities (e.g., cells, vesicles, virii) as described herein.
[00152] In some embodiments, multiple capture molecules are disposed on an
array, e.g., proteins,
peptides or additional nucleic acid molecules. In certain embodiments, the
proteins are immobilized using
methods and materials that minimize the denaturing of the proteins, that
minimize alterations in the
activity of the proteins, or that minimize interactions between the protein
and the surface on which they
are immobilized. The capture molecules can comprise one or more aptamer of the
invention. In one
embodiment, an array is constructed for the hybridization of a pool of
aptamers. The array can then be
used to identify pool members that bind a sample, thereby facilitating
characterization of a phenotype. See
FIGs. 10B-10C and related disclosure for further details.
[00153] Array surfaces useful may be of any desired shape, form, or size. Non-
limiting examples of
surfaces include chips, continuous surfaces, curved surfaces, flexible
surfaces, films, plates, sheets, or
tubes. Surfaces can have areas ranging from approximately a square micron to
approximately 500 cm2.
The area, length, and width of surfaces may be varied according to the
requirements of the assay to be
performed. Considerations may include, for example, ease of handling,
limitations of the material(s) of
which the surface is formed, requirements of detection systems, requirements
of deposition systems (e.g.,
arrayers), or the like.
[00154] In certain embodiments, it is desirable to employ a physical means for
separating groups or arrays
of binding islands or immobilized biomolecules: such physical separation
facilitates exposure of different
groups or arrays to different solutions of interest. Therefore, in certain
embodiments, arrays are situated
within microwell plates having any number of wells. In such embodiments, the
bottoms of the wells may
serve as surfaces for the formation of arrays, or arrays may be formed on
other surfaces and then placed
into wells. In certain embodiments, such as where a surface without wells is
used, binding islands may be
formed or molecules may be immobilized on a surface and a gasket having holes
spatially arranged so that
they correspond to the islands or biomolecules may be placed on the surface.
Such a gasket is preferably
liquid tight. A gasket may be placed on a surface at any time during the
process of making the array and
may be removed if separation of groups or arrays is no longer desired.
[00155] In some embodiments, the immobilized molecules can bind to one or more
biomarkers present in
a biological sample contacting the immobilized molecules. Contacting the
sample typically comprises
overlaying the sample upon the array.
[00156] Modifications or binding of molecules in solution or immobilized on an
array can be detected
using detection techniques known in the art. Examples of such techniques
include immunological
techniques such as competitive binding assays and sandwich assays;
fluorescence detection using
instruments such as confocal scanners, confocal microscopes, or CCD-based
systems and techniques such
as fluorescence, fluorescence polarization (FP), fluorescence resonant energy
transfer (FRET), total
internal reflection fluorescence (TIRF), fluorescence correlation spectroscopy
(FCS);
colorimetric/spectrometric techniques; surface plasmon resonance, by which
changes in mass of materials
adsorbed at surfaces are measured; techniques using radioisotopes, including
conventional radioisotope
-48-
CA 03018066 2018-09-17
WO 2017/161357 PCT/US2017/023108
binding and scintillation proximity assays (SPA); mass spectroscopy, such as
matrix-assisted laser
desorption/ionization mass spectroscopy (MALDI) and MALDI-time of flight (TOF)
mass spectroscopy;
ellipsometry, which is an optical method of measuring thickness of protein
films; quartz crystal
microbalance (QCM), a very sensitive method for measuring mass of materials
adsorbing to surfaces;
scanning probe microscopies, such as atomic force microscopy (AFM), scanning
force microscopy (SFM)
or scanning electron microscopy (SEM); and techniques such as electrochemical,
impedance, acoustic,
microwave, and IR/Raman detection. See, e.g., Mere L, et al., 'Miniaturized
FRET assays and
microfluidics: key components for ultra-high-throughput screening," Drug
Discovery Today 4(8): 363-369
(1999), and references cited therein; Lakowicz J R, Principles of Fluorescence
Spectroscopy, 2nd Edition,
Plenum Press (1999), or Jain KK: Integrative Omics, Pharmacoproteomics, and
Human Body Fluids. In:
Thongboonkerd V, ed., ed. Proteomics of Human Body Fluids: Principles, Methods
and Applications.
Volume 1: Totowa, Ni: Humana Press, 2007, each of which is herein incorporated
by reference in its
entirety.
[00157] Microarray technology can be combined with mass spectroscopy (MS)
analysis and other tools.
Electrospray interface to a mass spectrometer can be integrated with a
capillary in a microfluidics device.
For example, one commercially available system contains eTag reporters that
are fluorescent labels with
unique and well-defined electrophoretic mobilities; each label is coupled to
biological or chemical probes
via cleavable linkages. The distinct mobility address of each eTag reporter
allows mixtures of these tags
to be rapidly deconvoluted and quantitated by capillary electrophoresis. This
system allows concurrent
gene expression, protein expression, and protein function analyses from the
same sample Jain KK:
Integrative Omics, Pharmacoproteomics, and Human Body Fluids. In:
Thongboonkerd V, ed., ed.
Proteomics of Human Body Fluids: Principles, Methods and Applications. Volume
1: Totowa, NJ:
Humana Press, 2007, which is herein incorporated by reference in its entirety.
[00158] A biochip can include components for a microfluidic or nanofluidic
assay. A microfluidic device
can be used for isolating or analyzing biomarkers, such as determining a
biosignature. Microfluidic
systems allow for the miniaturization and compartmentalization of one or more
processes for detecting a
biosignature, and other processes. The microfluidic devices can use one or
more detection reagents in at
least one aspect of the system, and such a detection reagent can be used to
detect one or more biomarkers.
Various probes, antibodies, proteins, or other binding agents can be used to
detect a biomarker within the
microfluidic system. The detection agents, e.g., oligonucleotide probes of the
invention, may be
immobilized in different compartments of the microfluidic device or be entered
into a hybridization or
detection reaction through various channels of the device.
[00159] Nanofabrication techniques are opening up the possibilities for
biosensing applications that rely
on fabrication of high-density, precision arrays, e.g., nucleotide-based chips
and protein arrays otherwise
known as heterogeneous nanoarrays. Nanofluidics allows a further reduction in
the quantity of fluid
analyte in a microchip to nanoliter levels, and the chips used here are
referred to as nanochips. See, e.g.,
Unger M et al., Biotechniques 1999; 27(5):1008-14, Kartalov EP et al.,
Biotechniques 2006; 40(1):85-90,
each of which are herein incorporated by reference in their entireties.
Commercially available nanochips
-49-
CA 03018066 2018-09-17
WO 2017/161357 PCT/US2017/023108
currently provide simple one step assays such as total cholesterol, total
protein or glucose assays that can
be run by combining sample and reagents, mixing and monitoring of the
reaction. Gel-free analytical
approaches based on liquid chromatography (LC) and nanoLC separations
(Cutillas et al. Proteomics,
2005;5:101-112 and Cutillas etal., Mol Cell Proteomics 2005;4:1038-1051, each
of which is herein
incorporated by reference in its entirety) can be used in combination with the
nanochips.
[00160] An array suitable for identifying a disease, condition, syndrome or
physiological status can be
included in a kit. A kit can include, an aptamer of the invention, including
as non-limiting examples, one
or more reagents useful for preparing molecules for immobilization onto
binding islands or areas of an
array, reagents useful for detecting binding of biomarkers to immobilized
molecules, e.g., aptamers, and
instructions for use.
[00161] Further provided herein is a rapid detection device that facilitates
the detection of a particular
biosignature in a biological sample. The device can integrate biological
sample preparation with
polymerase chain reaction (PCR) on a chip. The device can facilitate the
detection of a particular
biosignature of a vesicle in a biological sample, and an example is provided
as described in Pipper etal.,
Angewandte Chemie, 47(21), p. 3900-3904 (2008), which is herein incorporated
by reference in its
entirety. A biosignature can be incorporated using micro-/nano-electrochemical
system (MEMS/NEMS)
sensors and oral fluid for diagnostic applications as described in Li et al.,
Adv Dent Res 18(1): 3-5 (2005),
which is herein incorporated by reference in its entirety.
[00162] As an alternative to planar arrays, assays using particles, such as
bead based assays are also
capable of use with an aptamer of the invention. Aptamers are easily
conjugated with commercially
available beads. See, e.g., Srinivas etal. Anal. Chem. 2011 Oct. 21, Aptamer
functionalized Microgel
Particles for Protein Detection; See also, review article on aptamers as
therapeutic and diagnostic agents,
Brody and Gold, Rev. Mol. Biotech. 2000, 74:5-13.
[00163] Multiparametric assays or other high throughput detection assays using
bead coatings with
cognate ligands and reporter molecules with specific activities consistent
with high sensitivity automation
can be used. In a bead based assay system, a binding agent such as an antibody
or aptamer can be
immobilized on an addressable microsphere. Each binding agent for each
individual binding assay can be
coupled to a distinct type of microsphere (i.e., microbead) and the assay
reaction takes place on the
surface of the microsphere, such as depicted in FIG. 1B. In a non-limiting
example, a binding agent for a
cell or microvesicle can be a capture antibody or aptamer coupled to a bead.
Dyed microspheres with
discrete fluorescence intensities are loaded separately with their appropriate
binding agent or capture
probes. The different bead sets carrying different binding agents can be
pooled as desired to generate
custom bead arrays. Bead arrays are then incubated with the sample in a single
reaction vessel to perform
the assay.
[00164] Bead-based assays can be used with one or more aptamers of the
invention. A bead substrate can
provide a platform for attaching one or more binding agents, including
aptamer(s). For multiplexing,
multiple different bead sets (e.g., Illumina, Luminex) can have different
binding agents (specific to
different target molecules). For example, a bead can be conjugated to an
aptamer of the invention used to
-50-
CA 03018066 2018-09-17
WO 2017/161357 PCT/US2017/023108
detect the presence (quantitatively or qualitatively) of an antigen of
interest, or it can also be used to
isolate a component present in a selected biological sample (e.g., cell, cell-
fragment or vesicle comprising
the target molecule to which the aptamer is configured to bind or associate).
Any molecule of organic
origin can be successfully conjugated to a polystyrene bead through use of
commercially available kits.
[00165] One or more aptamers of the invention can be used with any bead based
substrate, including but
not limited to magnetic capture method, fluorescence activated cell sorting
(FACS) or laser cytometry.
Magnetic capture methods can include, but are not limited to, the use of
magnetically activated cell sorter
(MACS) microbeads or magnetic columns. Examples of bead or particle based
methods that can be
modified to use an aptamer of the invention include methods and bead systems
described in U.S. Patent
Nos. 4,551,435, 4,795,698, 4,925,788, 5,108,933, 5,186,827, 5,200,084 or
5,158,871; 7,399,632;
8,124,015; 8,008,019; 7,955,802; 7,445,844; 7,274,316; 6,773,812; 6,623,526;
6,599,331; 6,057,107;
5,736,330; International Patent Publication No. WO/2012/174282;
WO/1993/022684.
[00166] Isolation or detection of circulating biomarkers, e.g., protein
antigens, from a biological sample,
or of the biomarker-comprising cells, cell fragments or vesicles may also be
achieved using an aptamer of
the invention in a cytometry process. As a non-limiting example, aptamers of
the invention can be used in
an assay comprising using a particle such as a bead or microsphere. The
invention provides aptamers as
binding agents, which may be conjugated to the particle. Flow cytometry can be
used for sorting
microscopic particles suspended in a stream of fluid. As particles pass
through they can be selectively
charged and on their exit can be deflected into separate paths of flow. It is
therefore possible to separate
populations from an original mix, such as a biological sample, with a high
degree of accuracy and speed.
Flow cytometry allows simultaneous multiparametric analysis of the physical
and/or chemical
characteristics of single cells flowing through an optical/electronic
detection apparatus. A beam of light,
usually laser light, of a single frequency (color) is directed onto a
hydrodynamically focused stream of
fluid. A number of detectors are aimed at the point where the stream passes
through the light beam; one in
line with the light beam (Forward Scatter or FSC) and several perpendicular to
it (Side Scatter or SSC)
and one or more fluorescent detectors.
[00167] Each suspended particle passing through the beam scatters the light in
some way, and fluorescent
chemicals in the particle may be excited into emitting light at a lower
frequency than the light source. This
combination of scattered and fluorescent light is picked up by the detectors,
and by analyzing fluctuations
in brightness at each detector (one for each fluorescent emission peak), it is
possible to deduce various
facts about the physical and chemical structure of each individual particle.
FSC correlates with the cell
size and SSC depends on the inner complexity of the particle, such as shape of
the nucleus, the amount
and type of cytoplasmic granules or the membrane roughness. Some flow
cytometers have eliminated the
need for fluorescence and use only light scatter for measurement.
[00168] Flow cytometers can analyze several thousand particles every second in
"real time" and can
actively separate out and isolate particles having specified properties. They
offer high-throughput
automated quantification, and separation, of the set parameters for a high
number of single cells during
each analysis session. Flow cytometers can have multiple lasers and
fluorescence detectors, allowing
-51-
CA 03018066 2018-09-17
WO 2017/161357 PCT/US2017/023108
multiple labels to be used to more precisely specify a target population by
their phenotype. Thus, a flow
cytometer, such as a multicolor flow cytometer, can be used to detect targets
of interest using multiple
fluorescent labels or colors. In some embodiments, the flow cytometer can also
sort or isolate different
targets of interest, such as by size or by different markers.
[00169] The flow cytometer may have one or more lasers, such as 1, 2, 3, 4, 5,
6, 7, 8, 9, 10 or more
lasers. In some embodiments, the flow cytometer can detect more than one color
or fluorescent label, such
as at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or
20 different colors or fluorescent
labels. For example, the flow cytometer can have at least 2, 3, 4, 5, 6, 7, 8,
9, 10, 11, 12, 13, 14, 15, 16,
17, 18, 19, or 20 fluorescence detectors.
[00170] Examples of commercially available flow cytometers include, but are
not limited to .the MoFloTM
XDP Cell Sorter (Beckman Coulter, Brea, CA), MoFloTM Legacy Cell Sorter
(Beckman Coulter, Brea,
CA), BD FACSAriaTM Cell Sorter (BD Biosciences, San Jose, CA), BDTM LSRII (BD
Biosciences, San
Jose, CA), and BD FACSCaliburTM (BD Biosciences, San Jose, CA). Use of
multicolor or multi-fluor
cytometers can be used in multiplex analysis. In some embodiments, the flow
cytometer can sort, and
thereby collect or sort more than one population of cells, microvesicles, or
particles, based one or more
characteristics. For example, two populations differ in size, such that the
populations have a similar size
range can be differentially detected or sorted. In another embodiment, two
different populations are
differentially labeled.
[00171] The data resulting from flow-cytometers can be plotted in 1 dimension
to produce histograms or
seen in 2 dimensions as dot plots or in 3 dimensions with newer software. The
regions on these plots can
be sequentially separated by a series of subset extractions which are termed
gates. Specific gating
protocols exist for diagnostic and clinical purposes especially in relation to
hematology. The plots are
often made on logarithmic scales. Because different fluorescent dye's emission
spectra overlap, signals at
the detectors have to be compensated electronically as well as
computationally. Fluorophores for labeling
biomarkers may include those described in Ortnerod, Flow Cytome try 2nd ed.,
Springer-Verlag, New
York (1999), and in Nida et al., Gynecologic Oncology 2005;4 889-894 which is
incorporated herein by
reference. In a multiplexed assay, including but not limited to a flow
cytometry assay, one or more
different target molecules can be assessed using an aptamer of the invention.
[00172] One or more aptamer of the invention can be disposed on any useful
planar or bead substrate. In
one aspect of the invention one or more aptamer of the invention is disposed
on a microfluidic device,
thereby facilitating assessing, characterizing or isolating a component of a
biological sample comprising a
polypeptide antigen of interest or a functional fragment thereof For example,
the circulating antigen or a
cell, cell fragment or cell-derived microvesicles comprising the antigen can
be assessed using one or more
aptamers of the invention (alternatively along with additional binding
agents). Microfluidic devices,
which may also be referred to as "lab-on-a-chip" systems, biomedical micro-
electro-mechanical systems
(bioMEMs), or multicomponent integrated systems, can be used for isolating and
analyzing such entities.
Such systems miniaturize and compartmentalize processes that allow for
detection of biosignatures and
other processes.
-52-
CA 03018066 2018-09-17
WO 2017/161357 PCT/US2017/023108
1001731A microfluidic device can also be used for isolation of a cell, cell
fragment or cell-derived
microvesicles through size differential or affinity selection. For example, a
microfluidic device can use
one more channels for isolating entities from a biological sample based on
size or by using one or more
binding agents. A biological sample can be introduced into one or more
microfluidic channels, which
selectively allows the passage of the entity. The selection can be based on a
property such as the size,
shape, deformability, or biosignature.
[00174] In one embodiment, a heterogeneous population of cells, cell
fragments, microvesicles or other
biomarkers (e.g., protein complexes) is introduced into a microfluidic device,
and one or more different
homogeneous populations of such entities can be obtained. For example,
different channels can have
different size selections or binding agents to select for different
populations of such entities. Thus, a
microfluidic device can isolate a plurality of entities wherein at least a
subset of the plurality comprises a
different biosignature from another subset of the plurality. For example, the
microfluidic device can
isolate at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 40, 50, 60, 70,
80, 90, or 100 different subsets,
wherein each subset comprises a different biosignature.
1001751111 some embodiments, the microfluidic device can comprise one or more
channels that permit
further enrichment or selection of targets of interest. A population that has
been enriched after passage
through a first channel can be introduced into a second channel, which allows
the passage of the desired
population to be further enriched, such as through one or more binding agents
present in the second
channel.
[00176] Array-based assays and bead-based assays can be used with a
microfluidic device. For example,
the binding agent, such as an oligonucleotide probe, can be coupled to beads
and the binding reaction
between the beads and targets of the binding agent can be performed in a
microfluidic device.
Multiplexing can also be performed using a microfluidic device. Different
compartments can comprise
different binding agents for different target populations. In one embodiment,
each population has a
different biosignature. The hybridization reaction between the microsphere and
target can be performed in
a microfluidic device and the reaction mixture can be delivered to a detection
device. The detection
device, such as a dual or multiple laser detection system can be part of the
microfluidic system and can
use a laser to identify each bead or microsphere by its color-coding, and
another laser can detect the
hybridization signal associated with each bead.
[00177] Any appropriate microfluidic device can be used in the methods of the
invention. Examples of
microfluidic devices that may be used include but are not limited to those
described in U.S. Pat. Nos.
7,591,936, 7,581,429, 7,579,136, 7,575,722, 7,568,399, 7,552,741, 7,544,506,
7,541,578, 7,518,726,
7,488,596, 7,485,214, 7,467,928, 7,452,713, 7,452,509, 7,449,096, 7,431,887,
7,422,725, 7,422,669,
7,419,822, 7,419,639, 7,413,709, 7,411,184, 7,402,229, 7,390,463, 7,381,471,
7,357,864, 7,351,592,
7,351,380, 7,338,637, 7,329,391, 7,323,140, 7,261,824, 7,258,837, 7,253,003,
7,238,324, 7,238,255,
7,233,865, 7,229,538, 7,201,881, 7,195,986, 7,189,581, 7,189,580, 7,189,368,
7,141,978, 7,138,062,
7,135,147, 7,125,711, 7,118,910, 7,118,661, 7,640,947, 7,666,361, 7,704,735;
and International Patent
Publication WO 2010/072410; each of which patents or applications are
incorporated herein by reference
-53-
CA 03018066 2018-09-17
WO 2017/161357 PCT/US2017/023108
in their entirety. Another example for use with methods disclosed herein is
described in Chen etal.,
`Microfluidic isolation and transcriptome analysis of serum vesicles," Lab on
a chip, Dec. 8, 2009 DOI:
10.1039/b916199f.
[00178] Other microfluidic devices for use with the invention include devices
comprising elastomeric
layers, valves and pumps, including without limitation those disclosed in U.S.
Patent Nos. 5,376,252,
6,408,878, 6,645,432, 6,719,868, 6,793,753, 6,899,137, 6,929,030, 7,040,338,
7,118,910, 7,144,616,
7,216,671, 7,250,128, 7,494,555, 7,501,245, 7,601,270, 7,691,333, 7,754,010,
7,837,946; U.S. Patent
Application Nos. 2003/0061687, 2005/0084421, 2005/0112882, 2005/0129581,
2005/0145496,
2005/0201901, 2005/0214173, 2005/0252773, 2006/0006067; and EP Patent Nos.
0527905 and 1065378;
each of which application is herein incorporated by reference..
[00179] The microfluidic device can have one or more binding agents attached
to a surface in a channel,
or present in a channel. For example, the microchannel can have one or more
capture agents, such as an
oligonucleotide probe of the invention. The surface of the channel can also be
contacted with a blocking
aptamer if desired. In one embodiment, a microchannel surface is treated with
avidin/streptavidin and a
capture agent, such as an antibody or aptamer, that is biotinylated can be
injected into the channel to bind
the avidin. In other embodiments, the capture agents are present in chambers
or other components of a
microfluidic device. The capture agents can also be attached to beads that can
be manipulated to move
through the microfluidic channels. In one embodiment, the capture agents are
attached to magnetic beads.
The beads can be manipulated using magnets.
[00180] A biological sample can be flowed into the microfluidic device, or a
microchannel, at rates such
as at least about 1,2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17,
18, 19, 20, 25, 30, 35, 40, 45, or 50
[11 per minute, such as between about 1-50, 5-40, 5-30, 3-20 or 5-15 .1 per
minute. One or more targets of
interest can be captured and directly detected in the microfluidic device.
Alternatively, the captured target
may be released and exit the microfluidic device prior to analysis. In another
embodiment, one or more
captured cells or microvesicles are lysed in the microchannel and the lysate
can be analyzed. Lysis buffer
can be flowed through the channel. The lysate can be collected and analyzed,
such as performing RT-
PCR, PCR, mass spectrometry, Western blotting, or other assays, to detect one
or more biomarkers of the
captured cells or microvesicles.
[00181] Microvesicles and related biomarkers can be analyzed using the
oligonucleotide probes of the
invention. Microvesicle isolation can be performed using various techniques
as, including without
limitation size exclusion chromatography, density gradient centrifugation,
differential centrifugation,
nanomembrane ultrafiltration, immunoabsorbent capture, affinity purification,
affinity capture,
immunoassay, immunoprecipitation, microfluidic separation, flow cytometry,
polymeric isolation (e.g.,
using polyethylene glycol (PEG)) or combinations thereof. Methods and
techniques for microvesicle and
vesicular payload isolation and analysis are disclosed in International Patent
Application Nos.
PCT/US2009/62880, filed October 30, 2009; PCT/US2009/006095, filed November
12, 2009;
PCT/US2011/26750, filed March 1, 2011; PCT/US2011/031479, filed April 6, 2011;
PCT/US11/48327,
filed August 18, 2011; PCT/US2008/71235, filed July 25, 2008; PCT/US10/58461,
filed November 30,
-54-
CA 03018066 2018-09-17
WO 2017/161357 PCT/US2017/023108
2010; PCT/US2011/21160, filed January 13, 2011; PCT/US2013/030302, filed March
11,2013;
PCT/US12/25741, filed February 17, 2012; PCT/2008/76109, filed September 12,
2008;
PCT/US12/42519, filed June 14, 2012; PCT/US12/50030, filed August 8, 2012;
PCT/U512/49615, filed
August 3, 2012; PCT/US12/41387, filed June 7,2012; PCT/U52013/072019, filed
November 26, 2013;
PCT/U52014/039858, filed May 28, 2013; PCT/IB2013/003092, filed October 23,
2013;
PCT/US13/76611, filed December 19, 2013; PCT/US14/53306, filed August 28,
2014; and
PCT/US15/62184, filed November 23, 2015; PCT/U516/40157, filed June 29, 2016;
PCT/US16/44595,
filed July 28, 2016; and PCT/US16/21632, filed March 9, 2016; each of which
applications is
incorporated herein by reference in its entirety.
[00182] The compositions and methods of the invention can be used in and with
various immune assay
formats. Immunoaffinity assays can be based on antibodies and aptamers
selectively immunoreactive with
proteins or other biomarkers of interest. These techniques include without
limitation immunoprecipitation,
Western blot analysis, molecular binding assays, enzyme-linked immunosorbent
assay (ELISA), enzyme-
linked immunofiltration assay (ELIFA), fluorescence activated cell sorting
(FACS),
immunohistochemistry (IHC) and the like. For example, an optional method of
detecting the expression of
a biomarker in a sample comprises contacting the sample with an antibody or
aptamer against the
biomarker, or an immunoreactive fragment thereof, or a recombinant protein
containing an antigen
binding region against the biomarker; and then detecting the binding of the
biomarker in the sample.
Various methods for producing antibodies and aptamers are known in the art.
Such binding agents can be
used to immunoprecipitate specific proteins from solution samples or to
immunoblot proteins separated
by, e.g., polyacrylamide gels. Immunocytochemical methods can also be used in
detecting specific protein
polymorphisms in tissues or cells. Other well-known immunoassay techniques can
also be used including,
e.g., ELISA, radioimmunoassay (RIA), immunoradiometric assays (IRMA) and
immunoenzymatic assays
(IEMA), including sandwich assays. See, e.g., U.S. Pat. Nos. 4,376,110 and
4,486,530, both of which are
incorporated herein by reference.
[00183] In alternative methods, a sample may be contacted with an antibody or
aptamer specific for a
biomarker under conditions sufficient for a complex to form, and then
detecting such complex. The
presence of the biomarker may be detected in a number of ways, such as by
Western blotting and ELISA
procedures for assaying a wide variety of tissues and samples, including
bodily fluids such as plasma or
serum. A wide range of immunoassay techniques using such an assay format are
available, see, e.g., U.S.
Pat. Nos. 4,016,043, 4,424,279 and 4,018,653. These include both single-site
and two-site or "sandwich"
assays of the non-competitive types, as well as in the traditional competitive
binding assays. These assays
also include direct binding of a labelled antibody or aptamer to a target
biomarker.
[00184] There are a number of variations of the sandwich assay technique which
can be encompassed
within the present invention. In a typical forward assay, an unlabeled binding
agent, e.g., an antibody or
aptamer, is immobilized on a solid substrate, and the sample to be tested
brought into contact with the
bound molecule. After a suitable period of of time sufficient to allow
formation of an complex, a second
binding agent specific to the antigen, labelled with a reporter molecule
capable of producing a detectable
-55-
CA 03018066 2018-09-17
WO 2017/161357 PCT/US2017/023108
signal is then added and incubated, allowing time sufficient for the formation
of another complex
comprising the labelled binding agent. Any unreacted material is washed away,
and the presence of the
antigen is determined by observation of a signal produced by the reporter
molecule. The results may either
be qualitative, by simple observation of the visible signal, or may be
quantitated by comparing with a
control sample containing known amounts of biomarker.
[00185] Variations on the above assay include a simultaneous assay, in which
both sample and labelled
binding agent are added simultaneously to the tethered binding agent. In a
typical forward sandwich
assay, a first binding agent, e.g., an antibody or aptamer, having specificity
for a tissue/cell/biomarker or
such target of interest is either covalently or passively bound to a solid
surface. The solid surface is
typically glass or a polymer, the most commonly used polymers being cellulose,
polyacrylamide, nylon,
polystyrene, polyvinyl chloride or polypropylene. The solid supports may be in
the form of tubes, beads,
discs of microplates, or any other surface suitable for conducting an
immunoassay. The binding processes
generally consist of cross-linking, covalently binding or physically
adsorbing, the polymer-antibody
complex to the support, which is then washed in preparation for the test
sample. An aliquot of the sample
to be tested is then added to the solid phase complex and incubated for a
period of time sufficient (e.g., 2-
40 minutes or overnight) and under suitable conditions (e.g. ,from room
temperature to 40 C such as
between 25 C and 32 C inclusive) to allow binding of the target to the
support. Following the incubation
period, the support is washed and incubated with a second binding agent
specific for a portion of the
biomarker. The second binding agent is linked to a reporter molecule which is
used to indicate the binding
of the second binding agent to the molecular marker.
[00186] An alternative method involves immobilizing the target biomarkers in
the sample and then
exposing the immobilized target to specific binding agents, e.g., antibodies
or aptamers, which may or
may not be labelled with a reporter molecule. Depending on the amount of
target and the strength of the
reporter molecule signal, a bound target may be detectable by direct labelling
with the binding agent.
Alternatively, a second labelled binding agent, specific to the first binding
agent, is exposed to the first
target complex to form a tertiary complex. The complex is detected by the
signal emitted by the reporter
molecule. A "reporter molecule" includes molecule which, by its chemical
nature, provides an analytically
identifiable signal which allows the detection of antigen-bound complexes.
Some commonly used reporter
molecules in this type of assay include enzymes, fluorophores or radionuclide
containing molecules (i.e.
radioisotopes) and chemiluminescent molecules. Examples of such detectable
labels are disclosed herein.
[00187] In the case of an enzyme immunoassay, an enzyme is conjugated to the
secondary binding agent.
Commonly used enzymes include horseradish peroxidase, glucose oxidase,13-
galactosidase and alkaline
phosphatase, amongst others. The substrates to be used with the specific
enzymes are generally chosen for
the production, upon hydrolysis by the corresponding enzyme, of a detectable
color change. Examples of
suitable enzymes include alkaline phosphatase and peroxidase. It is also
possible to employ fluorogenic
substrates, which yield a fluorescent product rather than the chromogenic
substrates noted above. In all
cases, the enzyme-labelled binding agent is added to the first bound molecular
marker complex, allowed
to bind, and then the excess reagent is washed away. A solution containing the
appropriate substrate is
-56-
CA 03018066 2018-09-17
WO 2017/161357 PCT/US2017/023108
then added to the tertiary complex comprising primary binding agent, antigen,
and secondary binding
agent. The substrate will react with the enzyme linked to the secondary
binding agent, giving a qualitative
visual signal, which may be further quantitated, usually
spectrophotometrically, to give an indication of
the amount of antigen which was present in the sample. Alternately,
fluorescent compounds, such as
fluorescein and rhodamine, may be chemically coupled to secondary binding
agent without altering their
binding capacity. When activated by illumination with light of a particular
wavelength, the fluorochrome-
labelled secondary binding agent adsorbs the light energy, inducing a state to
excitability in the molecule,
followed by emission of the light at a characteristic color visually
detectable with a light microscope. As
in the ETA, the fluorescent labelled secondary binding agent is allowed to
bind to antigen complex. After
washing off the unbound reagent, the remaining tertiary complex is then
exposed to the light of the
appropriate wavelength. The fluorescence observed indicates the presence of
the molecular marker of
interest. Immunofluorescence and ETA techniques are both very well established
in the art. However,
other reporter molecules, such as radioisotope, chemiluminescent or
bioluminescent molecules, may also
be employed.
[00188] Immunohistorchemistry (IHC) is a process of localizing antigens (e.g.,
proteins) in cells of a
tissue using binding agents (e.g., antibodies or aptamers) specifically to
antigens in the tissues. The
antigen-binding binding agent can be conjugated or fused to a tag that allows
its detection, e.g., via
visualization. In some embodiments, the tag is an enzyme that can catalyze a
color-producing reaction,
such as alkaline phosphatase or horseradish peroxidase. The enzyme can be
fused to the binding agent or
non-covalently bound, e.g., using a biotin-avadin/streptavidin system.
Alternatively, the binding agent can
be tagged with a fluorophore, such as fluorescein, rhodamine, DyLight Fluor or
Alexa Fluor. The binding
agent can be directly tagged or it can itself be recognized by a secondary
detection binding agent
(antibody or antigen) that carries the tag. Using IHC, one or more proteins
may be detected. The
expression of a gene product can be related to its staining intensity compared
to control levels. In some
embodiments, the gene product is considered differentially expressed if its
staining varies at least 1.2, 1.3,
1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2.0, 2.2, 2.5, 2.7, 3.0, 4, 5, 6, 7, 8, 9 or 10-
fold in the sample versus the control.
[00189] IHC comprises the application of such immunoassay formats to
histochemical techniques. In an
illustrative example, a tissue section is mounted on a slide and is incubated
with a binding agent. The
binding agents are typically polyclonal or monoclonal antibodies, and can be
aptamers such as
oligonucleotide probes of the invention, specific to the antigen. The primary
reaction comprises
contacting the tissue section with this primary binding agent, forming primary
complexes. The antigen-
antibody signal is then amplified using a second binding agent conjugated to a
complex of that can
provide a visible signal, such as enzymes including without limitation
peroxidase antiperoxidase (PAP),
avidin-biotin-peroxidase (ABC) or avidin-biotin alkaline phosphatase. In the
presence of substrate and
chromogen, the enzyme forms a colored deposit at the sites of primary
complexes. Immunofluorescence is
an alternate approach to visualize antigens. In this technique, the primary
signal is amplified using a
second binding agent conjugated to a fluorochrome. On UV light absorption, the
fluorochrome emits its
own light at a longer wavelength (fluorescence), thus allowing localization of
the primary complexes.
-57-
CA 03018066 2018-09-17
WO 2017/161357 PCT/US2017/023108
[00190] The invention provides methods of performing an IHC assay using an
oligonucleotide probe
library. This may be referred to as a polyligand histochemistry assay (PHC).
As an example of this
approach, a tissue section is contacted with an enriched oligonucleotide probe
library. Members of the
library can be labeled, e.g., with a biotin molecule, digoxigenin, or other
label as appropriate. The bound
library members are visualized using a secondary labeling system, e.g.,
streptavidin-horse radish
peroxidase (SA-HRP) or anti-digoxigenin horse radish peroxidase. The resulting
slides can be read and
scored as in typical antibody based IHC methods. See Examples 19-31 herein.
Oligonucleotide Probes / Aptamers
[00191] Aptamers have a number of desirable characteristics for use as
therapeutics and diagnostics
including high specificity and affinity, biological efficacy, and excellent
pharmacokinetic properties. In
addition, they offer certain advantages over antibodies and other protein
biologics. For example, aptamers
are produced by an entirely in vitro process, allowing for the rapid
synthesis. In vitro selection allows the
specificity and affinity of the aptamer to be tightly controlled. In addition,
aptamers as a class have
demonstrated little or no toxicity or immunogenicity. Whereas the efficacy of
many monoclonal
antibodies can be severely limited by immune response to antibodies
themselves, it is difficult to elicit
antibodies to aptamers most likely because aptamers cannot be presented by T-
cells via the MHC and the
immune response is generally trained not to recognize nucleic acid fragments.
Whereas most currently
approved antibody therapeutics are administered by intravenous infusion
(typically over 2-4 hours),
aptamers can be administered by subcutaneous injection. This difference is
primarily due to the
comparatively low solubility and thus large volumes necessary for most
therapeutic mAbs. With good
solubility (>150 mg/mL) and comparatively low molecular weight (aptamer: 10-50
kDa; antibody: 150
kDa), a weekly dose of aptamer may be delivered by injection in a volume of
less than 0.5 mL. In
addition, the small size of aptamers allows them to penetrate into areas of
conformational constrictions
that do not allow for antibodies or antibody fragments to penetrate,
presenting yet another advantage of
aptamer-based therapeutics or prophylaxis.
[00192] Aptamers are chemically synthesized and are readily scaled as needed
to meet production demand
for diagnostic or therapeutic applications. In addition, aptamers are
chemically robust. They can be
adapted to regain activity following exposure to factors such as heat and
denaturants and can be stored for
extended periods (>1 yr) at room temperature as lyophilized powders.
[00193] SELEX
[00194] The classical method for generating an aptamer is with the process
entitled "Systematic Evolution
of Ligands by Exponential Enrichment" ("SELEX") generally described in, e.g.,
U.S. patent application
Ser. No. 07/536,428, filed Jun. 11, 1990, now abandoned, U.S. Pat. No.
5,475,096 entitled "Nucleic Acid
Ligands", and U.S. Pat. No. 5,270,163 (see also WO 91/19813) entitled "Nucleic
Acid Ligands." Each
SELEX-identified nucleic acid ligand, i.e., each aptamer (or oligonucleotide
probe), is a specific ligand of
a given target compound or molecule. The SELEX process is based on the insight
that nucleic acids have
sufficient capacity for forming a variety of two- and three-dimensional
structures and sufficient chemical
versatility available within their monomers to act as ligands (i.e., form
specific binding pairs) with any
-58-
CA 03018066 2018-09-17
WO 2017/161357 PCT/US2017/023108
variety of chemical compounds, whether monomeric or polymeric. Molecules of
any size or composition
can serve as targets.
[00195] SELEX relies as a starting point upon a large library or pool of
single stranded oligonucleotides
comprising randomized sequences. The oligonucleotides can be modified or
unmodified DNA, RNA, or
DNA/RNA hybrids. In some examples, the pool comprises 100% random or partially
random
oligonucleotides. In other examples, the pool comprises random or partially
random oligonucleotides
containing at least one fixed and/or conserved sequence incorporated within
randomized sequence. In
other examples, the pool comprises random or partially random oligonucleotides
containing at least one
fixed and/or conserved sequence at its 5' and/or 3' end which may comprise a
sequence shared by all the
molecules of the oligonucleotide pool. Fixed sequences are sequences such as
hybridization sites for PCR
primers, promoter sequences for RNA polymerases (e.g., T3, T4, T7, and SP6),
restriction sites, or
homopolymeric sequences, such as poly A or poly T tracts, catalytic cores,
sites for selective binding to
affinity columns, and other sequences to facilitate cloning and/or sequencing
of an oligonucleotide of
interest. Conserved sequences are sequences, other than the previously
described fixed sequences, shared
by a number of aptamers that bind to the same target.
[00196] The oligonucleotides of the pool preferably include a randomized
sequence portion as well as
fixed sequences necessary for efficient amplification. Typically the
oligonucleotides of the starting pool
contain fixed 5' and 3' terminal sequences which flank an internal region of
30-50 random nucleotides.
The randomized nucleotides can be produced in a number of ways including
chemical synthesis and size
selection from randomly cleaved cellular nucleic acids. Sequence variation in
test nucleic acids can also
be introduced or increased by mutagenesis before or during the
selection/amplification iterations.
[00197] The random sequence portion of the oligonucleotide can be of any
appropriate length and can
comprise ribonucleotides and/or deoxyribonucleotides and can include modified
or non-natural
nucleotides or nucleotide analogs. See, e.g. U.S. Pat. No. 5,958,691; U.S.
Pat. No. 5,660,985; U.S. Pat.
No. 5,958,691; U.S. Pat. No. 5,698,687; U.S. Pat. No. 5,817,635; U.S. Pat. No.
5,672,695, and PCT
Publication WO 92/07065. Random oligonucleotides can be synthesized from
phosphodiester-linked
nucleotides using solid phase oligonucleotide synthesis techniques well known
in the art. See, e.g.,
Froehler et al., Nucl. Acid Res. 14:5399-5467 (1986) and Froehler et al., Tet.
Lett. 27:5575-5578 (1986).
Random oligonucleotides can also be synthesized using solution phase methods
such as triester synthesis
methods. See, e.g., Sood et al., Nucl. Acid Res. 4:2557 (1977) and Hirose et
al., Tet. Lett., 28:2449
(1978). Typical syntheses carried out on automated DNA synthesis equipment
yield 1014-1016 individual
molecules, a number sufficient for most SELEX experiments. Sufficiently large
regions of random
sequence in the sequence design increases the likelihood that each synthesized
molecule is likely to
represent a unique sequence.
[00198] The starting library of oligonucleotides may be generated by automated
chemical synthesis on a
DNA synthesizer. To synthesize randomized sequences, mixtures of all four
nucleotides are added at each
nucleotide addition step during the synthesis process, allowing for random
incorporation of nucleotides.
As stated above, in one embodiment, random oligonucleotides comprise entirely
random sequences;
-59-
CA 03018066 2018-09-17
WO 2017/161357 PCT/US2017/023108
however, in other embodiments, random oligonucleotides can comprise stretches
of nonrandom or
partially random sequences. Partially random sequences can be created by
adding the four nucleotides in
different molar ratios at each addition step.
[00199] The starting library of oligonucleotides may be for example, RNA, DNA,
or RNA/DNA hybrid. A
starting RNA library can be generated by transcribing a DNA library in vitro
using T7 RNA polymerase
or modified T7 RNA polymerases and purified. The library is then mixed with
the target under conditions
favorable for binding and subjected to step-wise iterations of binding,
partitioning and amplification,
using the same general selection scheme, to achieve virtually any desired
criterion of binding affinity and
selectivity. More specifically, starting with a mixture containing the
starting pool of nucleic acids, the
SELEX method includes steps of: (a) contacting the mixture with the target
under conditions favorable for
binding; (b) partitioning unbound nucleic acids from those nucleic acids which
have bound specifically to
target molecules; (c) dissociating the nucleic acid-target complexes; (d)
amplifying the nucleic acids
dissociated from the nucleic acid-target complexes to yield a ligand-enriched
mixture of nucleic acids; and
(e) reiterating the steps of binding, partitioning, dissociating and
amplifying through as many cycles as
desired to yield highly specific, high affinity nucleic acid ligands to the
target molecule. In those instances
where RNA aptamers are being selected, the SELEX method further comprises the
steps of: (i) reverse
transcribing the nucleic acids dissociated from the nucleic acid-target
complexes before amplification in
step (d); and (ii) transcribing the amplified nucleic acids from step (d)
before restarting the process.
[00200] Within a nucleic acid mixture containing a large number of possible
sequences and structures,
there is a wide range of binding affinities for a given target. A nucleic acid
mixture comprising, for
example, a 20 nucleotide randomized segment can have 420 candidate
possibilities. Those which have the
higher affinity constants for the target are most likely to bind to the
target. After partitioning, dissociation
and amplification, a second nucleic acid mixture is generated, enriched for
the higher binding affinity
candidates. Additional rounds of selection progressively favor better ligands
until the resulting nucleic
acid mixture is predominantly composed of only one or a few sequences. These
can then be cloned,
sequenced and individually tested for binding affinity as pure ligands or
aptamers.
[00201] Cycles of selection and amplification are repeated until a desired
goal is achieved. In the most
general case, selection/amplification is continued until no significant
improvement in binding strength is
achieved on repetition of the cycle. The method is typically used to sample
approximately 10" different
nucleic acid species but may be used to sample as many as about 1018 different
nucleic acid species.
Generally, nucleic acid aptamer molecules are selected in a 5 to 20 cycle
procedure. In one embodiment,
heterogeneity is introduced only in the initial selection stages and does not
occur throughout the
replicating process.
[00202] In one embodiment of SELEX, the selection process is so efficient at
isolating those nucleic acid
ligands that bind most strongly to the selected target, that only one cycle of
selection and amplification is
required. Such an efficient selection may occur, for example, in a
chromatographic-type process wherein
the ability of nucleic acids to associate with targets bound on a column
operates in such a manner that the
column is sufficiently able to allow separation and isolation of the highest
affinity nucleic acid ligands.
-60-
CA 03018066 2018-09-17
WO 2017/161357 PCT/US2017/023108
[00203] In many cases, it is not necessarily desirable to perform the
iterative steps of SELEX until a single
nucleic acid ligand is identified. The target-specific nucleic acid ligand
solution may include a family of
nucleic acid structures or motifs that have a number of conserved sequences
and a number of sequences
which can be substituted or added without significantly affecting the affinity
of the nucleic acid ligands to
the target. By terminating the SELEX process prior to completion, it is
possible to determine the sequence
of a number of members of the nucleic acid ligand solution family. The
invention provides for the
identification of aptamer pools and uses thereof that jointly can be used to
characterize a test sample. For
example, the aptamer pools can be identified through rounds of positive and
negative selection to identify
cells, tissue or microvesicles indicative of a disease or condition. The
invention further provides use of
such aptamer pools to stain, detect and/or quantify such cells, tissue or
microvesicles in a sample, thereby
allowing a diagnosis, prognosis or theranosis to be provided.
[00204] A variety of nucleic acid primary, secondary and tertiary structures
are known to exist. The
structures or motifs that have been shown most commonly to be involved in non-
Watson-Crick type
interactions are referred to as hairpin loops, symmetric and asymmetric
bulges, pseudoknots and myriad
combinations of the same. Such motifs can typically be formed in a nucleic
acid sequence of no more than
30 nucleotides. For this reason, it is often preferred that SELEX procedures
with contiguous randomized
segments be initiated with nucleic acid sequences containing a randomized
segment of between about 20
to about 50 nucleotides and in some embodiments, about 30 to about 40
nucleotides. In one example, the
5'-fixed:random:31-fixed sequence comprises a random sequence of about 30 to
about 50 nucleotides. The
random region may be referred to as the variable region herein.
[00205] The core SELEX method has been modified to achieve a number of
specific objectives. For
example, U.S. Pat. No. 5,707,796 describes the use of SELEX in conjunction
with gel electrophoresis to
select nucleic acid molecules with specific structural characteristics, such
as bent DNA. U.S. Pat. No.
5,763,177 describes SELEX based methods for selecting nucleic acid ligands
containing photoreactive
groups capable of binding and/or photocrosslinking to and/or photoinactivating
a target molecule. U.S.
Pat. No. 5,567,588 and U.S. Pat. No. 5,861,254 describe SELEX based methods
which achieve highly
efficient partitioning between oligonucleotides having high and low affinity
for a target molecule. U.S.
Pat. No. 5,496,938 describes methods for obtaining improved nucleic acid
ligands after the SELEX
process has been performed. U.S. Pat. No. 5,705,337 describes methods for
covalently linking a ligand to
its target.
[00206] SELEX can also be used to obtain nucleic acid ligands that bind to
more than one site on the
target molecule, and to obtain nucleic acid ligands that include non-nucleic
acid species that bind to
specific sites on the target. SELEX provides means for isolating and
identifying nucleic acid ligands
which bind to any envisionable target, including large and small biomolecules
such as nucleic acid-
binding proteins and proteins not known to bind nucleic acids as part of their
biological function as well
as lipids, cofactors and other small molecules. For example, U.S. Pat. No.
5,580,737 discloses nucleic acid
sequences identified through SELEX which are capable of binding with high
affinity to caffeine and the
closely related analog, theophylline.
-61-
CA 03018066 2018-09-17
WO 2017/161357 PCT/US2017/023108
[00207] Counter-SELEX is a method for improving the specificity of nucleic
acid ligands to a target
molecule by eliminating nucleic acid ligand sequences with cross-reactivity to
one or more non-target
molecules. Counter-SELEX is comprised of the steps of: (a) preparing a
candidate mixture of nucleic
acids; (b) contacting the candidate mixture with the target, wherein nucleic
acids having an increased
affinity to the target relative to the candidate mixture may be partitioned
from the remainder of the
candidate mixture; (c) partitioning the increased affinity nucleic acids from
the remainder of the candidate
mixture; (d) dissociating the increased affinity nucleic acids from the
target; e) contacting the increased
affinity nucleic acids with one or more non-target molecules such that nucleic
acid ligands with specific
affinity for the non-target molecule(s) are removed; and (f) amplifying the
nucleic acids with specific
affinity only to the target molecule to yield a mixture of nucleic acids
enriched for nucleic acid sequences
with a relatively higher affinity and specificity for binding to the target
molecule. As described above for
SELEX, cycles of selection and amplification are repeated until a desired goal
is achieved.
[00208] A potential problem encountered in the use of nucleic acids as
therapeutics and vaccines is that
oligonucleotides in their phosphodiester form may be quickly degraded in body
fluids by intracellular and
extracellular enzymes such as endonucleases and exonucleases before the
desired effect is manifest. The
SELEX method thus encompasses the identification of high-affinity nucleic acid
ligands containing
modified nucleotides conferring improved characteristics on the ligand, such
as improved in vivo stability
or improved delivery characteristics. Examples of such modifications include
chemical substitutions at the
ribose and/or phosphate and/or base positions. SELEX identified nucleic acid
ligands containing modified
nucleotides are described, e.g., in U.S. Pat. No. 5,660,985, which describes
oligonucleotides containing
nucleotide derivatives chemically modified at the 2' position of ribose, 5'
position of pyrimidines, and 8'
position of purines, U.S. Pat. No. 5,756,703 which describes oligonucleotides
containing various 2'-
modified pyrimidines, and U.S. Pat. No. 5,580,737 which describes highly
specific nucleic acid ligands
containing one or more nucleotides modified with 2'-amino (21--NH2), 2'-fluoro
(2'-F), and/or 21-0-methyl
(2'-0Me) substituents.
[00209] Modifications of the nucleic acid ligands contemplated in this
invention include, but are not
limited to, those which provide other chemical groups that incorporate
additional charge, polarizability,
hydrophobicity, hydrogen bonding, electrostatic interaction, and fluxionality
to the nucleic acid ligand
bases or to the nucleic acid ligand as a whole. Modifications to generate
oligonucleotide populations
which are resistant to nucleases can also include one or more substitute
internucleotide linkages, altered
sugars, altered bases, or combinations thereof Such modifications include, but
are not limited to, 2'-
position sugar modifications, 5-position pyrimidine modifications, 8-position
purine modifications,
modifications at exocyclic amines, substitution of 4-thiouridine, substitution
of 5-bromo or 5-iodo-uracil;
backbone modifications, phosphorothioate or ally' phosphate modifications,
methylations, and unusual
base-pairing combinations such as the isobases isocytidine and isoguanosine.
Modifications can also
include 3' and 5' modifications such as capping.
[00210] In one embodiment, oligonucleotides are provided in which the P(0)0
group is replaced by
P(0)S ("thioate"), P(S)S ("dithioate"), P(0)NR2 ("amidate"), P(0)R, P(0)OR',
CO or CH2 ("formacetal")
-62-
CA 03018066 2018-09-17
WO 2017/161357 PCT/US2017/023108
or 3'-amine (--NH--CH2--CH2--), wherein each R or R' is independently H or
substituted or unsubstituted
alkyl. Linkage groups can be attached to adjacent nucleotides through an --0--
, --N--, or --S-- linkage. Not
all linkages in the oligonucleotide are required to be identical. As used
herein, the term phosphorothioate
encompasses one or more non-bridging oxygen atoms in a phosphodiester bond
replaced by one or more
sulfur atoms.
[00211] In further embodiments, the oligonucleotides comprise modified sugar
groups, for example, one
or more of the hydroxyl groups is replaced with halogen, aliphatic groups, or
functionalized as ethers or
amines. In one embodiment, the 2'-position of the furanose residue is
substituted by any of an 0-methyl,
0-alkyl, 0-allyl, S-alkyl, S-allyl, or halo group. Methods of synthesis of 2-
modified sugars are described,
e.g., in Sproat, et al., Nucl. Acid Res. 19:733-738 (1991); Cotten, et al.,
Nucl. Acid Res. 19:2629-2635
(1991); and Hobbs, et al., Biochemistry 12:5138-5145 (1973). Other
modifications are known to one of
ordinary skill in the art. Such modifications may be pre-SELEX process
modifications or post-SELEX
process modifications (modification of previously identified unmodified
ligands) or may be made by
incorporation into the SELEX process.
[00212] Pre-SELEX process modifications or those made by incorporation into
the SELEX process yield
nucleic acid ligands with both specificity for their SELEX target and improved
stability, e.g., in vivo
stability. Post-SELEX process modifications made to nucleic acid ligands may
result in improved
stability, e.g., in vivo stability without adversely affecting the binding
capacity of the nucleic acid ligand.
[00213] The SELEX method encompasses combining selected oligonucleotides with
other selected
oligonucleotides and non-oligonucleotide functional units as described in U.S.
Pat. No. 5,637,459 and
U.S. Pat. No. 5,683,867. The SELEX method further encompasses combining
selected nucleic acid
ligands with lipophilic or non-immunogenic high molecular weight compounds in
a diagnostic or
therapeutic complex, as described, e.g., in U.S. Pat. No. 6,011,020, U.S. Pat.
No. 6,051,698, and PCT
Publication No. WO 98/18480. These patents and applications teach the
combination of a broad array of
shapes and other properties, with the efficient amplification and replication
properties of oligonucleotides,
and with the desirable properties of other molecules.
[00214] The identification of nucleic acid ligands to small, flexible peptides
via the SELEX method has
also been explored. U.S. Pat. No. 5,648,214 identified high affinity RNA
nucleic acid ligands to an 11
amino acid.
[00215] Aptamers / oligonucleotide probes with desired specificity and binding
affinity to the target(s) of
interest to the present invention can be selected by the SELEX N process as
described herein. As part of
the SELEX process, the sequences selected to bind to the target are then
optionally minimized to
determine the minimal sequence having the desired binding affinity. The
selected sequences and/or the
minimized sequences are optionally optimized by performing random or directed
mutagenesis of the
sequence to increase binding affinity or alternatively to determine which
positions in the sequence are
essential for binding activity. Additionally, selections can be performed with
sequences incorporating
modified nucleotides to stabilize the aptamer molecules against degradation in
vivo.
-63-
CA 03018066 2018-09-17
WO 2017/161357 PCT/US2017/023108
[00216] For an aptamer to be suitable for use as a therapeutic, it is
preferably inexpensive to synthesize,
and safe and stable in vivo. Wild-type RNA and DNA aptamers are typically not
stable is vivo because of
their susceptibility to degradation by nucleases. Resistance to nuclease
degradation can be greatly
increased by the incorporation of modifying groups at the 2'-position.
[00217] Fluoro and amino groups have been successfully incorporated into
oligonucleotide pools from
which aptamers have been subsequently selected. However, these modifications
greatly increase the cost
of synthesis of the resultant aptamer, and may introduce safety concerns in
some cases because of the
possibility that the modified nucleotides could be recycled into host DNA by
degradation of the modified
oligonucleotides and subsequent use of the nucleotides as substrates for DNA
synthesis.
[00218] Aptamers that contain 21-0-methyl ("21-0Me") nucleotides, as provided
herein, may overcome
one or more potential drawbacks. Oligonucleotides containing 2'-0Me
nucleotides are nuclease-resistant
and inexpensive to synthesize. Although 2'-0Me nucleotides are ubiquitous in
biological systems, natural
polymerases do not accept 21-0Me NTPs as substrates under physiological
conditions, thus there are no
safety concerns over the recycling of 21-0Me nucleotides into host DNA. The
SELEX method used to
generate 2'-modified aptamers is described, e.g., in U.S. Provisional Patent
Application Ser. No.
60/430,761, filed Dec. 3,2002, U.S. Provisional Patent Application Ser. No.
60/487,474, filed Jul. 15,
2003, U.S. Provisional Patent Application Ser. No. 60/517,039, filed Nov. 4,
2003, U.S. patent application
Ser. No. 10/729,581, filed Dec. 3, 2003, and U.S. patent application Ser. No.
10/873,856, filed Jun. 21,
2004, entitled "Method for in vitro Selection of 21-0-methyl substituted
Nucleic Acids," each of which is
herein incorporated by reference in its entirety.
Therapeutics
[00219] As used herein "therapeutically effective amount" refers to an amount
of a composition that
relieves (to some extent, as judged by a skilled medical practitioner) one or
more symptoms of a medical
condition such as a disease or disorder in a subject. Additionally, by
"therapeutically effective amount" of
a composition is meant an amount that returns to normal, either partially or
completely, physiological or
biochemical parameters associated with or causative of a disease or condition.
A clinician skilled in the art
can determine the therapeutically effective amount of a composition in order
to treat or prevent a
particular disease condition, or disorder when it is administered, such as
intravenously, subcutaneously,
intraperitoneally, orally, or through inhalation. The precise amount of the
composition required to be
therapeutically effective will depend upon numerous factors, e.g., such as the
specific activity of the
active agent, the delivery device employed, physical characteristics of the
agent, purpose for the
administration, in addition to many patient specific considerations. But a
determination of a
therapeutically effective amount is within the skill of an ordinarily skilled
clinician upon the appreciation
of the disclosure set forth herein.
[00220] The terms "treating," "treatment," "therapy," and "therapeutic
treatment" as used herein refer to
curative therapy, prophylactic therapy, or preventative therapy. An example of
"preventative therapy" is
the prevention or lessening the chance of a targeted disease (e.g., cancer or
other proliferative disease) or
related condition thereto. Those in need of treatment include those already
with the disease or condition as
-64-
CA 03018066 2018-09-17
WO 2017/161357 PCT/US2017/023108
well as those prone to have the disease or condition to be prevented. The
terms "treating," "treatment,"
"therapy," and "therapeutic treatment" as used herein also describe the
management and care of a
mammal for the purpose of combating a disease, or related condition, and
includes the administration of a
composition to alleviate the symptoms, side effects, or other complications of
the disease, condition.
Therapeutic treatment for cancer includes, but is not limited to, surgery,
chemotherapy, radiation therapy,
gene therapy, and immunotherapy.
[00221] As used herein, the term "agent" or "drug" or "therapeutic agent"
refers to a chemical compound,
a mixture of chemical compounds, a biological macromolecule, or an extract
made from biological
materials such as bacteria, plants, fungi, or animal (particularly mammalian)
cells or tissues that are
suspected of having therapeutic properties. The agent or drug can be purified,
substantially purified or
partially purified. An "agent" according to the present invention, also
includes a radiation therapy agent or
a "chemotherapuetic agent."
[00222] As used herein, the term "diagnostic agent" refers to any chemical
used in the imaging of diseased
tissue, such as, e.g., a tumor.
[00223] As used herein, the term "chemotherapuetic agent" refers to an agent
with activity against cancer,
neoplastic, and/or proliferative diseases, or that has ability to kill
cancerous cells directly.
[00224] As used herein, "pharmaceutical formulations" include formulations for
human and veterinary use
with no significant adverse toxicological effect. "Pharmaceutically acceptable
formulation" as used herein
refers to a composition or formulation that allows for the effective
distribution of the nucleic acid
molecules of the instant invention in the physical location most suitable for
their desired activity.
[00225] As used herein the term "pharmaceutically acceptable carrier" is
intended to include any and all
solvents, dispersion media, coatings, antibacterial and antifungal agents,
isotonic and absorption delaying
agents, and the like, compatible with pharmaceutical administration. The use
of such media and agents for
pharmaceutically active substances is well known in the art. Except insofar as
any conventional media or
agent is incompatible with the active compound, use thereof in the
compositions is contemplated.
[00226] Aptamer-Toxin Conjugates as a Cancer Therapeutic
[00227] Previous work has developed the concept of antibody-toxin conjugates
("immunoconjugates") as
potential therapies for a range of indications, mostly directed at the
treatment of cancer with a primary
focus on hematological tumors. A variety of different payloads for targeted
delivery have been tested in
pre-clinical and clinical studies, including protein toxins, high potency
small molecule cytotoxics,
radioisotopes, and liposome-encapsulated drugs. While these efforts have
successfully yielded several
FDA-approved therapies for hematological tumors, immunoconjugates as a class
(especially for solid
tumors) face challenges that have been attributable to multiple different
properties of antibodies, including
tendencies to develop neutralizing antibody responses to non-humanized
antibodies, limited penetration in
solid tumors, loss of target binding affinity as a result of toxin
conjugation, and imbalances between
antibody half-life and toxin conjugate half-life that limit the overall
therapeutic index (reviewed by Reff
and Heard, Critical Reviews in Oncology/Hematology, 40 (2001):25-35).
-65-
CA 03018066 2018-09-17
WO 2017/161357 PCT/US2017/023108
[00228] Aptamers are functionally similar to antibodies in target recognition,
although their absorption,
distribution, metabolism, and excretion ("ADME") properties are intrinsically
different and they generally
lack many of the immune effector functions generally associated with
antibodies (e.g., antibody-
dependent cellular cytotoxicity, complement-dependent cytotoxicity). In
comparing many of the
properties of aptamers and antibodies previously described, several factors
suggest that toxin-delivery via
aptamers offers several concrete advantages over delivery with antibodies,
ultimately affording them
better potential as therapeutics. Several examples of the advantages of toxin-
delivery via aptamers over
antibodies are as follows:
[00229] 1) Aptamer-toxin conjugates are entirely chemically synthesized.
Chemical synthesis provides
more control over the nature of the conjugate. For example, the stoichiometry
(ratio of toxins per aptamer)
and site of attachment can be precisely defined. Different linker chemistries
can be readily tested. The
reversibility of aptamer folding means that loss of activity during
conjugation is unlikely and provides
more flexibility in adjusting conjugation conditions to maximize yields.
[00230] 2) Smaller size allows better tumor penetration. Poor penetration of
antibodies into solid tumors is
often cited as a factor limiting the efficacy of conjugate approaches. See
Colcher, D., God, A.,
Pavlinkova, G., Beresford, G., Booth, B., Batra, S. K. (1999) "Effects of
genetic engineering on the
pharmacokinetics of antibodies," Q. J. Nucl. Med., 43: 132-139. Studies
comparing the properties of
unPEGylated anti-tenascin C aptamers with corresponding antibodies demonstrate
efficient uptake into
tumors (as defined by the tumor:blood ratio) and evidence that aptamer
localized to the tumor is
unexpectedly long-lived (t112>12 hours) (Hicke, B. J., Stephens, A. W.,
"Escort aptamers: a delivery
service for diagnosis and therapy", J. Clin. Invest., 106:923-928 (2000)).
[00231] 3) Tunable PK. Aptamer half-life/metabolism can be more easily tuned
to match properties of
payload, optimizing the ability to deliver toxin to the tumor while minimizing
systemic exposure.
Appropriate modifications to the aptamer backbone and addition of high
molecular weight PEGs should
make it possible to match the half-life of the aptamer to the intrinsic half-
life of the conjugated
toxin/linker, minimizing systemic exposure to non-functional toxin-bearing
metabolites (expected if
t1/2(aptamer)<<t112(toxin)) and reducing the likelihood that persisting
unconjugated aptamer will
functionally block uptake of conjugated aptamer (expected if
t112(aptamer)>>t112(toxin)).
[00232] 4) Relatively low material requirements. It is likely that dosing
levels will be limited by toxicity
intrinsic to the cytotoxic payload. As such, a single course of treatment will
likely entail relatively small
(<100 mg) quantities of aptamer, reducing the likelihood that the cost of
oligonucleotide synthesis will be
a barrier for aptamer-based therapies.
[00233] 5) Parenteral administration is preferred for this indication. There
will be no special need to
develop alternative formulations to drive patient/physician acceptance.
[00234] The invention provides a pharmaceutical composition comprising a
therapeutically effective
amount of an aptamer provided by the invention or a salt thereof, and a
pharmaceutically acceptable
carrier or diluent. The invention also provides a pharmaceutical composition
comprising a therapeutically
effective amount of the aptamer or a salt thereof, and a pharmaceutically
acceptable carrier or diluent.
-66-
CA 03018066 2018-09-17
WO 2017/161357 PCT/US2017/023108
Relatedly, the invention provides a method of treating or ameliorating a
disease or disorder, comprising
administering the pharmaceutical composition to a subject in need thereof.
Administering a
therapeutically effective amount of the composition to the subject may result
in: (a) an enhancement of the
delivery of the active agent to a disease site relative to delivery of the
active agent alone; or (b) an
enhancement of microvesicles clearance resulting in a decrease of at least
10%, 20%, 30%, 40%, 50%,
60%, 70%, 80%, or 90% in a blood level of microvesicles targeted by the
aptamer; or (c) an decrease in
biological activity of microvesicles targeted by the aptamer of at least 10%,
20%, 30%, 40%, 50%, 60%,
70%, 80%, or 90%. In an embodiment, the biological activity of microvesicles
comprises immune
suppression or transfer of genetic information. The disease or disorder can
include without limitation
those disclosed herein. For example, the disease or disorder may comprise a
neoplastic, proliferative, or
inflammatory, metabolic, cardiovascular, or neurological disease or disorder.
See, e.g., section
"Phenotypes."
Anti-target and multivalent oligonucleotides
[00235] As described herein, the target of oligonucleotide probes can be
identified. For example, when the
target comprises a protein or protein complex (e.g., a nucleoprotein or
lipoprotein), identifying the target
may comprise use of mass spectrometry (MS), peptide mass fingerprinting (PMF;
protein fingerprinting),
sequencing, N-terminal amino acid analysis, C-terminal amino acid analysis,
Edman degradation,
chromatography, electrophoresis, two-dimensional gel electrophoresis (2D gel),
antibody array, or
immunoassay. Such approaches can be applied to identify a number of targets
recognized by an
oligonucleotide probe library. For example, an oligonucleotide probe library
can be incubated with a
sample of interest, bound members of the library captured, and the targets
bound to the captured members
identified. See Example 9 herein for an example of such target identification
using mass spectrometry.
100236] The oligonucleotide aptamers to the various targets can be used for
multiple purposes. In some
embodiments, the aptamers are used as therapeutic agents. Immunotherapeutic
approaches using
antibodies that recognize foreign/misfolded antigens (e,g., anti-CD20, anti-
CD30, anti-CD33, anti-CD52,
anti-EGFR, anti-nucleolin, anti-nucleophosmin, etc.) can selectively kill
target cells via linked therapeutic
agents or by stimulating the immune system through activation of cell-mediated
cytotoxicity. Aptamers or
oligonucleotides are an attractive immunotherapeutic alternative for various
reasons such as low cost,
small size, ease and speed of synthesis, stability and low immunogenicity. In
an embodiment,
immunotherapeutic agents are conjugated to disease specific target
oligonucleotide or antibody (Ab) for
targeted cell killing via recruitment of complement proteins and the
downstream membrane attack
complex. See, e.g., Zhou and Rossi, Cell-type-specific, Aptamer-functionalized
Agents for Targeted
Disease Therapy, Mol Ther Nucleic Acids. 2014 Jun 17;3:e169. doi:
10.1038/mtna.2014.21; Pei et al.,
Clinical applications of nucleic acid aptamers in cancer, Mol Clin Oncol. 2014
May;2(3):341-348. Epub
2014 Feb 10. This approach can be applied to target diseased host cells such
as cancer cells, gram
negative bacteria, viral and/or parasitic infections, and the like.
[00237] In some embodiments, the invention provides a multipartite construct
comprising a binding agent
specific to a biological target with another binding agent specific to
immunomodulatory entity. Examples
-67-
CA 03018066 2018-09-17
WO 2017/161357 PCT/US2017/023108
of such constructs are shown in FIG. 8. In Design 1 in the figure, the
horizontal line indicates an
oligonucleotide construct, which construct comprises a 5' primer 801 (Primer
1), a variable region 802
that can be an aptamer to a target of interest, a 3' primer 803 (Primer 2),
and an immunomodulatory
domain region ("IMD") 804. The complete Design 1 construct can be used to
bring a target of interest in
proximity with an immunomodulatory agent. The primers can be designed for any
desired purpose, e.g.,
amplification, capture, modification, direct or indirect labeling, and the
like. In some embodiments, the
target of the variable region is a disease marker and thus the construct is
targeted to a diseased tissue, cell
or microvesicle. The immunomodulatory domain region can act as an immune
stimulator or suppressor.
Any appropriate immune stimulator or suppressor can be used, e.g., a small
molecule, antibody or an
aptamer. Thus, the construct can modulate the immune response at a target of
interest, e.g., at a cell or
microvesicle carrying the target. The basic construct can be modified as
desired. For example, Design 2 in
FIG. 8 shows the construct carrying a linker 805 between Primer 2 803 and the
IMD 804. Such linkers are
explained further below and can be inserted between any components of the
construct as desired. Linkers
can provide a desired space between the regions of the construct and can be
manipulated to influence
other properties such as stability. Design 3 in FIG. 8 shows another example
wherein the IMD 804 is an
oligonucleotide and the variable region 802 and IMD 804 lie between the
primers 801 and 803. One of
skill will appreciate that one or more linker, such as 805 of Design 2, can
also be inserted into Design 3,
e.g., between the variable region 802 and IMD 804. One of skill will further
appreciate that the ordering
of the oligonucleotide segments from 5' to 3' can be modified, e.g., reversed.
[00238] As noted, the multipartite constructs may be synthesized and/or
modified as desired. In some
embodiments of the invention, the multipartite oligonucleotide construct is
synthesized directly with or
without a linker in between the oligonucleotide segments. See, e.g., FIG. 8
Design 3, which can be
generated directly via amplification by Primer 1 801 and Primer 2 803. One or
more linker can act as a
spacer to create a desired spacing between the target of the variable region
segment 802 and the target of
the IMD segment 804. The spacing can be determined via computer modeling or
via experimentation due
to steric hindrance or other considerations.
[00239] The multipartite constructs can be generated against any appropriate
target. The targets can
include without limitation tumors or diseased tissues, cells, cancer cells,
circulating tumor cells (CTCs),
immune cells (e.g., B-cells, T-cells, macrophages, dendritic cells),
microvesicles, bacteria, viruses or other
parasites. The target can be large biological complexes, e.g., protein
complexes, ribonucleoprotein
complexes, lipid complexes, or a combination thereof It will be understood
that the specific target of the
multipartite constructs can be a certain member of the foregoing
macromolecular targets. For example,
consider that the desired target of the multipartite construct is a cell or
microvesicle. In such case, the
multipartite construct can be directed to a specific biomarker, e.g., a
surface antigen, of the cell or
microvesicle. As a non-limiting example, the target of interest can be B-cells
and the specifc target of the
variable region of the multipartite construct can be CD20. CD20 is a cellular
marker of B-cells targeted by
the monoclonal antibodies (mAb) rituximab, obinutuzumab, ofatumumab,
ibritumomab tiuxetan, and
tositumomab, which are used as agents in the treatment of B-cell lymphomas and
leukemias. As another
-68-
CA 03018066 2018-09-17
WO 2017/161357 PCT/US2017/023108
non-limiting example, the target of interest can be cancer cells and the
specifc target of the variable region
of the multipartite construct can be c-MET. MET is a membrane receptor that is
essential for embryonic
development and wound healing. Abnormal MET activation in cancer correlates
with poor prognosis,
where aberrantly active MET triggers tumor growth, formation of new blood
vessels (angiogenesis), and
cancer spread to other organs (metastasis). MET has been observed to be
deregulated in many types of
human malignancies, including cancers of kidney, liver, stomach, breast, and
brain. Other biomarkers can
be used as the specifc target as desired. For example, the biomarker can be
selected from any of Tables 3-
4, or 10-17 herein, or Table 4 of International Patent Application
PCT/US2016/040157, filed June 29,
2016.
[00240] As noted above, the IDM domain can be constructed to illicit a
complement mediated immune
response that can induce apoptosis. Such IDM can include but are not limited
to Clq, Clr, Cis, Cl, C3a,
C3b, C3d, C5a, C2, C4, and cytokines. The IDM region may comprise an
oligonucleotide sequence
including without limitation Toll-Like Receptor (TLR) agonists like CpG
sequences which are
immunostimulatory and/or polyG sequences which can be anti-proliferative or
pro-apoptotic. The moiety
can be vaccine like moiety or antigen that stimulates an immune response. In
an embodiment, the immune
stimulating moiety comprises a superantigen. In some embodiments, the
superantigen can be selected
from the group consisting of staphylococcal enterotoxins (SEs), a
Streptococcus pyogenes exotoxin
(SPE), a Staphylococcus aureus toxic shock-syndrome toxin (TSST-1), a
streptococcal mitogenic
exotoxin (SME), a streptococcal superantigen (SSA), a hepatitis surface
antigen, or a combination thereof.
Other bacterial antigens that can be used with the invention comprise
bacterial antigens such as Freund's
complete adjuvant, Freund's incomplete adjuvant, monophosphoryl-lipid
A/trehalose dicorynomycolate
(Ribi's adjuvant), BCG (Calmette-Guerin Bacillus; Mycobacterium bovis), and
Corynebacterium parvum.
The immune stimulating moiety can also be a non-specific immunostimulant, such
as an adjuvant or other
non-specific immunostimulator. Useful adjuvants comprise without limitation
aluminium salts, alum,
aluminium phosphate, aluminium hydroxide, squalene, oils, MF59, and AS03
("Adjuvant System 03").
The adjuvant can be selected from the group consisting of Cationic liposome-
DNA complex JVRS-100,
aluminum hydroxide vaccine adjuvant, aluminum phosphate vaccine adjuvant,
aluminum potassium
sulfate adjuvant, Alhydrogel, ISCOM(s)Tm, Freund's Complete Adjuvant, Freund's
Incomplete Adjuvant,
CpG DNA Vaccine Adjuvant, Cholera toxin, Cholera toxin B subunit, Liposomes,
Saponin Vaccine
Adjuvant, DDA Adjuvant, Squalene-based Adjuvants, Etx B subunit Adjuvant, IL-
12 Vaccine Adjuvant,
LTK63 Vaccine Mutant Adjuvant, TiterMax Gold Adjuvant, Ribi Vaccine Adjuvant,
Montanide ISA 720
Adjuvant, Corynebacterium-derived P40 Vaccine Adjuvant, MPLTM Adjuvant, AS04,
A502,
Lipopolysaccharide Vaccine Adjuvant, Muramyl Dipeptide Adjuvant, CRL1005,
Killed Corynebacterium
parvum Vaccine Adjuvant, Montanide ISA 51, Bordetella pertussis component
Vaccine Adjuvant,
Cationic Liposomal Vaccine Adjuvant, Adamantylamide Dipeptide Vaccine
Adjuvant, Arlacel A, VSA-3
Adjuvant, Aluminum vaccine adjuvant, Polygen Vaccine Adjuvant, AdjumerTM,
Algal Glucan, Bay
R1005, Theramide0, Stearyl Tyrosine, Specol, Algammulin, Avridine0, Calcium
Phosphate Gel, CTA1-
DD gene fusion protein, DOC/Alum Complex, Gamma Inulin, Gerbu Adjuvant, GM-
CSF, GMDP,
-69-
CA 03018066 2018-09-17
WO 2017/161357 PCT/US2017/023108
Recombinant hIEN-gamma/Interferon-g, Interleukin-113, Interleukin-2,
Interleukin-7, Sclavo peptide,
Rehydragel LV, Rehydragel HPA, Loxoribine, MF59, MTP-PE Liposomes, Murametide,
Murapalmitine,
D-Murapalmitine, NAGO, Non-Ionic Surfactant Vesicles, PMMA, Protein
Cochleates, QS-21, SPT
(Antigen Formulation), nanoemulsion vaccine adjuvant, AS03, Quil-A vaccine
adjuvant, RC529 vaccine
adjuvant, LTR192G Vaccine Adjuvant, E. coli heat-labile toxin, LT, amorphous
aluminum
hydroxyphosphate sulfate adjuvant, Calcium phosphate vaccine adjuvant,
Montanide Incomplete Seppic
Adjuvant, Imiquimod, Resiquimod, AF03, Flagellin, Poly(I:C), ISCOMATRIXO,
Abisco-100 vaccine
adjuvant, Albumin-heparin microparticles vaccine adjuvant, AS-2 vaccine
adjuvant, B7-2 vaccine
adjuvant, DHEA vaccine adjuvant, Immunoliposomes Containing Antibodies to
Costimulatory Molecules,
SAF-1, Sendai Proteoliposomes, Sendai-containing Lipid Matrices, Threonyl
muramyl dipeptide
(TMDP), Ty Particles vaccine adjuvant, Bupivacaine vaccine adjuvant, DL-PGL
(Polyester poly (DL-
lactide-co-glycolide)) vaccine adjuvant, IL-15 vaccine adjuvant, LTK72 vaccine
adjuvant, MPL-SE
vaccine adjuvant, non-toxic mutant El 12K of Cholera Toxin mCT-E112K, and
Matrix-S. Additional
adjuvants that can be used with the multipartite constructs of the invention
can be identified using the
Vaxjo database. See Sayers S, Ulysse G, Xiang Z, and He Y. Vaxjo: a web-based
vaccine adjuvant
database and its application for analysis of vaccine adjuvants and their uses
in vaccine development.
Journal of Biomedicine and Biotechnology. 2012;2012:831486. Epub 2012 Mar 13.
PMID: 22505817;
www.violinet.org/vaxjo/. Other useful non-specific immunostimulators comprise
histamine, interferon,
transfer factor, tuftsin, interleukin-1, female sex hormones, prolactin,
growth hormone vitamin D,
deoxycholic acid (DCA), tetrachlorodecaoxide (TCDO), and imiquimod or
resiquimod, which are drugs
that activate immune cells through the toll-like receptor 7. A multipartite
construct can be created that
comprises more than one immunomodulating moiety, e.g., using segments that
span CpG sequences
which are immunostimulatory with complement directed segments that can
stimulate apoptosis.
Modifications
[00241] Modifications to the one or more oligonucleotide of the invention can
be made to alter desired
characteristics, including without limitation in vivo stability, specificity,
affinity, avidity or nuclease
susceptibility. Alterations to the half life may improve stability in vivo or
may reduce stability to limit in
vivo toxicity. Such alterations can include mutations, truncations or
extensions. The 5' and/or 3' ends of
the multipartite oligonucleotide constructs can be protected or deprotected to
modulate stability as well.
Modifications to improve in vivo stability, specificity, affinity, avidity or
nuclease susceptibility or alter
the half life to influence in vivo toxicity may be at the 5' or 3' end and
include but are not limited to the
following: locked nucleic acid (LNA) incorporation, unlocked nucleic acid
(UNA) incorporation,
phosphorothioate backbone instead of phosphodiester backbone, amino modifiers
(i.e. C6-dT), dye
conjugates (Cy dues, Fluorophores, etc), Biotinylation, PEG linkers, Click
chemistry linkers,
dideoxynucleotide end blockers, inverted end bases, cholesterol TEG or other
lipid based labels.
[00242] Linkage options for segments of the oligonucleotide of the invention
can be on the 5' or 3' end of
an oligonucleotide or to a primary amine, sulfhydryl or carboxyl group of an
antibody and include but are
not limited to the following: Biotin-target oligonucleotide /Ab, streptavidin-
complement oligonucleotide
-70-
CA 03018066 2018-09-17
WO 2017/161357 PCT/US2017/023108
or vice versa, amino modified-target Ab/ oligonucleotide, thiol/carboxy-
complement oligonucleotide or
vice versa, Click chemistry-target Ab/ oligonucleotide, corresponding Click
chemistry partner-
complement oligonucleotide or vice versa. The linkages may be covalent or non-
covalent and may include
but are not limited to monovalent, multivalent (i.e. bi, tri or tetra-valent)
assembly, to a DNA scaffold (i.e.
DNA origami structure), drug/chemotherapeutic agent, nanoparticle,
microparticle or a micelle or
liposome.
[00243] A linker region can comprise a spacer with homo- or multifunctional
reactive groups that can vary
in length and type. These include but are not limited to the following: spacer
C18, PEG4, PEG6, PEG8,
and PEG12.
[00244] The multipartite oligonucleotide of the invention can further comprise
additional elements to add
desired biological effects. For example, the oligonucleotide of the invention
may comprise a membrane
disruptive moiety. The oligonucleotide of the invention may also be conjugated
to one or more chemical
moiety that provides such effects. For example, the oligonucleotide of the
invention may be conjugated to
a detergent-like moiety to disrupt the membrane of a target cell or
microvesicle. Useful ionic detergents
include sodium dodecyl sulfate (SDS, sodium lauryl sulfate (SLS)), sodium
laureth sulfate (SLS, sodium
lauryl ether sulfate (SLES)), ammonium lauryl sulfate (ALS), cetrimonium
bromide, cetrimonium
chloride, cetrimonium stearate, and the like. Useful non-ionic (zwitterionic)
detergents include
polyoxyethylene glycols, polysorbate 20 (also known as Tween 20), other
polysorbates (e.g., 40, 60, 65,
80, etc), Triton-X (e.g., X100, X114), 34(3-cholamidopropyl)dimethylammonio1-1-
propanesulfonate
(CHAPS), CHAPSO, deoxycholic acid, sodium deoxycholate, NP-40, glycosides,
octyl-thio-glucosides,
maltosides, and the like. One of skill will appreciate that functional
fragments, such as membrance
disruptive moieties, can be covalently or non-covalently attached to the
oligonucleotide of the invention.
[00245] Oligonucleotide segments, including those of a multipartite construct,
can include any desireable
base modification known in the art. In certain embodiments, oligonucleotide
segments are 10 to 50
nucleotides in length. One having ordinary skill in the art will appreciate
that this embodies
oligonucleotides of 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23,
24, 25, 26, 27, 28, 29, 30, 31, 32,
33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or 50
nucleotides in length, or any range
derivable there within.
[00246] In certain embodiments, a multipartite construct comprises a chimeric
oligonucleotide that
contains two or more chemically distinct regions, each made up of at least one
nucleotide. Such chimeras
can be referred to using terms such as multipartite, multivalent, or the like.
The oligonucleotides portions
may contain at least one region of modified nucleotides that confers one or
more beneficial properties,
e.g., increased nuclease resistance, bioavailability, increased binding
affinity for the target. Chimeric
nucleic acids of the invention may be formed as composite structures of two or
more oligonucleotides,
two or more types of oligonucleotides (e.g., both DNA and RNA segments),
modified oligonucleotides,
oligonucleosides and/or oligonucleotide mimetics. Such compounds have also
been referred to in the art
as hybrids. Representative United States patents that teach the preparation of
such hybrid structures
comprise, but are not limited to, US patent nos: 5,013,830; 5,149,797; 5,
220,007; 5,256,775; 5,366,878;
-71-
CA 03018066 2018-09-17
WO 2017/161357 PCT/US2017/023108
5,403,711; 5,491,133; 5,565,350; 5,623,065; 5,652,355; 5,652,356; and
5,700,922, each of which is herein
incorporated by reference in its entirety.
[00247] In certain embodiments, an oligonucleotide of the invention comprises
at least one nucleotide
modified at the 2' position of the sugar, including without limitation a 2'-0-
alkyl, 2'-0-alkyl-0-alkyl or 2'-
fluoro-modified nucleotide. In other embodiments, RNA modifications include 2'-
fluoro, 2'-amino and
2' 0-methyl modifications on the ribose of pyrimidines, a basic residue or an
inverted base at the 3' end
of the RNA. Such modifications are routinely incorporated into
oligonucleotides and these
oligonucleotides have been shown to have higher target binding affinity in
some cases than 2'-
deoxyoligonucleotides against a given target.
[00248] A number of nucleotide and nucleoside modifications have been shown to
make an
oligonucleotide more resistant to nuclease digestion, thereby prolonging in
vivo half- life. Specific
examples of modified oligonucleotides include those comprising backbones
comprising, for example,
phosphorothioates, phosphotriesters, methyl phosphonates, short chain alkyl or
cycloalkyl intersugar
linkages or short chain heteroatomic or heterocyclic intersugar linkages. The
constructs of the invention
can comprise oligonucleotides with phosphorothioate backbones and/or
heteroatom backbones, e.g., CH2
-NH-0-CH2, CH,--N(CH3)-0¨CH2 (known as a methylene(methylimino) or MMI
backbone], CH2 -0-N
(CH3)-CH2, CH2 -N (CH3)-N (CH3)-CH2 and 0-N (CH3)- CH2 -CH2 backbones, wherein
the native
phosphodiester backbone is represented as 0- P¨ 0- CH,); amide backbones (De
Mesmaeker et ah,
1995); morpholino backbone structures (Summerton and Weller, U.S. Pat. No.
5,034,506); peptide nucleic
acid (PNA) backbone (wherein the phosphodiester backbone of the
oligonucleotide is replaced with a
polyamide backbone, the nucleotides being bound directly or indirectly to the
aza nitrogen atoms of the
polyamide backbone (Nielsen, et al., 1991), each of which is herein
incorporated by reference in its
entirety. Phosphorus- containing linkages include, but are not limited to,
phosphorothioates, chiral
phosphorothioates, phosphorodithioates, phosphotriesters,
aminoalkylphosphotriesters, methyl and other
alkyl phosphonates comprising 3'alkylene phosphonates and chiral phosphonates,
phosphinates,
phosphoramidates comprising 3 `-amino phosphoramidate and
aminoalkylphosphoramidates,
thionophosphoramidates, thionoalkylphosphonates, thionoalkylphosphotriesters,
and boranophosphates
having normal 3 `-5' linkages, 2'-5' linked analogs of these, and those having
inverted polarity wherein
the adjacent pairs of nucleoside units are linked 3*-5* to 5*-3* or 2*-5* to
5*-2*; see U.S. Patent Nos.
3,687,808; 4,469,863; 4,476,301; 5,023,243; 5, 177,196; 5,188,897; 5,264,423;
5,276,019; 5,278,302;
5,286,717; 5,321, 131; 5,399,676; 5,405,939; 5,453,496; 5,455, 233; 5,466,677;
5,476,925; 5,519,126;
5,536,821; 5,541,306; 5,550,111; 5,563, 253; 5,571,799; 5,587,361; and
5,625,050, each of which is
herein incorporated by reference in its entirety. Morpholino-based oligomeric
compounds are known in
the art described in Braasch & Corey, Biochemistry vol. 41, no. 14, 2002,
pages 4503 -4510; Genesis vol.
30, 2001, page 3; Heasman, J. Dev. Biol. vol. 243, 2002, pages 209 - 214;
Nasevicius et al. Nat. Genet.
vol. 26, 2000, pages 216 -220; Lacerra et al. Proc. Natl. Acad. Sci. vol. 97,
2000, pages 9591 - 9596 and
U.S. Pat. No. 5,034,506, issued Jul. 23, 1991, each of which is herein
incorporated by reference in its
entirety. Cyclohexenyl nucleic acid oligonucleotide mimetics are described in
Wang et al., J. Am. Chem.
-72-
CA 03018066 2018-09-17
WO 2017/161357 PCT/US2017/023108
Soc. Vol. 122, 2000, pages 8595 - 8602, the contents of which is incorporated
herein in its entirety. An
oligonucleotide of the invention can comprise at least such modification as
desired.
[00249] Modified oligonucleotide backbones that do not include a phosphorus
atom therein have
backbones that can be formed by short chain alkyl or cycloalkyl
internucleoside linkages, mixed
heteroatom and alkyl or cycloalkyl internucleoside linkages, or one or more
short chain heteroatomic or
heterocyclic internucleoside linkages. These comprise those having morpholino
linkages (formed in part
from the sugar portion of a nucleoside); siloxane backbones; sulfide,
sulfoxide and sulfone backbones;
formacetyl and thioformacetyl backbones; methylene formacetyl and
thioformacetyl backbones; alkene
containing backbones; sulfamate backbones; methyleneimino and
methylenehydrazino backbones;
sulfonate and sulfonamide backbones; amide backbones; and others having mixed
N, 0, S and CH2
component parts; see U.S. Patent Nos. 5,034,506; 5,166,315; 5,185,444;
5,214,134; 5,216, 141;
5,235,033; 5,264,562; 5,264,564; 5,405,938; 5,434,257; 5,466,677; 5,470,967;
5,489,677; 5,541,307;
5,561,225; 5,596, 086; 5,602,240; 5,610,289; 5,602,240; 5,608,046; 5,610,289;
5,618,704; 5,623,070;
5,663,312; 5,633,360; 5,677,437; and 5,677,439, each of which is herein
incorporated by reference in its
entirety. An oligonucleotide of the invention can comprise at least such
modification as desired.
[00250] In certain embodiments, an oligonucleotide of the invention comprises
one or more substituted
sugar moieties, e.g., one of the following at the 2' position: OH, SH, SCH3,
F, OCN, OCK OCK, OCK
0(CH2)n Cth, 0(CH2)n NH2 or 0(CH2)n CH3 where n is from 1 to about 10; Ci to
CIO lower alkyl,
alkoxyalkoxy, substituted lower alkyl, alkaryl or aralkyl; CI; Br; CN; CF3;
0CF3; 0-, S-, or N-alkyl; 0-,
S-, or N-alkenyl; SOCK; SO2 CF13; 0NO2; N 02; N3; NH2; heterocycloalkyl;
heterocycloalkaryl;
aminoalkylamino; polyalkylamino; substituted silyl; an RNA cleaving group; a
reporter group; an
intercalator; a group for improving the pharmacokinetic properties of an
oligonucleotide; or a group for
improving the pharmacokinetic/pharmacodynamic properties of an oligonucleotide
and other substituents
having similar properties. A preferred modification includes 2'-methoxyethoxy
[2'-0- CH2CH2OCH3,
also known as 2'-0-(2-methoxyethyl)1. Other preferred modifications include 2*-
methoxy (2*-0-CH3),
2*-propoxy (2*-OCH2 CH2CH3) and 2*-fiuoro (2*-F). Similar modifications may
also be made at other
positions on the oligonucleotide, e.g., the 3' position of the sugar on the 3'
terminal nucleotide and the 5'
position of 5' terminal nucleotide. Oligonucleotides may also have sugar
mimetics such as cyclobutyls in
place of the pentofuranosyl group.
[00251] In certain embodiments, an oligonucleotide of the invention comprises
one or more base
modifications and/or substitutions. As used herein, "unmodified" or "natural"
bases include adenine (A),
guanine (G), thymine (T), cytosine (C) and uracil (U). Modified bases include,
without limitation, bases
found only infrequently or transiently in natural nucleic acids, e.g.,
hypoxanthine, 6-methyladenine, 5 -Me
pyrimidines, particularly 5-methylcytosine (also referred to as 5-methyl-2'
deoxy cytosine and often
referred to in the art as 5-Me-C), 5- hydroxymethylcytosine (HMC), glycosyl
HMC and gentobiosyl
HMC, as well as synthetic bases, e.g., 2-aminoadenine, 2-(methylamino)adenine,
2-
(imidazolylalkyl)adenine, 2- (aminoalklyamino)adenine or other
heterosubstituted alkyladenines, 2-
thiouracil, 2- thiothymine, 5-bromouracil, 5-hydroxymethyluracil, 8-
azaguanine, 7-deazaguanine, N6 (6-
-73-
CA 03018066 2018-09-17
WO 2017/161357 PCT/US2017/023108
aminohexyl)adenine and 2,6-diaminopurine (Kornberg, 1980; Gebeyehu, et ah,
1987). A "universal" base
known in the art, e.g., inosine, can also be included. 5-Me-C substitutions
can also be included. These
have been shown to increase nucleic acid duplex stability by 0.6- 1.20C. See,
e.g., Sanghvi et al.,
`Antisense Research & Applications', 1993, CRC PRESS pages 276 - 278. Further
suitable modified
bases are described in U.S. Patent Nos. 3,687,808, as well as 4,845,205;
5,130,302; 5,134,066; 5,175, 273;
5, 367,066; 5,432,272; 5,457,187; 5,459,255; 5,484,908; 5,502,177; 5,525,711;
5,552,540; 5,587,469;
5,596,091; 5,614,617; 5,750,692, and 5,681,941, each of which is herein
incorporated by reference.
[00252] It is not necessary for all positions in a given oligonucleotide to be
uniformly modified, and in
fact more than one of the aforementioned modifications may be incorporated in
a single oligonucleotide
or even at within a single nucleoside within an oligonucleotide.
[00253] In certain embodiments, both a sugar and an internucleoside linkage,
i.e., the backbone, of one or
more nucleotide units within an oligonucleotide of the invention are replaced
with novel groups. The base
can be maintained for hybridization with an appropriate nucleic acid target
compound. One such
oligomeric compound, an oligonucleotide mimetic that has been shown to retain
hybridization properties,
is referred to as a peptide nucleic acid (PNA). In PNA compounds, the sugar-
backbone of an
oligonucleotide is replaced with an amide containing backbone, for example, an
aminoethylglycine
backbone. The nucleobases are retained and are bound directly or indirectly to
aza nitrogen atoms of the
amide portion of the backbone. Representative patents that teach the
preparation of PNA compounds
comprise, but are not limited to, U.S. Patent Nos. 5,539,082; 5,714,331; and
5,719,262, each of which is
herein incorporated by reference. Further teaching of PNA compounds can be
found in Nielsen et al.
Science vol. 254, 1991, page 1497, which is herein incorporated by reference.
[00254] In certain embodiments, the oligonucleotide of the invention is linked
(covalently or non-
covalently) to one or more moieties or conjugates that enhance activity,
cellular distribution, or
localization. Such moieties include, without limitation, lipid moieties such
as a cholesterol moiety
(Letsinger et al. Proc. Natl. Acad. Sci. Usa. vol. 86, 1989, pages 6553 -
6556), cholic acid (Manoharan et
al. Bioorg. Med. Chem. Let. vol. 4, 1994, pages 1053 - 1060), a thioether,
e.g., hexyl-S- tritylthiol
(Manoharan et al. Ann. N. Y. Acad. Sci. Vol. 660, 1992, pages 306 - 309;
Manoharan et al. Bioorg. Med.
Chem. Let. vol. 3, 1993, pages 2765 -2770), a thiocholesterol (Oberhauser et
al. Nucl. Acids Res. vol. 20,
1992, pages 533 - 538), an aliphatic chain, e.g., dodecandiol or undecyl
residues (Kabanov et al. Febs
Lett. vol. 259, 1990, pages 327 - 330; Svinarchuk et al. Biochimie. vol. 75,
1993, pages 49 - 54), a
phospholipid, e.g., di-hexadecyl-rac-glycerol or triethylammonium 1 ,2-di-O-
hexadecyl- rac- glycero-3-
H-phosphonate (Manoharan et al. Tetrahedron Lett. vol. 36, 1995, pages 3651 -
3654; Shea et al. Nucl.
Acids Res. vol. 18, 1990, pages 3777 - 3783), a polyamine or a polyethylene
glycol chain (Mancharan et
al. Nucleosides & Nucleotides vol. 14, 1995, pages 969 - 973), or adamantane
acetic acid (Manoharan et
al. Tetrahedron Lett. vol. 36, 1995, pages 3651 - 3654), a palmityl moiety
(Mishra et al. Biochim.
Biophys. Acta vol. 1264, 1995, pages 229 - 237), or an octadecylamine or
hexylamino- carbonyl-t
oxycholesterol moiety (Crooke et al. J. Pharmacol. Exp. Ther. vol. 277, 1996,
pages 923 - 937), each of
which is herein incorporated by reference in its entirety. See also U.S.
Patent Nos. 4,828,979; 4,948,882;
-74-
CA 03018066 2018-09-17
WO 2017/161357 PCT/US2017/023108
5,218,105; 5,525,465; 5,541,313; 5,545,730; 5,552,538; 5,578,717; 5,580,731;
5,580,731; 5,591,584;
5,109,124; 5,118,802; 5,138,045; 5,414,077; 5,486,603; 5,512,439; 5,578,718;
5,608,046; 4,587,044;
4,605,735; 4,667,025; 4,762,779; 4,789,737; 4,824,941; 4,835,263; 4,876,335;
4,904,582; 4,958,013;
5,082,830; 5,112,963; 5,214,136; 5,082,830; 5,112,963; 5,214,136; 5,245,022;
5,254,469; 5,258,506;
5,262,536; 5,272,250; 5,292,873; 5,317,098; 5,371,241,5,391,723;
5,416,203,5,451,463; 5,510,475;
5,512,667; 5,514,785; 5,565,552; 5,567,810; 5,574,142; 5,585,481; 5,587,371;
5,595,726; 5,597,696;
5,599,923; 5,599,928 and 5,688,941, each of which is herein incorporated by
reference in its entirety.
[00255] The oligonucleotide of the invention can be modified to incorporate a
wide variety of modified
nucleotides as desired. For example, the construct may be synthesized entirely
of modified nucleotides or
with a subset of modified nucleotides. The modifications can be the same or
different. Some or all
nucleotides may be modified, and those that are modified may contain the same
modification. For
example, all nucleotides containing the same base may have one type of
modification, while nucleotides
containing other bases may have different types of modification. All purine
nucleotides may have one
type of modification (or are unmodified), while all pyrimidine nucleotides
have another, different type of
modification (or are unmodified). Thus, the construct may comprise any
combination of desired
modifications, including for example, ribonucleotides (2'-OH),
deoxyribonucleotides (2'-deoxy), 2'-
amino nucleotides (2'-NH2), 2'- fluoro nucleotides (2'-F) and 2' -0-methyl (2'-
0Me) nucleotides.
[00256] In some embodiments, the oligonucleotide of the invention is
synthesized using a transcription
mixture containing modified nucleotides in order to generate a modified
construct. For example, a
transcription mixture may contain only 2'-0Me A, G, C and U and/or T
triphosphates (2'-0Me ATP, 2'-
OMe UTP and/or 2*-0Me TTP, 2*-0Me CTP and 2*-0Me GTP), referred to as an MNA
or mRmY
mixture. Oligonucleotides generated therefrom are referred to as MNA
oligonucleotides or mRmY
oligonucleotides and contain only 2'-0-methyl nucleotides. A transcription
mixture containing all 2'-OH
nucleotides is referred to as an "rN" mixture, and oligonucleotides generated
therefrom are referred to as
"rN", "rRrY" or RNA oligonucleotides. A transcription mixture containing all
deoxy nucleotides is
referred to as a "dN" mixture, and oligonucleotides generated therefrom are
referred to as "dN", "dRdY"
or DNA oligonucleotides. Aternatively, a subset of nucleotides (e.g., C, U and
/or T) may comprise a first
modified nucleotides (e.g, 2'-0Me) nucleotides and the remainder (e.g., A and
G) comprise a second
modified nucleotide (e.g., 2'-OH or 2'-F). For example, a transcription
mixture containing 2'-F U and 2'-
OMe A, G and C is referred to as a "fUmV" mixture, and oligonucleotides
generated therefrom are
referred to as "fUmV" oligonucleotides. A transcription mixture containing 2'-
F A and G, and 2'-0Me C
and U and/or T is referred to as an "fRmY" mixture, and oligonucleotides
generated therefrom are
referred to as "fRmY" oligonucleotides. A transcription mixture containing 2'-
F A and 2'-0Me C, G and
U and/or T is referred to as "fAmB" mixture, and oligonucleotides generated
therefrom are referred to as
"fAmB" oligonucleotides.
[00257] One of skill in the art can improve pre-identified aptamer segments
(e.g., variable regions or
immunomodulatory regions that comprise an aptamer to a biomarker target or
other entity) using various
process modifications. Examples of such process modifications include, but are
not limited to, truncation,
-75-
CA 03018066 2018-09-17
WO 2017/161357 PCT/US2017/023108
deletion, substitution, or modification of a sugar or base or internucleotide
linkage, capping, and
PEGylation. In addition, the sequence requirements of an aptamer may be
explored through doped
reselections or aptamer medicinal chemistry. Doped reselections are carried
out using a synthetic,
degenerate pool that has been designed based on the aptamer of interest. The
level of degeneracy usually
varies from about 70-85% from the aptamer of interest. In general, sequences
with neutral mutations are
identified through the doped reselection process. Aptamer medicinal chemistry
is an aptamer
improvement technique in which sets of variant aptamers are chemically
synthesized. These variants are
then compared to each other and to the parent aptamer. Aptamer medicinal
chemistry is used to explore
the local, rather than global, introduction of substituents. For example, the
following modifications may
be introduced: modifications at a sugar, base, and/or internucleotide linkage,
such as 2'-deoxy, 2'-ribo, or
2'-0-methyl purines or pyrimidines, phosphorothioate linkages may be
introduced between nucleotides, a
cap may be introduced at the 5' or 3' end of the aptamer (such as 3' inverted
dT cap) to block degradation
by exonucleases, or a polyethylene glycol (PEG) element may be added to the
aptamer to increase the
half-life of the aptamer in the subject.
[00258] Additional compositions comprising an oligonucleotide of the invention
and uses thereof are
further described below. As the invention provides methods to identify
oligonucleotide probes that bind to
specific tissues, cells, microvesicles or other biological entities of
interest, the oligonucleotide probes of
the invention target such entities and are inherently drug candidates, agents
that can be used for targeted
drug delivery, or both.
Pharmaceutical Compositions
[00259] In an aspect, the invention provides pharmaceutical compositions
comprising one or more
oligonucleotide of the invention, e.g., as a standalone drug, as a drug
delivery agent, as a multipartite
construct as described above, or any combination thereof. The invention
further provides methods of
administering such compositions.
[00260] The term "condition," as used herein means an interruption, cessation,
or disorder of a bodily
function, system, or organ. Representative conditions include, but are not
limited to, diseases such as
cancer, inflammation, diabetes, and organ failure.
[00261] The phrase "treating," "treatment of," and the like include the
amelioration or cessation of a
specified condition.
[00262] The phrase "preventing," "prevention of," and the like include the
avoidance of the onset of a
condition.
[00263] The term "salt," as used herein, means two compounds that are not
covalently bound but are
chemically bound by ionic interactions.
[00264] The term "pharmaceutically acceptable," as used herein, when referring
to a component of a
pharmaceutical composition means that the component, when administered to an
animal, does not have
undue adverse effects such as excessive toxicity, irritation, or allergic
response commensurate with a
reasonable benefit/risk ratio. Accordingly, the term "pharmaceutically
acceptable organic solvent," as
used herein, means an organic solvent that when administered to an animal does
not have undue adverse
-76-
CA 03018066 2018-09-17
WO 2017/161357 PCT/US2017/023108
effects such as excessive toxicity, irritation, or allergic response
commensurate with a reasonable
benefit/risk ratio. Preferably, the pharmaceutically acceptable organic
solvent is a solvent that is generally
recognized as safe ("GRAS") by the United States Food and Drug Administration
("FDA"). Similarly, the
term "pharmaceutically acceptable organic base," as used herein, means an
organic base that when
administered to an animal does not have undue adverse effects such as
excessive toxicity, irritation, or
allergic response commensurate with a reasonable benefit/risk ratio.
[00265] The phrase "injectable" or "injectable composition," as used herein,
means a composition that can
be drawn into a syringe and injected subcutaneously, intraperitoneally, or
intramuscularly into an animal
without causing adverse effects due to the presence of solid material in the
composition. Solid materials
include, but are not limited to, crystals, gummy masses, and gels. Typically,
a formulation or composition
is considered to be injectable when no more than about 15%, preferably no more
than about 10%, more
preferably no more than about 5%, even more preferably no more than about 2%,
and most preferably no
more than about 1% of the formulation is retained on a 0.22 gm filter when the
formulation is filtered
through the filter at 98 F. There are, however, some compositions of the
invention, which are gels, that
can be easily dispensed from a syringe but will be retained on a 0.22 gm
filter. In one embodiment, the
term "injectable," as used herein, includes these gel compositions. In one
embodiment, the term
"injectable," as used herein, further includes compositions that when warmed
to a temperature of up to
about 40 C. and then filtered through a 0.22 gm filter, no more than about
15%, preferably no more than
about 10%, more preferably no more than about 5%, even more preferably no more
than about 2%, and
most preferably no more than about 1% of the formulation is retained on the
filter. In one embodiment, an
example of an injectable pharmaceutical composition is a solution of a
pharmaceutically active compound
(for example, one or more oligonucleotide of the invention, e.g., a
multipartite construct, an anti-C1Q
oligonucleotide, a 10.36 oligonucleotide, as described above, or any
combination thereof) in a
pharmaceutically acceptable solvent. One of skill will appreciate that
injectable solutions have inherent
properties, e.g., sterility, pharmaceutically acceptable excipients and free
of harmful measures of pyrogens
or similar contaminants.
[00266] The term "solution," as used herein, means a uniformly dispersed
mixture at the molecular or
ionic level of one or more substances (solute), in one or more other
substances (solvent), typically a
liquid.
[00267] The term "suspension," as used herein, means solid particles that are
evenly dispersed in a
solvent, which can be aqueous or non-aqueous.
[00268] The term "animal," as used herein, includes, but is not limited to,
humans, canines, felines,
equines, bovines, ovines, porcines, amphibians, reptiles, and avians.
Representative animals include, but
are not limited to a cow, a horse, a sheep, a pig, an ungulate, a chimpanzee,
a monkey, a baboon, a
chicken, a turkey, a mouse, a rabbit, a rat, a guinea pig, a dog, a cat, and a
human. In one embodiment, the
animal is a mammal. In one embodiment, the animal is a human. In one
embodiment, the animal is a non-
human. In one embodiment, the animal is a canine, a feline, an equine, a
bovine, an ovine, or a porcine.
-77-
CA 03018066 2018-09-17
WO 2017/161357 PCT/US2017/023108
[00269] The phrase "drug depot," as used herein means a precipitate, which
includes one or more
oligonucleotide of the invention, e.g., a multipartite construct, an anti-C1Q
oligonucleotide, a 10.36
oligonucleotide, as described above, or any combination thereof, formed within
the body of a treated
animal that releases the oligonucleotide over time to provide a
pharmaceutically effective amount of the
oligonucleotide.
[00270] The phrase "substantially free of," as used herein, means less than
about 2 percent by weight. For
example, the phrase "a pharmaceutical composition substantially free of water"
means that the amount of
water in the pharmaceutical composition is less than about 2 percent by weight
of the pharmaceutical
composition.
[00271] The term "effective amount," as used herein, means an amount
sufficient to treat or prevent a
condition in an animal.
[00272] The nucleotides that make up the oligonucleotide of the invention can
be modified to, for
example, improve their stability, i.e., improve their in vivo half-life,
and/or to reduce their rate of
excretion when administered to an animal. The term "modified" encompasses
nucleotides with a
covalently modified base and/or sugar. For example, modified nucleotides
include nucleotides having
sugars which are covalently attached to low molecular weight organic groups
other than a hydroxyl group
at the 3 position and other than a phosphate group at the 5' position.
Modified nucleotides may also
include 2' substituted sugars such as 2'-0-methyl-; 2'-0-alkyl; 2'-0-ally1; 2'-
S-alkyl; 2'-S-ally1; 2'-fluoro-;
2'-halo or 2'-azido-ribose; carbocyclic sugar analogues; a-anomeric sugars;
and epimeric sugars such as
arabinose, xyloses or lyxoses, pyranose sugars, furanose sugars, and
sedoheptulose.
[00273] Modified nucleotides are known in the art and include, but are not
limited to, alkylated purines
and/or pyrimidines; acylated purines and/or pyrimidines; or other
heterocycles. These classes of
pyrimidines and purines are known in the art and include, pseudoisocytosine;
N4,N4-ethanocytosine; 8-
hydroxy-N6-methyladenine; 4-acetylcytosine, 5-(carboxyhydroxylmethyl) uracil;
5-fluorouracil; 5-
bromouracil; 5-carboxymethylaminomethy1-2-thiouracil; 5-
carboxymethylaminomethyl uracil;
dihydrouracil; inosine; N6-isopentyl-adenine; 1-methyladenine; 1-
methylpseudouracil; 1-methylguanine;
2,2-dimethylguanine; 2-methyladenine; 2-methylguanine; 3-methylcytosine; 5-
methylcytosine; N6-
methyladenine; 7-methylguanine; 5-methylaminomethyl uracil; 5-methoxy amino
methyl-2-thiouracil; 0-
D-mannosylqueosine; 5-methoxycarbonylmethyluracil; 5-methoxyuracil; 2
methylthio-N6-
isopentenyladenine; uracil-5-oxyacetic acid methyl ester; psueouracil; 2-
thiocytosine; 5-methy1-2
thiouracil, 2-thiouracil; 4-thiouracil; 5-methyluracil; N-uracil-5-oxyacetic
acid methylester; uracil 5-
oxyacetic acid; queosine; 2-thiocytosine; 5-propyluracil; 5-propylcytosine; 5-
ethyluracil; 5-ethylcytosine;
5-butyluracil; 5-pentyluracil; 5-pentylcytosine; and 2,6,-diaminopurine;
methylpsuedouracil; 1-
methylguanine; and 1-methylcytosine.
[00274] An oligonucleotide of the invention can also be modified by replacing
one or more
phosphodiester linkages with alternative linking groups. Alternative linking
groups include, but are not
limited to embodiments wherein P(0)0 is replaced by P(0)S, P(S)S, P(0)NR2,
P(0)R, P(0)OR', CO, or
CH2, wherein each R or R' is independently H or a substituted or unsubstituted
Cl-C20 alkyl. A preferred
-78-
CA 03018066 2018-09-17
WO 2017/161357 PCT/US2017/023108
set of R substitutions for the P(0)NR2 group are hydrogen and methoxyethyl.
Linking groups are
typically attached to each adjacent nucleotide through an ¨0¨ bond, but may be
modified to include ¨
N¨ or ¨S¨ bonds. Not all linkages in an oligomer need to be identical.
[00275] The oligonucleotide of the invention can also be modified by
conjugation to a polymer, for
example, to reduce the rate of excretion when administered to an animal. For
example, the oligonucleotide
can be "PEGylated," i.e., conjugated to polyethylene glycol ("PEG"). In one
embodiment, the PEG has an
average molecular weight ranging from about 20 kD to 80 kD. Methods to
conjugate an oligonucleotide
with a polymer, such PEG, are known to those skilled in the art (See, e.g.,
Greg T. Hermanson,
Bioconjugate Techniques, Academic Press, 1966).
[00276] The oligonucleotide of the invention, e.g., a multipartite construct,
an anti-C1Q oligonucleotide, a
10.36 oligonucleotide, as described above, or any combination thereof, can be
used in the pharmaceutical
compositions disclosed herein or known in the art.
[00277] In one embodiment, the pharmaceutical composition further comprises a
solvent.
[00278] In one embodiment, the solvent comprises water.
[00279] In one embodiment, the solvent comprises a pharmaceutically acceptable
organic solvent. Any
useful and pharmaceutically acceptable organic solvents can be used in the
compositions of the invention.
[00280] In one embodiment, the pharmaceutical composition is a solution of the
salt in the
pharmaceutically acceptable organic solvent.
[00281] In one embodiment, the pharmaceutical composition comprises a
pharmaceutically acceptable
organic solvent and further comprises a phospholipid, a sphingomyelin, or
phosphatidyl choline. Without
wishing to be bound by theory, it is believed that the phospholipid,
sphingomyelin, or phosphatidyl
choline facilitates formation of a precipitate when the pharmaceutical
composition is injected into water
and can also facilitate controlled release of the oligonucleotide from the
resulting precipitate. Typically,
the phospholipid, sphingomyelin, or phosphatidyl choline is present in an
amount ranging from greater
than 0 to 10 percent by weight of the pharmaceutical composition. In one
embodiment, the phospholipid,
sphingomyelin, or phosphatidyl choline is present in an amount ranging from
about 0.1 to 10 percent by
weight of the pharmaceutical composition. In one embodiment, the phospholipid,
sphingomyelin, or
phosphatidyl choline is present in an amount ranging from about 1 to 7.5
percent by weight of the
pharmaceutical composition. In one embodiment, the phospholipid,
sphingomyelin, or phosphatidyl
choline is present in an amount ranging from about 1.5 to 5 percent by weight
of the pharmaceutical
composition. In one embodiment, the phospholipid, sphingomyelin, or
phosphatidyl choline is present in
an amount ranging from about 2 to 4 percent by weight of the pharmaceutical
composition.
[00282] The pharmaceutical compositions can optionally comprise one or more
additional excipients or
additives to provide a dosage form suitable for administration to an animal.
When administered to an
animal, the oligonucleotide containing pharmaceutical compositions are
typically administered as a
component of a composition that comprises a pharmaceutically acceptable
carrier or excipient so as to
provide the form for proper administration to the animal. Suitable
pharmaceutical excipients are described
in Remington's Pharmaceutical Sciences 1447-1676 (Alfonso R. Gennaro ed., 19th
ed. 1995),
-79-
CA 03018066 2018-09-17
WO 2017/161357 PCT/US2017/023108
incorporated herein by reference. The pharmaceutical compositions can take the
form of solutions,
suspensions, emulsion, tablets, pills, pellets, capsules, capsules containing
liquids, powders, suppositories,
emulsions, aerosols, sprays, suspensions, or any other form suitable for use.
[00283] In one embodiment, the pharmaceutical compositions are formulated for
intravenous or parenteral
administration. Typically, compositions for intravenous or parenteral
administration comprise a suitable
sterile solvent, which may be an isotonic aqueous buffer or pharmaceutically
acceptable organic solvent.
Where necessary, the compositions can also include a solubilizing agent.
Compositions for intravenous
administration can optionally include a local anesthetic such as lidocaine to
lessen pain at the site of the
injection. Generally, the ingredients are supplied either separately or mixed
together in unit dosage form,
for example, as a dry lyophilized powder or water free concentrate in a
hermetically sealed container such
as an ampoule or sachette indicating the quantity of active agent. Where
oligonucleotide-containing
pharmaceutical compositions are to be administered by infusion, they can be
dispensed, for example, with
an infusion bottle containing, for example, sterile pharmaceutical grade water
or saline. Where the
pharmaceutical compositions are administered by injection, an ampoule of
sterile water for injection,
saline, or other solvent such as a pharmaceutically acceptable organic solvent
can be provided so that the
ingredients can be mixed prior to administration.
[00284] In another embodiment, the pharmaceutical compositions are formulated
in accordance with
routine procedures as a composition adapted for oral administration.
Compositions for oral delivery can
be in the form of tablets, lozenges, aqueous or oily suspensions, granules,
powders, emulsions, capsules,
syrups, or elixirs, for example. Oral compositions can include standard
excipients such as mannitol,
lactose, starch, magnesium stearate, sodium saccharin, cellulose, and
magnesium carbonate. Typically, the
excipients are of pharmaceutical grade. Orally administered compositions can
also contain one or more
agents, for example, sweetening agents such as fructose, aspartame or
saccharin; flavoring agents such as
peppermint, oil of wintergreen, or cherry; coloring agents; and preserving
agents, to provide a
pharmaceutically palatable preparation. Moreover, when in tablet or pill form,
the compositions can be
coated to delay disintegration and absorption in the gastrointestinal tract
thereby providing a sustained
action over an extended period of time. Selectively permeable membranes
surrounding an osmotically
active driving compound are also suitable for orally administered
compositions. A time-delay material
such as glycerol monostearate or glycerol stearate can also be used.
[00285] The pharmaceutical compositions further comprising a solvent can
optionally comprise a suitable
amount of a pharmaceutically acceptable preservative, if desired, so as to
provide additional protection
against microbial growth. Examples of preservatives useful in the
pharmaceutical compositions of the
invention include, but are not limited to, potassium sorbate, methylparaben,
propylparaben, benzoic acid
and its salts, other esters of parahydroxybenzoic acid such as butylparaben,
alcohols such as ethyl or
benzyl alcohol, phenolic compounds such as phenol, or quaternary compounds
such as benzalkonium
chlorides (e.g., benzethonium chloride).
[00286] In one embodiment, the pharmaceutical compositions of the invention
optionally contain a
suitable amount of a pharmaceutically acceptable polymer. The polymer can
increase the viscosity of the
-80-
CA 03018066 2018-09-17
WO 2017/161357 PCT/US2017/023108
pharmaceutical composition. Suitable polymers for use in the compositions and
methods of the invention
include, but are not limited to, hydroxypropylcellulose,
hydoxypropylmethylcellulose (HPMC), chitosan,
polyacrylic acid, and polymethacrylic acid.
[00287] Typically, the polymer is present in an amount ranging from greater
than 0 to 10 percent by
weight of the pharmaceutical composition. In one embodiment, the polymer is
present in an amount
ranging from about 0.1 to 10 percent by weight of the pharmaceutical
composition. In one embodiment,
the polymer is present in an amount ranging from about 1 to 7.5 percent by
weight of the pharmaceutical
composition. In one embodiment, the polymer is present in an amount ranging
from about 1.5 to 5 percent
by weight of the pharmaceutical composition. In one embodiment, the polymer is
present in an amount
ranging from about 2 to 4 percent by weight of the pharmaceutical composition.
In one embodiment, the
pharmaceutical compositions of the invention are substantially free of
polymers.
[00288] In one embodiment, any additional components added to the
pharmaceutical compositions of the
invention are designated as GRAS by the FDA for use or consumption by animals.
In one embodiment,
any additional components added to the pharmaceutical compositions of the
invention are designated as
GRAS by the FDA for use or consumption by humans.
[00289] The components of the pharmaceutical composition (the solvents and any
other optional
components) are preferably biocompatible and non-toxic and, over time, are
simply absorbed and/or
metabolized by the body.
[00290] As described above, the pharmaceutical compositions of the invention
can further comprise a
solvent.
[00291] In one embodiment, the solvent comprises water.
[00292] In one embodiment, the solvent comprises a pharmaceutically acceptable
organic solvent.
[00293] In an embodiment, the oligonucleotide of the invention, e.g., a
multipartite construct, an anti-C1Q
oligonucleotide, a 10.36 oligonucleotide, as described above, or any
combination thereof, are available as
the salt of a metal cation, for example, as the potassium or sodium salt.
These salts, however, may have
low solubility in aqueous solvents and/or organic solvents, typically, less
than about 25 mg/mL. The
pharmaceutical compositions of the invention comprising (i) an amino acid
ester or amino acid amide and
(ii) a protonated oligonucleotide, however, may be significantly more soluble
in aqueous solvents and/or
organic solvents. Without wishing to be bound by theory, it is believed that
the amino acid ester or amino
acid amide and the protonated oligonucleotide form a salt, such as illustrated
above, and the salt is soluble
in aqueous and/or organic solvents.
[00294] Similarly, without wishing to be bound by theory, it is believed that
the pharmaceutical
compositions comprising (i) an oligonucleotide of the invention; (ii) a
divalent metal cation; and (iii)
optionally a carboxylate, a phospholipid, a phosphatidyl choline, or a
sphingomyelin form a salt, such as
illustrated above, and the salt is soluble in aqueous and/or organic solvents.
[00295] In one embodiment, the concentration of the oligonucleotide of the
invention in the solvent is
greater than about 2 percent by weight of the pharmaceutical composition. In
one embodiment, the
concentration of the oligonucleotide of the invention in the solvent is
greater than about 5 percent by
-81-
CA 03018066 2018-09-17
WO 2017/161357 PCT/US2017/023108
weight of the pharmaceutical composition. In one embodiment, the concentration
of the oligonucleotide in
the solvent is greater than about 7.5 percent by weight of the pharmaceutical
composition. In one
embodiment, the concentration of the oligonucleotide in the solvent is greater
than about 10 percent by
weight of the pharmaceutical composition. In one embodiment, the concentration
of the oligonucleotide in
the solvent is greater than about 12 percent by weight of the pharmaceutical
composition. In one
embodiment, the concentration of the oligonucleotide in the solvent is greater
than about 15 percent by
weight of the pharmaceutical composition. In one embodiment, the concentration
of the oligonucleotide in
the solvent is ranges from about 2 percent to 5 percent by weight of the
pharmaceutical composition. In
one embodiment, the concentration of the oligonucleotide in the solvent is
ranges from about 2 percent to
7.5 percent by weight of the pharmaceutical composition. In one embodiment,
the concentration of the
oligonucleotide in the solvent ranges from about 2 percent to 10 percent by
weight of the pharmaceutical
composition. In one embodiment, the concentration of the oligonucleotide in
the solvent is ranges from
about 2 percent to 12 percent by weight of the pharmaceutical composition. In
one embodiment, the
concentration of the oligonucleotide in the solvent is ranges from about 2
percent to 15 percent by weight
of the pharmaceutical composition. In one embodiment, the concentration of the
oligonucleotide in the
solvent is ranges from about 2 percent to 20 percent by weight of the
pharmaceutical composition.
[00296] Any pharmaceutically acceptable organic solvent can be used in the
pharmaceutical compositions
of the invention. Representative, pharmaceutically acceptable organic solvents
include, but are not limited
to, pyrrolidone, N-methyl-2-pyrrolidone, polyethylene glycol, propylene glycol
(i.e., 1,3-propylene
glycol), glycerol formal, isosorbid dimethyl ether, ethanol, dimethyl
sulfoxide, tetraglycol,
tetrahydrofurfuryl alcohol, triacetin, propylene carbonate, dimethyl
acetamide, dimethyl formamide,
dimethyl sulfoxide, and combinations thereof.
[00297] In one embodiment, the pharmaceutically acceptable organic solvent is
a water soluble solvent. A
representative pharmaceutically acceptable water soluble organic solvents is
triacetin.
[00298] In one embodiment, the pharmaceutically acceptable organic solvent is
a water miscible solvent.
Representative pharmaceutically acceptable water miscible organic solvents
include, but are not limited
to, glycerol formal, polyethylene glycol, and propylene glycol.
[00299] In one embodiment, the pharmaceutically acceptable organic solvent
comprises pyrrolidone. In
one embodiment, the pharmaceutically acceptable organic solvent is pyrrolidone
substantially free of
another organic solvent.
[00300] In one embodiment, the pharmaceutically acceptable organic solvent
comprises N-methy1-2-
pyrrolidone. In one embodiment, the pharmaceutically acceptable organic
solvent is N-methy1-2-
pyrrolidone substantially free of another organic solvent.
[00301] In one embodiment, the pharmaceutically acceptable organic solvent
comprises polyethylene
glycol. In one embodiment, the pharmaceutically acceptable organic solvent is
polyethylene glycol
substantially free of another organic solvent.
-82-
CA 03018066 2018-09-17
WO 2017/161357 PCT/US2017/023108
[00302] In one embodiment, the pharmaceutically acceptable organic solvent
comprises propylene glycol.
In one embodiment, the pharmaceutically acceptable organic solvent is
propylene glycol substantially free
of another organic solvent.
[00303] In one embodiment, the pharmaceutically acceptable organic solvent
comprises glycerol formal.
In one embodiment, the pharmaceutically acceptable organic solvent is glycerol
formal substantially free
of another organic solvent.
[00304] In one embodiment, the pharmaceutically acceptable organic solvent
comprises isosorbid
dimethyl ether. In one embodiment, the pharmaceutically acceptable organic
solvent is isosorbid dimethyl
ether substantially free of another organic solvent.
[00305] In one embodiment, the pharmaceutically acceptable organic solvent
comprises ethanol. In one
embodiment, the pharmaceutically acceptable organic solvent is ethanol
substantially free of another
organic solvent.
[00306] In one embodiment, the pharmaceutically acceptable organic solvent
comprises dimethyl
sulfoxide. In one embodiment, the pharmaceutically acceptable organic solvent
is dimethyl sulfoxide
substantially free of another organic solvent.
[00307] In one embodiment, the pharmaceutically acceptable organic solvent
comprises tetraglycol. In one
embodiment, the pharmaceutically acceptable organic solvent is tetraglycol
substantially free of another
organic solvent.
[00308] In one embodiment, the pharmaceutically acceptable organic solvent
comprises tetrahydrofurfuryl
alcohol. In one embodiment, the pharmaceutically acceptable organic solvent is
tetrahydrofurfuryl alcohol
substantially free of another organic solvent.
[00309] In one embodiment, the pharmaceutically acceptable organic solvent
comprises triacetin. In one
embodiment, the pharmaceutically acceptable organic solvent is triacetin
substantially free of another
organic solvent.
[00310] In one embodiment, the pharmaceutically acceptable organic solvent
comprises propylene
carbonate. In one embodiment, the pharmaceutically acceptable organic solvent
is propylene carbonate
substantially free of another organic solvent.
[00311] In one embodiment, the pharmaceutically acceptable organic solvent
comprises dimethyl
acetamide. In one embodiment, the pharmaceutically acceptable organic solvent
is dimethyl acetamide
substantially free of another organic solvent.
[00312] In one embodiment, the pharmaceutically acceptable organic solvent
comprises dimethyl
formamide. In one embodiment, the pharmaceutically acceptable organic solvent
is dimethyl formamide
substantially free of another organic solvent.
[00313] In one embodiment, the pharmaceutically acceptable organic solvent
comprises at least two
pharmaceutically acceptable organic solvents.
[00314] In one embodiment, the pharmaceutically acceptable organic solvent
comprises N-methy1-2-
pyrrolidone and glycerol formal. In one embodiment, the pharmaceutically
acceptable organic solvent is
-83-
CA 03018066 2018-09-17
WO 2017/161357 PCT/US2017/023108
N-methyl-2-pyn-olidone and glycerol formal. In one embodiment, the ratio of N-
methyl-2-pyrrolidone to
glycerol formal ranges from about 90:10 to 10:90.
[00315] In one embodiment, the pharmaceutically acceptable organic solvent
comprises propylene glycol
and glycerol formal. In one embodiment, the pharmaceutically acceptable
organic solvent is propylene
glycol and glycerol formal. In one embodiment, the ratio of propylene glycol
to glycerol formal ranges
from about 90:10 to 10:90.
[00316] In one embodiment, the pharmaceutically acceptable organic solvent is
a solvent that is
recognized as GRAS by the FDA for administration or consumption by animals. In
one embodiment, the
pharmaceutically acceptable organic solvent is a solvent that is recognized as
GRAS by the FDA for
administration or consumption by humans.
[00317] In one embodiment, the pharmaceutically acceptable organic solvent is
substantially free of water.
In one embodiment, the pharmaceutically acceptable organic solvent contains
less than about 1 percent by
weight of water. In one embodiment, the pharmaceutically acceptable organic
solvent contains less about
0.5 percent by weight of water. In one embodiment, the pharmaceutically
acceptable organic solvent
contains less about 0.2 percent by weight of water. Pharmaceutically
acceptable organic solvents that are
substantially free of water are advantageous since they are not conducive to
bacterial growth.
Accordingly, it is typically not necessary to include a preservative in
pharmaceutical compositions that are
substantially free of water. Another advantage of pharmaceutical compositions
that use a
pharmaceutically acceptable organic solvent, preferably substantially free of
water, as the solvent is that
hydrolysis of the oligonucleotide is minimized. Typically, the more water
present in the solvent the more
readily the oligonucleotide can be hydrolyzed. Accordingly, oligonucleotide
containing pharmaceutical
compositions that use a pharmaceutically acceptable organic solvent as the
solvent can be more stable
than oligonucleotide containing pharmaceutical compositions that use water as
the solvent.
[00318] In one embodiment, comprising a pharmaceutically acceptable organic
solvent, the
pharmaceutical composition is injectable.
[00319] In one embodiment, the injectable pharmaceutical compositions are of
sufficiently low viscosity
that they can be easily drawn into a 20 gauge and needle and then easily
expelled from the 20 gauge
needle. Typically, the viscosity of the injectable pharmaceutical compositions
are less than about 1,200
cps. In one embodiment, the viscosity of the injectable pharmaceutical
compositions are less than about
1,000 cps. In one embodiment, the viscosity of the injectable pharmaceutical
compositions are less than
about 800 cps. In one embodiment, the viscosity of the injectable
pharmaceutical compositions are less
than about 500 cps. Injectable pharmaceutical compositions having a viscosity
greater than about 1,200
cps and even greater than about 2,000 cps (for example gels) are also within
the scope of the invention
provided that the compositions can be expelled through an 18 to 24 gauge
needle.
[00320] In one embodiment, comprising a pharmaceutically acceptable organic
solvent, the
pharmaceutical composition is injectable and does not form a precipitate when
injected into water.
[00321] In one embodiment, comprising a pharmaceutically acceptable organic
solvent, the
pharmaceutical composition is injectable and forms a precipitate when injected
into water. Without
-84-
CA 03018066 2018-09-17
WO 2017/161357 PCT/US2017/023108
wishing to be bound by theory, it is believed, for pharmaceutical compositions
that comprise a protonated
oligonucleotide and an amino acid ester or amide, that the a-amino group of
the amino acid ester or amino
acid amide is protonated by the oligonucleotide to form a salt, such as
illustrated above, which is soluble
in the pharmaceutically acceptable organic solvent but insoluble in water.
Similarly, when the
pharmaceutical composition comprises (i) an oligonucleotide; (ii) a divalent
metal cation; and (iii)
optionally a carboxylate, a phospholipid, a phosphatidyl choline, or a
sphingomyelin, it is believed that
the components of the composition form a salt, such as illustrated above,
which is soluble in the
pharmaceutically acceptable organic solvent but insoluble in water.
Accordingly, when the
pharmaceutical compositions are injected into an animal, at least a portion of
the pharmaceutical
composition precipitates at the injection site to provide a drug depot.
Without wishing to be bound by
theory, it is believed that when the pharmaceutically compositions are
injected into an animal, the
pharmaceutically acceptable organic solvent diffuses away from the injection
site and aqueous bodily
fluids diffuse towards the injection site, resulting in an increase in
concentration of water at the injection
site, that causes at least a portion of the composition to precipitate and
form a drug depot. The precipitate
can take the form of a solid, a crystal, a gummy mass, or a gel. The
precipitate, however, provides a depot
of the oligonucleotide at the injection site that releases the oligonucleotide
over time. The components of
the pharmaceutical composition, i.e., the amino acid ester or amino acid
amide, the pharmaceutically
acceptable organic solvent, and any other components are biocompatible and non-
toxic and, over time, are
simply absorbed and/or metabolized by the body.
[00322] In one embodiment, comprising a pharmaceutically acceptable organic
solvent, the
pharmaceutical composition is injectable and forms liposomal or micellar
structures when injected into
water (typically about 500 ttL are injected into about 4 mL of water). The
formation of liposomal or
micellar structures are most often formed when the pharmaceutical composition
includes a phospholipid.
Without wishing to be bound by theory, it is believed that the oligonucleotide
in the form of a salt, which
can be a salt formed with an amino acid ester or amide or can be a salt with a
divalent metal cation and
optionally a carboxylate, a phospholipid, a phosphatidyl choline, or a
sphingomyelin, that is trapped
within the liposomal or micellar structure. Without wishing to be bound by
theory, it is believed that when
these pharmaceutically compositions are injected into an animal, the liposomal
or micellar structures
release the oligonucleotide over time.
[00323] In one embodiment, the pharmaceutical composition further comprising a
pharmaceutically
acceptable organic solvent is a suspension of solid particles in the
pharmaceutically acceptable organic
solvent. Without wishing to be bound by theory, it is believed that the solid
particles comprise a salt
formed between the amino acid ester or amino acid amide and the protonated
oligonucleotide wherein the
acidic phosphate groups of the oligonucleotide protonates the amino group of
the amino acid ester or
amino acid amide, such as illustrated above, or comprises a salt formed
between the oligonucleotide;
divalent metal cation; and optional carboxylate, phospholipid, phosphatidyl
choline, or sphingomyelin, as
illustrated above. Pharmaceutical compositions that are suspensions can also
form drug depots when
injected into an animal.
-85-
CA 03018066 2018-09-17
WO 2017/161357 PCT/US2017/023108
[00324] By varying the lipophilicity and/or molecular weight of the amino acid
ester or amino acid amide
it is possible to vary the properties of pharmaceutical compositions that
include these components and
further comprise an organic solvent. The lipophilicity and/or molecular weight
of the amino acid ester or
amino acid amide can be varied by varying the amino acid and/or the alcohol
(or amine) used to form the
amino acid ester (or amino acid amide). For example, the lipophilicity and/or
molecular weight of the
amino acid ester can be varied by varying the R1 hydrocarbon group of the
amino acid ester. Typically,
increasing the molecular weight of R1 increase the lipophilicity of the amino
acid ester. Similarly, the
lipophilicity and/or molecular weight of the amino acid amide can be varied by
varying the R3 or R4
groups of the amino acid amide.
[00325] For example, by varying the lipophilicity and/or molecular weight of
the amino acid ester or
amino acid amide it is possible to vary the solubility of the oligonucleotide
of the invention in water, to
vary the solubility of the oligonucleotide in the organic solvent, vary the
viscosity of the pharmaceutical
composition comprising a solvent, and vary the ease at which the
pharmaceutical composition can be
drawn into a 20 gauge needle and then expelled from the 20 gauge needle.
[00326] Furthermore, by varying the lipophilicity and/or molecular weight of
the amino acid ester or
amino acid amide (i.e., by varying R1 of the amino acid ester or R3 and R4 of
the amino acid amide) it is
possible to control whether the pharmaceutical composition that further
comprises an organic solvent will
form a precipitate when injected into water. Although different
oligonucleotides exhibit different
solubility and behavior, generally the higher the molecular weight of the
amino acid ester or amino acid
amide, the more likely it is that the salt of the protonated oligonucleotide
and the amino acid ester of the
amide will form a precipitate when injected into water. Typically, when R1 of
the amino acid ester is a
hydrocarbon of about C16 or higher the pharmaceutical composition will form a
precipitate when injected
into water and when R1 of the amino acid ester is a hydrocarbon of about C12
or less the pharmaceutical
composition will not form a precipitate when injected into water. Indeed, with
amino acid esters wherein
R1 is a hydrocarbon of about C12 or less, the salt of the protonated
oligonucleotide and the amino acid
ester is, in many cases, soluble in water. Similarly, with amino acid amides,
if the combined number of
carbons in R3 and R4 is 16 or more the pharmaceutical composition will
typically form a precipitate when
injected into water and if the combined number of carbons in R3 and R4 is 12
or less the pharmaceutical
composition will not form a precipitate when injected into water. Whether or
not a pharmaceutical
composition that further comprises a pharmaceutically acceptable organic
solvent will form a precipitate
when injected into water can readily be determined by injecting about 0.05 mL
of the pharmaceutical
composition into about 4 mL of water at about 98 F. and determining how much
material is retained on a
0.22 wn filter after the composition is mixed with water and filtered.
Typically, a formulation or
composition is considered to be injectable when no more than 10% of the
formulation is retained on the
filter. In one embodiment, no more than 5% of the formulation is retained on
the filter. In one
embodiment, no more than 2% of the formulation is retained on the filter. In
one embodiment, no more
than 1% of the formulation is retained on the filter.
-86-
CA 03018066 2018-09-17
WO 2017/161357 PCT/US2017/023108
[00327] Similarly, in pharmaceutical compositions that comprise a protonated
oligonucleotide and a
diester or diamide of aspartic or glutamic acid, it is possible to vary the
properties of pharmaceutical
compositions by varying the amount and/or lipophilicity and/or molecular
weight of the diester or diamide
of aspartic or glutamic acid. Similarly, in pharmaceutical compositions that
comprise an oligonucleotide;
a divalent metal cation; and a carboxylate, a phospholipid, a phosphatidyl
choline, or a sphingomyelin, it
is possible to vary the properties of pharmaceutical compositions by varying
the amount and/or
lipophilicity and/or molecular weight of the carboxylate, phospholipid,
phosphatidyl choline, or
sphingomyelin.
[00328] Further, when the pharmaceutical compositions that further comprises
an organic solvent form a
depot when administered to an animal, it is also possible to vary the rate at
which the oligonucleotide is
released from the drug depot by varying the lipophilicity and/or molecular
weight of the amino acid ester
or amino acid amide. Generally, the more lipophilic the amino acid ester or
amino acid amide, the more
slowly the oligonucleotide is released from the depot. Similarly, when the
pharmaceutical compositions
that further comprises an organic solvent and also further comprise a
carboxylate, phospholipid,
phosphatidyl choline, sphingomyelin, or a diester or diamide of aspartic or
glutamic acid and form a depot
when administered to an animal, it is possible to vary the rate at which the
oligonucleotide is released
from the drug depot by varying the amount and/or lipophilicity and/or
molecular weight of the
carboxylate, phospholipid, phosphatidyl choline, sphingomyelin, or the diester
or diamide of aspartic or
glutamic acid.
[00329] Release rates from a precipitate can be measured injecting about 50 uL
of the pharmaceutical
composition into about 4 mL of deionized water in a centrifuge tube. The time
that the pharmaceutical
composition is injected into the water is recorded as T=0. After a specified
amount of time, T, the sample
is cooled to about ¨9 C. and spun on a centrifuge at about 13,000 rpm for
about 20 min. The resulting
supernatant is then analyzed by HPLC to determine the amount of
oligonucleotide present in the aqueous
solution. The amount of oligonucleotide in the pellet resulting from the
centrifugation can also be
determined by collecting the pellet, dissolving the pellet in about 10 uL of
methanol, and analyzing the
methanol solution by HPLC to determine the amount of oligonucleotide in the
precipitate. The amount of
oligonucleotide in the aqueous solution and the amount of oligonucleotide in
the precipitate are
determined by comparing the peak area for the HPLC peak corresponding to the
oligonucleotide against a
standard curve of oligonucleotide peak area against concentration of
oligonucleotide. Suitable HPLC
conditions can be readily determined by one of ordinary skill in the art.
[00330] Methods of Treatment
[00331] The pharmaceutical compositions of the invention are useful in human
medicine and veterinary
medicine. Accordingly, the invention further relates to a method of treating
or preventing a condition in an
animal comprising administering to the animal an effective amount of the
pharmaceutical composition of
the invention.
-87-
CA 03018066 2018-09-17
WO 2017/161357 PCT/US2017/023108
[00332] In one embodiment, the invention relates to methods of treating a
condition in an animal
comprising administering to an animal in need thereof an effective amount of a
pharmaceutical
composition of the invention.
[00333] In one embodiment, the invention relates to methods of preventing a
condition in an animal
comprising administering to an animal in need thereof an effective amount of a
pharmaceutical
composition of the invention.
[00334] Methods of administration include, but are not limited to,
intradermal, intramuscular,
intraperitoneal, intravenous, subcutaneous, intranasal, epidural, oral,
sublingual, intracerebral,
intravaginal, transdermal, rectal, by inhalation, or topical. The mode of
administration is left to the
discretion of the practitioner. In some embodiments, administration will
result in the release of the
oligonucleotide of the invention, e.g., an aptamer, an drug targeting aptamer,
a multipartite construct, or
any combination thereof, into the bloodstream.
[00335] In one embodiment, the method of treating or preventing a condition in
an animal comprises
administering to the animal in need thereof an effective amount of an
oligonucleotide by parenterally
administering the pharmaceutical composition of the invention. In one
embodiment, the pharmaceutical
compositions are administered by infusion or bolus injection. In one
embodiment, the pharmaceutical
composition is administered subcutaneously.
[00336] In one embodiment, the method of treating or preventing a condition in
an animal comprises
administering to the animal in need thereof an effective amount of an
oligonucleotide by orally
administering the pharmaceutical composition of the invention. In one
embodiment, the composition is in
the form of a capsule or tablet.
[00337] The pharmaceutical compositions can also be administered by any other
convenient route, for
example, topically, by absorption through epithelial or mucocutaneous linings
(e.g., oral, rectal, and
intestinal mucosa, etc.).
[00338] The pharmaceutical compositions can be administered systemically or
locally.
[00339] The pharmaceutical compositions can be administered together with
another biologically active
agent.
[00340] In one embodiment, the animal is a mammal.
[00341] In one embodiment the animal is a human.
[00342] In one embodiment, the animal is a non-human animal.
[00343] In one embodiment, the animal is a canine, a feline, an equine, a
bovine, an ovine, or a porcine.
[00344] The effective amount administered to the animal depends on a variety
of factors including, but not
limited to the type of animal being treated, the condition being treated, the
severity of the condition, and
the specific multipartite construct being administered. A treating physician
can determine an effective
amount of the pharmaceutical composition to treat a condition in an animal.
[00345] In one embodiment, the multipartite construct can inhibit
angiogenesis. In one embodiment, the
multipartite construct can inhibit angiogenesis and the disease being treated
is cancer. In one embodiment,
the aptamer can inhibit angiogenesis and the disease being treated is a solid
tumor.
-88-
CA 03018066 2018-09-17
WO 2017/161357 PCT/US2017/023108
[00346] The multipartite construct can be a multipartite construct that
inhibits a neoplastic growth or a
cancer. In embodiments, the cancer comprises an acute lymphoblastic leukemia;
acute myeloid leukemia;
adrenocortical carcinoma; AIDS-related cancers; AIDS-related lymphoma; anal
cancer; appendix cancer;
astrocytomas; atypical teratoid/rhabdoid tumor; basal cell carcinoma; bladder
cancer; brain stem glioma;
brain tumor (including brain stem glioma, central nervous system atypical
teratoid/rhabdoid tumor, central
nervous system embryonal tumors, astrocytomas, craniopharyngioma,
ependymoblastoma, ependymoma,
medulloblastoma, medulloepithelioma, pineal parenchymal tumors of intermediate
differentiation,
supratentorial primitive neuroectodermal tumors and pineoblastoma); breast
cancer; bronchial tumors;
Burkitt lymphoma; cancer of unknown primary site; carcinoid tumor; carcinoma
of unknown primary site;
central nervous system atypical teratoid/rhabdoid tumor; central nervous
system embryonal tumors;
cervical cancer; childhood cancers; chordoma; chronic lymphocytic leukemia;
chronic myelogenous
leukemia; chronic myeloproliferative disorders; colon cancer; colorectal
cancer; craniopharyngioma;
cutaneous T-cell lymphoma; endocrine pancreas islet cell tumors; endometrial
cancer;
ependymoblastoma; ependymoma; esophageal cancer; esthesioneuroblastoma; Ewing
sarcoma;
extracranial germ cell tumor; extragonadal germ cell tumor; extrahepatic bile
duct cancer; gallbladder
cancer; gastric (stomach) cancer; gastrointestinal carcinoid tumor;
gastrointestinal stromal cell tumor;
gastrointestinal stromal tumor (GIST); gestational trophoblastic tumor;
glioma; hairy cell leukemia; head
and neck cancer; heart cancer; Hodgkin lymphoma; hypopharyngeal cancer;
intraocular melanoma; islet
cell tumors; Kaposi sarcoma; kidney cancer; Langerhans cell histiocytosis;
laryngeal cancer; lip cancer;
liver cancer; malignant fibrous histiocytoma bone cancer; medulloblastoma;
medulloepithelioma;
melanoma; Merkel cell carcinoma; Merkel cell skin carcinoma; mesothelioma;
metastatic squamous neck
cancer with occult primary; mouth cancer; multiple endocrine neoplasia
syndromes; multiple myeloma;
multiple myeloma/plasma cell neoplasm; mycosis fungoides; myelodysplastic
syndromes;
myeloproliferative neoplasms; nasal cavity cancer; nasopharyngeal cancer;
neuroblastoma; Non-Hodgkin
lymphoma; nonmelanoma skin cancer; non-small cell lung cancer; oral cancer;
oral cavity cancer;
oropharyngeal cancer; osteosarcoma; other brain and spinal cord tumors;
ovarian cancer; ovarian
epithelial cancer; ovarian germ cell tumor; ovarian low malignant potential
tumor; pancreatic cancer;
papillomatosis; paranasal sinus cancer; parathyroid cancer; pelvic cancer;
penile cancer; pharyngeal
cancer; pineal parenchymal tumors of intermediate differentiation;
pineoblastoma; pituitary tumor; plasma
cell neoplasm/multiple myeloma; pleuropulmonary blastoma; primary central
nervous system (CNS)
lymphoma; primary hepatocellular liver cancer; prostate cancer; rectal cancer;
renal cancer; renal cell
(kidney) cancer; renal cell cancer; respiratory tract cancer; retinoblastoma;
rhabdomyosarcoma; salivary
gland cancer; Sezary syndrome; small cell lung cancer; small intestine cancer;
soft tissue sarcoma;
squamous cell carcinoma; squamous neck cancer; stomach (gastric) cancer;
supratentorial primitive
neuroectodermal tumors; T-cell lymphoma; testicular cancer; throat cancer;
thymic carcinoma; thymoma;
thyroid cancer; transitional cell cancer; transitional cell cancer of the
renal pelvis and ureter; trophoblastic
tumor; ureter cancer; urethral cancer; uterine cancer; uterine sarcoma;
vaginal cancer; vulvar cancer;
-89-
CA 03018066 2018-09-17
WO 2017/161357 PCT/US2017/023108
WaldenstrOm macroglobulinemia; or Wilm's tumor. The compositions and methods
of the invention can
be used to treat these and other cancers.
Oligonucleotide Probe Methods
[00347] Nucleic acid sequences fold into secondary and tertiary motifs
particular to their nucleotide
sequence. These motifs position the positive and negative charges on the
nucleic acid sequences in
locations that enable the sequences to bind to specific locations on target
molecules, including without
limitation proteins and other amino acid sequences. These binding sequences
are known in the field as
aptamers. Due to the trillions of possible unique nucleotide sequences in even
a relatively short stretch of
nucleotides (e.g., 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24,
25, 26, 27, 28, 29, 30, 31, 32,
33, 34, 35, 36, 37, 38, 39 or 40 nucleotides), a large variety of motifs can
be generated, resulting in
aptamers for almost any desired protein or other target.
[00348] As described above, aptamers can be created by randomly generating
oligonucleotides of a
specific length, typically 20-80 base pairs long, e.g., 20, 21, 22, 23, 24,
25, 26, 27, 28, 29, 30, 31, 32, 33,
34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52,
53, 54, 55, 56, 57, 58, 59, 60, 61,
62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79 or 80
base pairs. These random
oligonucleotides are then incubated with the target of interest (e.g., tissue,
cell, microvesicle, protein, etc).
After several wash steps, the oligonucleotides that bind to the target are
collected and amplified. The
amplified aptamers are iteratively added to the target and the process is
repeated, often 15-20 times. A
common version of this process known to those of skill in the art as the SELEX
method.
[00349] The end result comprises one or more oligonucleotide probes / aptamers
with high affinity to the
target. The invention provides further processing of such resulting aptamers
that can be use to provide
desirable characteristics: 1) competitive binding assays to identify aptamers
to a desired epitope; 2) motif
analysis to identify high affinity binding aptamers in silico; and 3) aptamer
selection assays to identify
aptamers that can be used to detect a particular disease. The methods are
described in more detail below
and further in the Examples.
[00350] The invention further contemplates aptamer sequences that are highly
homologous to the
sequences that are discovered by the methods of the invention. "High homology"
typically refers to a
homology of 40% or higher, preferably 60% or higher, 70% or higher, more
preferably 80% or higher,
even more preferably 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or
higher between a
polynucleotide sequence sequence and a reference sequence. In an embodiment,
the reference sequence
comprises the sequence of one or more aptamer provided herein. Percent
homologies (also referred to as
percent identity) are typically carried out between two optimally aligned
sequences. Methods of alignment
of sequences for comparison are well-known in the art. Optimal alignment of
sequences and comparison
can be conducted, e.g., using the algorithm in "Wilbur and Lipman, Proc Natl
Acad Sci USA 80: 726-30
(1983)". Homology calculations can also be performed using BLAST, which can be
found on the NCBI
server at: www.ncbi.nlm.nih.gov/BLAST/ (Altschul S F, et al, Nucleic Acids
Res. 1997; 25(17):3389-
402; Altschul S F, et al, J Mol. Biol. 1990; 215(3):403-10). In the case of an
isolated polynucleotide
which is longer than or equivalent in length to the reference sequence, e.g.,
a sequence identified by the
-90-
CA 03018066 2018-09-17
WO 2017/161357 PCT/US2017/023108
methods herein, the comparison is made with the full length of the reference
sequence. Where the isolated
polynucleotide is shorter than the reference sequence, e.g., shorter than a
sequence identified by the
methods herein, the comparison is made to a segment of the reference sequence
of the same length
(excluding any loop required by the homology calculation).
[00351] The invention further contemplates aptamer sequences that are
functional fragments of the
sequences that are discovered by the methods of the invention. In the context
of an aptamer sequence, a
"functional fragment" of the aptamer sequence may comprise a subsequence that
binds to the same target
as the full length sequence. In some instances, a candidate aptamer sequence
is from a member of a library
that contains a 5' leader sequences and/or a 3' tail sequence. Such leader
sequences or tail sequences may
serve to facilitate primer binding for amplification or capture, etc. In these
embodiments, the functional
fragment of the full length sequence may comprise the subsequence of the
candidate aptamer sequence
absent the leader and/or tail sequences.
[00352] Competitive Antibody Addition
[00353] Known aptamer production methods may involve eluting all bound
aptamers from the target
sequence. In some cases, this may not easily identify the desired aptamer
sequence. For example, when
trying to replace an antibody in an assay, it may be desirable to only collect
aptamers that bind to the
specific epitope of the antibody being replaced. The invention provides a
method comprising addition of
an antibody that is to be replaced to the aptamer/target reaction in order to
allow for the selective
collection of aptamers which bind to the antibody epitope. In an embodiment,
the method comprises
incubating a reaction mixture comprising randomly generated oligonucleotides
with a target of interest,
removing unbound aptamers from the reaction mixture that do not bind the
target, adding an antibody to
the reaction mixture that binds to that epitope of interest, and collecting
the aptamers that are displaced by
the antibody. The target can be a a biological entity such as disclosed
herein, e.g., a protein.
[00354] Motif Analysis
[00355] In aptamer experiments, multiple aptamer sequences can be identified
that bind to a given target.
These aptamers will have various binding affinities. It can be time consuming
and laborious to generate
quantities of these many aptamers sufficient to assess the affinities of each.
To identify large numbers of
aptamers with the highest affinities without physically screening large
subsets, the invention provides a
method comprising the analysis of the two dimensional structure of one or more
high affinity aptamers to
the target of interest. In an embodiment, the method comprises screening the
database for aptamers that
have similar two-dimensional structures, or motifs, but not necessarily
similar primary sequences. In an
embodiment, the method comprises identifying a high affinity aptamer using
traditional methods such as
disclosed herein or known in the art (e.g. surface plasmon resonance binding
assay), approximating the
two-dimensional structure of the high affinity aptamer, and identifying
aptamers from a pool of sequences
that are predicted to have a similar two-dimensional structure to the high
affinity aptamer. The method
thereby provides a pool of candidates that also bind the target of interest.
The two-dimensional structure
of an oligo can be predicting using methods known in the art, e.g., via free
energy (AG) calculations
performed using a commercially available software program such as Vienna or
mFold, for example as
-91-
CA 03018066 2018-09-17
WO 2017/161357 PCT/US2017/023108
described in Mathews, D., Sabina, J., Zucker, M. & Turner, H. Expanded
sequence dependence of
thermodynamic parameters provides robust prediction of RNA secondary
structure. J. Mol. Biol. 288,
911-940 (1999); Hofacker et al., Monatshefte f. Chemie 125: 167-188 (1994);
and Hofacker, I. L. Vienna
RNA secondary structure server. Nucleic Acids Res. 31, 3429-3431 (2003), the
contents of which are
incorporated herein by reference in their entirety. See FIGs. 2A-2B.The pool
of sequences can be
sequenced from a pool of randomly generated aptamer candidates using a high-
throughput sequencing
platform, such as the Ion Torrent platform from Thermo Fisher Scientific
(Waltham, MA) or
HiSeq/NextSeq/MiSeq platform from Illumina, Inc (San Diego, CA). Identifying
aptamers from a pool of
sequences that are predicted to have a similar two-dimensional structure to
the high affinity aptamer may
comprise loading the resulting sequences into the software program of choice
to identify members of the
pool of sequences with similar two-dimensional structures as the high affinity
aptamer. The affinities of
the pool of sequences can then be determined in situ, e.g., surface plasmon
resonance binding assay or the
like.
[00356] Aptamer Subtraction Methods
[00357] In order to develop an assay to detect a disease, for example, cancer,
one typically screens a large
population of known biomarkers from normal and diseased patients in order to
identify markers that
correlate with disease. This process works where discriminating markers are
already described. In order to
address this problem, the invention provides a method comprising subtracting
out non-discriminating
aptamers from a large pool of aptamers by incubating them initially with non-
target tissue, microvesicles,
cells, or other targets of interest. The non-target entities can be from a
normal! healthy / non-diseased
sample. The aptamers that did not bind to the normal non-target entities are
then incubated with diseased
entities. The aptamers that bind to the diseased entities but that did not
bind the normal entities are then
possible candidates for an assay to detect the disease. This process is
independent of knowing the
existence of a particular marker in the diseased sample.
[00358] Subtraction methods can be used to identify aptamers that
preferentially recognize a desired
population of targets. In an embodiment, the subtraction method is used to
identify aptamers that
preferentially recognize target from a diseased target population over a
control (e.g., normal or non-
diseased) population. The diseased target population may be a tissue or a
population of cells or
microvesicles from a diseased individual or individuals, whereas the control
population comprises
corresponding tissue, cells or microvesicles from a non-diseased individual or
individuals. The disease
can be a cancer or other disease disclosed herein or known in the art.
Accordingly, the method provides
aptamers that preferentially identify disease targets versus control targets.
[00359] Circulating microvesicles can be isolated from control samples, e.g.,
plasma from "normal"
individuals that are absent a disease of interest, such as an absence of
cancer. Vesicles in the sample are
isolated using a method disclosed herein or as known in the art. For example,
vesicles can be isolated
from the plasma by one of the following methods: filtration, ultrafiltration,
nanomembrane ultrafiltration,
the ExoQuick reagent (System Biosciences, Inc., Mountain View, CA),
centrifugation, ultracentrifugation,
using a molecular crowding reagent (e.g., TEXTS from Life Technologies),
polymer precipitation (e.g.,
-92-
CA 03018066 2018-09-17
WO 2017/161357
PCT/US2017/023108
polyethylene glycol (PEG)), affinity isolation, affmity selection,
immunoprecipitation, chromatography,
size exclusion, or a combination of any of these methods. The microvesicles
isolated in each case will be a
mixture of vesicle types and will be various sizes although
ultracentrifugation methods may have more
tendencies to produce exosomal-sized vesicles. Randomly generated
oligonucleotide libraries (e.g.,
produced as described in the Examples herein) are incubated with the isolated
normal vesicles. The
aptamers that do not bind to these vesicles are isolated, e.g., by
precipitating the vesicles (e.g, with PEG)
and collecting the supernatant containing the non-binding aptamers. These non-
binding aptamers are then
contacted with vesicles isolated from diseased patients (e.g., using the same
methods as described above)
to allow the aptamers to recognize the disease vesicles. Next, aptamers that
are bound to the diseased
vesicles are collected. In an embodiment, the vesicles are isolated then lysed
using a chaotropic agent
(e.g., SDS or a similar detergent), and the aptamers are then captured by
running the lysis mixture over an
affinity column. The affinity column may comprise streptavidin beads in the
case of biotin conjugated
aptamer pools. The isolated aptamers are the amplified. The process can then
then repeated, e.g., 1, 2, 3, 4,
5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20 or more times to
achieve aptamers having a desired
selectivity for the target.
[00360] In one aspect of the invention, an aptamer profile is identified that
can be used to characterize a
biological sample of interest. In an embodiment, a pool of randomly generated
oligonucleotides, e.g., at
, 10 0- 1 -012,
least 10, 102, 103, 104, 105, 106, 107, 108, 109, 1010, 10", 1013,
1014, 1015, 1016, 1017, 1018, iv or at
least 1020 oligonucleotides, is contacted with a biological component or
target of interest from a control
population. The oligonucleotides that do not bind the biological component or
target of interest from the
control population are isolated and then contacted with a biological component
or target of interest from a
test population. The oligonucleotides that bind the biological component or
target of interest from the test
population are retained. The retained oligonucleotides can be used to repeat
the process by contacting the
retained oligonucleotides with the biological component or target of interest
from the control population,
isolating the retained oligonucleotides that do not bind the biological
component or target of interest from
the control population, and again contacting these isolated oligonucleotides
with the biological component
or target of interest from the test population and isolating the binding
oligonucleotides. The "component"
or "target" can be anything that is present in sample to which the
oligonucleotides are capable of binding
(e.g., tissue, cells, microvesicles, polypeptides, peptide, nucleic acid
molecules, carbodyhrates, lipids,
etc.). The process can be repeated any number of desired iterations, e.g.,
1,2, 3,4, 5, 6, 7, 8,9, 10, 11, 12,
13, 14, 15, 16, 17, 18, 19 or 20 or more times. The resulting oligonucleotides
comprise aptamers that can
differentially detect the test population versus the control. These aptamers
provide an aptamer profile,
which comprises a biosignature that is determined using one or more aptamer,
e.g., a biosignature
comprising a presense or level of the component or target which is detected
using the one or more
aptamer.
[00361] An exemplary process is illustrated in FIG. 3, which demonstrates the
method to identify aptamer
that preferentially recognize cancer exosomes using exosomes from normal (non-
cancer) individuals as a
control. In the figure, exosomes are exemplified but one of skill will
appreciate that other microvesicles
-93-
CA 03018066 2018-09-17
WO 2017/161357 PCT/US2017/023108
can be used in the same manner. The resulting aptamers can provide a profile
that can differentially detect
the cancer exosomes from the normal exosomes. One of skill will appreciate
that the same steps can be
used to derive an aptamer profile to characterize any disease or condition of
interest. The process can also
be applied with tissue, cells, or other targets of interest.
[00362] In an embodiment, the invention provides an isolated polynucleotide
that encodes a polypeptide,
or a fragment thereof, identified by the methods above. The invention further
provides an isolated
polynucleotide having a nucleotide sequence that is at least 60% identical to
the nucleotide sequence
identified by the methods above. More preferably, the isolated nucleic acid
molecule is at least 65%, 70%,
75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more,
identical to the
nucleotide sequence identified by the methods above. In the case of an
isolated polynucleotide which is
longer than or equivalent in length to the reference sequence, e.g., a
sequence identified by the methods
above, the comparison is made with the full length of the reference sequence.
Where the isolated
polynucleotide is shorter than the reference sequence, e.g., shorter than a
sequence identified by the
methods above, the comparison is made to a segment of the reference sequence
of the same length
(excluding any loop required by the homology calculation).
[00363] In a related aspect, the invention provides a method of characterizing
a biological phenotype
using an aptamer profile. The aptamer profile can be determined using the
method above. The aptamer
profile can be determined for a test sample and compared to a control aptamer
profile. The phenotype may
be a disease or disorder such as a cancer. Characterizing the phenotype can
include without limitation
providing a diagnosis, prognosis, or theranosis. Thus, the aptamer profile can
provide a diagnostic,
prognostic and/or theranostic readout for the subject from whom the test
sample is obtained.
[00364] In another embodiment, an aptamer profile is determined for a test
sample by contacting a pool of
aptamer molecules to the test sample, contacting the same pool of aptamers to
a control sample, and
identifying one or more aptamer molecules that differentially bind a component
or target in the test
sample but not in the control sample (or vice versa). A "component" or
"target" as used in the context of
the biological test sample or control sample can be anything that is present
in sample to which the
aptamers are capable of binding (e.g., tissue, cells, microvesicles,
polypeptides, peptide, nucleic acid
molecules, carbodyhrates, lipids, etc.). For example, if a sample is a plasma
or serum sample, the aptamer
molecules may bind a polypeptide biomarker that is solely expressed or
differentially expressed (over- or
underexpressed) in a disease state as compared to a non-diseased subject.
Comparison of the aptamer
profile in the test sample as compared to the control sample may be based on
qualitative and quantitative
measure of aptamer binding (e.g., binding versus no binding, or level of
binding in test sample versus
different level of binding in the reference control sample).
[00365] In an aspect, the invention provides a method of identifying a target-
specific aptamer profile,
comprising contacting a biological test sample with a pool of aptamer
molecules, contacting the pool to a
control biological sample, identifying one or more aptamers that bind to a
component in said test sample
but not to the control sample, thereby identifying an aptamer profile for said
biological test sample. In an
embodiment, a pool of aptamers is selected against a disease sample and
compared to a reference sample,
-94-
CA 03018066 2018-09-17
WO 2017/161357 PCT/US2017/023108
the aptamers in a subset that bind to a component(s) in the disease sample but
not in the reference sample
can be sequenced using conventional sequencing techniques to identify the
subset that bind, thereby
identifying an aptamer profile for the particular disease sample. In this way,
the aptamer profile provides
an individualized platform for detecting disease in other samples that are
screened. Furthermore, by
selecting an appropriate reference or control sample, the aptamer profile can
provide a diagnostic,
prognostic and/or theranostic readout for the subject from whom the test
sample is obtained.
[00366] In a related aspect, the invention provides a method of selecting a
pool of aptamers, comprising:
(a) contacting a biological control sample with a pool of oligonucleotides;
(b) isolating a first subset of the
pool of oligonucleotides that do not bind the biological control sample; (c)
contacting the biological test
sample with the first subset of the pool of oligonucleotides; and (d)
isolating a second subset of the pool
of oligonucleotides that bind the biological test sample, thereby selecting
the pool of aptamers. The pool
of oligonucleotides may comprise any number of desired sequences, e.g., at
least 10, 102, 103, 104, 105,
106, 102, 108, 109, 1010, 1011, 1012, 1013, 1014, 1015, 1016, 1012, 1018, 1019
or at least 10" oligonucleotides
may be present in the starting pool. Steps (a)-(d) may be repeated to further
hone the pool of aptamers. In
an embodiment, these steps are repeated at least 1, 2, 3, 4, 5, 6, 7, 8, 9,
10, 11, 12, 13, 14, 15, 16, 17, 18,
19 or at least 20 times.
[00367] As described herein, the biological test sample and biological control
sample may comprise
tissues, cells, microvesicles, or biomarkers of interest. In an embodiment,
the biological test sample and
optionally biological control sample comprise a bodily fluid. The bodily fluid
may comprise without
limitation peripheral blood, sera, plasma, ascites, urine, cerebrospinal fluid
(CSF), sputum, saliva, bone
marrow, synovial fluid, aqueous humor, amniotic fluid, cerumen, breast milk,
broncheoalveolar lavage
fluid, semen, prostatic fluid, Cowper's fluid, pre-ejaculatory fluid, female
ejaculate, sweat, fecal matter,
hair, tears, cyst fluid, pleural fluid, peritoneal fluid, malignant fluid,
pericardial fluid, lymph, chyme,
chyle, bile, interstitial fluid, menses, pus, sebum, vomit, vaginal
secretions, mucosal secretion, stool
water, pancreatic juice, lavage fluids from sinus cavities, bronchopulmonary
aspirates or other lavage
fluids. Tthe biological test sample and optionally biological control may also
comprise a tumor sample,
e.g., cells from a tumor or tumor tissue. In other embodiments, the biological
test sample and optionally
biological control sample comprise a cell culture medium. In embodiments, the
biological test sample
comprises a diseased sample and the biological control sample comprises a non-
diseased sample.
Accordingly, the pool of aptamers may be used to provide a diagnostic,
prognostic and/or theranostic
readout for the disease.
[00368] As noted, the invention can be used to assess microvesicles.
Microvesicles are powerful
biomarkers because the vesicles provide one biological entity that comprises
multiple pieces of
information. For example as described, a vesicle can have multiple surface
antigens, each of which
provides complementary information. Consider a cancer marker and a tissue
specific marker. If both
markers are individually present in a sample, e.g., both are circulating
proteins or nucleic acids, it may not
be ascertainable whether the cancer marker and the tissue specific marker are
derived from the same
anatomical locale. However, if both the cancer marker and the tissue specific
marker are surface antigens
-95-
CA 03018066 2018-09-17
WO 2017/161357 PCT/US2017/023108
on a single microvesicle, the vesicle itself links the two markers and
provides an indication of a disease
(via the cancer marker) and origin of the disease (via the tissue specific
marker). Furthermore, the vesicle
can have any number of surface antigens and also payload that can be assessed.
Accordingly, the
invention provides a method for identifying binding agents comprising
contacting a plurality of
extracellular microvesicles with a randomly generated library of binding
agents, identifying a subset of
the library of binding agents that have an affinity to one or more components
of the extracellular
microvesicles. The binding agents may comprise aptamers, antibodies, and/or
any other useful type of
binding agent disclosed herein or known in the art.
[00369] In a related aspect, the invention provides a method for identifying a
plurality of target ligands
comprising, (a) contacting a reference microvesicle population with a
plurality of ligands that are capable
of binding one or more microvesicle surface markers, (b) isolating a plurality
of reference ligands,
wherein the plurality of reference ligands comprise a subset of the plurality
of ligands that do not have an
affinity for the reference microvesicle population; (c) contacting one or more
test microvesicle with the
plurality of reference ligands; and (d) identifying a subset of ligands from
the plurality of reference
ligands that form complexes with a surface marker on the one or more test
microvesicle, thereby
identifying the plurality of target ligands. The term "ligand" can refer a
molecule, or a molecular group,
that binds to another chemical entity to form a larger complex. Accordingly, a
binding agent comprises a
ligand. The plurality of ligands may comprise aptamers, antibodies and/or
other useful binding agents
described herein or known in the art. The process can also be applied to
tissue samples. See, e.g.,
Examples 19-31 herien.
[00370] The invention further provides kits comprising one or more reagent to
carry out the methods
above. In an embodiment, the one or more reagent comprises a library of
potential binding agents that
comprises one or more of an aptamer, antibody, and other useful binding agents
described herein or
known in the art.
[00371] Negative and Positive Aptamer Selection
[00372] Aptamers can be used in various biological assays, including numerous
types of assays which rely
on a binding agent. For example, aptamers can be used instead of or along side
antibodies in various
immunoassay formats, such as sandwich assays, flow cytometry and IHC. The
invention provides an
aptamer screening method that identifies aptamers that do not bind to any
surfaces (substrates, tubes,
filters, beads, other antigens, etc.) throughout the assay steps and bind
specifically to an antigen of
interest. The assay relies on negative selection to remove aptamers that bind
non-target antigen
components of the final assay. The negative selection is followed by positive
selection to identify
aptamers that bind the desired antigen.
[00373] In an aspect, the invention provides a method of identifying an
aptamer specific to a target of
interest, comprising (a) contacting a pool of candidate aptamers with one or
more assay components,
wherein the assay components do not comprise the target of interest; (b)
recovering the members of the
pool of candidate aptamers that do not bind to the one or more assay
components in (a); (c) contacting the
members of the pool of candidate aptamers recovered in (b) with the target of
interest in the presence of
-96-
CA 03018066 2018-09-17
WO 2017/161357 PCT/US2017/023108
one or more confounding target; and (d) recovering a candidate aptamer that
binds to the target of interest
in step (c), thereby identifying the aptamer specific to the target of
interest. In the method, steps (a) and
(b) provide negative selection to remove aptamers that bind non-target
entities. Conversely, steps (c) and
(d) provide positive selection by identifying aptamers that bind the target of
interest but not other
confounding targets, e.g., other antigens that may be present in a biological
sample which comprises the
target of interest. The pool of candidate aptamers may comprise at least 10,
102, 103, 104, 105, 106, 107,
108, 109, 1010, 1011, 1012, 1013, 1014, 1015, 1016, 1017, 1018,
1019 or at least 1020 nucleic acid sequences.
[00374] In some embodiments, steps (a)-(b) are optional. In other embodiments,
steps (a)-(b) are repeated
at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or
at least 20 times before positive
selection in step (c) is performed. The positive selection can also be
performed in multiple rounds. Steps
(c)-(d) can be repeated at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13,
14, 15, 16, 17, 18, 19 or at least 20
times before identifying the aptamer specific to the target of interest.
Multiple rounds may provide
improved stringency of selection.
100375] In some embodiments, the one or more assay components contacted with
the aptamer pool during
negative selection comprise one or more of a substrate, a bead, a planar
array, a column, a tube, a well, or
a filter. One of skill will appreciate that the assay components can include
any substance that may be part
of a desired biological assay.
100376] The target of interest can be any appropriate entity that can be
detected when recognized by an
aptamer. In an embodiment, the target of interest comprises a protein or
polypeptide. As used herein,
"protein," "polypeptide" and "peptide" are used interchangeably unless stated
otherwise. The target of
interest can be a nucleic acid, including DNA, RNA, and various subspecies of
any thereof as disclosed
herein or known in the art. The target of interest can comprise a lipid. The
target of interest can comprise a
carbohydrate. The target of interest can also be a complex, e.g., a complex
comprising protein, nucleic
acids, lipids and/or carbohydrates. In some embodiments, the target of
interest comprises a tissue, cell, or
microvesicle. In such cases, the aptamer may be a binding agent to a surface
antigen or disease antigen.
100377] The surface antigen can be a biomarker of a disease or disorder. In
such cases, the aptamer may
be used to provide a diagnosis, prognosis or theranosis of the disease or
disorder. For example, the one or
more protein may comprise one or more of PSMA, PCSA, B7H3, EpCam, ADAM-10,
BCNP, EGFR,
IL1B, KLK2, MMP7, p53, PBP, SERPINB3, SPDEF, SSX2, and SSX4. These markers can
be used detect
a prostate cancer. Additional surface antigens and disease antigens are
provided in Tables 3-4 herein.
[00378] The one or more confounding target can be an antigen other than the
target of interest. For
example, a confounding target can be another entity that may be present in a
sample to be assayed. As a
non-limiting example, consider that the sample to be assessed is a tissue or
blood sample from an
individual. The target of interest may be a protein, e.g., a surface antigen,
which is present in the sample.
In this case, a confounding target could be selected from any other antigen
that is likely to be present in
the sample. Accordingly, the positive selection should provide candidate
aptamers that recognize the
target of interest but have minimal, if any, interactions with the confounding
targets. In some
embodiments, the target of interest and the one or more confounding target
comprise the same type of
-97-
CA 03018066 2018-09-17
WO 2017/161357 PCT/US2017/023108
biological entity, e.g., all protein, all nucleic acid, all carbohydrate, or
all lipids. As a non-limiting
example, the target of interest can be a protein selected from the group
consisting of SSX4, SSX2, PBP,
KLK2, SPDEF, and EpCAM, and the one or more confounding target comprises the
other members of
this group. In other embodiments, the target of interest and the one or more
confounding target comprise
different types of biological entities, e.g., any combination of protein,
nucleic acid, carbohydrate, and
lipids. The one or more confounding targets may also comprise different types
of biological entities, e.g.,
any combination of protein, nucleic acid, carbohydrate, and lipids.
[00379] In an embodiment, the invention provides an isolated polynucleotide,
or a fragment thereof,
identified by the methods above. The invention further provides an isolated
polynucleotide having a
nucleotide sequence that is at least 60% identical to the nucleotide sequence
identified by the methods
above. The isolated polynucleotide is also referred to as an aptamer or
oligonucleotide probe. More
preferably, the isolated nucleic acid molecule is at least 65%, 70%, 75%, 80%,
85%, 90%, 91%, 92%,
93%, 94%, 95%, 96%, 97%, 98%, 99% or more, identical to the nucleotide
sequence identified by the
methods above. In the case of an isolated polynucleotide which is longer than
or equivalent in length to
the reference sequence, e.g., a sequence identified by the methods above, the
comparison is made with the
full length of the reference sequence. Where the isolated polynucleotide is
shorter than the reference
sequence, e.g., shorter than a sequence identified by the methods above, the
comparison is made to a
segment of the reference sequence of the same length (excluding any loop
required by the homology
calculation).
[00380] In a related aspect, the invention provides a method of selecting a
group of aptamers, comprising:
(a) contacting a pool of aptamers to a population of microvesicles from a
first sample; (b) enriching a
subpool of aptamers that show affinity to the population of microvesicles from
the first sample; (c)
contacting the subpool to a second population of microvesicles from a second
sample; and (d) depleting a
second subpool of aptamers that show affinity to the second population of
microvesicles from the second
sample, thereby selecting the group of aptamers that have preferential
affinity for the population of
microvesicles from the first sample. The first sample and/or second sample may
comprise a biological
fluid such as disclosed herein. For example, the biological fluid may include
without limitation blood, a
blood derivative, plasma, serum or urine. The first sample and/or second
sample may also be derived from
a cell culture.
[00381] In another related aspect, the invention provides a method of
selecting a group of aptamers,
comprising: (a) contacting a pool of aptamers to a tissue from a first sample;
(b) enriching a subpool of
aptamers that show affinity to the tissue from the first sample; (c)
contacting the subpool to a second
tissue from a second sample; and (d) depleting a second subpool of aptamers
that show affinity to the
second tissue from the second sample, thereby selecting the group of aptamers
that have preferential
affinity for the tissue from the first sample as compared to the second
sample. The first sample and/or
second sample may comprise a fixed tissue such as disclosed herein. For
example, the fixed tissue may
include FFPE tissue. The first sample and/or second sample may comprise a
tumor sample.
-98-
CA 03018066 2018-09-17
WO 2017/161357 PCT/US2017/023108
[00382] In an embodiment, the first sample comprises a cancer sample and the
second sample comprises a
control sample, such as a non-cancer sample. The first sample and/or and the
second sample may each
comprise a pooled sample. For example, the first sample and/or second sample
can comprise bodily fluid
from 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25,
30, 40, 50, 60, 70, 80, 90, 100 or
more than 100 individuals. In such cases, the members of a pool may be chosen
to represent a desired
phenotype. In a non-limiting example, the members of the first sample pool may
be from patients with a
cancer and the members of the second sample pool may be from non-cancer
controls. With tissue samples,
the first sample may comprise tissues from different individuals, e.g., from
2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12,
13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 40, 50, 60, 70, 80, 90, 100 or more
than 100 individuals. As a non-
limiting example, the first sample may comprise a fixed tissue from each
individual.
[00383] Steps (a)-(d) can be repeated a desired number of times in order to
further enrich the pool in
aptamers that have preferential affinity for the target from the first sample.
For example, steps (a)-(d) can
be repeated 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19,
20 or more than 20 times. The
output from step (d) can be used as the input to repeated step (a). In
embodiment, the first sample and/or
second sample are replaced with a different sample before repeating steps (a)-
(d). In a non-limiting
example, members of a first sample pool may be from patients with a cancer and
members of a second
sample pool may be from non-cancer controls. During subsequent repetitions of
steps (a)-(d), the first
sample pool may comprise samples from different cancer patients than in the
prior round/s. Similarly, the
second sample pool may comprise samples from different controls than in the
prior round/s.
[00384] In still another related aspect, the invention provides a method of
enriching a plurality of
oligonucleotides, comprising: (a) contacting a first sample with the plurality
of oligonucleotides; (b)
fractionating the first sample contacted in step (a) and recovering members of
the plurality of
oligonucleotides that fractionated with the first sample; (c) contacting the
recovering members of the
plurality of oligonucleotides from step (b) with a second sample; (d)
fractionating the second sample
contacted in step (c) and recovering members of the plurality of
oligonucleotides that did not fractionate
with the second sample; (e) contacting the recovering members of the plurality
of oligonucleotides from
step (d) with a third sample; and (f) fractionating the third sample contacted
in step (a) and recovering
members of the plurality of oligonucleotides that fractionated with the third
sample; thereby enriching the
plurality of oligonucleotides. The samples can be of any appropriate form as
described herein, e.g., tissue,
cells, microvesicles, etc. The first and third samples may have a first
phenotype while the second sample
has a second phenotype. Thus, positive selection occurs for the samples
associated with the first
phenotype and negative selection occurs for the samples associated with the
second phenotype. In one
non-limiting example of such selection schemes, the first phenotype comprises
biopsy-positive breast
cancer and the second phenotype comprises non-breast cancer (biopsy-negative
or healthy).
[00385] In some embodiments, the first phenotype comprises a medical
condition, disease or disorder and
the second phenotype comprises a healthy state or a different state of the
medical condition, disease or
disorder. The first phenotype can be a healthy state and the second phenotype
comprises a medical
condition, disease or disorder. The medical condition, disease or disorder can
be any detectable medical
-99-
CA 03018066 2018-09-17
WO 2017/161357 PCT/US2017/023108
condition, disease or disorder, including without limitation a cancer, a
premalignant condition, an
inflammatory disease, an immune disease, an autoimmune disease or disorder, a
cardiovascular disease or
disorder, neurological disease or disorder, infectious disease or pain.
Various types of such conditions are
disclosed herein. See, e.g., Section "Phenotypes" herein.
[00386] Any useful method to isolate microvesicles in whole or in part can be
used to fractionate the
samples as appropriate. Several useful techniques are described herein. In an
embodiment, the
fractionating comprises ultracentrifugation in step (b) and polymer
precipitation in steps (d) and (f). In
other embodiments, polymer precipitation is used in all steps. The polymer can
be polyethylene glycol
(PEG). Any appropriate form of PEG may be used. For example, the PEG may be
PEG 8000. The PEG
may be used at any appropriate concentration. For example, the PEG can be used
at a concentration of
1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14% or 15% to isolate
the microvesicles.
In some embodiments, the PEG is used at a concentration of 6%.
[00387] When the sample comprises an FFPE tissue sample, the sample can be
subjected to epitope
retrival, also known as antigen retrival, prior ro the enrichment process.
Although tissue fixation is useful
for the preservation of tissue morphology, this process can also have a
negative impact on immuno
detection methods. For example, fixation can alter protein biochemistry such
that the epitope of interest is
masked and can no longer bind to the primary antibody. Masking of the epitope
can be caused by cross-
linking of amino acids within the epitope, cross-linking unrelated peptides at
or near an epitope, altering
the conformation of an epitope, or altering the electrostatic charge of the
antigen. Epitope retrieval refers
to any technique in which the masking of an epitope is reversed and epitope-
recognition is restored.
Techniques for epitope retrieval are known in the art. For example, enzymes
including Proteinase K,
Trypsin, and Pepsin have been used successfully to restore epitope binding.
Without being bound by
theory, the mechanism of action may be the cleavage of peptides that may be
masking the epitope.
Heating the sample may also reverse some cross-links and allows for
restoration of secondary or tertiary
structure of the epitope. Change in pH or cation concentration may also
influence epitope availability.
[00388] The contacting can be performed in the presence of a competitor, which
may reduce non-specific
binding events. Any useful competitor can be used. In an embodiment, the
competitor comprises at least
one of salmon sperm DNA, tRNA, dextran sulfate and carboxymethyl dextran. As
desired, different
competitors or competitor concentrations can be used at different contacting
steps.
[00389] The method can be repeated to achieve a desired enrichment. In an
embodiment, steps (a)-(f) are
repeated at least once. These steps can be repeated 1, 2, 3, 4, 5, 6, 7, 8, 9,
10, 11, 12, 13, 14, 15, 16, 17,
18, 19, 20, or more than 20 times as desired. At the same time, each of the
contacting steps can be
repeated as desired. In some embodiments, the method further comprises: (i)
repeating steps (a)-(b) at
least once prior to step (c), wherein the recovered members of the plurality
of oligonucleotides that
fractionated with the first sample in step (b) are used as the input plurality
of oligonucleotides for the
repetition of step (a); (ii) repeating steps (c)-(d) at least once prior to
step (e), wherein the recovered
members of the plurality of oligonucleotides that did not fractionate with the
second sample in step (d) are
used as the input plurality of oligonucleotides for the repetition of step
(c); and/or (iii) repeating steps (e)-
-100-
CA 03018066 2018-09-17
WO 2017/161357 PCT/US2017/023108
(f) at least once, wherein the recovered members of the plurality of
oligonucleotides that fractionated with
the third sample in step (f) are used as the input plurality of
oligonucleotides for the repetition of step (e).
Repetitions (i)-(iii) can be repeated any desired number of times, e.g., (i)-
(iii) can be repeated 1, 2, 3, 4, 5,
6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 or more than 20 times.
In an embodiment, (i)-(iii) each
comprise three repetitions.
[00390] The method may further comprise identifying the members of the
selected group of aptamers or
oligonucleotides, e.g., by DNA sequencing. The sequencing may be performed by
Next Generation
sequencing as desired and after or before any desired step in the method.
[00391] The method may also comprise identifying the targets of the selected
group of
aptamersioligonucleotides. Useful methods to identify such targets are
disclosed herein. In a non-limiting
example, an enriched oligonucleotide library is contacted with an appropriate
sample (e.g., the first or
third sample), the library is cross-linked to the sample, and the library is
recovered. Proteins cross-linked
with the recovered library are identified, e.g., by mass spectrometry.
[00392] Oligonucleotide Probe Target Identification
[00393] The methods and kits above can be used to identify binding agents that
differentiate between two
target populations. The invention further provides methods of identifying the
targets of such binding
agents. For example, the methods may further comprise identifying a surface
marker of a cell or
microvesicle that is recognized by the binding agent.
[00394] In an embodiment, the invention provides a method of identifying a
target of a binding agent
comprising: (a) contacting the binding agent with the target to bind the
target with the binding agent,
wherein the target comprises a surface antigen of a cell or microvesicle; (b)
disrupting the cell or
microvesicle under conditions which do not disrupt the binding of the target
with the binding agent; (c)
isolating the complex between the target and the binding agent; and (d)
identifying the target bound by the
binding agent. The binding agent can be a binding agent identified by the
methods above, e.g., an
oligonucleotide probe, ligand, antibody, or other useful binding agent that
can differentiate between two
target populations, e.g., by differentiating between biomarkers thereof.
100395] An illustrative schematic for carrying on the method is shown in FIG.
4. The figure shows a
binding agent 402, here an oligonucleotide probe or aptamer for purposes of
illustration, tethered to a
substrate 401. The binding agent 402 can be covalently attached to substrate
401. The binding agent 402
may also be non-covalently attached. For example, binding agent 402 can
comprise a label which can be
attracted to the substrate, such as a biotin group which can form a complex
with an avidin/streptavidin
molecule that is covalently attached to the substrate. This can allow a
complex to be formed between the
aptamer and the microvesicle while in solution, followed by capture of the
aptamer using the biotin label.
The binding agent 402 binds to a surface antigen 403 of cell or microvesicle
404. In the step signified by
arrow (i), the cell or microvesicle 405 is disrupted while leaving the complex
between the binding agent
402 and surface antigen 403 intact. Disrupted cell or microvesicle 405 is
removed, e.g., via washing or
buffer exchange, in the step signified by arrow (ii). In the step signified by
arrow (iii), the surface antigen
403 is released from the binding agent 402. The surface antigen 403 can be
analyzed to determine its
-101-
CA 03018066 2018-09-17
WO 2017/161357 PCT/US2017/023108
identity using methods disclosed herein and/or known in the art. The target of
the method can be any
useful biological entity associated with a cell or microvesicle. For example,
the target may comprise a
protein, nucleic acid, lipid or carbohydrate, or other biological entity
disclosed herein or known in the art.
[00396] In some embodiments of the method, the target is cross-linked to the
binding agent prior
disrupting the cell or microvesicle. Without being bound by theory, this step
may assist in maintaining the
complex between the binding agent and the target during the disruption
process. Any useful method of
crosslinking disclosed herein or known in the art can be used. In embodiments,
the cross-linking
comprises photocrosslinking, an imidoester crosslinker, dimethyl suberimidate,
an N-
Hydroxysuccinimide-ester crosslinker, bissulfosuccinimidyl suberate (BS3), an
aldehyde, acrolein,
crotonaldehyde, formaldehyde, a carbodiimide crosslinker, N,N'-
dicyclohexylcarbodiimide (DDC), N,N-
diisopropylcarbodiimide (DIC), 1-Ethyl-3-[3-dimethylaminopropylicarbodiimide
hydrochloride (EDC or
EDAC), Succinimidy1-4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC), a
Sulfosuccinimidy1-
4-(N-maleimidomethyl)cyclohexane-1-carboxylate (Sulfo-SMCC), a Sulfo-N-
hydroxysuccinimidy1-2-(6-
[biotinamido1-2-(p-azido benzamido)-hexanoamido) ethy1-1,3'-dithioproprionate
(Sulfo-SBED), 24N2-(4-
Azido-2,3,5,6-tetrafluorobenzoy1)-N6-(6-biotin-amidocaproy1)-L-lysinyllethyl
methanethiosulfonate
(Mts-Atf-Biotin; available from Thermo Fisher Scientific Inc, Rockford IL.), 2-
{N24N6-(4-Azido-
2,3,5,6-tetrafluorobenzoy1-6-amino-caproy1)-N6-(6-biotinamidocaproy1)-L-
lysinylamidollethyl
methanethiosultonate (Mts-Atf-LC-Biotin; available from Thermo Fisher
Scientific Inc), a photoreactive
amino acid (e.g., L-Photo-Leucine and L-Photo-Methionine, see, e.g., Suchanek,
M., et al. (2005). Photo-
leucine and photo-methionine allow identification of protein-protein
interactions. Nat. Methods 2:261-
267), an N-Hydroxysuccinimide (NHS) crosslinker, an NHS-Azide reagent (e.g.,
NHS-Azide, NHS-
PEG4-Azide, NHS-PEG12-Azide; each available from Thermo Fisher Scientific,
Inc.), an NHS-
Phosphine reagent (e.g., NHS-Phosphine, Sulfo-NHS-Phosphine; each available
from Thermo Fisher
Scientific, Inc.), or any combination or modification thereof.
[00397] A variety of methods can be used to disrupt the cell or microvesicle.
For example, the cellular or
vesicular membrane can be disrupted using mechanical forces, chemical agents,
or a combination thereof.
In embodiments, disrupting the cell or microvesicle comprises use of one or
more of a detergent, a
surfactant, a solvent, an enzyme, or any useful combination thereof The enzyme
may comprise one or
more of lysozyme, lysostaphin, zymolase, cellulase, mutanolysin, a glycanase,
a protease, and mannase.
The detergent or surfactant may comprise one or more of a octylthioglucoside
(OTG), octyl beta-
glucoside (OG), a nonionic detergent, Triton X, Tween 20, a fatty alcohol, a
cetyl alcohol, a stearyl
alcohol, cetostearyl alcohol, an oleyl alcohol, a polyoxyethylene glycol alkyl
ether (Brij), octaethylene
glycol monododecyl ether, pentaethylene glycol monododecyl ether, a
polyoxypropylene glycol alkyl
ether, a glucoside alkyl ether, decyl glucoside, lauryl glucoside, octyl
glucoside, a polyoxyethylene glycol
octylphenol ethers, a polyoxyethylene glycol alkylphenol ether, nonoxyno1-9, a
glycerol alkyl ester,
glyceryl laurate, a polyoxyethylene glycol sorbitan alkyl esters, polysorbate,
a sorbitan alkyl ester,
cocamide MEA, cocamide DEA, dodecyldimethylamine oxide, a block copolymers of
polyethylene glycol
and polypropylene glycol, poloxamers, polyethoxylated tallow amine (POEA), a
zwitterionic detergent, 3-
-102-
CA 03018066 2018-09-17
WO 2017/161357 PCT/US2017/023108
1(3-cholamidopropyl)dimethylammoniol-1-propanesulfonate (CHAPS), a linear
alkylbenzene sulfonate
(LAS), a alkyl phenol ethoxylate (APE), cocamidopropyl hydroxysultaine, a
betaine, cocamidopropyl
betaine, lecithin, an ionic detergent, sodium dodecyl sulfate (SDS),
cetrimonium bromide (CTAB), cetyl
trimethylammonium chloride (CTAC), octenidine dihydrochloride, cetylpyridinium
chloride (CPC),
benzalkonium chloride (BAC), benzethonium chloride (BZT), 5-Bromo-5-nitro-1,3-
dioxane,
dimethyldioctadecylammonium chloride, dioctadecyldimethylammonium bromide
(DODAB), sodium
deoxycholate, nonyl phenoxypolyethoxylethanol (Tergitol-type NP-40; NP-40),
ammonium lauryl sulfate,
sodium laureth sulfate (sodium lauryl ether sulfate (SLES)), sodium myreth
sulfate, an alkyl carboxylate,
sodium stearate, sodium lauroyl sarcosinate, a carboxylate-based
fluorosurfactant, perfluorononanoate,
perfluorooctanoate (PFOA or PFO), and a biosurfactant. Mechanical methods of
disruption that can be
used comprise without limitation mechanical shear, bead milling, homogenation,
microfluidization,
sonication, French Press, impingement, a colloid mill, decompression, osmotic
shock, thermolysis, freeze-
thaw, desiccation, or any combination thereof.
[00398] As shown in FIG. 4, the binding agent may be tethered to a substrate.
The binding agent can be
tethered before or after the complex between the binding agent and target is
formed. The substrate can be
any useful substrate such as disclosed herein or known in the art. In an
embodiment, the substrate
comprises a microsphere. In another embodiment, the substrate comprises a
planar substrate. In another
embodiment, the substrate comprises column material. The binding agent can
also be labeled. Isolating
the complex between the target and the binding agent may comprise capturing
the binding agent via the
label. As a non-limiting example, the label can be a biotin label. In such
cases, the binding agent can be
attached to the substrate via a biotin-avidin/streptavidin binding event.
[00399] Methods of identifying the target after release from the binding agent
will depend on the type of
target of interest. For example, when the target comprises a protein,
identifying the target may comprise
use of mass spectrometry (MS), peptide mass fingerprinting (PMF; protein
fingerprinting), sequencing, N-
terminal amino acid analysis, C-terminal amino acid analysis, Edman
degradation, chromatography,
electrophoresis, two-dimensional gel electrophoresis (2D gel), antibody array,
and immunoassay. Nucleic
acids can be identified by amplification, hybridization or sequencing.
[00400] One of skill will appreciate that the method can be used to identify
any appropriate target,
including those not associated with a membrane. For example, with respect to
the FIG. 4, all steps except
for the step signified by arrow (i) (i.e., disrupting the cell or microvesicle
405), could be performed for a
tissue lysate or a circulating target such as a protein, nucleic acid, lipid,
carbohydrate, or combination
thereof. The target can be any useful target, including without limitation a
tissue, a cell, an organelle, a
protein complex, a lipoprotein, a carbohydrate, a microvesicle, a virus, a
membrane fragment, a small
molecule, a heavy metal, a toxin, a drug, a nucleic acid, mRNA, microRNA, a
protein-nucleic acid
complex, and various combinations, fragments and/or complexes of any of these.
[00401] In an aspect, the invention provides a method of identifying at least
one protein associated with at
least one cell or microvesicle in a biological sample, comprising: a)
contacting the at least one cell or
microvesicle with an oligonucleotide probe library, b) isolating at least one
protein bound by at least one
-103-
CA 03018066 2018-09-17
WO 2017/161357 PCT/US2017/023108
member of the oligonucleotide probe library in step a); and c) identifying the
at least one protein isolated
in step b). The isolating can be performed using any useful method such as
disclosed herein, e.g., by
immunopreciption or capture to a substrate. Similarly, the identifying can be
performed using any useful
method such as disclosed herein, including without limitation use of mass
spectrometry, 2-D gel
electrophoresis or an antibody array. Examples of such methodology are
presented herein in Examples 9-
11.
[00402] The targets identified by the methods of the invention can be
detected, e.g., using the
oligonucleotide probes of the invention, for various purposes as desired. For
example, an identified
surface antigen can be used to detect a cell or microvesicle displaying such
antigen. In an aspect, the
invention provides a method of detecting at least one cell or microvesicle in
a biological sample
comprising contacting the biological sample with at least one binding agent to
at least one surface antigen
and detecting the at least one cell or microvesicle recognized by the binding
agent to the at least one
protein. In an embodiment, the at least one surface antigen is selected from
Tables 3-4 herein. The at least
one surface antigen can be selected those disclosed in International Patent
Application Nos.
PCT/US2009/62880, filed October 30, 2009; PCT/US2009/006095, filed November
12, 2009;
PCT/US2011/26750, filed March 1, 2011; PCT/US2011/031479, filed April 6, 2011;
PCT/US11/48327,
filed August 18, 2011; PCT/US2008/71235, filed July 25, 2008; PCT/US10/58461,
filed November 30,
2010; PCT/US2011/21160, filed January 13, 2011; PCT/US2013/030302, filed March
11,2013;
PCT/US12/25741, filed February 17, 2012; PCT/2008/76109, filed September 12,
2008;
PCT/US12/42519, filed June 14, 2012; PCT/US12/50030, filed August 8, 2012;
PCT/US12/49615, filed
August 3, 2012; PCT/US12/41387, filed June 7,2012; PCT/US2013/072019, filed
November 26, 2013;
PCT/US2014/039858, filed May 28, 2013; PCT/IB2013/003092, filed October 23,
2013;
PCT/US13/76611, filed December 19, 2013; PCT/US14/53306, filed August 28,
2014; and
PCT/US15/62184, filed November 23, 2015; PCT/US16/40157, filed June 29, 2016;
PCT/US16/44595,
filed July 28, 2016; and PCT/US16/21632, filed March 9, 2016; each of which
applications is
incorporated herein by reference in its entirety. The at least one surface
antigen can be a protein in any of
Tables 10-17 herein. See Example 9. The at least one binding agent may
comprise any useful binding
agent, including without limitation a nucleic acid, DNA molecule, RNA
molecule, antibody, antibody
fragment, aptamer, peptoid, zDNA, peptide nucleic acid (PNA), locked nucleic
acid (LNA), lectin,
peptide, dendrimer, membrane protein labeling agent, chemical compound, or a
combination thereof In
some embodiments, the at least one binding agent comprises at least one
oligonucleotide, such as an
oligonucleotide probe as provided herein. The cell can be part of a tissue.
[00403] The at least one binding agent can be used to capture and/or detect
the at least one cell or
microvesicle, which can be a circulating cell or microvesicle, including
without limitation a microvesicle
shed into bodily fluids. Methods of detecting soluble biomarkers and
circulating cells or microvesicles
using binding agents are provided herein. See, e.g., FIGs. 2A-B, which figures
describe sandwich assay
formats. In some embodiments, the at least one binding agent used to capture
the at least one cell or
microvesicle is bound to a substrate. Any useful substrate can be used,
including without limitation a
-104-
CA 03018066 2018-09-17
WO 2017/161357 PCT/US2017/023108
planar array, a column matrix, or a microbead. See, e.g., FIGs. 2A-B. In some
embodiments, the at least
one binding agent used to detect the at least one cell or microvesicle is
labeled. Various useful labels are
provided herein or known in the art, including without limitation a magnetic
label, a fluorescent moiety,
an enzyme, a chemiluminescent probe, a metal particle, a non-metal colloidal
particle, a polymeric dye
particle, a pigment molecule, a pigment particle, an electrochemically active
species, a semiconductor
nanocrystal, a nanoparticle, a quantum dot, a gold particle, a fluorophore, or
a radioactive label.
[00404] In an embodiment, the detecting is used to characterize a phenotype.
The phenotype can be any
appropriate phenotype of interest. In some embodiments, the phenotype is a
disease or disorder. The
characterizing may comprise providing diagnostic, prognostic and/or
theranostic information for the
disease or disorder. The characterizing may be performed by comparing a
presence or level of the at least
one cell or microvesicle to a reference. The reference can be selected per the
characterizing to be
performed. For example, when the phenotype comprises a disease or disorder,
the reference may comprise
a presence or level of the at least one microvesicle in a sample from an
individual or group of individuals
without the disease or disorder. The comparing can be determining whether the
presence or level of the
cell or microvesicle differs from that of the reference. In some embodiments,
the detected cell or
microvesicle is found at higher levels in a healthy sample as compared to a
diseased sample. In another
embodiment, the detected cell or microvesicle is found at higher levels in a
diseased sample as compared
to a healthy sample. When multiplex assays are performed, e.g., using a
plurality of binding agents to
different biomarkers, some antigens may be observed at a higher level in the
biological samples as
compared to the reference whereas other antigens may be observed at a lower
level in the biological
samples as compared to the reference.
[00405] The method can be used to detect the at least one cell or microvesicle
in any appropriate
biological sample. For example, the biological sample may comprise a bodily
fluid, tissue sample or cell
culture. The bodily fluid or tissue sample can be from a subject having or
suspected of having a medical
condition, a disease or a disorder. Thus, the method can be used to provide a
diagnostic, prognostic, or
theranostic read out for the subject. Any appropriate bodily fluid can be
used, including without limitation
peripheral blood, sera, plasma, ascites, urine, cerebrospinal fluid (CSF),
sputum, saliva, bone marrow,
synovial fluid, aqueous humor, amniotic fluid, cerumen, breast milk,
broncheoalveolar lavage fluid,
semen, prostatic fluid, cowper's fluid or pre-ejaculatory fluid, female
ejaculate, sweat, fecal matter, hair
oil, tears, cyst fluid, pleural and peritoneal fluid, pericardial fluid,
lymph, chyme, chyle, bile, interstitial
fluid, menses, pus, sebum, vomit, vaginal secretions, mucosal secretion, stool
water, pancreatic juice,
lavage fluids from sinus cavities, bronchopulmonary aspirates, blastocyl
cavity fluid, or umbilical cord
blood.
[00406] The method of the invention can be used to detect or characterize any
appropriate disease or
disorder of interest, including without limitation Breast Cancer, Alzheimer's
disease, bronchial asthma,
Transitional cell carcinoma of the bladder, Giant cellular
osteoblastoclastoma, Brain Tumor, Colorectal
adenocarcinoma, Chronic obstructive pulmonary disease (COPD), Squamous cell
carcinoma of the cervix,
acute myocardial infarction (AMI) / acute heart failure, Chron's Disease,
diabetes mellitus type II,
-105-
CA 03018066 2018-09-17
WO 2017/161357 PCT/US2017/023108
Esophageal carcinoma, Squamous cell carcinoma of the larynx, Acute and chronic
leukemia of the bone
marrow, Lung carcinoma, Malignant lymphoma, Multiple Sclerosis, Ovarian
carcinoma, Parkinson
disease, Prostate adenocarcinoma, psoriasis, Rheumatoid Arthritis, Renal cell
carcinoma, Squamous cell
carcinoma of skin, Adenocarcinoma of the stomach, carcinoma of the thyroid
gland, Testicular cancer,
ulcerative colitis, or Uterine adenocarcinoma.
[00407] In some embodiments, the disease or disorder comprises a cancer, a
premalignant condition, an
inflammatory disease, an immune disease, an autoimmune disease or disorder, a
cardiovascular disease or
disorder, neurological disease or disorder, infectious disease or pain. The
cancer can include without
limitation one of acute lymphoblastic leukemia; acute myeloid leukemia;
adrenocortical carcinoma;
AIDS-related cancers; AIDS-related lymphoma; anal cancer; appendix cancer;
astrocytomas; atypical
teratoid/rhabdoid tumor; basal cell carcinoma; bladder cancer; brain stem
glioma; brain tumor (including
brain stem glioma, central nervous system atypical teratoid/rhabdoid tumor,
central nervous system
embryonal tumors, astrocytomas, craniopharyngioma, ependymoblastoma,
ependymoma,
medulloblastoma, medulloepithelioma, pineal parenchymal tumors of intermediate
differentiation,
supratentorial primitive neuroectodermal tumors and pineoblastoma); breast
cancer; bronchial tumors;
Burkitt lymphoma; cancer of unknown primary site; carcinoid tumor; carcinoma
of unknown primary site;
central nervous system atypical teratoid/rhabdoid tumor; central nervous
system embryonal tumors;
cervical cancer; childhood cancers; chordoma; chronic lymphocytic leukemia;
chronic myelogenous
leukemia; chronic myeloproliferative disorders; colon cancer; colorectal
cancer; craniopharyngioma;
cutaneous T-cell lymphoma; endocrine pancreas islet cell tumors; endometrial
cancer;
ependymoblastoma; ependymoma; esophageal cancer; esthesioneuroblastoma; Ewing
sarcoma;
extracranial germ cell tumor; extragonadal germ cell tumor; extrahepatic bile
duct cancer; gallbladder
cancer; gastric (stomach) cancer; gastrointestinal carcinoid tumor;
gastrointestinal stromal cell tumor;
gastrointestinal stromal tumor (GIST); gestational trophoblastic tumor;
glioma; hairy cell leukemia; head
and neck cancer; heart cancer; Hodgkin lymphoma; hypopharyngeal cancer;
intraocular melanoma; islet
cell tumors; Kaposi sarcoma; kidney cancer; Langerhans cell histiocytosis;
laryngeal cancer; lip cancer;
liver cancer; lung cancer; malignant fibrous histiocytoma bone cancer;
medulloblastoma;
medulloepithelioma; melanoma; Merkel cell carcinoma; Merkel cell skin
carcinoma; mesothelioma;
metastatic squamous neck cancer with occult primary; mouth cancer; multiple
endocrine neoplasia
syndromes; multiple myeloma; multiple myeloma/plasma cell neoplasm; mycosis
fungoides;
myelodysplastic syndromes; myeloproliferative neoplasms; nasal cavity cancer;
nasopharyngeal cancer;
neuroblastoma; Non-Hodgkin lymphoma; nonmelanoma skin cancer; non-small cell
lung cancer; oral
cancer; oral cavity cancer; oropharyngeal cancer; osteosarcoma; other brain
and spinal cord tumors;
ovarian cancer; ovarian epithelial cancer; ovarian germ cell tumor; ovarian
low malignant potential tumor;
pancreatic cancer; papillomatosis; paranasal sinus cancer; parathyroid cancer;
pelvic cancer; penile
cancer; pharyngeal cancer; pineal parenchymal tumors of intermediate
differentiation; pineoblastoma;
pituitary tumor; plasma cell neoplasm/multiple myeloma; pleuropulmonary
blastoma; primary central
nervous system (CNS) lymphoma; primary hepatocellular liver cancer; prostate
cancer; rectal cancer;
-106-
CA 03018066 2018-09-17
WO 2017/161357 PCT/US2017/023108
renal cancer; renal cell (kidney) cancer; renal cell cancer; respiratory tract
cancer; retinoblastoma;
rhabdomyosarcoma; salivary gland cancer; Sezary syndrome; small cell lung
cancer; small intestine
cancer; soft tissue sarcoma; squamous cell carcinoma; squamous neck cancer;
stomach (gastric) cancer;
supratentorial primitive neuroectodermal tumors; T-cell lymphoma; testicular
cancer; throat cancer;
thymic carcinoma; thymoma; thyroid cancer; transitional cell cancer;
transitional cell cancer of the renal
pelvis and ureter; trophoblastic tumor; ureter cancer; urethral cancer;
uterine cancer; uterine sarcoma;
vaginal cancer; vulvar cancer; Waldenstrom macroglobulinemia; or Wilm's tumor.
The premalignant
condition can include without limitation Barrett's Esophagus. The autoimmune
disease can include
without limitation one of inflammatory bowel disease (IBD), Crohn's disease
(CD), ulcerative colitis
(UC), pelvic inflammation, vasculitis, psoriasis, diabetes, autoimmune
hepatitis, multiple sclerosis,
myasthenia gravis, Type I diabetes, rheumatoid arthritis, psoriasis, systemic
lupus erythematosis (SLE),
Hashimoto's Thyroiditis, Grave's disease, Ankylosing Spondylitis Sjogrens
Disease, CREST syndrome,
Scleroderma, Rheumatic Disease, organ rejection, Primary Sclerosing
Cholangitis, or sepsis. The
cardiovascular disease can include without limitation one of atherosclerosis,
congestive heart failure,
vulnerable plaque, stroke, ischemia, high blood pressure, stenosis, vessel
occlusion or a thrombotic event.
The neurological disease can include without limitation one of Multiple
Sclerosis (MS), Parkinson's
Disease (PD), Alzheimer's Disease (AD), schizophrenia, bipolar disorder,
depression, autism, Prion
Disease, Pick's disease, dementia, Huntington disease (HD), Down's syndrome,
cerebrovascular disease,
Rasmussen's encephalitis, viral meningitis, neurospsychiatric systemic lupus
erythematosus (NPSLE),
amyotrophic lateral sclerosis, Creutzfeldt-Jacob disease, Gerstmann-Straussler-
Scheinker disease,
transmissible spongiform encephalopathy, ischemic reperfusion damage (e.g.
stroke), brain trauma,
microbial infection, or chronic fatigue syndrome. The pain can include without
limitation one of
fibromyalgia, chronic neuropathic pain, or peripheral neuropathic pain. The
infectious disease can include
without limitation one of a bacterial infection, viral infection, yeast
infection, Whipple 's Disease, Prion
Disease, cirrhosis, methicillin-resistant staphylococcus aureus, HIV, HCV,
hepatitis, syphilis, meningitis,
malaria, tuberculosis, or influenza. One of skill will appreciate that
oligonucleotide probes or plurality of
oligonucleotides or methods of the invention can be used to assess any number
of these or other related
diseases and disorders.
[00408] In a related aspect, the invention provides a kit comprising a reagent
for carrying out the methods
herein. In still another related aspect, the invention provides for use of a
reagent for carrying out the
methods. The reagent may comprise at least one binding agent to the at least
one protein. The binding
agent may be an oligonucleotide probe as provided herein.
[00409] Sample Characterization
[00410] The oligonucleotide probe / aptamers of the invention can be used to
characterize a biological
sample. For example, an oligonucleotide probe or oligonucleotide probe library
can be used to provide a
biosignature for the sample. The biosignature can indicate a characteristic of
the sample, such as a
diagnosis, prognosis or theranosis of a disease or disorder associated with
the sample. In some
embodiments, the biosignature comprises a presence or level of one or more
biomarker present in the
-107-
CA 03018066 2018-09-17
WO 2017/161357 PCT/US2017/023108
sample. In some embodiments, biosignature comprises a presence or level of the
oligonucleotide probe or
members of the oligonucleotide probe library that associated with the sample
(e.g., by forming a complex
with the sample).
[00411] In an aspect, the invention provides an aptamer comprising a nucleic
acid sequence that is at least
about 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 96, 97, 98, 99 or 100 percent
homologous to any one of SEQ
ID NOs. 1-206506; or a functional variation or fragment of any preceding
sequence. A functional
variation or fragment includes a sequence comprising modifications that is
still capable of binding a target
molecule, wherein the modifications comprise without limitation at least one
of a deletion, insertion, point
mutation, truncation or chemical modification. In a related aspect, the
invention provides a method of
characterizing a disease or disorder, comprising: (a) contacting a biological
test sample with one or more
aptamer of the invention, e.g., any of those in this paragraph or
modifications thereof; (b) detecting a
presence or level of a complex between the one or more aptamer and the target
bound by the one or more
aptamer in the biological test sample formed in step (a); (c) contacting a
biological control sample with
the one or more aptamer; (d) detecting a presence or level of a complex
between the one or more aptamer
and the target bound by the one or more aptamer in the biological control
sample formed in step (c); and
(e) comparing the presence or level detected in steps (b) and (d), thereby
characterizing the disease or
disorder.
[00412] The biological test sample and biological control sample can each
comprise a tissue sample, a cell
culture, or a biological fluid. In some embodiments, the biological test
sample and biological control
sample comprise the same sample type, e.g., both the test and control samples
are tissue samples or both
are fluid samples. In other embodiments, different sample types may be used
for the test and control
samples. For example, the control sample may comprise an engineered or
otherwise artificial sample. In
some embodiments, the tissue samples comprise fixed samples.
[00413] The biological fluid may comprise a bodily fluid. The bodily fluid may
include without limitation
one or more of peripheral blood, sera, plasma, ascites, urine, cerebrospinal
fluid (CSF), sputum, saliva,
bone marrow, synovial fluid, aqueous humor, amniotic fluid, cerumen, breast
milk, broncheoalveolar
lavage fluid, semen, prostatic fluid, cowper's fluid or pre-ejaculatory fluid,
female ejaculate, sweat, fecal
matter, hair, tears, cyst fluid, pleural and peritoneal fluid, pericardial
fluid, lymph, chyme, chyle, bile,
interstitial fluid, menses, pus, sebum, vomit, vaginal secretions, mucosal
secretion, stool water, pancreatic
juice, lavage fluids from sinus cavities, bronchopulmonary aspirates,
blastocyl cavity fluid, or umbilical
cord blood. In some embodiments, the bodily fluid comprises blood, serum or
plasma.
[00414] The biological fluid may comprise microvesicles. For example, the
biological fluid can be a
tissue, cell culture, or bodily fluid which comprises microvesicles released
from cells in the sample. The
microvesicles can be circulating microvesicles. The biological fluid may
comprise cells. For example, the
biological fluid can be a tissue, cell culture, or bodily fluid which
comprises cells circulating in the
sample.
[00415] The one or more aptamer can bind a target biomarker, e.g., a biomarker
useful in characterizing
the sample. The biomarker may comprise a polypeptide or fragment thereof; or
other useful biomarker
-108-
CA 03018066 2018-09-17
WO 2017/161357 PCT/US2017/023108
described herein or known in the art (lipid, carbohydrate, complex, nucleic
acid, etc). In embodiments, the
polypeptide or fragment thereof is soluble or membrane bound. Membrane bound
polypeptides may
comprise a cellular surface antigen or a microvesicle surface antigen. The
biomarker can be a biomarker
selected from Table 3 or Table 4. The biomarker can be selected from one of
International Patent
Application Nos. PCT/US2009/62880, filed October 30, 2009; PCT/U52009/006095,
filed November 12,
2009; PCT/US2011/26750, filed March 1, 2011; PCT/US2011/031479, filed April 6,
2011;
PCT/US11/48327, filed August 18, 2011; PCT/US2008/71235, filed July 25, 2008;
PCT/US10/58461,
filed November 30, 2010; PCT/US2011/21160, filed January 13, 2011;
PCT/US2013/030302, filed March
11,2013; PCT/US12/25741, filed February 17, 2012; PCT/2008/76109, filed
September 12, 2008;
PCT/U512/42519, filed June 14, 2012; PCT/US12/50030, filed August 8, 2012;
PCT/U512/49615, filed
August 3, 2012; PCT/US12/41387, filed June 7,2012; PCT/U52013/072019, filed
November 26, 2013;
PCT/U52014/039858, filed May 28, 2013; PCT/IB2013/003092, filed October 23,
2013;
PCT/US13/76611, filed December 19, 2013; PCT/US14/53306, filed August 28,
2014; and
PCT/US15/62184, filed November 23, 2015; PCT/U516/40157, filed June 29, 2016;
PCT/US16/44595,
filed July 28, 2016; and PCT/US16/21632, filed March 9, 2016; each of which
applications is
incorporated herein by reference in its entirety.
[00416] The characterizing can comprises a diagnosis, prognosis or theranosis
of the disease or disorder.
Various diseases and disorders can be characterized using the compositions and
methods of the invention,
including without limitation a cancer, a premalignant condition, an
inflammatory disease, an immune
disease, an autoimmune disease or disorder, a cardiovascular disease or
disorder, a neurological disease or
disorder, an infectious disease, and/or pain. See, e.g., section herein
"Phenotypes" for further details. In
embodiments, the disease or disorder comprises a proliferative or neoplastic
disease or disorder. For
example, the disease or disorder can be a cancer. In some embodiments, the
cancer comprises a breast
cancer, ovarian cancer, prostate cancer, lung cancer, colorectal cancer,
melanoma, pancreatic cancer,
kidney cancer, or brain cancer.
[00417] FIG. 10A is a schematic 1000 showing an assay configuration that can
be used to detect and/or
quantify a target of interest using one or more oligonucleotide probe of the
invention. Capture aptamer
1002 is attached to substrate 1001. The substrate can be a planar substrate,
well, microbead, or other
useful substrate as disclosed herein or known in the art. Target of interest
1003 is bound by capture
aptamer 1002. The target of interest can be any appropriate entity that can be
detected when recognized by
an aptamer or other binding agent. The target of interest may comprise a
protein or polypeptide, a nucleic
acid, including DNA, RNA, and various subspecies thereof, a lipid, a
carbohydrate, a complex, e.g., a
complex comprising protein, nucleic acids, lipids and/or carbohydrates. In
some embodiments, the target
of interest comprises a tissue, cell or microvesicle. The target of interest
can be a cellular surface antigen
or microvesicle surface antigen. The target of interest may be a biomarker,
e.g., as disclosed herein. The
target of interest can be isolated from a sample using various techniques as
described herein, e.g.,
chromatography, filtration, centrifugation, flow cytometry, affinity capture
(e.g., to a planar surface,
column or bead), and/or using microfluidics. Detection aptamer 1004 is also
bound to target of interest
-109-
CA 03018066 2018-09-17
WO 2017/161357 PCT/US2017/023108
1003. Detection aptamer 1004 carries label 1005 which can be detected to
identify target captured to
substrate 1001 via capture aptamer 1002. The label can be a fluorescent,
radiolabel, enzyme, or other
detectable label as disclosed herein. Either capture aptamer 1002 or detection
aptamer 1004 can be
substituted with another binding agent, e.g., an antibody. For example, the
target may be captured with an
antibody and detected with an aptamer, or vice versa. When the target of
interest comprises a complex, the
capture and detection agents (aptamer, antibody, etc) can recognize the same
or different targets. For
example, when the target is a cell or microvesicle, the capture agent may
recognize one surface antigen
while the detection agent recognizes microvesicle surface antigen.
Alternately, the capture and detection
agents can recognize the same surface antigen.
[00418] The aptamers of the invention may be identified and/or used for
various purposes in the form of
DNA or RNA. Unless otherwise specified, one of skill in the art will
appreciate that an aptamer may
generally be synthesized in various forms of nucleic acid. The aptamers may
also carry various chemical
modifications and remain within the scope of the invention.
[00419] In some embodiments, an aptamer of the invention is modified to
comprise at least one chemical
modification. The modification may include without limitation a chemical
substitution at a sugar position;
a chemical substitution at a phosphate position; and a chemical substitution
at a base position of the
nucleic acid. In some embodiments, the modification is selected from the group
consisting of:
biotinylation, incorporation of a fluorescent label, incorporation of a
modified nucleotide, a 2'-modified
pyrimidine, 3' capping, conjugation to an amine linker, conjugation to a high
molecular weight, non-
immunogenic compound, conjugation to a lipophilic compound, conjugation to a
drug, conjugation to a
cytotoxic moiety, and labeling with a radioisotope, or other modification as
disclosed herein. The position
of the modification can be varied as desired. For example, the biotinylation,
fluorescent label, or cytotoxic
moiety can be conjugated to the 5' end of the aptamer. The biotinylation,
fluorescent label, or cytotoxic
moiety can also be conjugated to the 3' end of the aptamer.
[00420] In some embodiments, the cytotoxic moiety is encapsulated in a
nanoparticle. The nanoparticle
can be selected from the group consisting of: liposomes, dendrimers, and comb
polymers. In other
embodiments, the cytotoxic moiety comprises a small molecule cytotoxic moiety.
The small molecule
cytotoxic moiety can include without limtation vinblastine hydrazide,
calicheamicin, vinca alkaloid, a
cryptophycin, a tubulysin, dolastatin-10, dolastatin-15, auristatin E,
rhizoxin, epothilone B, epithilone D,
taxoids, maytansinoids and any variants and derivatives thereof In still other
embodiments, the cytotoxic
moiety comprises a protein toxin. For example, the protein toxin can be
selected from the group consisting
of diphtheria toxin, ricin, abrin, gelonin, and Pseudomonas exotoxin A. Non-
immunogenic, high
molecular weight compounds for use with the invention include polyalkylene
glycols, e.g., polyethylene
glycol. Appropriate radioisotopes include yttrium-90, indium-111, iodine-131,
lutetium-177, copper-67,
rhenium-186, rhenium-188, bismuth-212, bismuth-213, astatine-211, and actinium-
225. The aptamer may
be labeled with a gamma-emitting radioisotope.
[00421] In some embodiments of the invention, an active agent is conjugated to
the aptamer. For example,
the active agent may be a therapeutic agent or a diagnostic agent. The
therapeutic agent may be selected
-110-
CA 03018066 2018-09-17
WO 2017/161357 PCT/US2017/023108
from the group consisting of tyrosine kinase inhibitors, kinase inhibitors,
biologically active agents,
biological molecules, radionuclides, adriamycin, ansamycin antibiotics,
asparaginase, bleomycin,
busulphan, cisplatin, carboplatin, carmustine, capecotabine, chlorambucil,
cytarabine, cyclophosphamide,
camptothecin, dacarbazine, dactinomycin, daunorubicin, dexrazoxane, docetaxel,
doxorubicin, etoposide,
epothilones, floxuridine, fludarabine, fluorouracil, gemcitabine, hydroxyurea,
idarubicin, ifosfamide,
irinotecan, lomustine, mechlorethamine, mercaptopurine, melphalan,
methotrexate, rapamycin (sirolimus),
mitomycin, mitotane, mitoxantrone, nitrosurea, paclitaxel, pamidronate,
pentostatin, plicamycin,
procarbazine, rituximab, streptozocin, teniposide, thioguanine, thiotepa,
taxanes, vinblastine, vincristine,
vinorelbine, taxol, combretastatins, discodermolides, transplatinum, anti-
vascular endothelial growth
factor compounds ("anti-VEGFs"), anti-epidermal growth factor receptor
compounds ("anti-EGFRs"), 5-
fluorouracil and derivatives, radionuclides, polypeptide toxins, apoptosis
inducers, therapy sensitizers,
enzyme or active fragment thereof, and combinations thereof.
[00422] Oligonucleotide Pools to Characterize a Sample
[00423] The complexity and heterogeneity present in biology challenges the
understanding of biological
systems and disease. Diversity exists at various levels, e.g., within and
between cells, tissues, individuals
and disease states. See, e.g., FIG. 11A. FIG. 11B overviews various biological
entities that can be
assessed to characterize such samples. As shown in FIG. 11B, as one moves from
assessing DNA, to
RNA, to protein, and finally to protein complexes, the amount of diversity and
complexity increases
dramatically. The oligonucleotide probe library method of the invention can be
used characterize complex
biological sources, e.g., tissue samples, cells, circulating tumor cells,
microvesicles, and complexes such
as protein and proteolipid complexes.
[00424] Current methods to characterize biological samples may not adequately
address such complexity
and diversity. As shown in FIG. 11C, such current methods often have a trade
off between measuring
diversity and complexity. As an example, consider high throughput sequencing
technology. Next
generation approaches may query many 1000s of molecular targets in a single
assay. However, such
approaches only probe individual DNA and/or RNA molecules, and thus miss out
on the great diversity of
proteins and biological complexes. On the other hand, flow cytometry can probe
biological complexes,
but are limited to a small number of pre-defined ligands. For example, a
single assay can probe a handful
of differentially labeled antibodies to pre-defined targets.
[00425] The oligonucleotide probe libraries of the invention address the above
challenges. The size of the
starting library can be adjusted to measure as many different entities as
there are library members. For
example, the initial untrained oligonucleotide library has the potential to
measure 1012 or more biological
features. A larger and/or different library can be constructed as desired. The
technology is adapted to find
differences between samples without assumptions about what "should be
different." For example, the
probe library may distinguish based on individual proteins, protein
modifications, protein complexes,
lipids, nucleic acids, different folds or conformations, or whatever is there
that distinguishes a sample of
interest. Thus, the method provides an unbiased approach to identify
differences in biological samples that
can be used to identify different populations of interest.
-111-
CA 03018066 2018-09-17
WO 2017/161357 PCT/US2017/023108
[00426] In the context herein, the use of the oligonucleotide library probe to
assess a sample may be
referred to as Adaptive Dynamic Artificial Poly-ligand Targeting, or ADAPTTm
(alternately referred to as
Topological Oligonucleotide Profiling: TOPTm). Although as noted the terms
aptamer and
oligonucleotides are typically used interchangeable herein, some differences
between "classic" individual
aptamers and ADAPT probes are as follows. Individual aptamers may comprise
individual
oligonucleotides selected to bind to a known specific target in an antibody-
like "key-in-lock" binding
mode. They may be evaluated individually based on specificity and binding
affinity to the intended target.
However, ADAPT probes may comprise a library of oligonucleotides intended to
produce multi-probe
signatures. The ADAPT probes comprise numerous potential binding modalities
(electrostatic,
hydrophobic, Watson-Crick, multi-oligo complexes, etc.). The ADAPT probe
signatures have the
potential to identify heterogeneous patient subpopulations. For example, a
single ADAPT library can be
assembled to differentiate multiple biological states. Unlike classic single
aptamers, the binding targets
may or may not be isolated or identified. It will be understood that screening
methods that identify
individual aptamers, e.g., SELEX, can also be used to enrich a naive library
of oligonucleotides to identify
a ADAPT probe library.
[00427] The general method of the invention is outlined in FIG. 11D. One input
to the method comprises
a randomized oligonucleotide library with the potential to measure 1012 or
more biological features. As
outlined in the figure, the method identifies a desired number (e.g., ¨105-
106) that are different between
two input sample types. The randomized oligonucleotide library is contacted
with a first and a second
sample type, and oligonucleotides that bind to each sample are identified. The
bound oligonucleotide
populations are compared and oligonucleotides that specifically bind to one or
the other biological input
sample are retained for the oligonucleotide probe library, whereas
oligonucleotides that bind both
biological input samples are discarded. This trained oligonucleotide probe
library can then be contacted
with a new test sample and the identities of oligonucleotides that bind the
test sample are determined. The
test sample is characterized based on the profile of oligonucleotides that
bound. See, e.g., FIG. 1111.
[00428] Extracellular vesicles provide an attractive vehicle to profile the
biological complexity and
diversity driven by many inter-related sources. There can be a great deal of
heterogeneity between patient-
to-patient microvesicle populations, or even in microvesicle populations from
a single patient under
different conditions (e.g., stress, diet, exercise, rest, disease, etc).
Diversity of molecular phenotypes
within microvesicle populations in various disease states, even after
microvesicle isolation and sorting by
vesicle biomarkers, can present challenges identifying surface binding
ligands. This situation is further
complicated by vesicle surface-membrane protein complexes. The oligonucleotide
probe library can be
used to address such challenges and allow for characterization of biological
phenotypes. The approach
combines the power of diverse oligonucleotide libraries and high throuput
(next-generation) sequencing
technologies to probe the complexity of extracellular microvesicles. See FIG.
11E.
[00429] ADAPTTm profiling may provide quantitative measurements of dynamic
events in addition to
detection of presence/absence of various biomarkers in a sample. For example,
the binding probes may
detect protein complexes or other post-translation modifications, allowing for
differentiation of samples
-112-
CA 03018066 2018-09-17
WO 2017/161357 PCT/US2017/023108
with the same proteins but in different biological configurations. Such
configurations are illustrated in
FIGs. 11F-G. In FIG. 11F, microvesicles with various surface markers are shown
from an example
microvesicle sample population: Sample Population A. The indicated Bound
Probing Oligonucleotides
1101 are contacted to two surface markers 1102 and 1103 in a given special
relationship. Here, probes
unique to these functional complexes and spatial relationships may be
retained. In contrast, in
microvesicle Sample Population B shown in FIG. 11F, the two surface markers
1102 and 1103 are found
in disparate spacial relationship. Here, probes 1101 are not bound due to
absence of the spatial
relationship of the interacting components 1102 and 1103.
[00430] An illustrative approach 1110 for using ADAPT profiling to assess a
sample is shown in FIG.
11H. The probing library 1111 is mixed with sample 1112. The sample can be as
described herein, e.g., a
bodily fluid from a subject having or suspected of having a disease. The
probes are allowed to bind the
sample 1120 and the microvesicles are pelleted 1115. The supernatant 1114
comprising unbound
oligonucleotides is discarded. Oligonucleotide probes bound to the pellet 1115
are eluted 1116 and
sequenced 1117. The profile 1118 generated by the bound oligonucleotide probes
as determined by the
sequening 1117 is used to characterize the sample 1112. For example, the
profile 1118 can be compared
to a reference, e.g., to determine if the profile is similar or different from
a reference profile indicative of a
disease or healthy state, or other phenotypic characterization of interest.
The comparison may indicate the
presence of a disease, provide a diagnosis, prognosis or theranosis, or
otherwise characterize a phenotype
associated with the sample 1112. FIG. 11I illustrates another schematic for
using ADAPT profiling to
characterize a phenotype. A patient sample such as a bodily fluid disclosed
herein is collected 1121. The
sample is contacted with the ADAPT library pool 1122. Microvesicles (MVs) are
isolated from the
contacted sample 1123, e.g., using ultracentrifugation, filtration, polymer
precipitation or other
appropriate technique or combination of techniques disclosed herein.
Oligonucleotides that bound the
isolated microvesicles are collected and identity is determined 1124. The
identity of the bound
oligonucleotides can be determined by any useful technique such as sequencing,
high throughput
sequencing (e.g., NGS), amplification including without limitation qPCR, or
hybridization such as to a
planar or particle based array. The identity of the bound oligonucleotides is
used to characterize the
sample, e.g., as containing disease related microvesicles.
[00431] The approaches outlined in FIG. 11 can be adapted to any desired
sample type, e.g., tissues, cells,
microvesicles, circulating biomarkers, and constituents of any of these.
[00432] In an aspect, the invention provides a method of characterizing a
sample by contacting the sample
with a pool of different oligonucleotides (which can be referred to as an
aptamer pool or oligonucleotide
probe library), and determining the frequency at which various
oligonucleotides in the pool bind the
sample. For example, a pool of oligonucleotides is identified that
preferentially bind to tissues, cells or
microvesicles from cancer patients as compared to non-cancer patients. A test
sample, e.g., from a patient
suspected of having the cancer, is collected and contacted with the pool of
oligonucleotides.
Oligonucleotides that bind the test sample are eluted from the test sample,
collected and identified, and the
composition of the bound oligonucleotides is compared to those known to bind
cancer samples. Various
-113-
CA 03018066 2018-09-17
WO 2017/161357 PCT/US2017/023108
sequencing, amplification and hybridization techinques can be used to identify
the eluted
oligonucleotides. For example, when a large pool of oligonucleotides is used,
oligonucleotide
identification can be performed by high throughput methods such as next
generation sequencing or via
hybridization. If the test sample is bound by the oligonucleotide pool in a
similar manner (e.g., as
determined by bioinformatics classification methods) to the sample from cancer
patients, then the test
sample is indicative of cancer as well. Using this method, a pool of
oligonucleotides that bind one or more
antigen can be used to characterize the sample without necessarily knowing the
precise target of each
member of the pool of oligonucleotides. Thus, the pool of oligonucleotides
provide a biosignature.
Examples 5-7 and 9-31 and others herein illustrate embodiments of the
invention.
[00433] In an aspect, the invention provides a method for characterizing a
condition for a test sample
comprising: contacting a sample with a plurality of oligonucleotide capable of
binding one or more
target(s) present in the sample, identifying a set of oligonucleotides that
form a complex with the sample
wherein the set is predetermined to characterize a condition for the sample,
thereby characterizing a
condition for a sample. The sample can be any useful sample such as disclosed
herein, e.g., a tissue, cell,
microvesicle, or biomarker sample, or any useful combination thereof
[00434] In an related aspect, the invention provides a method for identifying
a set of oligonucleotides
associated with a test sample, comprising: (a) contacting a sample with a
plurality of oligonucleotides,
isolating a set of oligonucleotides that form a complex with the sample, (b)
determining sequence and/or
copy number for each of the oligonucleotides, thereby identifying a set of
oligonucleotides associated
with the test sample. The sample can be any useful sample such as disclosed
herein, e.g., a tissue, cell,
microvesicle, or biomarker sample, or any useful combination thereof
[00435] In still another related aspect, the invention provides a method of
diagnosing a sample as
cancerous or predisposed to be cancerous, comprising contacting the sample
with a plurality of
oligonucleotides that are predetermined to preferentially form a complex with
a cancer sample as
compared to a non-cancer sample. The sample can be any useful sample such as
disclosed herein, e.g., a
tissue, cell, microvesicle, or biomarker sample, or any useful combination
thereof
[00436] The oligonucleotides can be identified by sequencing, e.g., by dye
termination (Sanger)
sequencing or high throughput methods. High throughput methods can comprise
techiques to rapidly
sequence a large number of nucleic acids, including next generation techniques
such as Massively parallel
signature sequencing (MPSS; Polony sequencing; 454 pyrosequencing; Illumina
(Solexa;
MiSeq/HiSeq/NextSeq/etc) sequencing; SOLiD sequencing; Ion Torrent
semiconductor sequencing; DNA
nanoball sequencing; Heliscope single molecule sequencing; Single molecule
real time (SMRT)
sequencing, or other methods such as Nanopore DNA sequencing; Tunnelling
currents DNA sequencing;
Sequencing by hybridization; Sequencing with mass spectrometry; Microfluidic
Sanger sequencing;
Microscopy-based techniques; RNAP sequencing; In vitro virus high-throughput
sequencing. The
oligonucleotides may also be identified by hybridization techniques. For
example, a microarray having
addressable locals to hybridize and thereby detect the various members of the
pool can be used.
Alternately, detection can be based on one or more differentially labelled
oligonucleotides that hybridize
-114-
CA 03018066 2018-09-17
WO 2017/161357 PCT/US2017/023108
with various members of the oligonucleotide pool. The detectable signal of the
label can be associated
with a nucleic acid molecule that hybridizes with a stretch of nucleic acids
present in various
oligonucleotides. The stretch can be the same or different as to one or more
oligonucleotides in a
library. The detectable signal can comprise fluorescence agents, including
color-coded barcodes which are
known, such as in U.S. Patent Application Pub. No. 20140371088, 2013017837,
and 20120258870. Other
detectable labels (metals, radioisotopes, etc) can be used as desired.
[00437] The plurality or pool of oligonucleotides can comprise any desired
number of oligonucleotides to
allow characterization of the sample. In various embodiments, the pool
comprises at least 2, 3, 4, 5, 6, 7,
8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 40, 50, 60, 70, 80,
90, 100, 150, 200, 250, 300, 350,
400, 450, 500, 600, 700, 800, 900, 1000, 2000, 3000, 4000, 5000, 6000, 7000,
8000, 9000, or at least
10000 different oligonucleotide members.
[00438] The plurality of oligonucleotides can be pre-selected through one or
more steps of positive or
negative selection, wherein positive selection comprises selection of
oligonucleotides against a sample
having substantially similar characteristics compared to the test sample, and
wherein negative selection
comprises selection of oligonucleotides against a sample having substantially
different characteristics
compared to the test sample. Substantially similar characteristics mean that
the samples used for positive
selection are representative of the test sample in one or more characteristic
of interest. For example, the
samples used for positive selection can be from cancer patients or cell lines
and the test sample can be a
sample from a patient having or suspected to have a cancer. Substantially
different characteristics mean
that the samples used for negative selection differ from the test sample in
one or more
phenotype/characteristic of interest. For example, the samples used for
negative selection can be from
individuals or cell lines that do not have cancer (e.g., "normal," "healthy"
or otherwise "control" samples)
and the test sample can be a sample from a patient having or suspected to have
a cancer. The cancer can
be a breast cancer, ovarian cancer, prostate cancer, lung cancer, colorectal
cancer, melanoma, brain
cancer, pancreatic cancer, kidney cancer, or other cancer such as disclosed
herein.
[00439] By selecting samples representative of the desired phenotypes to
detect and/or distinguish, the
characterizing can comprise a diagnosis, prognosis or theranosis for any
number of diseases or disorders.
Various diseases and disorders can be characterized using the compositions and
methods of the invention,
including without limitation a cancer, a premalignant condition, an
inflammatory disease, an immune
disease, an autoimmune disease or disorder, a cardiovascular disease or
disorder, a neurological disease or
disorder, an infectious disease, and/or pain. See, e.g., section herein
"Phenotypes" for further details. In
embodiments, the disease or disorder comprises a proliferative or neoplastic
disease or disorder. For
example, the disease or disorder can be a cancer.
[00440] FIG. 10B is a schematic 1010 showing use of an oligonucleotide pool to
characterize a phenotype
of a sample, such as those listed above. A pool of oligonucleotides to a
target of interst is provided 1011.
For example, the pool of oligonucleotides can be enriched to target a tissue,
cell, microvesicle biomarker,
or any combination thereof The members of the pool may bind different targets
(e.g., different proteins)
or different epitopes of the same target (e.g., different epitopes of a single
protein). The pool is contacted
-115-
CA 03018066 2018-09-17
WO 2017/161357 PCT/US2017/023108
with a test sample to be characterized 1012. For example, the test sample may
be a biological sample from
an individual having or suspected of having a given disease or disorder. The
mixture is washed to remove
unbound oligonucleotides. The remaining oligonucleotides are eluted or
otherwise disassociated from the
sample and collected 1013. The collected oligonucleotides are identified,
e.g., by sequencing or
hybridization 1014. The presence and/or copy number of the identified is used
to characterize the
phenotype 1015.
[00441] FIG. 10C is a schematic 1020 showing an implementation of the method
in FIG. 10B. A pool of
oligonucleotides identified as binding a microvesicle population is provided
1019. The input sample
comprises a test sample comprising microvesicles 1022. For example, the test
sample may be a biological
sample from an individual having or suspected of having a given disease or
disorder. The pool is
contacted with the isolated microvesicles to be characterized 1023. The
microvesicle population can be
isolated before or after the contacting 1023 from the sample using various
techniques as described herein,
e.g., chromatography, filtration, ultrafiltration, centrifugation,
ultracentrifugation, flow cytometry, affinity
capture (e.g., to a planar surface, column or bead), polymer precipitation,
and/or using microfluidics. The
mixture is washed to remove unbound oligonucleotides and the remaining
oligonucleotides are eluted or
otherwise disassociated from the sample and collected 1024. The collected
oligonucleotides are identified
1025 and the presence and/or copy number of the retained oligonucleotides is
used to characterize the
phenotype 1026 as above.
[00442] As noted, in embodiment of FIG. 10C, the pool of oligonucleotides 1019
is directly contacted
with a biological sample that comprises or is expected to comprise
microvesicles. Microvesicles are
thereafter isolated from the sample and the mixture is washed to remove
unbound oligonucleotides and
the remaining oligonucleotides are disassociated and collected 1024. The
following steps are performed as
above. As an example of this alternate configuration, a biological sample,
e.g., a blood, serum or plasma
sample, is directly contacted with the pool of oligonucleotides. Microvesicles
are then isolated by various
techniques disclosed herein, including without limitation ultracentrifugation,
ultrafiltration, flow
cytometry, affinity isolation, polymer precipitation, chromatography, various
combinations thereof, or the
like. Remaining oligonucleotides are then identified, e.g., by sequencing,
hybridization or amplification.
[00443] In other embodiments, an enriched library of oligonucleotide probes is
used to assess a tissue
sample. In some embodiments, the pool is used to stain the sample in a manner
similar to IHC. Such
method may be referred to herein as PHC, or polyligand histochemistry. FIG.
10D provides an outline
1030 of such method. An aptamer pool is provided that has been enriched
against a tissue of interest 1031.
The pool is contacted with a tissue sample 1032. The tissue sample can be in a
format such as described
herein. As a non-limiting example, the tissue sample can be a fixed tumor
sample. The sample may be a
FFPE sample fixed to a glass slide or membrane. The sample is washed to remove
unbound members of
the aptamer pool and the remaining aptamers are visualized 1033. Any
appropriate method to visualize the
aptamers can be used. In an example, the aptamer pool is biotinylated and the
bound aptamer are
visualized using streptavidin-horse radish peroxidase (SA-HRP). As described
herein, other useful
visualization methods are known in the art, including alternate labeling. The
visualized sample is scored
-116-
CA 03018066 2018-09-17
WO 2017/161357 PCT/US2017/023108
to determine the amount of staining 1034. For example a pathologist can score
the slide as in IHC. The
score can be used to characterize the sample 1035 as described herein. For
example, a score of +1 or
higher may indicate that the sample is a cancer sample, or is a cancer sample
expressing a given
biomarker. See Examples 19-31 herein.
[00444] In a related aspect, the invention provides a composition of matter
comprising a plurality of
oligonucleotides that can be used to carry out the methods comprising use of
an oligonucleotide pool to
characterize a phenotype. The plurality of oligonucleotides can comprise any
of those described herein.
[00445] In an aspect, the invention provides a method for identifying
oligonucleotides specific for a test
sample. The method comprises: (a) enriching a plurality of oligonucleotides
for a sample to provide a set
of oligonucleotides predetermined to form a complex with a target sample; (b)
contacting the plurality in
(a) with a test sample to allow formation of complexes of oligonucleotides
with test sample; (c)
recovering oligonucleotides that formed complexes in (b) to provide a
recovered subset of
oligonucleotides; and (d) profiling the recovered subset of oligonucleotides
by high-throughput
sequencing, amplification or hybridization, thereby identifying
oligonucleotides specific for a test sample.
The test sample may comprise tissue, cells, microvesicles, biomarkers, or
other biological entities of
interest. The oligonucleotides may comprise RNA, DNA or both. In some
embodiment, the method
further comprises performing informatics analysis to identify a subset of
oligonucleotides comprising
sequence identity of at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%,
91%, 92%, 93%, 94%,
95%, 96%, 97%, 98%, or at least 99% to the oligonucleotides predetermined to
form a complex with the
target sample.
[00446] One of skill will appreciate that the method can be used to identify
any appropriate target. The
target can be any useful target, including without limitation a cell, an
organelle, a protein complex, a
lipoprotein, a carbohydrate, a microvesicle, a virus, a membrane fragment, a
small molecule, a heavy
metal, a toxin, a drug, a nucleic acid (including without limitation microRNA
(miR) and messenger RNA
(mRNA)), a protein-nucleic acid complex, and various combinations, fragments
and/or complexes of any
of these. The target can, e.g., comprise a mixture of such biological
entities.
[00447] In an aspect, the invention also provides a method comprising
contacting an oligonucleotide or
plurality of oligonucleotides with a sample and detecting the presence or
level of binding of the
oligonucleotide or plurality of oligonucleotides to a target in the sample,
wherein the oligonucleotide or
plurality of oligonucleotides can be those provided by the invention above.
The sample may comprise a
biological sample, an organic sample, an inorganic sample, a tissue, a cell
culture, a bodily fluid, blood,
serum, a cell, a microvesicle, a protein complex, a lipid complex, a
carbohydrate, or any combination,
fraction or variation thereof. The target may comprise a cell, an organelle, a
protein complex, a
lipoprotein, a carbohydrate, a microvesicle, a membrane fragment, a small
molecule, a heavy metal, a
toxin, or a drug.
[00448] In another aspect, the invention provides a method comprising: a)
contacting a sample with an
9 1
oligonucleotide probe library comprising at least 106, 107, 108, 10 , 1010,
10", 1012, iO3, 1014 , 1015, 1016,
1017, or at least 1018 different oligonucleotide sequences oligonucleotides to
form a mixture in solution,
-117-
CA 03018066 2018-09-17
WO 2017/161357 PCT/US2017/023108
wherein the oligonucleotides are capable of binding a plurality of entities in
the sample to form
complexes, wherein optionally the oligonucleotide probe library comprises an
oligonucleotide or plurality
of oligonucleotides as provided by the invention above; b) partitioning the
complexes formed in step (a)
from the mixture; and c) recovering oligonucleotides present in the complexes
partitioned in step (b) to
identify an oligonucleotide profile for the sample.
[00449] In still another aspect, the invention provides a method for
generating an enriched oligonucleotide
probe library comprising: a) contacting a first oligonucleotide library with a
biological test sample and a
biological control sample, wherein complexes are formed between biological
entities present in the
biological samples and a plurality of oligonucleotides present in the first
oligonucleotide library; b)
partitioning the complexes formed in step (a) and isolating the
oligonucleotides in the complexes to
produce a subset of oligonucleotides for each of the biological test sample
and biological control sample;
c) contacting the subsets of oligonucleotides in (b) with the biological test
sample and biological control
sample wherein complexes are formed between biological entities present in the
biological samples and a
second plurality of oligonucleotides present in the subsets of
oligonucleotides to generate a second subset
group of oligonucleotides; and d) optionally repeating steps b)-c), one, two,
three or more times to
produce a respective third, fourth, fifth or more subset group of
oligonucleotides, thereby producing the
enriched oligonucleotide probe library. In a related aspect, the invention
provides a plurality of
oligonucleotides comprising at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13,
14, 15, 16, 17, 18, 19, 20, 25, 30,
40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 125, 150, 175, 200, 300,
400, 500, 600, 700, 800, 900,
1000, 2000, 3000, 4000, 5000, 6000, 7000, 8000, 9000, 10000, 20000, 30000,
40000, 50000, 60000,
70000, 80000, 90000, 100000, 200000, 300000, 400000, or 500000 different
oligonucleotide sequences,
wherein the plurality results from the method in this paragraph, wherein the
library is capable of
distinguishing a first phenotype from a second phenotype. In some embodiments,
the first phenotype
comprises a disease or disorder and the second phenotype comprises a healthy
state; or wherein the first
phenotype comprises a disease or disorder and the second phenotype comprises a
different disease or
disorder; or wherein the first phenotype comprises a stage or progression of a
disease or disorder and the
second phenotype comprises a different stage or progression of the same
disease or disorder; or wherein
the first phenotype comprises a positive response to a therapy and the second
phenotype comprises a
negative response to the same therapy.
[00450] In yet another aspect, the invention provides a method of
characterizing a disease or disorder,
comprising: a) contacting a biological test sample with the oligonucleotide or
plurality of oligonucleotides
provided by the invention; b) detecting a presence or level of complexes
formed in step (a) between the
oligonucleotide or plurality of oligonucleotides provided by the invention and
a target in the biological
test sample; and c) comparing the presence or level detected in step (b) to a
reference level from a
biological control sample, thereby characterizing the disease or disorder. The
step of detecting may
comprise performing sequencing of all or some of the oligonucleotides in the
complexes, amplification of
all or some of the oligonucleotides in the complexes, and/or hybridization of
all or some of the
oligonucleotides in the complexes to an array. The sequencing may be high-
throughput or next generation
-118-
CA 03018066 2018-09-17
WO 2017/161357 PCT/US2017/023108
sequencing. In some embodiments, the step of detecting comprises visualizing
the oligonucleotide or
plurality of oligonucleotides in association with the biological test sample.
For example, polyligand
histochemistry (PHC) as provided by the invention may be used.
[00451] In the methods of the invention, the biological test sample and
biological control sample may each
comprise a tissue sample, a cell culture, or a biological fluid. In some
embodiments, the biological fluid
comprises a bodily fluid. Useful bodily fluids within the method of the
invention comprise peripheral
blood, sera, plasma, ascites, urine, cerebrospinal fluid (CSF), sputum,
saliva, bone marrow, synovial fluid,
aqueous humor, amniotic fluid, cerumen, breast milk, broncheoalveolar lavage
fluid, semen, prostatic
fluid, cowper's fluid or pre-ejaculatory fluid, female ejaculate, sweat, fecal
matter, hair, tears, cyst fluid,
pleural and peritoneal fluid, pericardial fluid, lymph, chyme, chyle, bile,
interstitial fluid, menses, pus,
sebum, vomit, vaginal secretions, mucosal secretion, stool water, pancreatic
juice, lavage fluids from
sinus cavities, bronchopulmonary aspirates, blastocyl cavity fluid, or
umbilical cord blood. In some
preferred embodiments, the bodily fluid comprises blood, serum or plasma. The
biological fluid may
comprise microvesicles. In such case, the complexes may be formed between the
oligonucleotide or
plurality of oligonucleotides and at least one of the microvesicles.
[00452] The biological test sample and biological control sample may further
comprise isolated
microvesicles, wherein optionally the microvesicles are isolated using at
least one of chromatography,
filtration, ultrafiltration, centrifugation, ultracentrifugation, flow
cytometry, affinity capture (e.g., to a
planar surface, column or bead), polymer precipitation, and using
microfluidics. The vesicles can also be
isolated after contact with the oligonucleotide or plurality of
oligonucleotides.
[00453] The biological test sample and biological control sample may comprise
tissue. The tissue can be
formalin fixed paraffin embedded (FFPE) tissue. In some embodiments, the FFPE
tissue comprises at
least one of a fixed tissue, unstained slide, bone marrow core or clot, biopsy
sample, surgical sample, core
needle biopsy, malignant fluid, and fine needle aspirate (FNA). The FFPE
tissue can be fixed on a
substrate, e.g., a glass slide or membrane.
[00454] In various embodiments of the methods of the invention, the
oligonucleotide or plurality of
oligonucleotides binds a polypeptide or fragment thereof The polypeptide or
fragment thereof can be
soluble or membrane bound, wherein optionally the membrane comprises a
cellular or microvesicle
membrane. The membrane could also be from a fragment of a cell, organelle or
microvesicle. In some
embodiments, the polypeptide or fragment thereof comprises a biomarker in
Table 3, Table 4 or any one
of Tables 10-17. For example, the polypeptide or fragment thereof could be a
general vesicle marker such
as in Table 3 or a tissue-related or disease-related marker such as in Table
4, or a vesicle associated
biomarker provided in any one of Tables 10-17. The oligonucleotide or
plurality of oligonucleotides may
bind a microvesicle surface antigen in the biological sample. For example, the
oligonucleotide or plurality
of oligonucleotides can be enriched from a naïve library against
microvesicles.
[00455] As noted above, the microvesicles may be isolated in whole or in part
using polymer
precipitation. In an embodiment, the polymer comprises polyethylene glycol
(PEG). Any appropriate form
of PEG may be used. For example, the PEG may be PEG 8000. The PEG may be used
at any appropriate
-119-
CA 03018066 2018-09-17
WO 2017/161357 PCT/US2017/023108
concentration. For example, the PEG can be used at a concentration of 1%, 2%,
PA, 4 /0, 5%, 6%, 70o,
8%, 90, 10%, 110o, 12%, 13%, 14% or 15% to isolate the microvesicles. In some
embodiments, the PEG
is used at a concentration of 6%.
[00456] The disease or disorder detected by the oligonucleotide, plurality of
oligonucleotides, or methods
provided here may comprise any appropriate disease or disorder of interest,
including without limitation
Breast Cancer, Alzheimer's disease, bronchial asthma, Transitional cell
carcinoma of the bladder, Giant
cellular osteoblastoclastoma, Brain Tumor, Colorectal adenocarcinoma, Chronic
obstructive pulmonary
disease (COPD), Squamous cell carcinoma of the cervix, acute myocardial
infarction (AMI) / acute heart
failure, Chron's Disease, diabetes mellitus type II, Esophageal carcinoma,
Squamous cell carcinoma of
the larynx, Acute and chronic leukemia of the bone marrow, Lung carcinoma,
Malignant lymphoma,
Multiple Sclerosis, Ovarian carcinoma, Parkinson disease, Prostate
adenocarcinoma, psoriasis,
Rheumatoid Arthritis, Renal cell carcinoma, Squamous cell carcinoma of skin,
Adenocarcinoma of the
stomach, carcinoma of the thyroid gland, Testicular cancer, ulcerative
colitis, or Uterine adenocarcinoma.
[00457] In some embodiments, the disease or disorder comprises a cancer, a
premalignant condition, an
inflammatory disease, an immune disease, an autoimmune disease or disorder, a
cardiovascular disease or
disorder, neurological disease or disorder, infectious disease or pain. The
cancer can include without
limitation one of acute lymphoblastic leukemia; acute myeloid leukemia;
adrenocortical carcinoma;
AIDS-related cancers; AIDS-related lymphoma; anal cancer; appendix cancer;
astrocytomas; atypical
teratoid/rhabdoid tumor; basal cell carcinoma; bladder cancer; brain stem
glioma; brain tumor (including
brain stem glioma, central nervous system atypical teratoid/rhabdoid tumor,
central nervous system
embryonal tumors, astrocytomas, craniopharyngioma, ependymoblastoma,
ependymoma,
medulloblastoma, medulloepithelioma, pineal parenchymal tumors of intermediate
differentiation,
supratentorial primitive neuroectodermal tumors and pineoblastoma); breast
cancer; bronchial tumors;
Burkitt lymphoma; cancer of unknown primary site; carcinoid tumor; carcinoma
of unknown primary site;
central nervous system atypical teratoid/rhabdoid tumor; central nervous
system embryonal tumors;
cervical cancer; childhood cancers; chordoma; chronic lymphocytic leukemia;
chronic myelogenous
leukemia; chronic myeloproliferative disorders; colon cancer; colorectal
cancer; craniopharyngioma;
cutaneous T-cell lymphoma; endocrine pancreas islet cell tumors; endometrial
cancer;
ependymoblastoma; ependymoma; esophageal cancer; esthesioneuroblastoma; Ewing
sarcoma;
extracranial germ cell tumor; extragonadal germ cell tumor; extrahepatic bile
duct cancer; gallbladder
cancer; gastric (stomach) cancer; gastrointestinal carcinoid tumor;
gastrointestinal stromal cell tumor;
gastrointestinal stromal tumor (GIST); gestational trophoblastic tumor;
glioma; hairy cell leukemia; head
and neck cancer; heart cancer; Hodgkin lymphoma; hypopharyngeal cancer;
intraocular melanoma; islet
cell tumors; Kaposi sarcoma; kidney cancer; Langerhans cell histiocytosis;
laryngeal cancer; lip cancer;
liver cancer; lung cancer; malignant fibrous histiocytoma bone cancer;
medulloblastoma;
medulloepithelioma; melanoma; Merkel cell carcinoma; Merkel cell skin
carcinoma; mesothelioma;
metastatic squamous neck cancer with occult primary; mouth cancer; multiple
endocrine neoplasia
syndromes; multiple myeloma; multiple myeloma/plasma cell neoplasm; mycosis
fungoides;
-120-
CA 03018066 2018-09-17
WO 2017/161357 PCT/US2017/023108
myelodysplastic syndromes; myeloproliferative neoplasms; nasal cavity cancer;
nasopharyngeal cancer;
neuroblastoma; Non-Hodgkin lymphoma; nonmelanoma skin cancer; non-small cell
lung cancer; oral
cancer; oral cavity cancer; oropharyngeal cancer; osteosarcoma; other brain
and spinal cord tumors;
ovarian cancer; ovarian epithelial cancer; ovarian germ cell tumor; ovarian
low malignant potential tumor;
pancreatic cancer; papillomatosis; paranasal sinus cancer; parathyroid cancer;
pelvic cancer; penile
cancer; pharyngeal cancer; pineal parenchymal tumors of intermediate
differentiation; pineoblastoma;
pituitary tumor; plasma cell neoplasm/multiple myeloma; pleuropulmonary
blastoma; primary central
nervous system (CNS) lymphoma; primary hepatocellular liver cancer; prostate
cancer; rectal cancer;
renal cancer; renal cell (kidney) cancer; renal cell cancer; respiratory tract
cancer; retinoblastoma;
rhabdomyosarcoma; salivary gland cancer; Sezary syndrome; small cell lung
cancer; small intestine
cancer; soft tissue sarcoma; squamous cell carcinoma; squamous neck cancer;
stomach (gastric) cancer;
supratentorial primitive neuroectodermal tumors; T-cell lymphoma; testicular
cancer; throat cancer;
thymic carcinoma; thymoma; thyroid cancer; transitional cell cancer;
transitional cell cancer of the renal
pelvis and ureter; trophoblastic tumor; ureter cancer; urethral cancer;
uterine cancer; uterine sarcoma;
vaginal cancer; vulvar cancer; Waldenstrom macroglobulinemia; or Wilm's tumor.
The premalignant
condition can include without limitation Barrett's Esophagus. The autoimmune
disease can include
without limitation one of inflammatory bowel disease (IBD), Crohn's disease
(CD), ulcerative colitis
(UC), pelvic inflammation, vasculitis, psoriasis, diabetes, autoimmune
hepatitis, multiple sclerosis,
myasthenia gravis, Type I diabetes, rheumatoid arthritis, psoriasis, systemic
lupus erythematosis (SLE),
Hashimoto's Thyroiditis, Grave's disease, Ankylosing Spondylitis Sjogrens
Disease, CREST syndrome,
Scleroderma, Rheumatic Disease, organ rejection, Primary Sclerosing
Cholangitis, or sepsis. The
cardiovascular disease can include without limitation one of atherosclerosis,
congestive heart failure,
vulnerable plaque, stroke, ischemia, high blood pressure, stenosis, vessel
occlusion or a thrombotic event.
The neurological disease can include without limitation one of Multiple
Sclerosis (MS), Parkinson's
Disease (PD), Alzheimer's Disease (AD), schizophrenia, bipolar disorder,
depression, autism, Prion
Disease, Pick's disease, dementia, Huntington disease (HD), Down's syndrome,
cerebrovascular disease,
Rasmussen's encephalitis, viral meningitis, neurospsychiatric systemic lupus
erythematosus (NPSLE),
amyotrophic lateral sclerosis, Creutzfeldt-Jacob disease, Gerstmann-Straussler-
Scheinker disease,
transmissible spongiform encephalopathy, ischemic reperfusion damage (e.g.
stroke), brain trauma,
microbial infection, or chronic fatigue syndrome. The pain can include without
limitation one of
fibromyalgia, chronic neuropathic pain, or peripheral neuropathic pain. The
infectious disease can include
without limitation one of a bacterial infection, viral infection, yeast
infection, Whipple 's Disease, Prion
Disease, cirrhosis, methicillin-resistant staphylococcus aureus, HIV, HCV,
hepatitis, syphilis, meningitis,
malaria, tuberculosis, or influenza. One of skill will appreciate that the
oligonucleotide or plurality of
oligonucleotides or methods of the invention can be used to assess any number
of these or other related
diseases and disorders.
[00458] In some embodiments of the invention, the oligonucleotide or plurality
of oligonucleotides and
methods of use thereof are useful for characterizing certain diseases or
disease states. As desired, a pool of
-121-
CA 03018066 2018-09-17
WO 2017/161357 PCT/US2017/023108
oligonucleotides useful for characterizing various diseases is assembled to
create a master pool that can be
used to probe useful for characterizing the various diseases. One of skill
will also appreciate that pools of
oligonucleotides useful for characterizing specific diseases or disorders can
be created as well. The
sequences provided herein can also be modified as desired so long as the
functional aspects are still
maintained (e.g., binding to various targets or ability to characterize a
phenotype). For example, the
oligonucleotides may comprise DNA or RNA, incorporate various non-natural
nucleotides, incorporate
other chemical modifications, or comprise various deletions or insertions.
Such modifications may
facilitate synthesis, stability, delivery, labeling, etc, or may have little
to no effect in practice. In some
cases, some nucleotides in an oligonucleotide may be substituted while
maintaining functional aspects of
the oligonucleotide. Similarly, 5' and 3' flanking regions may be substituted.
In still other cases, only a
portion of an oligonucleotide may be determined to direct its functionality
such that other portions can be
deleted or substituted. Numerous techniques to synthesize and modify
nucleotides and polynucleotides are
disclosed herein or are known in the art.
[00459] In an aspect, the invention provides a kit comprising a reagent for
carrying out the methods of the
invention provided herein. In a similar aspect, the invention contemplates use
of a reagent for carrying out
the methods of the invention provided herein. In embodiments, the reagent
comprises an oligonucleotide
or plurality of oligonucleotides. The oligonucleotide or plurality of
oligonucleotides can be those provided
herein. The reagent may comprise various other useful components including
without limitation
microRNA (miR) and messenger RNA (mRNA)), a protein-nucleic acid complex, and
various
combinations, fragments and/or complexes of any of these. The one or more
reagent can be one or more
of: a) a reagent configured to isolate a microvesicle, optionally wherein the
at least one reagent configured
to isolate a microvesicle comprises a binding agent to a microvesicle antigen,
a column, a substrate, a
filtration unit, a polymer, polyethylene glycol, PEG4000, PEG8000, a particle
or a bead; b) at least one
oligonucleotide configured to act as a primer or probe in order to amplify,
sequence, hybridize or detect
the oligonucleotide or plurality of oligonucleotides; c) a reagent configured
to remove one or more
abundant protein from a sample, wherein optionally the one or more abundant
protein comprises at least
one of albumin, immunoglobulin, fibrinogen and fibrin; d) a reagent for
epitope retrieval; and e) a reagent
for PHC visualization.
[00460] Detecting Watson-Crick base pairing with an oligonucleotide probe
[00461] The oligonucleotide probes provided by the invention can bind via non-
Watson Crick base
pairing. However, in some cases, the oligonucleotide probes provided by the
invention can bind via
Watson Crick base pairing. The oligonucleotide probe libraries of the
invention, e.g., as described above,
can query both types of binding events simultaneously. For example, some
oligonucleotide probes may
bind protein antigens in the classical aptamer sense, whereas other
oligonucleotide probes may bind
tissues, cells, microvesicles or other targets via nucleic acids associated
with such targets, e.g., nucleic
acid (including without limitation microRNA and mRNA) on the surface of the
targets. Such surface
bound nucleic acids can be associated with proteins. For example, they may
comprise Argonaute-
microRNA complexes. The argonaute protein can be Agol, Ago2, Ago3 and/or Ago4.
-122-
CA 03018066 2018-09-17
WO 2017/161357 PCT/US2017/023108
[00462] In addition to the oligonucleotide probe library approach described
herein which relies on
determining a sequence of the oligonucleotides (e.g., via sequencing,
hybridization or amplification),
assays can also be designed to detect Watson Crick base pairing. In some
embodiments, these approaches
rely on Ago2-mediated cleavage wherein an Ago2-microRNA complex can be used to
detected using
oligonucleotide probes. For further details, see PCT/US15/62184, filed
November 23, 2015, which
application is incorporated by reference herein in its entirety.
[00463] Tissue ADAPT
[00464] As noted herein, the invention provides methods of enriching
oligonucleotide libraries against
various biological samples, including tissue samples. Tissue samples may be
fixed. Fixation may be used
in the preparation of histological sections by which biological tissues are
preserved from decay, thereby
preventing autolysis or putrefaction. The principal macromolecules inside a
cell are proteins and nucleic
acids. Fixation terminates any ongoing biochemical reactions, and may also
increase the mechanical
strength or stability of the treated tissues. Thus, tissue fixation can be
used to preserve cells and tissue
components and to do this in such a way as to allow for the preparation of
thin, stained sections. Such
samples are available for many biological specimens, e.g., tumor samples.
Thus, fixed tissues provide a
desirable sample source for various applications of the oligonucleotide probe
libraries of the invention.
This process may be referred to as "tissue ADAPT."
1004651 Tissue ADAPT according to the invention has been used to provide
various oligonucleotide
probes. In an aspect, the invention provides an oligonucleotide comprising a
region corresponding to: a) a
variable sequence as described in any one of Examples 19-31; b) a variable
sequence as described in any
one of Tables 20-23, 25, 27, 38- 40, or 45; or c) a sequence listed in any one
of SEQ ID NO. 1-206506. In
some embodiments, the oligonucleotide further comprises a 5' region with
sequence 5'-
CTAGCATGACTGCAGTACGT (SEQ ID NO. 4), a 3' region with sequence 5'-
CTGTCTCTTATACACATCTGACGCTGCCGACGA (SEQ ID NO. 5), or both. The invention
further
provides an oligonucleotide comprising a nucleic acid sequence or a portion
thereof that is at least 50, 55,
60, 65, 70, 75, 80, 85, 90, 95, 96, 97, 98, 99 or 100 percent homologous to
such oligonucleotide
sequences. In a related aspect, the invention provides a plurality of
oligonucleotides comprising at least 1,
2, 3,4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 40,
45, 50, 55, 60, 65, 70, 75, 80, 85,
90, 95, 100, 125, 150, 175, 200, 300, 400, 500, 600, 700, 800, 900, 1000,
2000, 3000, 4000, 5000, 6000,
7000, 8000, 9000, 10000, 20000, 30000, 40000, 50000, 60000, 70000, 80000,
90000, or at least 100000
different oligonucleotide sequences as described above.
[00466] As described herein, many useful modifications can be made to nucleic
acid molecules. In an
embodiment, the oligonucleotide or the plurality of oligonucleotides of the
invention comprise a DNA,
RNA, 2'-0-methyl or phosphorothioate backbone, or any combination thereof In
some embodiments, the
oligonucleotide or the plurality of oligonucleotides comprises at least one of
DNA, RNA, PNA, LNA,
UNA, and any combination thereof. The oligonucleotide or at least one member
of the plurality of
oligonucleotides can have at least one functional modification selected from
the group consisting of DNA,
RNA, biotinylation, a non-naturally occurring nucleotide, a deletion, an
insertion, an addition, and a
-123-
CA 03018066 2018-09-17
WO 2017/161357 PCT/US2017/023108
chemical modification. In some embodiments, the chemical modification
comprises at least one of C18,
polyethylene glycol (PEG), PEG4, PEG6, PEG8, PEG12 and digoxygenin.
[00467] The oligonucleotide or plurality of oligonucleotides of the invention
can be labeled using any
useful label such as described herein. For example, the oligonucleotide or
plurality of oligonucleotides can
be attached to a nanoparticle, liposome, gold, magnetic label, fluorescent
label, light emitting particle,
biotin moiety, or radioactive label.
[00468] Tissue ADAPT provides for the enrichment of oligonucleotide libraries
against samples of
interest. In an aspect, the invention provides a method of enriching an
oligonucleotide library using
multiple rounds of positive and negative selection. The method of enriching a
plurality of oligonucleotides
may comprise: a) performing at least one round of positive selection, wherein
the positive selection
comprises: i) contacting at least one sample with the plurality of
oligonucleotides, wherein the at least one
sample comprises tissue; and ii) recovering members of the plurality of
oligonucleotides that associated
with the at least one sample; b) optionally performing at least one round of
negative selection, wherein the
negative selection comprises: i) contacting at least one additional sample
with the plurality of
oligonucleotides, wherein at least one additonal sample comprises tissue; ii)
recovering members of the
plurality of oligonucleotides that did not associate with the at least one
additonal sample; and c)
amplifying the members of the plurality of oligonucleotides recovered in at
least one or step (a)(ii) and
step (b)(ii), thereby enriching the oligonucleotide library. Various
alternatives of these processes are
useful and described herein, such as varying the rounds of enrichment, and
varying performance or
positive and negative selection steps. In an embodiments, the recovered
members of the plurality of
oligonucleotides in step (a)(ii) are used as the input for the next iteration
of step (a)(i). In an embodiment,
the recovered members of the plurality of oligonucleotides in step (b)(ii) are
used as the input for the next
iteration of step (a)(i). The unenriched oligonucleotide library may possess
great diversity. For example,
the unenriched oligonucleotide library may comprise at least 2, 3, 4, 5, 6, 7,
8, 9, 10, 11, 12, 13, 14, 15,
16, 17, 18, 19, 20, 25, 30, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95,
100, 125, 150, 175, 200, 300, 400,
500, 600, 700, 800, 900, 1000, 2000, 3000, 4000, 5000, 6000, 7000, 8000, 9000,
10000, 20000, 30000,
40000, 50000, 60000, 70000, 80000, 90000, 100000, 200000, 300000, 400000,
500000, 106, 107, 108, 109,
1010, 1011, 1012, 1013, 1014, 1015, 1016, 1017, or at least 1018 different
oligonucleotide sequences. In an
embodiment, the unenriched oligonucleotide library comprises the naïve F-Trim
library as described
herein.
[00469] In embodiments of the enrichment methods of the invention, the at
least one sample and/or at
least one additional sample comprise tissue. As desired, such tissue may be
fixed using methods described
herein or known in the art. The fixed tissue may be archived. The fixed tissue
may comprise formalin
fixed paraffin embedded (FFPE) tissue. In embodiment, the FFPE tissue
comprises at least one of a fixed
tissue, unstained slide, bone marrow core or clot, biopsy sample, surgical
sample, core needle biopsy,
malignant fluid, and fine needle aspirate (FNA). The FFPE tissue can be fixed
on a substrate. For
example, the substrate can be a glass slide, membrane, or any other useful
material.
-124-
CA 03018066 2018-09-17
WO 2017/161357 PCT/US2017/023108
[00470] In some embodiment, the at least one sample and/or the at least one
additional sample are fixed on
different substrates. As a non-limiting example, the at least one sample is
fixed on one glass slide whereas
the at least one additional sample is fixed on a different glass slide. As
desired, such slides may be from
different patients, different tumors, a same tumor at different time points,
multiple slices of the same
tumor, etc. Alternately, the at least one sample and/or the at least one
additional sample is fixed on a
single substrate. As a non-limiting example, the at least one sample and at
least one additional sample are
fixed on a same glass slide, such as a tumor sample and normal adjacent tissue
to the tumor. In some
embodiments, the at least one sample and/or the at least one additional sample
are lysed (see, e.g.,
Example 29), scraped from a substrate (see, e.g., Example 30), or subjected to
microdissection (see, e.g.,
Example 31). Lysed samples can be arrayed on a substrate. The invention
contemplates any useful
substrate. In some embodiments, the substrate comprises a membrane. For
example, the membrane can be
a nitrocellulose membrane.
[00471] In various embodiments of the enrichment methods of the invention, the
at least one sample and
the at least one additional sample differ in a phenotype of interest. The at
least one sample and the at least
one additional sample can be from different sections of a same substrate. As a
non-limiting example, the
samples may comprise cancer tissue and normal adjacent tissue from a fixed
tissue sample. In such cases,
the at least one sample and the at least one additional sample may be scraped
or microdissected from the
same substrate to facilitate enrichment.
[00472] The oligonucleotide library can be enriched for analysis of any
desired phenotype. In
embodiments, the phenotype comprises a tissue, anatomical origin, medical
condition, disease, disorder,
or any combination thereof. For example, the tissue can be muscle, epithelial,
connective and nervous
tissue, or any combination thereof. For example, the anatomical origin can be
the stomach, liver, small
intestine, large intestine, rectum, anus, lungs, nose, bronchi, kidneys,
urinary bladder, urethra, pituitary
gland, pineal gland, adrenal gland, thyroid, pancreas, parathyroid, prostate,
heart, blood vessels, lymph
node, bone marrow, thymus, spleen, skin, tongue, nose, eyes, ears, teeth,
uterus, vagina, testis, penis,
ovaries, breast, mammary glands, brain, spinal cord, nerve, bone, ligament,
tendon, or any combination
thereof. As described further below, the phenotype can be related to at least
one of diagnosis, prognosis,
theranosis, medical condition, disease or disorder.
[00473] In various embodiments of the enrichment methods of the invention, the
method further
comprises determining a target of the enriched members of the oligonucleotide
library. Techniques for
such determining are provided herein. See, e.g., Examples 9-10, 17 and 19.
[00474] Tissue ADAPT further comprises analysis of biological samples. In an
aspect, the invention
provides a method of characterizing a phenotype in a sample comprising: a)
contacting the sample with at
least one oligonucleotide or plurality of oligonucleotides; and b) identifying
a presence or level of a
complex formed between the at least one oligonucleotide or plurality of
oligonucleotides and the sample,
wherein the presence or level is used to characterize the phenotype. In a
related aspect, the invention
provides a method of visualizing a sample comprising: a) contacting the sample
with at least one
oligonucleotide or plurality of oligonucleotides; b) removing the at least one
oligonucleotide or members
-125-
CA 03018066 2018-09-17
WO 2017/161357 PCT/US2017/023108
of the plurality of oligonucleotides that do not bind the sample; and c)
visualizing the at least one
oligonucleotide or plurality of oligonucleotides that bound to the sample. The
visualization can be used to
characterize a phenotype.
[00475] The sample to be characterized can be any useful sample, including
without limitation a tissue
sample, bodily fluid, cell, cell culture, microvesicle, or any combination
thereof. In some embodiments,
the tissue sample comprises fixed tissue. The tissue may be fixed using any
useful technique for fixation
known in the art. Examples of fixation methods include heat fixation,
immersion, perfusion, chemical
fixation, cross-linked (for example, with an aldehyde such as formaldehyde or
glutaraldehyde),
precipitation (e.g., using an alcohol such as methanol, ethanol and acetone,
and acetic acid), oxidation
(e.g., using osmium tetroxide, potassium dichromate, chromic acid, and
potassium permanganate),
mercurials, picrates, Bouin solution, hepes-glutamic acid buffer-mediated
organic solvent protection
effect (HOPE), and freezing. In preferred embodiments, the fixed tissue is
formalin fixed paraffin
embedded (FFPE) tissue. In various embodiments, the FFPE sample comprises at
least one of a fixed
tissue, unstained slide, bone marrow core or clot, biopsy sample, surgical
sample, core needle biopsy,
malignant fluid, and fine needle aspirate (FNA).
[00476] Any useful technique for identifying a presence or level can be used
for applications of tissue
ADAPT, including without limitation nucleic acid sequencing, amplification,
hybridization, gel
electrophoresis, chromatography, or visualization. In some embodiments, the
hybridization comprises
contacting the sample with at least one labeled probe that is configured to
hybridize with at least one
oligonucleotide or plurality of oligonucleotides. The at least one labeled
probe can be directly or indirectly
attached to a label. The label can be, e.g., a fluorescent, radioactive or
magnetic label. An indirect label
can be, e.g., biotin or digoxigenin. See, e.g., Example 28. In some
embodiments, the sequencing
comprises next generation sequencing, dye termination sequencing, and/or
pyrosequencing of the at least
one oligonucleotide or plurality of oligonucleotides. The visualization may be
that of a signal linked
directly or indirectly to the at least one oligonucleotide or plurality of
oligonucleotides. The signal can be
any useful signal, e.g., a fluorescent signal or an enzymatic signal. In some
embodiments, the enzymatic
signal is produced by at least one of a luciferase, firefly luciferase,
bacterial luciferase, luciferin, malate
dehydrogenase, urease, peroxidase, horseradish peroxidase (HRP), alkaline
phosphatase (AP), 13-
galactosidase, glucoamylase, lysozyme, a saccharide oxidase, glucose oxidase,
galactose oxidase, glucose-
6-phosphate dehydrogenase, a heterocyclic oxidase, unease, xanthine oxidase,
lactoperoxidase, and
microperoxidase. Visualization may comprise use of light microscopy or
fluorescent microscopy. Various
examples of visualization using polyligand histochemistry (PHC) are provided
herein. See Examples 19-
31.
[00477] In the methods of the invention directed to characterizing or
visualizing a sample, the target of at
least one of the at least one oligonucleotide or plurality of oligonucleotides
may be known. For example,
an oligonucleotide may bind a known protein target. In some embodiments, the
target of at least one the at
least one oligonucleotide or plurality of oligonucleotides is unknown. For
example, the at least one
oligonucleotide or plurality of oligonucleotides may themselves provide a
biosignature or other useful
-126-
CA 03018066 2018-09-17
WO 2017/161357 PCT/US2017/023108
result that does not necessarily require knowledge of the antigens bound by
some or all of the
oligonucleotides. In some embodiments, the targets of a portion of the
oligonucleotides are known
whereas the targets of another portion of the oligonucleotides have not been
identified.
[00478] In the methods of characterizing or visualizing a sample, the at least
one oligonucleotide or
plurality of oligonucleotides can be as provided herein. The at least one
oligonucleotide or plurality of
oligonucleotides may have been determined using the enrichment methods of the
invention provided
herein, e.g., enrichment via tissue ADAPT. For example, the at least one
oligonucleotide or plurality of
oligonucleotides may comprise nucleic acids may have a sequence or a portion
thereof that is at least 50,
55, 60, 65, 70, 75, 80, 85, 90, 95, 96, 97, 98, 99 or 100 percent homologous
to an oligonucleotide
sequence according to at least one of SEQ ID NOs. 1-206506.
[00479] For example, the at least one oligonucleotide or plurality of
oligonucleotides may comprise
nucleic acids may have a sequence or a portion thereof that is at least 50,
55, 60, 65, 70, 75, 80, 85, 90, 95,
96, 97, 98, 99 or 100 percent homologous to an oligonucleotide sequence
according to at least 1, 2, 3, 4, 5,
6, 7, 8, 9, 10, 12, 15, 20 or all of SEQ ID NOs. 2922-2926, 2929-2947 and 2950-
2952. In such cases, the
phenotype may be, e.g., lung cancer or prostate cancer. See Example 14.
[00480] In another example, the at least one oligonucleotide or plurality of
oligonucleotides may comprise
nucleic acids having a sequence or a portion thereof that is at least 50, 55,
60, 65, 70, 75, 80, 85, 90, 95,
96, 97, 98, 99 or 100 percent homologous to an oligonucleotide sequence
according to at least 1, 2, 3, 4, 5,
6, 7, 8, 9, 10, 12, 15, 20 or all of SEQ ID NOs. 2953-2961 and 2971-2979. In
such cases, the phenotype
may be, e.g., prostate cancer. See Example 17.
[00481] In yet another example, the at least one oligonucleotide or plurality
of oligonucleotides may
comprise nucleic acids having a sequence or a portion thereof that is at least
50, 55, 60, 65, 70, 75, 80, 85,
90, 95, 96, 97, 98, 99 or 100 percent homologous to an oligonucleotide
sequence according to at least 1, 2,
3, 4, 5, 6, 7, 8, 9, 10, 12, 15, 20, 25, 30, 35, 40, 50 or all of SEQ ID NOs.
3039-3061. In such cases, the
phenotype may be, e.g., HER2 status (+/-). See Example 19.
[00482] In still another example, the at least one oligonucleotide or
plurality of oligonucleotides may
comprise nucleic acids having a sequence or a portion thereof that is at least
50, 55, 60, 65, 70, 75, 80, 85,
90, 95, 96, 97, 98, 99 or 100 percent homologous to an oligonucleotide
sequence according to at least 1, 2,
3, 4, 5, 6, 7, 8, 9, 10, 12, 15, 20, 25, 30, 35, 40, 50, 60, 70, 80, 90, 100,
200, 300, 400, 500, 600, 700, 800,
900, 1000, 2000, 3000, 4000, 5000, 6000, 7000, 8000, 9000, 10000, 20000,
30000, 40000, 50000, 60000,
70000, 80000, 90000, 100000, 150,000 or all of SEQ ID NOs. 3062-103061 and
103062-203061. In such
cases, the phenotype may be, e.g., response to anti-HER2 therapy, wherein
optionally the anti-HER2
therapy comprises traztuzamab. See Examples 20-22.
[00483] In an example, the at least one oligonucleotide or plurality of
oligonucleotides may comprise
nucleic acids having a sequence or a portion thereof that is at least 50, 55,
60, 65, 70, 75, 80, 85, 90, 95,
96, 97, 98, 99 or 100 percent homologous to an oligonucleotide sequence
according to at least 1, 2, 3, 4, 5,
6, 7, 8, 9, 10, 12, 15, 20, 25, 30, 35, 40, 50, 60, 70, 80, 90, 100, 200, 300,
400, 500, 600, 700, 800, 900,
-127-
CA 03018066 2018-09-17
WO 2017/161357 PCT/US2017/023108
1000, 2000, 3000, 4000 or all of SEQ ID NOs. 203064-203067 and 203076-206478.
In such cases, the
phenotype may be, e.g., response to at least one of FOLFOX and bevazicumab.
See Example 24.
[00484] In another example, the at least one oligonucleotide or plurality of
oligonucleotides may comprise
nucleic acids having a sequence or a portion thereof that is at least 50, 55,
60, 65, 70, 75, 80, 85, 90, 95,
96, 97, 98, 99 or 100 percent homologous to an oligonucleotide sequence
according to at least 1, 2, 3, 4, 5,
6, 7, 8, 9, 10, 12, 15 or all of SEQ ID NOs. 206491-206506. In such cases, the
phenotype may be, e.g., a
tissue identity, including without limitation whether the tissue comprises
breast, colon, kidney, lung or
pancreatic tissue. See Example 29.
[00485] In the methods of the invention, including enriching an
oligonucleotide library, characterizing a
sample or visualizing a sample, the phenotype can be a biomarker status. In
some embodiments, the
biomarker is selected from Table 4 or FIGs. 26A-B. In some embodiments, the
biomarker status
comprises at least one of HER2 positive, HER2 negative, EGFR positive, EGFR
negative, TUBB3
positive, or TUBB3 negative. See, e.g., Examples 19-23, 24, 26. In some
embodiments, the biomarker
status comprises expression, copy number, mutation, insertion, deletion or
other alteration of at least one
of ALK, AR, ER, ERCC1, Her2/Neu, MGMT, MLH1, MSH2, MSH6, PD-1, PD-L1, PD-Li
(22c3),
PMS2, PR, PTEN, RRM1, TLE3, TOP2A, TOP01, TrkA, TrkB, TrkC, TS, and TUBB3. In
various
embodiments, the biomarker status comprises the presence or absence of at
least one of EGFR vIII or
MET Exon 14 Skipping. In embodiments, the biomarker status comprises
expression, copy number,
fusion, mutation, insertion, deletion or other alteration of at least one of
ALK, BRAF, NTRK1, NTRK2,
NTRK3, RET, ROS1, and RSP03. In embodiments, the biomarker status comprises
expression, copy
number, fusion, mutation, insertion, deletion or other alteration of at least
one of ABL2, ACSL3, ACSL6,
AFF1, AFF3, AFF4, AKAP9, AKT2, AKT3, ALDH2, ALK, APC, ARFRP1, ARHGAP26,
ARHGEF12,
ARID1A, ARID2, ARNT, ASPSCR1, ASXL1, ATF1, ATIC, ATM, ATP1A1, ATR, AURKA,
AURKB,
AXIN1, AXL, BAP1, BARD1, BCL10, BCL11A, BCL2L11, BCL3, BCL6, BCL7A, BCL9, BCR,
BIRC3, BLM, BMPR1A, BRAF, BRCA1, BRCA2, BRIP1, BUB1B, Cllorf30 (EMSY),
C2orf44,
CACNA1D, CALR, CAMTA1, CANT1, CARD ii, CARS, CASC5, CASP8, CBFA2T3, CBFB, CBL,
CBLB, CCDC6, CCNB lIP1, CCND1, CCND2, CCND3, CCNE1, CD274 (PDL1), CD74, CD79A,
CDC73, CDH11, CDK4, CDK6, CDK8, CDKN1B, CDKN2A, CDX2, CHEK1, CHEK2, CHIC2,
CHN1,
CIC, CIITA, CLP1, CLTC, CLTCL1, CNBP, CNTRL, COPB1, CREB1, CREB3L1, CREB3L2,
CREBBP, CRKL, CRTC1, CRTC3, CSF1R, CSF3R, CTCF, CTLA4, CTNNA1, CTNNB1, CYLD,
CYP2D6, DAXX, DDR2, DDX10, DDX5, DDX6, DEK, DICER1, DOT1L, EBF1, ECT2L, EGFR,
ELK4, ELL, EML4, EP300, EPHA3, EPHA5, EPHB1, EPS15, ERBB2 (HER2), ERBB3
(HER3),
ERBB4 (HER4), ERC1, ERCC2, ERCC3, ERCC4, ERCC5, ERG, ESR1, ETV1, ETV5, ETV6,
EWSR1,
EXT1, EXT2, EZH2, EZR, FANCA, FANCC, FANCD2, FANCE, FANCG, FANCL, FAS, FBX011,
FBX1V7, FCRL4, FGF10, FGF14, FGF19, FGF23, FGF3, FGF4, FGF6, FGFR1, FGFR1OP,
FGFR2,
FGFR3, FGFR4, FH, FHIT, FIP1L1, FLCN, FLI1, FLT1, FLT3, FLT4, FNBP1, FOXA1,
FOX01,
FOXP1, FUBP1, FUS, GAS7, GATA3, GID4 (C17orf39), GMPS, GNA13, GNAQ, GNAS,
GOLGA5,
GOPC, GPHN, GPR124, GRIN2A, GSK3B, H3F3A, H3F3B, HERPUD1, HGF, HIP1, HMGA1,
-128-
CA 03018066 2018-09-17
WO 2017/161357 PCT/US2017/023108
HMGA2, HNRNPA2B1, HOOK3, HSP9OAA1, HSP90AB1, IDH1, IDH2, IGF1R, IKZFl, IL2,
IL21R,
IL6ST, IL7R, IRF4, ITK, JAK1, JAK2, JAK3, JAZFl, KDM5A, KDR (VEGFR2), KEAP1,
KIAA1549,
KIF5B, KIT, KLHL6, KMT2A (MLL), KMT2C (MLL3), KMT2D (MLL2), KRAS, KTN1, LCK,
LCP1,
LGR5, LHFP, LIFR, LPP, LRIG3, LRP1B, LYL1, MAF, MALT1, MAML2, MAP2K1, MAP2K2,
MAP2K4, MAP3K1, MCL1, MDM2, MDM4, MDS2, MEF2B, MEN1, MET (cMET), MITF, MLF1,
MLH1 (NGS), MLLT1, MLLT10, MLLT3, MLLT4, MLLT6, MNX1, MRE11A, MSH2 (NGS), MSH6
(NGS), MSI2, MTOR, MYB, MYC, MYCN, MYD88, MYH11, MYH9, NACA, NCKIPSD, NCOA1,
NCOA2, NCOA4, NF1, NF2, NFE2L2, NFIB, NFKB2, NFKBIA, NIN, NOTCH2, NPM1, NR4A3,
NSD1, NT5C2, NTRK1, NTRK2, NTRK3, NUP214, NUP93, NUP98, NUTM1, PALB2, PAX3,
PAX5,
PAX7, PBRM1, PBX1, PCM1, PCSK7, PDCD1 (PD1), PDCD1LG2 (PDL2), PDGFB, PDGFRA,
PDGFRB, PDK1, PERI, PICALM, PIK3CA, PIK3R1, PIK3R2, PIM1, PML, PMS2 (NGS),
POLE,
POT1, POU2AF1, PPARG, PRCC, PRDM1, PRDM16, PRKAR1A, PRRX1, PSIP1, PTCH1, PTEN
(NGS), PTPN11, PTPRC, RABEP1, RAC1, RAD50, RAD51, RAD51B, RAF1, RALGDS,
RANBP17,
RAP1GDS1, RARA, RB1, RBM15, REL, RET, RICTOR, RMI2, RNF43, ROS1, RPL22, RPL5,
RPN1,
RPTOR, RUNX1, RUNX1T1, SBDS, SDC4, SDHAF2, SDHB, SDHC, SDHD, SEPT9, SET,
SETBP1,
SETD2, SF3B1, SH2B3, SH3GL1, SLC34A2, SMAD2, SMAD4, SMARCB1, SMARCE1, SMO,
SNX29, SOX10, SPECC1, SPEN, SRGAP3, SRSF2, SRSF3, SS18, SS18L1, STAT3, STAT4,
STAT5B,
STIL, STK11, SUFU, SUZ12, SYK, TAF15, TCF12, TCF3, TCF7L2, TETI, TET2, TFEB,
TFG, TFRC,
TGFBR2, TLX1, TNFAIP3, TNFRSF14, TNFRSF17, TOP1, TP53, TPM3, TPM4, TPR, IRAF7,
TRIM26, TRIM27, TRIM33, TRIP11, TRRAP, TSC1, TSC2, TSHR, TTL, U2AF1, USP6,
VEGFA,
VEGFB, VTI1A, WHSC1, WHSC1L1, WIF1, WISP3, WRN, WT1, WWTR1, XPA, XPC, XP01,
YWHAE, ZMYM2, ZNF217, ZNF331, ZNF384, ZNF521, and ZNF703. The biomarker status
may
comprise expression, copy number, fusion, mutation, insertion, deletion or
other alteration of at least one
of ABIl, ABL1, ACKR3, AKT1, AMER1 (FAM123B), AR, ARAF, ATP2B3, ATRX, BCL11B,
BCL2,
BCL2L2, BCOR, BCORL1, BRD3, BRD4, BTG1, BTK, C15orf65, CBLC, CD79B, CDH1,
CDK12,
CDKN2B, CDKN2C, CEBPA, CHCHD7, CNOT3, COL 1A1, COX6C, CRLF2, DDB2, DDIT3,
DNM2,
DNMT3A, EIF4A2, ELF4, ELN, ERCC1 (NGS), ETV4, FAM46C, FANCF, FEV, FOXL2,
FOX03,
FOX04, FSTL3, GATA1, GATA2, GNAll, GPC3, HEY1, HIST1H3B, HIST1H4I, HLF,
HMGN2P46,
HNF1A, HOXA11, HOXA13, HOXA9, HOXC11, HOXC13, HOXD11, HOXD13, HRAS, IKBKE,
INHBA, IRS2, JUN, KAT6A (MYST3), KAT6B, KCNJ5, KDM5C, KDM6A, KDSR, KLF4, KLK2,
LASP1, LM01, LM02, MAFB, MAX, MECOM, MED12, MKL1, MLLT11, MN1, MPL, MSN,
MTCP1, MUC1, MUTYH, MYCL (MYCL1), NBN, NDRG1, NKX2-1, NONO, NOTCH1, NRAS,
NUMA1, NUTM2B, OLIG2, OMD, P2RY8, PAFAH1B2, PAK3, PATZ1, PAX8, PDE4DIP, PHF6,
PHOX2B, PIK3CG, PLAG1, PMS1, POU5F1, PPP2R1A, PRF1, PRKDC, RAD21, RECQL4,
RHOH,
RNF213, RPL10, SEPT5, SEPT6, SFPQ, SLC45A3, SMARCA4, SOCS1, SOX2, SPOP, SRC,
SSX1,
STAG2, TALI, TAL2, TBL1XR1, TCEA1, TCL1A, TERT, TFE3, TFPT, THRAP3, TLX3,
TMPRSS2,
UBR5, VHL, WAS, ZBTB16, and ZRSR2. The biomarker status can be for a biomarker
in any one of
PCT/US2007/69286, filed May 18, 2007; PCT/US2009/60630, filed October 14,
2009; PCT/
-129-
CA 03018066 2018-09-17
WO 2017/161357 PCT/US2017/023108
2010/000407, filed February 11,2010; PCT/US12/41393, filed June 7,2012;
PCT/US2013/073184, filed
December 4, 2013; PCT/US2010/54366, filed October 27, 2010; PCT/US11/67527,
filed December 28,
2011; PCT/US15/13618, filed January 29, 2015; and PCT/US16/20657, filed March
3, 2016; each of
which applications is incorporated herein by reference in its entirety.
Examples of additional biomarkers
that can be incorporated into the methods and compositions of the invention
include without limitation
those disclosed in International Patent Application Nos. PCT/US2009/62880,
filed October 30, 2009;
PCT/US2009/006095, filed November 12, 2009; PCT/US2011/26750, filed March 1,
2011;
PCT/US2011/031479, filed April 6,2011; PCT/US11/48327, filed August 18, 2011;
PCT/US2008/71235,
filed July 25, 2008; PCT/US10/58461, filed November 30, 2010;
PCT/US2011/21160, filed January 13,
2011; PCT/US2013/030302, filed March 11,2013; PCT/US12/25741, filed February
17, 2012;
PCT/2008/76109, filed September 12, 2008; PCT/US12/42519, filed June 14, 2012;
PCT/US12/50030,
filed August 8, 2012; PCT/US12/49615, filed August 3, 2012; PCT/US12/41387,
filed June 7, 2012;
PCT/US2013/072019, filed November 26, 2013; PCT/US2014/039858, filed May 28,
2013;
PCT/IB2013/003092, filed October 23, 2013; PCT/US13/76611, filed December 19,
2013;
PCT/US14/53306, filed August 28, 2014; and PCT/US15/62184, filed November 23,
2015;
PCT/US16/40157, filed June 29, 2016; PCT/US16/44595, filed July 28, 2016; and
PCT/US16/21632,
filed March 9, 2016; each of which applications is incorporated herein by
reference in its entirety. The
methods of the invention can be used to enrich oligonucleotide libraries and
analyze samples given any
desired biomarker status for which appropriate samples are available.
[00486] In the methods of the invention, including enriching an
oligonucleotide library, characterizing a
sample or visualizing a sample, the phenotype can be a phenotype comprises a
disease or disorder. The
methods can be employed to assist in providing a diagnosis, prognosis and/or
theranosis for the disease or
disorder. For example, the enriching may be performed using sample such that
the enriched library can be
used to assist in providing a diagnosis, prognosis and/or theranosis for the
disease or disorder. Similarly,
the characterizing may comprise assisting in providing a diagnosis, prognosis
and/or theranosis for the
disease or disorder. The visualization may also comprise assisting in
providing a diagnosis, prognosis
and/or theranosis for the disease or disorder. In some embodiments, the
theranosis comprises predicting a
treatment efficacy or lack thereof, classifying a patient as a responder or
non-responder to treatment, or
monitoring a treatment efficacy. The theranosis can be directed to any
appropriate treatment, e.g., the
treatment may comprise at least one of chemotherapy, immunotherapy, targeted
cancer therapy, a
monoclonal antibody, an anti-HER2 antibody, trastuzumab, an anti-VEGF
antibody, bevacizumab, and/or
platinum / taxane therapy. In some embodiments, the treatment comprises at
least one of afatinib, afatinib
+ cetuximab, alectinib, aspirin, atezolizumab, bicalutamide, cabozantinib,
capecitabine, carboplatin,
ceritinib, cetuximab, cisplatin, crizotinib, dabrafenib, dacarbazine,
doxorubicin, enzalutamide, epirubicin,
erlotinib, everolimus, exemestane + everolimus, fluorouracil, fulvestrant,
gefitinib, gemcitabine, hormone
therapies, irinotecan, lapatinib, liposomal-doxorubicin, matinib, mitomycin-c,
nab-paclitaxel, nivolumab,
olaparib, osimertinib, oxaliplatin, palbociclib combination therapy,
paclitaxel, palbociclib, panitumumab,
pembrolizumab, pemetrexed, pertuzumab, sunitinib, T-DM1, temozolomide
docetaxel, temsirolimus,
-130-
CA 03018066 2018-09-17
WO 2017/161357 PCT/US2017/023108
topotecan, trametinib, trastuzumab, vandetanib, and vemurafenib. The hormone
therapy can be one or
more of tamoxifen, toremifene, fulvestrant, letrozole, anastrozole,
exemestane, megestrol acetate,
leuprolide, goserelin, bicalutamide, flutamide, abiraterone, enzalutamide,
triptorelin, abarelix, and
degarelix.
[00487] The theranosis can be for a therapy listed in FIGs. 26A-B, or in any
one of PCT/US2007/69286,
filed May 18, 2007; PCT/US2009/60630, filed October 14, 2009; PCT/
2010/000407, filed February 11,
2010; PCT/US12/41393, filed June 7,2012; PCT/US2013/073184, filed December
4,2013;
PCT/US2010/54366, filed October 27, 2010; PCT/US11/67527, filed December 28,
2011;
PCT/US15/13618, filed January 29, 2015; and PCT/US16/20657, filed March 3,
2016; each of which
applications is incorporated herein by reference in its entirety. The
likelihood of benefit or lack of benefit
of these therapies for treating various cancers can be related to a biomarker
status. For example, anti-
HER2 treatments may be of most benefit for patients whose tumors express HER2,
and vice versa. Using
appropriate samples for enrichment (e.g., known responders or non-responders),
tissue ADAPT may be
used to provide improved theranosis as compared to conventional companion
diagnostics. See, e.g.,
Examples 20-22; see also Examples 24, 27.
[00488] In the methods of the invention directed to characterizing a sample,
the characterizing may
comprise comparing the presence or level to a reference. In some embodiments,
the reference comprises a
presence or level determined in a sample from an individual without a disease
or disorder, or from an
individual with a different state of a disease or disorder. The presence or
level can be that of a visual level,
such as an IHC score, determined by the visualizing. As a non-limiting
example, the comparison to the
reference of at least one oligonucleotide or plurality of oligonucleotides
provided by the invention
indicates that the sample comprises a cancer sample or a non-cancer/normal
sample.
[00489] In some embodiments of the methods of the invention, one or more
sample comprises a bodily
fluid. The bodily fluid can be any useful bodily fluid, including without
limitation peripheral blood, sera,
plasma, ascites, urine, cerebrospinal fluid (CSF), sputum, saliva, bone
marrow, synovial fluid, aqueous
humor, amniotic fluid, cerumen, breast milk, broncheoalveolar lavage fluid,
semen, prostatic fluid,
cowper's fluid or pre-ejaculatory fluid, female ejaculate, sweat, fecal
matter, hair oil, tears, cyst fluid,
pleural and peritoneal fluid, pericardial fluid, lymph, chyme, chyle, bile,
interstitial fluid, menses, pus,
sebum, vomit, vaginal secretions, mucosal secretion, stool water, pancreatic
juice, lavage fluids from
sinus cavities, bronchopulmonary aspirates, blastocyl cavity fluid, or
umbilical cord blood.
[00490] In the methods of the invention, including characterizing a sample or
visualizing a sample, the
sample can be from a subject suspected of having or being predisposed to a
medical condition, disease, or
disorder.
[00491] In the methods of the invention, including enriching an
oligonucleotide library, characterizing a
sample or visualizing a sample, the medical condition, the disease or disorder
may be a cancer, a
premalignant condition, an inflammatory disease, an immune disease, an
autoimmune disease or disorder,
a cardiovascular disease or disorder, neurological disease or disorder,
infectious disease or pain. In some
embodiments, the cancer comprises comprises an acute lymphoblastic leukemia;
acute myeloid leukemia;
-13 1-
CA 03018066 2018-09-17
WO 2017/161357 PCT/US2017/023108
adrenocortical carcinoma; AIDS-related cancers; AIDS-related lymphoma; anal
cancer; appendix cancer;
astrocytomas; atypical teratoid/rhabdoid tumor; basal cell carcinoma; bladder
cancer; brain stem glioma;
brain tumor (including brain stem glioma, central nervous system atypical
teratoid/rhabdoid tumor, central
nervous system embryonal tumors, astrocytomas, craniopharyngioma,
ependymoblastoma, ependymoma,
medulloblastoma, medulloepithelioma, pineal parenchymal tumors of intermediate
differentiation,
supratentorial primitive neuroectodermal tumors and pineoblastoma); breast
cancer; bronchial tumors;
Burkitt lymphoma; cancer of unknown primary site; carcinoid tumor; carcinoma
of unknown primary site;
central nervous system atypical teratoid/rhabdoid tumor; central nervous
system embryonal tumors;
cervical cancer; childhood cancers; chordoma; chronic lymphocytic leukemia;
chronic myelogenous
leukemia; chronic myeloproliferative disorders; colon cancer; colorectal
cancer; craniopharyngioma;
cutaneous T-cell lymphoma; endocrine pancreas islet cell tumors; endometrial
cancer;
ependymoblastoma; ependymoma; esophageal cancer; esthesioneuroblastoma; Ewing
sarcoma;
extracranial germ cell tumor; extragonadal germ cell tumor; extrahepatic bile
duct cancer; gallbladder
cancer; gastric (stomach) cancer; gastrointestinal carcinoid tumor;
gastrointestinal stromal cell tumor;
gastrointestinal stromal tumor (GIST); gestational trophoblastic tumor;
glioma; hairy cell leukemia; head
and neck cancer; heart cancer; Hodgkin lymphoma; hypopharyngeal cancer;
intraocular melanoma; islet
cell tumors; Kaposi sarcoma; kidney cancer; Langerhans cell histiocytosis;
laryngeal cancer; lip cancer;
liver cancer; lung cancer; malignant fibrous histiocytoma bone cancer;
medulloblastoma;
medulloepithelioma; melanoma; Merkel cell carcinoma; Merkel cell skin
carcinoma; mesothelioma;
metastatic squamous neck cancer with occult primary; mouth cancer; multiple
endocrine neoplasia
syndromes; multiple myeloma; multiple myeloma/plasma cell neoplasm; mycosis
fungoides;
myelodysplastic syndromes; myeloproliferative neoplasms; nasal cavity cancer;
nasopharyngeal cancer;
neuroblastoma; Non-Hodgkin lymphoma; nonmelanoma skin cancer; non-small cell
lung cancer; oral
cancer; oral cavity cancer; oropharyngeal cancer; osteosarcoma; other brain
and spinal cord tumors;
ovarian cancer; ovarian epithelial cancer; ovarian germ cell tumor; ovarian
low malignant potential tumor;
pancreatic cancer; papillomatosis; paranasal sinus cancer; parathyroid cancer;
pelvic cancer; penile
cancer; pharyngeal cancer; pineal parenchymal tumors of intermediate
differentiation; pineoblastoma;
pituitary tumor; plasma cell neoplasm/multiple myeloma; pleuropulmonary
blastoma; primary central
nervous system (CNS) lymphoma; primary hepatocellular liver cancer; prostate
cancer; rectal cancer;
renal cancer; renal cell (kidney) cancer; renal cell cancer; respiratory tract
cancer; retinoblastoma;
rhabdomyosarcoma; salivary gland cancer; Sezary syndrome; small cell lung
cancer; small intestine
cancer; soft tissue sarcoma; squamous cell carcinoma; squamous neck cancer;
stomach (gastric) cancer;
supratentorial primitive neuroectodermal tumors; T-cell lymphoma; testicular
cancer; throat cancer;
thymic carcinoma; thymoma; thyroid cancer; transitional cell cancer;
transitional cell cancer of the renal
pelvis and ureter; trophoblastic tumor; ureter cancer; urethral cancer;
uterine cancer; uterine sarcoma;
vaginal cancer; vulvar cancer; Waldenstrom macroglobulinemia; or Wilm's tumor.
In some embodiments,
the premalignant condition comprises Barrett's Esophagus. In some embodiments,
the autoimmune
disease comprises inflammatory bowel disease (IBD), Crohn's disease (CD),
ulcerative colitis (UC),
-132-
CA 03018066 2018-09-17
WO 2017/161357 PCT/US2017/023108
pelvic inflammation, vasculitis, psoriasis, diabetes, autoimmune hepatitis,
multiple sclerosis, myasthenia
gravis, Type I diabetes, rheumatoid arthritis, psoriasis, systemic lupus
erythematosis (SLE), Hashimoto's
Thyroiditis, Grave's disease, Ankylosing Spondylitis Sjogrens Disease, CREST
syndrome, Scleroderma,
Rheumatic Disease, organ rejection, Primary Sclerosing Cholangitis, or sepsis.
In some embodiments, the
cardiovascular disease comprises atherosclerosis, congestive heart failure,
vulnerable plaque, stroke,
ischemia, high blood pressure, stenosis, vessel occlusion or a thrombotic
event. In some embodiments, the
neurological disease comprises Multiple Sclerosis (MS), Parkinson's Disease
(PD), Alzheimer's Disease
(AD), schizophrenia, bipolar disorder, depression, autism, Prion Disease,
Pick's disease, dementia,
Huntington disease (HD), Down's syndrome, cerebrovascular disease, Rasmussen's
encephalitis, viral
meningitis, neurospsychiatric systemic lupus erythematosus (NPSLE),
amyotrophic lateral sclerosis,
Creutzfeldt-Jacob disease, Gerstmann-Straussler-Scheinker disease,
transmissible spongiform
encephalopathy, ischemic reperfusion damage (e.g. stroke), brain trauma,
microbial infection, or chronic
fatigue syndrome. In some embodiments, the pain comprises fibromyalgia,
chronic neuropathic pain, or
peripheral neuropathic pain. In some embodiments, the infectious disease
comprises a bacterial infection,
viral infection, yeast infection, Whipple's Disease, Prion Disease, cirrhosis,
methicillin-resistant
staphylococcus aureus, HIV, HCV, hepatitis, syphilis, meningitis, malaria,
tuberculosis, influenza.
[00492] In an aspect, the invention provides a kit comprising at least one
reagent for carrying out the
methods provided by the invention, including enriching an oligonucleotide
library, characterizing a
sample or visualizing a sample. In a related aspect, the invention provides
use of at least one reagent for
carrying out the methods provided by the invention, including enriching an
oligonucleotide library,
characterizing a sample or visualizing a sample. In some embodiments, the at
least one reagent comprises
an oligonucleotide or a plurality of oligonucleotides provided herein.
Additional useful reagents are also
provided herein. See, e.g., the protocols provided in the Examples.
[00493] The at least one oligonucleotide or plurality of oligonucleotides
provided by tissue ADAPT can
be used for various purposes. As described above, such oligonucleotides can be
used to characterize
and/or visualize a sample. As the oligonucleotides are selected to associate
with tissues of interest, such
associations can also be used for other purposes. In an aspect, the invention
provides a method of imaging
at least one cell or tissue, comprising contacting the at least one cell or
tissue with at least one
oligonucleotide or plurality of oligonucleotides provided herein, and
detecting the at least one
oligonucleotide or the plurality of oligonucleotides in contact with at least
one cell or tissue. In a non-
limiting example, such method can be used for medical imaging of a tumor or
tissue in a patient.
[00494] For example, the at least one oligonucleotide or plurality of
oligonucleotides may comprise
nucleic acids may have a sequence or a portion thereof that is at least 50,
55, 60, 65, 70, 75, 80, 85, 90, 95,
96, 97, 98, 99 or 100 percent homologous to an oligonucleotide sequence
according to at least 1, 2, 3, 4, 5,
6, 7, 8, 9, 10, 12, 15, 20 or all of SEQ ID NOs. 2922-2926, 2929-2947 and 2950-
2952. In such cases, the
imaging may be, e.g., directed to lung or prostate tissue. See Example 14.
[00495] In another example, the at least one oligonucleotide or plurality of
oligonucleotides may comprise
nucleic acids having a sequence or a portion thereof that is at least 50, 55,
60, 65, 70, 75, 80, 85, 90, 95,
-133-
CA 03018066 2018-09-17
WO 2017/161357 PCT/US2017/023108
96, 97, 98, 99 or 100 percent homologous to an oligonucleotide sequence
according to at least 1, 2, 3, 4, 5,
6, 7, 8, 9, 10, 12, 15, 20 or all of SEQ ID NOs. 2953-2961 and 2971-2979. In
such cases, the phenotype
may be, e.g., prostate cancer. See Example 17.
[00496] In yet another example, the at least one oligonucleotide or plurality
of oligonucleotides may
comprise nucleic acids having a sequence or a portion thereof that is at least
50, 55, 60, 65, 70, 75, 80, 85,
90, 95, 96, 97, 98, 99 or 100 percent homologous to an oligonucleotide
sequence according to at least 1, 2,
3, 4, 5, 6, 7, 8, 9, 10, 12, 15, 20, 25, 30, 35, 40, 50 or all of SEQ ID NOs.
3039-3061. In such cases, the
imaging may be, e.g., directed to HER2 status of a cell or tissue. See Example
19.
[00497] In still another example, the at least one oligonucleotide or
plurality of oligonucleotides may
comprise nucleic acids having a sequence or a portion thereof that is at least
50, 55, 60, 65, 70, 75, 80, 85,
90, 95, 96, 97, 98, 99 or 100 percent homologous to an oligonucleotide
sequence according to at least 1, 2,
3, 4, 5, 6, 7, 8, 9, 10, 12, 15, 20, 25, 30, 35, 40, 50, 60, 70, 80, 90, 100,
200, 300, 400, 500, 600, 700, 800,
900, 1000, 2000, 3000, 4000, 5000, 6000, 7000, 8000, 9000, 10000, 20000,
30000, 40000, 50000, 60000,
70000, 80000, 90000, 100000, 150,000 or all of SEQ ID NOs. 3062-103061 and
103062-203061. In such
cases, the imaging may be, e.g., directed to a HER2 status of a cell or
tissue. See Examples 20-22.
[00498] In an example, the at least one oligonucleotide or plurality of
oligonucleotides may comprise
nucleic acids having a sequence or a portion thereof that is at least 50, 55,
60, 65, 70, 75, 80, 85, 90, 95,
96, 97, 98, 99 or 100 percent homologous to an oligonucleotide sequence
according to at least 1, 2, 3, 4, 5,
6, 7, 8, 9, 10, 12, 15, 20, 25, 30, 35, 40, 50, 60, 70, 80, 90, 100, 200, 300,
400, 500, 600, 700, 800, 900,
1000, 2000, 3000, 4000 or all of SEQ ID NOs. 203064-203067 and 203076-206478.
In such cases, the
imaging may be, e.g., directed to colorectal cells or tissue. See Example 24.
[00499] In another example, the at least one oligonucleotide or plurality of
oligonucleotides may comprise
nucleic acids having a sequence or a portion thereof that is at least 50, 55,
60, 65, 70, 75, 80, 85, 90, 95,
96, 97, 98, 99 or 100 percent homologous to an oligonucleotide sequence
according to at least 1, 2, 3, 4, 5,
6, 7, 8, 9, 10, 12, 15 or all of SEQ ID NOs. 206491-206506. In such cases, the
imaging may be, e.g.,
directed to a tissue, including without limitation breast, colon, kidney, lung
or pancreatic tissue. See
Example 29.
[00500] In the imaging methods provided by the invention, the at least one
oligonucleotide or the plurality
of oligonucleotides can carry various useful chemical structures or
modifications such as described herein.
Such modifications can be made to enhance binding, stability, allow detection,
or for other useful
purposes.
[00501] In the imaging methods provided by the invention, the at least one
oligonucleotide or the plurality
of oligonucleotides can be administered to a subject prior to the detecting.
Such method may allow
imaging of at least one cell or tissue in the subject. In some embodiments,
the at least one cell or tissue
comprises neoplastic, malignant, tumor, hyperplastic, or dysplastic cells. In
some embodiments, the at
least one cell or tissue comprises at least one of lymphoma, leukemia, renal
carcinoma, sarcoma,
hemangiopericytoma, melanoma, abdominal cancer, gastric cancer, colon cancer,
cervical cancer, prostate
cancer, pancreatic cancer, breast cancer, or non-small cell lung cancer cells.
The at least one cell or tissue
-134-
CA 03018066 2018-09-17
WO 2017/161357 PCT/US2017/023108
can be from any desired tissue or related to desired any medicial condition,
disease or disorder such as
described herein.
[00502] As the oligonucleotides provided by tissue ADAPT are selected to
associate with tissues of
interest, such associations can also be used in therapeutic applications such
as targeted drug delivery. The
oligonucleotides may provide therapeutic benefit alone or by providing
targeted delivery of
immunomodulators, drugs and the like. In an aspect, the invention provides a
pharmaceutical composition
comprising a therapeutically effective amount of a construct comprising the at
least one oligonucleotide or
the plurality of oligonucleotides as provided herein, or a salt thereof, and a
pharmaceutically acceptable
carrier, diluent, or both. In some embodiments, the at least one
oligonucleotide or plurality of
oligonucleotides associates with one or more protein listed in Table 28.
[00503] For example, the at least one oligonucleotide or plurality of
oligonucleotides may comprise
nucleic acids having a sequence or a portion thereof that is at least 50, 55,
60, 65, 70, 75, 80, 85, 90, 95,
96, 97, 98, 99 or 100 percent homologous to an oligonucleotide sequence
according to at least 1, 2, 3, 4, 5,
6, 7, 8, 9, 10, 12, 15,20 or all of SEQ ID NOs. 2922-2926, 2929-2947 and 2950-
2952. Such
pharmaceutical composition may be useful for therapy related to a cancer,
wherein optionally the cancer
comprises lung cancer or prostate cancer. See Example 14.
[00504] In another example, the at least one oligonucleotide or plurality of
oligonucleotides may comprise
nucleic acids having a sequence or a portion thereof that is at least 50, 55,
60, 65, 70, 75, 80, 85, 90, 95,
96, 97, 98, 99 or 100 percent homologous to an oligonucleotide sequence
according to at least 1, 2, 3, 4, 5,
6, 7, 8, 9, 10, 12, 15,20 or all of SEQ ID NOs. 2953-2961 and 2971-2979. Such
pharmaceutical
composition may be useful for therapy related to a cancer, wherein optionally
the cancer comprises
prostate cancer. See Example 17.
[00505] In still another example, the at least one oligonucleotide or
plurality of oligonucleotides may
comprise nucleic acids having a sequence or a portion thereof that is at least
50, 55, 60, 65, 70, 75, 80, 85,
90, 95, 96, 97, 98, 99 or 100 percent homologous to an oligonucleotide
sequence according to at least 1, 2,
3, 4, 5, 6, 7, 8, 9, 10, 12, 15, 20, 25, 30, 35, 40, 50 or all of SEQ ID NOs.
3039-3061. Such pharmaceutical
composition may be useful for therapy related to a cancer, wherein optionally
the cancer comprises breast
cancer. See Example 19.
[00506] In yet another example, the at least one oligonucleotide or plurality
of oligonucleotides may
comprise nucleic acids having a sequence or a portion thereof that is at least
50, 55, 60, 65, 70, 75, 80, 85,
90, 95, 96, 97, 98, 99 or 100 percent homologous to an oligonucleotide
sequence according to at least 1, 2,
3, 4, 5, 6, 7, 8, 9, 10, 12, 15, 20, 25, 30, 35, 40, 50, 60, 70, 80, 90, 100,
200, 300, 400, 500, 600, 700, 800,
900, 1000, 2000, 3000, 4000, 5000, 6000, 7000, 8000, 9000, 10000, 20000,
30000, 40000, 50000, 60000,
70000, 80000, 90000, 100000, 150,000 or all of SEQ ID NOs. 3062-103061 and
103062-203061. Such
pharmaceutical composition may be useful for therapy related to a cancer,
wherein optionally the cancer
comprises breast cancer. See Examples 20-22.
[00507] In an example, the at least one oligonucleotide or plurality of
oligonucleotides may comprise
nucleic acids having a sequence or a portion thereof that is at least 50, 55,
60, 65, 70, 75, 80, 85, 90, 95,
-135-
CA 03018066 2018-09-17
WO 2017/161357 PCT/US2017/023108
96, 97, 98, 99 or 100 percent homologous to an oligonucleotide sequence
according to at least 1, 2, 3, 4, 5,
6, 7, 8, 9, 10, 12, 15, 20, 25, 30, 35, 40, 50, 60, 70, 80, 90, 100, 200, 300,
400, 500, 600, 700, 800, 900,
1000, 2000, 3000, 4000 or all of SEQ ID NOs. 203064-203067 and 203076-206478.
Such pharmaceutical
composition may be useful for therapy related to a cancer, wherein optionally
the cancer comprises
colorectal cancer. See Example 24.
[00508] In yet another example, the at least one oligonucleotide or plurality
of oligonucleotides may
comprise nucleic acids having a sequence or a portion thereof that is at least
50, 55, 60, 65, 70, 75, 80, 85,
90, 95, 96, 97, 98, 99 or 100 percent homologous to an oligonucleotide
sequence according to at least 1, 2,
3, 4, 5, 6, 7, 8, 9, 10, 12, 15 or all of SEQ ID NOs. 206491-206506. Such
pharmaceutical composition
may be useful for therapy related to a cancer, wherein optionally the cancer
comprises a cancer of the
breast, colon, kidney, lung or pancreas. See Example 29.
[00509] The at least one oligonucleotide or the plurality of oligonucleotides
within the pharmaceutical
composition can have any useful desired chemical modification. In an
embodiment, the at least one
oligonucleotide or the plurality of oligonucleotides is attached to a toxin or
chemotherapeutic agent. The
at least one oligonucleotide or the plurality of oligonucleotides may be
comprised within a multipartite
construct. The at least one oligonucleotide or the plurality of
oligonucleotides can be attached to a
liposome or nanoparticle. In some embodiments, the liposome or nanoparticle
comprises a toxin or
chemotherapeutic agent. In such cases, the at least one oligonucleotide or the
plurality of oligonucleotides
can be used to target a therapeutic agent to a desired cell, tissue, organ or
the like.
[00510] In a related aspect, the invention provides a method of treating or
ameliorating a disease or
disorder in a subject in need thereof, comprising administering the
pharmaceutical composition of the
invention to the subject. In another related aspect, the invention provides a
method of inducing
cytotoxicity in a subject, comprising administering the pharmaceutical
composition of the invention to the
subject. Any useful means of administering can be used, including without
limitation at least one of
intradermal, intramuscular, intraperitoneal, intravenous, subcutaneous,
intranasal, epidural, oral,
sublingual, intracerebral, intravaginal, transdermal, rectal, by inhalation,
topical administration, or any
combination thereof.
[00511] The oligonucleotide or plurality of oligonucleotides provided by
tissue ADAPT can be used for
imaging or therapeutic applications of any desired medical condition, disease
or disorder, such as those
described herein (see above). As a non-limiting example, the oligonucleotide
or plurality of
oligonucleotides can be used for imaging of tumors from various anatomical
locals, or for treatment of
cancers derived from various tissues.
Kits
[00512] The invention also provides a kit comprising one or more reagent to
carry out the methods of the
invention. For example, the one or more reagent can be the one or more
aptamer, a buffer, blocker,
enzyme, or combination thereof The one or more reagent may comprise any useful
reagents for carrying
out the subject methods, including without limitation aptamer libraries,
substrates such as microbeads or
planar arrays or wells, reagents for biomarker and/or microvesicle isolation
(e.g., via chromatography,
-136-
CA 03018066 2018-09-17
WO 2017/161357 PCT/US2017/023108
filtration, ultrafiltration, centrifugation, ultracentrifugation, flow
cytometry, affinity capture (e.g., to a
planar surface, column or bead), polymer precipitation, and/or using
microfluidics), aptamers directed to
specific targets, aptamer pools that facilitate detection of a
tissue/cell/microvesicle/biomarker population,
reagents such as primers for nucleic acid sequencing or amplification, arrays
for nucleic acid
hybridization, detectable labels, solvents or buffers and the like, various
linkers, various assay
components, blockers, and the like. The one or more reagent may also comprise
various compositions
provided by the invention. In an embodiment, the one or more reagent comprises
one or more aptamer of
the invention. The one or more reagent can comprise a substrate, such as a
planar substate, column or
bead. The kit can contain instructions to carry out various assays using the
one or more reagent. The one
or more reagent may comprise a reagent for performing a PHC assay, including
components of enzymatic
detection systems and substrates thereof useful for staining a tissue sample.
[00513] In an embodiment, the kit comprises an oligonucleotide probe or
composition provided herein.
The kit can be configured to carry out the methods provided herein. For
example, the kit can include an
aptamer of the invention, a substrate, or both an aptamer of the invention and
a substrate.
[00514] In an embodiment, the kit is configured to carry out an assay. For
example, the kit can contain one
or more reagent and instructions for detecting the presence or level of a
biological entity in a biological
sample. In such cases, the kit can include one or more binding agent to a
biological entity of interest. The
one or more binding agent can be bound to a substrate. The one or more binding
agent can be modified to
allow capture, detection or visualization. For example, the one or more
binding agent can be biotinylated
or conjugated to digoxigenin.
[00515] In an embodiment, the kit comprises a set of oligonucleotides that
provide a particular
oligonucleotide profile for a biological sample. An oligonucleotide profile
can include, without limitation,
a profile that can be used to characterize a particular disease or disorder.
For example, the disease or
disorder can be a proliferative disease or disorder, including without
limitation a cancer. In some
embodiments, the cancer comprises a breast cancer.
EXAMPLES
Example 1: Aptamer TarEet Identification
[00516] In this Example, aptamers conjugated to microspheres are used to
assist in determining the target
of two aptamers identified by library screening methods as described above.
The general approach is
shown in FIG. 9. The approach is used to verify the targets of CAR003, an
aptamer identified by library
screening to recognize EpCAM. CAR003 is an aptamer candidate identified using
the above
methodology. As an RNA aptamer, CAR003 with alternate tail sequence has the
following RNA sequence
(SEQ ID NO. 3):
100517] 5' -auccagagug acgcagcagu cuuuucugau ggacacgugg uggucuagua
ucacuaagcc accgugucca-3'
-137-
CA 03018066 2018-09-17
WO 2017/161357 PCT/US2017/023108
[00518] In this approach, the sequence of CAR003 is randomly rearranged before
linkage to the
microspheres. The microspheres are used as controls to bind to targets that
are similar but not identical to
the intended target molecule.
[00519] The protocol used is as follows:
[00520] 1) The candidate aptamers (here, CAR003) and negative control aptamers
(here, randomly
arranged CAR003) are synthesized with modifications to allow capture (here,
the aptamers are
biotinylated) and crosslinking (here, using the Sulfo-SBED Biotin Label
Transfer Reagent and Kit,
Catalog Number 33073 from Thermo Fisher Scientific Inc., Rockford, IL, to
allow photocrosslinking).
[00521] 2) Each of the aptamers is individually mixed with microvesicles
having the target of interest
(here, BrCa cell line microvesicles).
[00522] 3) After incubation to allow the aptamers to bind target, ultraviolet
light is applied to the mixtures
to trigger crosslinking of the aptamers with the microvesicle targets.
[00523] 4) The microvesicles are lysed, thereby releasing the crosslinked
aptamer-target complex into
solution.
[00524] 5) The crosslinked aptamer-target complexes are captured from solution
using a streptavidin
coated substrate.
[00525] 6) The crosslinked aptamer-target complexes for each aptamer are run
individually on SDS-
PAGE gel electrophoresis. The captured protein targets are visualized with
Coomasie Blue staining.
[00526] 7) The crosslinking and binding steps may be promiscuous so that
multiple bands including the
intended target but also random proteins will appear on each of the gels. The
intended target will be found
in a band that appears on the gel with the candidate aptamer (here, CAR003)
but not the related negative
control aptamers (here, randomly arranged CAR003). The bands corresponding to
the target are excised
from the gel.
[00527] 8) Mass spectrometry (MS) is used to identify the aptamer target from
the excised bands.
Example 2: Disease Diagnosis
[00528] This example illustrates the use of oligonucleotide probes of the
invention to diagnose a
proliferative disease.
[00529] A suitable quantity of an oligonucleotide or pool of oligonucleotides
that bind a BrCa-derived
population of microvesicles, such as identified in Example 12 or various
Examples below, is synthesized
via chemical means known in the art. The oligonucleotides are conjugated to a
diagnostic agent suitable
for detection, such as a fluorescent moiety, using a conjugation method known
in the art.
[00530] The composition is applied to microvesicles isolated from blood
samples taken from a test cohort
of patients suffering from a proliferative disease associated with the
overexpression of microvesicles, e.g.
breast cancer. The composition is likewise applied to microvesicles isolated
from blood samples taken
from a negative control cohort, not suffering from a proliferative disease.
[00531] The use of appropriate detection techniques (e.g., microbead assay or
flow cytometry) on the test
cohort samples indicates the presence of disease, while the same techniques
applied to the control cohort
samples indicate the absence of disease.
-138-
CA 03018066 2018-09-17
WO 2017/161357 PCT/US2017/023108
[00532] The results show that the oligonucleotides of the present invention
are useful in diagnosing
proliferative diseases.
Example 3: Theranostics
[00533] This example illustrates the use of oligonucleotide probes of the
present invention to provide a
theranosis for a drug for treating a proliferative disease.
[00534] A suitable quantity of an oligonucleotide or pool of oligonucleotides
that bind breast cancer
tissue, such as identified in Examples 19-21 or various Examples below, is
synthesized via chemical
means known in the art. The probes are conjugated to an agent suitable for
detection, such as a biotin
moiety, which can then be detected using streptavidin constructs such as
streptavidin-horse radish
peroxidase using immunohistochemistry (IHC) techniques. The oligonucleotide
probe or panel of
oligonucleotide probes are within a suitable composition, such as a buffered
solution.
[00535] Treatment selection. The probes are applied to tumor tissue samples
taken from a test cohort of
patients suffering from a proliferative disease, e.g. breast cancer, that
responded to a certain treatment,
e.g., trautuzamab. The probes are likewise applied to tumor tissue taken from
a control cohort consisting
of patients suffering from the same proliferative disease that did not respond
to the treatment. The use of
appropriate detection techniques (e.g., IHC) on the test cohort samples
indicates that probes which bind
the samples are useful for identifying patients that will respond to the
treatment, while the same
techniques applied to the control cohort samples identifies probes useful for
identifying patients that will
not respond to the treatment.
[00536] Treatment monitoring. In another setting, the probes are applied to
tumor tissue samples from a
test cohort of patients suffering from a proliferative disease, e.g. breast
cancer, prior to or during a course
of treatment, such as surgery, radiotherapy and/or chemotherapy. The probes
are then applied to tumor
tissue samples from the patients over a time course. The use of appropriate
detection techniques (e.g.,
IHC) on the test cohort samples indicates whether the detected population of
disease-related cells
increases, decreases, or remains steady in concentration over time during the
course of treatment. An
increase in the population of disease-related cells post-treatment may
indicate that the treatment is less
effective whereas a decrease in the population of disease-related cells post-
treatment may indicate that the
treatment has a beneficial effect.
[00537] The results show that the oligonucleotide probes of the present
invention are useful in theranosing
proliferative diseases.
Example 4: Therapeutic 01i2onuc1e0tide Probes
[00538] This example illustrates the use of oligonucleotide probes of the
present invention to treat a
proliferative disease.
[00539] A suitable quantity of an oligonucleotide or pool of oligonucleotides
that bind breast cancer tumor
tissue, such as identified in Examples 19-21 or various Examples below, is
synthesized via chemical
means known in the art. The oligonucleotides are conjugated to a
chemotherapeutic agent, such as Doxil,
using a conjugation method known in the art. The conjugate is formulated in an
aqueous composition.
-139-
CA 03018066 2018-09-17
WO 2017/161357 PCT/US2017/023108
[00540] The composition is administered intravenously, in one or more doses,
to a test cohort of subjects
suffering from breast cancer. A control cohort suffering from breast cancer is
administered a placebo
intravenously, according to a corresponding dosage regimen.
[00541] Pathological analysis of tumor samples and/or survival indicates that
mortality and/or morbidity
are improved in the test cohort over the control cohort.
[00542] The results show that the oligonucleotides of the present invention
are useful in treating
proliferative diseases.
Example 5: 0112onuc1eot1de ¨ Sequencin2 Detection Method
[00543] This example illustrates the use of an oligonucleotide pool to detect
microvesicles that are
indicative of a phenotype of interest. The method makes use of a pool of
oligonucleotides that have been
enriched against a target of interest that is indicative of a phenotype of
interest. The method in this
Example allows efficient use of a library of oligonucleotides to
preferentially recognize a target entity.
[00544] For purposes of illustration, the method is described in the Example
with a microvesicle target
from a bodily fluid sample. One of skill will appreciate that the method can
be extended to other types of
target entity (e.g., cells, proteins, various other biological complexes),
sample (e.g., tissue, cell culture,
biopsy, other bodily fluids) and other phenotypes (other cancers, other
diseases, etc) by enriching an
aptamer library against the desired input samples.
[00545] General workflow:
[00546] 1) Obtain sample (plasma, serum, urine or any other biological sample)
of patients with unknown
medical etymology and pre-treating them accordingly to ensure availability of
the target of interest (see
below). Where the target of interest is a microvesicle population, the
microvesicles can be isolated and
optionally tethered to a solid support such as a microbead.
[00547] 2) Expose pre-treated sample to an oligonucleotide pool carrying
certain specificity against target
of interest. As described herein, an oligonucleotide pool carrying certain
specificity against the target of
interest can be enriched using various selection schemes, e.g., using non-
cancer microvesicles for negative
selection and cancer microvesicles for positive selection as described above.
DNA or RNA
oligonucleotides can be used as desired.
[00548] 3) Contact oligonucleotide library with the sample.
[00549] 4) Elute any oligonucleotides bound to the target.
[00550] 5) Sequence the eluted oligonucleotides. Next generation sequencing
methods can be used.
[00551] 6) Analyze oligonucleotide profile from the sequencing. A profile of
oligonucleotides known to
bind the target of interest indicates the presence of the target within the
input sample. The profile can be
used to characterize the sample, e.g., as cancer or non-cancer.
[00552] Protocol variations:
[00553] Various configurations of the assay can be performed. Four exemplary
protocols are presented for
the purposes of the oligonucleotide-sequencing assay. Samples can be any
appropriate biological sample.
The protocols can be modified as desired. For example, the microvesicles can
be isolated using alternate
-140-
CA 03018066 2018-09-17
WO 2017/161357 PCT/US2017/023108
techniques instead or or in addition to ultracentrifitgation. Such techniques
can be disclosed herein, e.g.,
polymer precipitation (e.g., PEG), column chromatography, and/or affmity
isolation.
[00554] Protocol 1:
[00555] Ultracentrifugation of 1-5 ml bodily fluid samples (e.g.,
plasma/serum/urine) (120K x g, no
sucrose) with two washes of the precipitate to isolate microvesicles.
[00556] Measure total protein concentration of recovered sample containing the
isolated microvesicles.
[00557] Conjugate the isolated microvesicles to magnetic beads (for example
MagPlex beads (Luminex
Corp. Austin TX)).
[00558] Incubate conjugated microvesicles with oligonucleotide pool of
interest.
[00559] Wash unbound oligonucleotides by retaining beads using magnet.
[00560] Elute oligonucleotides bound to the microvesicles.
[00561] Amplify and purify the eluted oligonucleotides.
[00562] Oligonucleotide sequencing (for example, Next generation methods; Ion
Torrent: fusion PCR,
emulsion PCR, sequencing).
[00563] Assess oligonucleotide profile.
[00564] Protocol 2:
[00565] This alternate protocol does not include a microvesicle isolation
step, microvesicles conjugation
to the beads, or separate partitioning step. This may present non-specific
binding of the oligonucleotides
against the input sample.
[00566] Remove cells/debris from bodily fluid sample and dilute sample with
PBS containing MgCl2
(2mM).
[00567] Pre-mix sample prepared above with oligonucleotide library.
[00568] Ultracentrifugation of oligonucleotide/sample mixture (120K x g, no
sucrose). Wash precipitated
microvesicles.
[00569] Recover precipitate and elute oligonucleotides bound to microvesicles.
[00570] Amplify and purify the eluted oligonucleotides.
[00571] Oligonucleotide sequencing (for example, Next generation methods; Ion
Torrent: fusion PCR,
emulsion PCR, sequencing).
[00572] Assess oligonucleotide profile.
[00573] Protocol 3:
[00574] This protocol uses filtration instead of ultracentrifugation and
should require less time and sample
volume.
[00575] Remove cells/debris from bodily fluid sample and dilute it with PBS
containing MgCl2 (2mM).
[00576] Pre-mix sample prepared above with oligonucleotide library.
[00577] Load sample into filter (i.e., 150K or 300K MWCO filter or any other
that can eliminate unbound
or unwanted oligonucleotides). Centrifuge sample to concentrate. Concentrated
sample should contain
microvesicles.
-141-
CA 03018066 2018-09-17
WO 2017/161357 PCT/US2017/023108
[00578] Wash concentrate. Variant 1: Dilute concentrate with buffer specified
above to the original
volume and repeat centrifugation. Variant 2: Dilute concentrate with buffer
specified above to the original
volume and transfer concentrate to new filter unit and centrifuge. Repeat
twice.
[00579] Recover concentrate and elute oligonucleotides bound to microvesicles.
[00580] Amplify and purify the eluted oligonucleotides.
[00581] Oligonucleotide sequencing (for example, Next generation methods; Ion
Torrent: fusion PCR,
emulsion PCR, sequencing).
[00582] Assess oligonucleotide profile.
[00583] Protocol 4:
[00584] Ultracentrifugation of 1-5 ml bodily fluid sample (120K x g, no
sucrose) with 2 washes of the
precipitate to isolate microvesicles.
[00585] Pre-mix microvesicles with oligonucleotide pool.
[00586] Load sample into 300K MWCO filter unite and centrifuge (2000xg).
Concentration rate is ¨3x.
[00587] Wash concentrate. Variant 1: Dilute concentrate with buffer specified
above to the original
volume and centrifuge. Repeat twice. Variant 2: Dilute concentrate with buffer
specified above to the
original volume and transfer concentrate to new filter unit and centrifuge.
Repeat twice
[00588] Recover concentrate and elute oligonucleotides bound to microvesicles.
[00589] Amplify and purify the eluted oligonucleotides.
[00590] Oligonucleotide sequencing (for example, Next generation methods; Ion
Torrent: fusion PCR,
emulsion PCR, sequencing).
[00591] Assess oligonucleotide profile.
[00592] In alterations of the above protocols, polymer precipitation is used
to isolate microvesicles from
the patient samples. For example, the oligonucleotides are added to the sample
and then PEG4000 or
PEG8000 at 4% or 8% concentration is used to precipitate and thereby isolate
microvesicles. Elution,
recovery and sequence analysis continues as above.
Example 6: Plasma/Serum probing with an Oligonucleotide Probe Library
[00593] The following protocol is used to probe a plasma or serum sample using
an oligonucleotide probe
library.
[00594] Input oligonucleotide library:
[00595] Use 2 ng input of oligonucleotide library per sample.
[00596] Input oligonucleotide library is a mixture of two libraries, cancer
and non-cancer enriched,
concentration is 16.3 ng/ul.
[00597] Dilute to 0.2ng/u1 working stock using Aptamer Buffer (3mM MgCl2 in 1X
PBS)
[00598] Add lOul from working stock (equal to 2 ng library) to each optiseal
tube
[00599] Materials:
[00600] PBS, Hyclone SH30256.01, LN: AYG165629, bottle# 8237, exp. 7/2015
[00601] Round Bottom Centrifuge Tubes, Beckman 326820, LN:P91207
[00602] OptiSeal Centrifuge tubes and plugs, polyallomer Konical, Beckman
361621, lot# Z10804SCA
-142-
CA 03018066 2018-09-17
WO 2017/161357 PCT/US2017/023108
[00603] Ultracentrifuge rotor: 50.4 TI
[00604] Ultracentrifuge rotor: 50.4 TI, Beckman Cans ID/4 0478
[00605] Protocol:
[00606] 1 Pre-chill tabletop centrifuge, ultracentrifuge, buckets, and rotor
at 4 C.
[00607] 2 Thaw plasma or serum samples
[00608] 3 Dilute lml of samples with 1:2 with Aptamer Buffer (3mM MgCl2 in 1X
PBS)
[00609] 4 Spin at 2000xg, 30 min, 4 C to remove debris (tabletop centrifuge)
[00610] 5 Transfer supernatants for all samples to a round bottom conical
[00611] 6 Spin at 12,000xg, 45 min, 4 C in ultracentrifuge to remove
additional debris.
[00612] 7 Transfer supernatant about 1.8m1 for all samples into new OptiSeal
bell top tubes (uniquely
marked).
[00613] 8 Add 2ng (in 10 ul) of DNA Probing library to each optiseal tube
[00614] 9 QS to 4.5 ml with Aptamer Buffer
[00615] 10 Fix caps onto the OptiSeal bell top tubes
[00616] 11 Apply Parafilm around caps to prevent leakage
[00617] 12 Incubate plasma and oligonucleotide probe library for 1 hour at
room temperature with rotation
[00618] 13 Remove parafilm (but not caps)
[00619] 14 Place correct spacer on top of each plugged tube
[00620] 15 Mark pellet area on the tubes, insure this marking is facing
outwards from center.
[00621] 16 Spin tubes at 120,000 x g, 2hr, 4 C (inner row, 33,400 rpm) to
pellet microvesicles.
[00622] 17 Check marking is still pointed away from center.
[00623] 18 Completely remove supernatant from pellet, by collecting liquid
from opposite side of pellet
marker and using a 10 ml syringe barrel and 21G2 needle
[00624] 19 Discard supernatant in appropriate biohazard waste container
[00625] 20 Add 1 ml of 3 mM MgCl2 diluted with 1X PBS
[00626] 21 Gentle vortex, 1600rpm for 5 sec and incubate 5 min at RT.
[00627] 22 QS to ¨4.5 mL with 3 mM Mg C12 diluted with 1X PBS
[00628] 23 Fix caps onto the OptiSeal bell top tubes.
[00629] 24 Place correct spacer on top of each plugged tube.
[00630] 25 Mark pellet area on the tubes, insure this marking is facing
outwards from center.
[00631] 26 Spin tubes at 120,000 x g, 70 min, 4 C (inner row 33,400 rpm) to
pellet microvesicles
[00632] 27 Check marking in still pointed away from center.
[00633] 28 Completely remove supernatant from pellet, by collecting liquid
from opposite side of pellet
marker and using a 10 ml syringe barrel and 21G2 needle
[00634] 29 Discard supernatant in appropriate biohazard waste container
[00635] 30 Add 1 ml of 3 mM MgCl2 diluted with 1X PBS
[00636] 31 Gentle vortex, 1600rpm for 5 sec and incubate 5 min at RT.
[00637] 32 QS to ¨4.5 mL with 3 mM Mg C12 diluted with 1X PBS
-143-
CA 03018066 2018-09-17
WO 2017/161357 PCT/US2017/023108
[00638] 33 Fix caps onto the OptiSeal bell top tubes.
[00639] 34 Place correct spacer on top of each plugged tube.
[00640] 35 Mark pellet area on the tubes, insure this marking is facing
outwards from center.
[00641] 36 Spin tubes at 120,000 x g, 70 min, 4 C (inner row 33,400 rpm) to
pellet microvesicles
[00642] 37 Check marking is still pointed away from center.
[00643] 38 Save an aliquot of the supernatant (100u1 into a 1.5m1 tube)
[00644] 39 Completely remove supernatant from pellet, by collecting liquid
from opposite side of pellet
marker and using a 10 ml syringe barrel and 21G2 needle
[00645] 40 Add 50 ul of Rnase-free water to the side of the pellet
[00646] 41 Leave for 15min incubation on bench top
[00647] 42 Cut top off tubes using clean scissors.
[00648] 43 Resuspend pellet, pipette up and down on the pellet side
[00649] 44 Measure the volume, make a note on the volume in order to normalize
all samples
[00650] 45 Transfer the measured resuspended eluted microvesicles with bound
oligonucleotides to a
Rnase free 1.5m1 Eppendorf tube
[00651] 46 Normalize all samples to 100u1 to keep it even across samples and
between experiments.
[00652] Next Generation Sequencing Sample Preparation:
[00653] I) Use 50 ul of sample from above, resuspended in 100 ul H20 and
containing microvesicle/oligo
complexes, as template in Transposon PCR, 14 cycles.
[00654] II) AMPure transposon PCR product, use entire recovery for indexing
PCR, 10 cycles.
[00655] III) Check indexing PCR product on gel, proceed with AMPure if band is
visible. Add 3 cylces if
band is invisible, check on gel. After purification quantify product with
QuBit and proceed with
denaturing and dilting for loading on HiSeq flow cell (Illumina Inc., San
Diego, CA).
[00656] IV) 5 samples will be multiplexed per one flow cell. 10 samples per
HiSeq.
Example 7: Oligonucleotide probe library
[00657] This Example presents development of an oligonucleotide probe library
to detect biological
entities. In this Example, steps were taken to reduce the presence of double
stranded oligonucleotides
(dsDNA) when probing the patient samples. The data were also generated
comparing the effects of 8%
and 6% PEG used to precipitate microvesicles (and potentially other biological
entities) from the patient
samples.
[00658] Protocol:
[00659] 1) Pre-chill tabletop centrifuge at 4 C.
[00660] 2) Protease inhibition: dissolve 2 tablets of "cOmplete ULTRA MINI
EDTA-free EASYpack"
protease inhibitor in 1100 ul of H20 (20x stock of protease inhibitor).
[00661] 3) Add 50 ul of protease inhibitor to the sample (on top of frozen
plasma) and start thawing: 1 ml
total ea.
[00662] 4) To remove cells/debris, spin samples at 10,000 x g, 20 min, 4 C.
Collect 1 ml supernatant
(SN).
-144-
CA 03018066 2018-09-17
WO 2017/161357 PCT/US2017/023108
[00663] 5) Mix 1 ml supernatant from step 4 with lml of 2xPBS 6 mM MgC13,
collect 400 ul into 3 tubes
(replicates A, B, C) and use it in step 6.
[00664] 6) Add competitor per Table 5: make dilutions in 1xPBS, 3mM MgCl2, mix
well, pour into
trough, pipet using multichannel.
Table 5: Competitors
Volume
Buffer to
Intermediate Number from stock to Final
make Type of Stock Final
units stock of make
Competitor Concentration intermediate uV1olume
Concentration
concentration samples intermediate
stock
stock, ul
Salmon
ng/ul DNA 40 425.5 0.8
ng/ul tRNA 40 425.5 0.8
x Si 20 0.5 280 65.5 2555.6 425.5 0.01
[00665] 7) Incubate for 10 min, RT, end-over-end rotation
[00666] Pool of 6-3S and 8-3S oligonucleotide probing libraries is ready: 2.76
ng/ul (-185 ng). Save pool
stock and dilutions. New pool can be made by mixing 171.2u1 (500ng) of library
6-3S (2.92 ng/ul) with
190.8u1 (500ng) of library 8-3S (2.62 ng/ul). Aliquot pooled library into 30
ul and store at -80C.
[00667] Add ssDNA oligonucleotide probing library to the final concentration
2.5 pg/ul for binding. Make
dilutions in 1xPBS, 3mM MgCl2.
Table 6: Probe library calculations
Volume
ul from
ul of per
Original Required original Final
buffer to Final Number of sample
stock, Lib Name working stock to
concentration
make volume, ul samples from
ng/ul stock (ng/ul) make (pg/ul)
working working
working
stock
Pooled
2.76 library 6- 0.1 26.1 694.1 720.2 60 10.9 2.5
3S/8-3S
[00668] 8) Binding: Incubate for lh at RT with rotation.
[00669] 9) Prepare polymer solution: 20% PEG8000 in lx PBS 3mM MgCl2 (dilute
40% PEG8000 with
2xPBS with 6mM MgCl2). Add 20% PEG8000 to sample to the final concentration
6%. Invert few times
to mix, incubate for 15 min at 4C
Table 7: PEG calculations
Volume Volume of Sample Total 20%
PEG PEG stock, Final conc., Final Total
20% PEG buffer to volume PEG
-145-
CA 03018066 2018-09-17
WO 2017/161357 PCT/US2017/023108
MW volume, ul to add, ul adjust final before samples
needed, ml
volume, ul adding PEG
8000 20 6 622.8 186.9 -0.4 436.4 60 11.2
[00670] 10) Spin at 10,000 x g for 5 min, RT.
[00671] 11) Remove SN, add lml 1xPBS, 3 mM MgC12 and wash pellet by gentle
invertion with lml
aptamer buffer.
[00672] 12) Remove buffer, Re-suspend pellets in 100 ul H20: incubate at RT
for 10 min on mixmate
900rpm to re-suspend.
[00673] 13) Make sure each sample is re-suspended by pipeting after step 13.
Make notes on hardly re-
suspendable samples.
[00674] 14) 50 ul of re-suspended sample to indexing PCR -> next generation
sequencing (NGS).
[00675] 15) Keep leftover at 4C
[00676] Technical Validation:
100677] The current protocol was tested versus a protocol using 8% PEG8000 to
precipitate microvesicles.
The current protocol further comprises steps to reduce dsDNA in the
oligonucleotide probing libraries.
[00678] FIG. 5A shows the within sample variance (black) between binding
replicates and the between
sample variance (grey). Black is on top of grey, thus any observable grey
oligo is informative about
differences in the biology of two paitent samples. This evaluation of Sources
of Variance shows that the
technical variances is significantly smaller than the biological variance.
[00679] FIG. 5B shows the impact of using a higher proportion of single
stranded DNA and PEG 6%
isolation (white bars) compared to when there is a higher amount of double
stranded DNA and 8% PEG
(grey). This data indicates that the protocol in this Example improves
biological separation between
patients.
[00680] The plots in FIG. 5C show the difference between an earlier protocol
(PEG 8% with increased
dsDNA) and a modified protocol of the Example (PEG 6% no dsDNA). The black is
the scatter between
replicates (independent binding events) and the grey is the difference between
patients. This data shows
that the signal to noise increased significantly using the newer protocol.
[00681] Patient testing:
[00682] The protocol above was used to test patient samples having the
following characteristics:
Table 8: Patient characteristics
Sample Type Description
Cancer Mixed type carcinoma;Malignant;
Cancer Invasive, predominant intraductal component (8500/3)
Fibrocystic Changes;Invasive lobular carcinoma - 8520/3 ;Lobular carcinoma in
situ - 8520/2;Benign;In situ and grade 3 intraepith;Malignant;Fat necrosis,
Cancer periductal inflammation, malignant cellsFat
necrosis;Inflammation;Benign;
Cancer Invasive, predominant intraductal component (8500/3)
Cancer Mucinous (colloid) adenocarcinoma (8480/3)
Cancer Invasive lobular carcinoma -
8520/3;Microcalcifications;Benign;Malignant;
-146-
CA 03018066 2018-09-17
WO 2017/161357
PCT/US2017/023108
Cancer Otherfibrocystic changeInvasive, NOS (8500/3)
Cancer Invasive ductal carcinoma, not otherwise specified (NOS) -
8500/3;Malignant;
Cancer Invasive ductal carcinoma, not otherwise specified (NOS) -
8500/3;Malignant;
Cancer Intraductal carcinoma, non-infiltrating, NOS (in situ) (8500/2)
Atypical lobular hyperplasia
Otherfibrocystic changes, inter and intralobular fibrosis, apocrine
metaplasia,
Cancer columnar cell change, microcalcificationsInvasive, NOS (8500/3)
Cancer FibroadenomaInvasive, NOS (8500/3)
Ductal carcinoma in situ - 8500/2;Invasive ductal carcinoma, not otherwise
specified (NOS) - 8500/3;Microcalcifications;Benign;In situ and grade 3
Cancer intraepith;Malignant;
Ductal carcinoma in situ - 8500/2;Invasive lobular carcinoma - 8520/3;Lobular
Cancer carcinoma in situ - 8520/2;In situ and grade 3
intraepith;Malignant;
Ductal carcinoma in situ - 8500/2;Invasive ductal carcinoma, not otherwise
specified (NOS) - 8500/3;Microcalcifications;Benign;In situ and grade 3
intraepith;Malignant;Focal Micropapillary Features, invasive ductal carcinoma
with micropapillary features, invasive ductal carcinoma with mucinous and
micropapillary featInvasive ductal carcinoma with micropapillary and mucinous
Cancer features;Invasive micropapillary carcinoma - 8507/3 ;Malignant;
Cancer Invasive, predominant intraductal component (8500/3)
Cancer Invasive ductal carcinoma, not otherwise specified (NOS) -
8500/3;Malignant;
Cancer Invasive, NOS (8500/3)
Cancer Infiltrating duct and lobular carcinoma (8522/3)
Cancer Invasive, predominant in situ component (8522/3)
Non-Cancer Otherusual ductal hyperplasia, apocrine metaplasia, microcysts,
elastosis
Non-Cancer Otherstromal fibrosis, fibrous cyst wall
Otherfibrocystic change, stromal fibrosis, cyst formation,
microcalcifications,
Non-Cancer apocrine metaplasia, sclerosing adenosis, usual ductal hyperplasia
Otherfibrocystic changes, apocrine metaplasia, cystic change, usual ductal
Non-Cancer hyperplasia
Non-Cancer Otherfibrocystic change, microcalcifications
Non-Cancer Fibroadenoma
Non-Cancer Otherintraductal papilloma, sclerosis, microcalcifications, stromal
fibrosis
Non-Cancer Fibroadenoma
Non-Cancer Otherfat necrosis
Non-Cancer Otherstromal fibrosis, microcalcifications
Non-Cancer Otherfibrocystic change, microcystic change, focal secretory
features
Non-Cancer Otherstromal fibrosis
Fibroadenoma Otheradenosis, columnar cell change/hyperplasia, usual ductal
Non-Cancer hyperplasia
Non-Cancer OtherFNA - insufficient material for diagnosis
Non-Cancer Otherintraductal papilloma
Otherfibrocystic changes, duct ectasia, usual ductal hyperplasia, apocrine
Non-Cancer metaplasia, microcalcifications
[00683] Microvesicles (and potentially other biological entities) were
precipitated in blood (plasma)
samples from the above patients using polymer precipitation with PEG as
indicated above. The protocol
was used to probe the samples with the oligonucleotide probe libraries.
Sequences that bound the PEG
precipitated samples were identified using next generation sequencing (NGS).
-147-
CA 03018066 2018-09-17
WO 2017/161357 PCT/US2017/023108
[00684] FIG. 5D shows scatter plots of a selection of results from testing the
40 patients listed previously.
The spread in the data indicates that large numbers of oligos were detected
that differed between samples.
The number of significant oligos found is much greater than would be expected
randomly as shown in
Table 9. The table shows the number of oligonucleotides sorted by copy number
detected and p-value.
The d-14 indicates the number copies of a sequence observed for the data in
the rows.
Table 9: Expected versus observed sequences
Total Numbef P-0,1 P-0,05 P-0,01 P-0,005
d-50 83,632 47,020 $0,843 5,934 2,471
d400 52,647 .29306 19,446 3,893 1,615
d-2CV 28,753 14,681 9,880 2,189 914
-
d-500 10,155 4,342 2,927 725 315
d7-5.0 1000% 56,2%> 36õ9%. Z.1% 10%
d400 100,0% 55,3% 36.9% 7,4% 3,1%
d-2(X) ram .513% 34.4% 7.6% 3.2%
d-500 IMO% 42.8% 28S% 7.1%
Maximum expeded 10.0% 5.0% 1.0% 03%,
.õ,
[00685] As a control, the cancer and non-cancer samples were randomly divided
into two groups. Such
randomization of the samples significantly reduced the number of oligos found
that differentiate between
sample groups. Indeed, there was a 50-fold increase in informative oligos
between the cancer/non-cancer
grouping versus random grouping. FIG. 5E shows data as in Table 9 and
indicates the number of
observed informative oligos between the indicated sample groups.
[00686] FIG. 5F shows distinct groups of oligos that differentiate between
cancer and non-cancer
samples. The figure shows a heatmap of the 40 samples tested with oligos
selected that had more than 500
copies and p-value less than 0.005. There are clear subpopulations emerging
with a distinct non-cancer
cohort at the top. The non-cancer samples have boxes around them on the left
axis. FIG. 5G is similar and
shows results with an additional 20 cancer and 20 non-cancer samples. As
shown, analysis with the 80
samples provides the emergence of more distinct and larger clusters.
[00687] The data for the additional 80 samples was also used to compare the
consistency of informative
oligos identified in different screening experiments. Of the 315 informative
oligos identified using the
first set of 40 patients, 86% of them showed fold-change in a consistent
manner when tested on the
independent set of 40 patients.
Example 8: Enrichment of Olioonucleotide probes usino a balanced library
desion
[00688] In this Example, a naïve ADAPT oligonucleotide library was screened to
enrich oligonucleotides
that identify microvesicles circulating in the blood of breast cancer patients
and rnicrovesicles circulating
in the blood of healthy, control individuals (i.e., without breast cancer).
The input library was the naïve F-
TRin-35n-B 8-3s library, which comprises a 5' region (5' CTAGCATGACTGCAGTACGT
(SEQ ID NO.
4)) followed by the random naïve aptamer sequences of 35 nucleotides and a 3'
region (5'
CTGICTCTTATACACATCTGACGCTGCCGACGA (SEQ ID NO. 5)). The -balanced" design is
described in
Example 23 of Int'l Patent Publication WO/2015/031694 (Appl. No.
PCT/US2014/053306, filed August
-148-
CA 03018066 2018-09-17
WO 2017/161357 PCT/US2017/023108
28, 2014), which is incorporated by reference herein in its entirety. The
working library comprised
approximately 2 x 1013 synthetic oligonucleotide sequences. The naïve library
may be referred to as the
"LO Library" herein.
[00689] The LO Library was enriched against fractionated plasma samples from
breast cancer patients and
from healthy (non-breast cancer) controls using the protocol shown in FIG.
12A. In Step 1, an aliquot of
approximately 10" sequences of PCR-amplified LO was incubated with pooled
blood-plasma from 59
breast cancer patients with positive biopsy (represented by "Source A" in FIG.
12A). In parallel, another
aliquot of 10" sequences was incubated with pooled blood-plasma from 30
patients with suspected breast
cancer who proved negative on biopsy and 30 self declared healthy women
(represented by "Source B" in
FIG. 12A). In Step 2, microvesicles (extracellular vesicles, "EV") were
precipitated using
ultracentrifugation (UC) from both LO-samples. The EV-associated
oligodeoxynucleotides (ODNs) were
recovered from the respective pellets. In Step 3, a counter-selection step
(Step 3) was carried out by
incubation of each enriched library with plasma from the different cohorts to
drive the selection pressure
towards enrichment of ODNs specifically associated with each sample cohort. In
this step, sequences
contained in the EV pellets were discarded. In Step 4, a second positive
selection was performed. In this
step, the sequences contained in the respective supernatants (sn) from Step 3
were mixed with plasma
from another aliquot of each positive control sample-population, and EVs were
again isolated. EV-
associated ODNs were recovered, representing two single-round libraries called
library Li for positive
enrichment of cancer (positive biopsy) patients, and library L2 for the
positive enrichment against control
patients. In a final step, Li and L2 were amplified by PCR, reverted to single
stranded DNA (ssDNA),
and mixed to yield library L3.
[00690] This enrichment scheme was iterated two times more using L3 as the
input to further reduce the
complexity of the profiling library to approximately 106 different sequences.
In Step 2, UC was used for
partitioning of microvesicles, which may increase the specificity for the EV
fraction. In Steps 3 and 4,
partitioning was performed using PEG-precipitation. This procedure enriches
for ODNs specific for each
biological source. Library L3 contains those ODNs that are associated with
targets characteristic for EV-
populations from both sources, i.e. ODNs acting as aptamers that bind to
molecules preferentially
expressed in each source. A total of biopsy-positive (n = 59), biopsy-negative
(n = 30), and self-declared
normal (n = 30) were used in the first round of L3 enrichment, while only the
cancer and non-cancer
samples were used in the subsequent rounds.
[00691] The enriched libraries were characterized using next-generation-
sequencing (NGS) to measure
copy numbers of sequences contained in each profiling library. NGS of LO shows
that the vast majority of
sequences existed in low copy numbers, whereas libraries Li and L2 showed
significantly higher average
counts per sequence (FIG. 12B) and a reduced amount of different sequences,
with unaltered total valid
reads, (FIG. 12C) consistent with an enrichment process.
Example 9: Analysis of ADAPT-identified biomarkers
[00692] As described herein, e.g., in the section entitled "Aptamer Target
Identification," an unknown
target recognized by an aptamer can be identified. In this Example, an
oligonucleotide probe library (also
-149-
CA 03018066 2018-09-17
WO 2017/161357 PCT/US2017/023108
referred to as Adaptive Dynamic Artificial Poly-ligand Targeting (ADAPT)
libraries or Topographical
Oligonucleotide Probe "TOP" libraries) was developed as described here and
targets of the screened
oligonucleotides were determined. This Example used a ADAPT library generated
by enriching
microvesicles collected from the blood of breast cancer patients and normal
controls (i.e., non-cancer
individuals). The enrichment protocols are described herein in Example 8.
[00693] Materials & Methods
[00694] SBED library conjugation
[00695] A naive F-TRin-35n-B 8-3s library was enriched against microvesicles
from normal female
plasma. The naive unenriched library comprised a 5' region (5'
CTAGCATGACTGCAGTACGT (SEQ ID
NO. 4)) followed by the random naive aptamer sequences of 35 nucleotides and a
3' region (5'
CTGICICTTATACACATCTGACGCTGCCGACGA (SEQ ID NO. 5)). The naïve library may be
referred to
as the "LO Library" herein and the enriched library referred to as the "L2
library." See Example 8. The
screened library was PCR amplified with a C6-amine sense primer (C6 Amine-5'
CTAGCATGACTGCAGTACGT 3' (SEQ ID NO. 4)) and a 5' phosphorylated anti-sense
primer (5' Phos
TCGTCGGCAGCGTCA (SEQ ID NO. 6)), the purified product was strand separated and
conjugated with
sulfo-SBED (Thermo Scientific) according to Vinkenborg et al. (Angew Chem Int
Ed Engl. 2012,
51:9176-80) with the following modifications: The reaction was scaled down to
5mg C6-amine DNA
library (8.6 M) in 25mM HEPES-KOH, 0.1M NaCl, pH 8.3 and incubated with
either 100-fold molar
excess of sulfo-SBED or DMSO in a 21uL volume for 30 min at room temp in the
dark. The SBED-
conjugated library was immediately separated from the unconjugated library and
free sulfo-SBED by
injection onto a Waters X-BridgeTM OST C-18 column (4.6 mm x 50 mm) and
fractionated by HPLC
(Agilent 1260 Infinity) with a linear gradient Buffer A: 100 mM TEAA, pH7.0,
0% ACN to 100 mM
TEAA, pH7.0, 25% ACN at 0.2m1/min, 65 C. There SBED-conjugated fractions were
desalted into water
with Glen Gel-PakTM Cartridges and concentrated by speed-vac. SBED conjugation
was confirmed by
LC-MS and/or a dot blot with streptavidin-HRP detection.
[00696] Binding reaction and cross-linking
[00697] SBED library functionalization was tested by performing the ADAPT
assay with SBED vs
DMSO mock conjugated control C6-amine library and sequenced on a HiSeq 2500TM
(Illumina Corp.).
The aptamer precipitation was performed with forty-eight ADAPT reactions
incubated for lhr with end-
over-end rotation at room temp with a 5ng input of SBED conjugated library per
200 ML of plasma (pre-
spun to remove cellular debris at 10,000 xg for 20min, 4 C) in 1X PBS, 3mM
MgCl2, 0.01mM dextran
sulfate, 40 ng/u1 salmon sperm DNA and 40 ng/u1 yeast transfer RNA, and
cOmplete ULTRA Mini
EDTA-free TM protease inhibitors (Roche) equivalent to ¨240ng library and 9.6
mls plasma. A duplicate
set of 48 reactions was prepared with the DMSO control C6-amine library.
Aptamer library-protein
complexes were precipitated with incubation in 6% PEG8000 for 15 min at 4 C
then centrifuged at
10,000 xg for 5 min. Pellets were washed with lml lx PBS, 3mM MgCl2 by gentle
inversion to remove
unbound aptamers. The washed pellets were resuspended in 100 L of water and
subjected to photo-cross-
-150-
CA 03018066 2018-09-17
WO 2017/161357 PCT/US2017/023108
linking at 365nm with a hand-held 3UV (254NM/302NM/365NM) lamp, 115 volts
(Thermo Scientific)
for 10 min on ice with 1-2 cm between the 96-well plate and lamp.
[00698] Oligonucleonde precipitation
[00699] Cross-linked reactions were subsequently pooled (-4.8m1) per library
or 4.8 ml of 1X PBS (AP
bead only control) and incubated with 10 uL of Prepared Dynabeadst MyOneTM
Streptavidin Cl
(10mg/m1) (Life Technologies) (pre-washed with 1X PBS, 0.01% Triton X-100)
shaking for 1 hr at room
temp. Beads were transferred to an eppendorf tube and lysed for 20 min with
lysis buffer (50 mM Tris-
HC1, 10mM MgCl2, 200mM NaCl, 0.5% Triton X-100, 5% glycerol, pH 7.5) on ice,
washed 3 times with
wash buffer 1 (10mM Tris-HC1, 1mM EDTA, 2M NaCl, 1% Triton X-100), followed by
2 times with
wash buffer 2 (10mM Tris-HC1, 1mM EDTA, 2M NaCl, 0.01% Triton X-100) as
described by
Vinkenborg et al. (Angew Chem Int Ed Engl. 2012, 51:9176-80). Cross-linked
proteins were eluted by
boiling 15 min in 1X LDS sample buffer with reducing agent added (Life
Technologies) and loaded on a
4-12% SDS-PAGE gradient gel (Life Technology). Proteins and DNA were detected
with double staining
with Imperial Blue Protein Stain (Thermo Scientific) followed by Prot-SIL2 TM
silver stain kit (Sigma)
used according to manufacturer's instructions in order to enhance sensitivity
and reduce background.
[00700] Protein identification
[00701] Protein bands that appeared to differ between the cancer and normal
were excised from the
gradient gels and subjected to liquid chromatography-tandem mass spectrometry
(LC-MS/MS).
[00702] Results
[00703] ADAPT protein targets were identified from bands cut from a silver
stained SDS-PAGE gel
(FIG. 6). Aptamer-SBED protein complexes (lane 3) or Aptamer-DMSO protein
complexes (control-lane
4) were precipitated with 6% PEG8000, subjected to UV photo-cross-linking, and
pulled-down with
Streptavidin coated beads. Eluate was analyzed under reducing conditions by
SDS-PAGE and silver
staining. Aptamer library alone (5ng) (lane 1) was loaded as a control for
migration of the library (second
to bottom arrows) and an equal volume of eluate from a bead only sample (lane
4) was loaded as a
streptavidin control to control for potential leaching of the streptavidin
monomer (bottom arrow) under the
harsh elution conditions. Upper arrows ("Targets") indicate specific or more
predominant bands identified
with the SBED-conjugated library vs. the mock DMSO treated control C6-amine
library. Indicated target
protein bands were cut out and sent for LC-MS/MS protein identification or
indicated DNA library bands
were eluted, reamplified and sequenced. The identified proteins are those that
appeared as upregulated in
the normal samples.
[00704] Tables 10-17 list human proteins that were identified in 8 bands
excised from the silver stained
gel. In all tables the proteins are those identified in the oligo-SBED protein
complexes with proteins
identified in the corresponding control lanes removed. The band numbers in the
tables indicate different
bands cut from the gel (FIG. 6). Accession numbers in the table are from the
UniProt database
(www.uniprot.org). "GN=" is followed by the gene name. Various protein
classifications indicated in the
Tables 10-17 include Nucleic Acid Binding Proteins (NAB), Tumor suppressors
(TS), cell
adhesion/cytoskeletal (CA/CK) and abundant plasma proteins (ABP).
-151-
CA 03018066 2018-09-17
WO 2017/161357
PCT/US2017/023108
Table 10: Band 3
Accession Class Protein name
number
P02538 CA/CK Keratin, type II cytoskeletal 6A GN=KRT6A
P15924 CA/CK Desmoplakin GN=DSP
P04259 CA/CK Keratin, type II cytoskeletal 6B GN=KRT6B
P60709 CA/CK Actin, cytoplasmic 1 GN=ACTB
P20930 CA/CK Filaggrin GN=FLG
P07476 CA/CK Involucrin GN=IVL
P31947 TS 14-3-3 protein sigma GN=SFN
Q7Z794 CA/CK Keratin, type II cytoskeletal lb GN=KRT77
P02545 NAB Prelamin-A/C GN=LMNA
P19012 CA/CK Keratin, type I cytoskeletal 15 GN=KRT15
P47929 CA/CK Galectin-7 GN=LGALS7
& TS
P11142 Heat shock cognate 71 kDa protein GN=HSPA8
P58107 NAB Epiplakin GN=EPPK1
P08107 Heat shock 70 kDa protein 1A/1B GN=HSPA1A
Q02413 CA/CK Desmoglein-1 GN=DSG1
P06396 CA/CK Gelsolin GN=GSN
060814 NAB Histone H2B type 1-K GN=HIST1H2BK
P68104 NAB Elongation factor 1-alpha 1 GN=EEF1A1
P05387 NAB 60S acidic ribosomal protein P2 GN=RPLP2
Q7RTS7 CA/CK Keratin, type II cytoskeletal 74 GN=KRT74
P31946 TS 14-3-3 protein beta/alpha GN=YWHAB
Q13835 CA/CK Plakophilin-1 GN=PKP 1
P14923 CA/CK Junction plakoglobin GN=JUP
P09651 NAB Heterogeneous nuclear ribonucleoprotein Al GN=HNRNPA1
P07900 Heat shock protein HSP 90-alpha GN=HSP9OAA1
Q96KK5 NAB Histone H2A type 1-H GN=HIST1H2AH
P04406- CA/CK Glyceraldehyde-3-phosphate dehydrogenase GN=GAPDH
P10412 NAB Histone H1.4 GN=HIST1H1E
P04792 Heat shock protein beta-1 GN=HSPB1
Q9NZT1 Calmodulin-like protein 5 GN=CALML5
P81605 Dermcidin GN=DCD
P27348 TS 14-3-3 protein theta GN=YWHAQ
P55072 NAB Transitional endoplasmic reticulum ATPase GN=VCP
Q09666 NAB Neuroblast differentiation-associated protein AHNAK GN=AHNAK
P23246 NAB Splicing factor, proline- and glutamine-rich GN=SFPQ
Q15149 CA/CK Plectin GN=PLEC
Q8NC51 NAB Plasminogen activator inhibitor 1 RNA-binding protein GN=SERBP1
P07237 Protein disulfide-isomerase GN=P4HB
060437 CA/CK Periplakin GN=PPL
P01717 ABP Ig lambda chain V-IV region Hil
P55884 NAB Eukaryotic translation initiation factor 3 subunit B GN=EIF3B
P11021 78 kDa glucose-regulated protein GN=HSPA5
P01024 Complement C3 GN=C3
P04350 CA/CK Tubulin beta-4A chain GN=TUBB4A
P01857 ABP Ig gamma-1 chain C region GN=IGHG1
P61247 NAB 40S ribosomal protein S3a GN=RPS3A
P62937 Peptidyl-prolyl cis-trans isomerase A GN=PPIA
015020 CA/CK Spectrin beta chain, non-erythrocytic 2 GN=SPTBN2
P30101 Protein disulfide-isomerase A3 GN=PDIA3
Q6KB66 CA/CK Keratin, type II cytoskeletal 80 GN=KRT80
Q9UJU6 CA/CK Drebrin-like protein GN=DBNL
-152-
CA 03018066 2018-09-17
WO 2017/161357
PCT/US2017/023108
P47914 NAB 60S ribosomal protein L29 GN=RPL29
P39023 NAB 60S ribosomal protein L3 GN=RPL3
A6NMY6 CA/CK Putative annexin A2-like protein GN=ANXA2P2
P60174 CA/CK Triosephosphate isomerase GN=TPI1
P35241 CA/CK Radixin GN=RDX
P07305 NAB Histone H1.0 GN=H1F0
P15259 CA/CK Phosphoglyce rate mutase 2 GN=PGAM2
POCGO5 ABP Ig lambda-2 chain C regions GN=IGLC2
Q92817 CA/CK Envoplakin GN=EVPL
P06733 NAB MBP-1 of Alpha-enolase GN=EN01
P22626 NAB Heterogeneous nuclear ribonucleoproteins A2/B1 GN=HNRNPA2B1
P62424 NAB 60S ribosomal protein L7a GN=RPL7A
P60660 CA/CK Myosin light polypeptide 6 GN=MYL6
P04083 NAB Annexin Al GN=ANXA1
Q14134 NAB Tripartite motif-containing protein 29 GN=TRIM29
P39019 NAB 40S ribosomal protein S19 GN=RPS19
Q8WVV4 CA/CK Protein POF1B GN=P0F1B
Q02878 NAB 60S ribosomal protein L6 GN=RPL6
Q9Y6X9 NAB MORC family CW-type zinc finger protein 2 GN=MORC2
Q9NQC3 NAB Reticulon-4 GN=RTN4
Q5T753 CA/CK Late cornified envelope protein lE GN= CA/CK E
Table 11: Band 9
Accession Class Protein name
number
P61626 Lysozyme C GN=LYZ
Q9HCK1 NAB DBF4-type zinc finger-containing protein 2 GN=ZDBF2
Table 12: Band 1
Accession Class Protein name
number
P01834 ABP Ig kappa chain C region GN=IGKC
P01765 ABP Ig heavy chain V-III region TIL
P04003 NAB C4b-binding protein alpha chain GN=C4BPA
P60709 CA/CK Actin, cytoplasmic 1 GN=ACTB
Q5T751 CA/CK Late cornified envelope protein 1C GN=LCE1C
Table 13: Band 5
Accession Class Protein name
number
P01860 ABP Ig gamma-3 chain C region GN=IGHG3
060902 NAB Short stature homeobox
protein 2 GN=SHOX2
Table 14: Band 7
Accession Class Protein name
number
Q04695 CA/CK Keratin, type I cytoskeletal 17 GN=KRT17
Q7Z794 CA/CK Keratin, type II cytoskeletal lb GN=KRT77
Q6KB66 CA/CK Keratin, type II cytoskeletal 80 GN=KRT80
P01833 Polymeric immunoglobulin receptor GN=PIGR
P01042 Kininogen-1 GN=KNG1
Q02413 CA/CK Desmoglein-1 GN=DSG1
-153-
CA 03018066 2018-09-17
WO 2017/161357
PCT/US2017/023108
P15924 CA/CK Desmoplakin GN=DSP
Q8TF72 Protein Shroom3 GN=SHROOM3
P02671 ABP Fibrinogen alpha chain GN=FGA
Q5T749 CA/CK Keratinocyte proline-rich protein GN=KPRP
Q5VZP5 Inactive dual specificity phosphatase 27 GN=DUSP27
Q5T751 CA/CK Late comified envelope protein 1C GN=LCE1C
Q9UL12 Sarcosine dehydrogenase, mitochondrial GN=SARDH
P00698 Lysozyme C OS=Gallus gallus GN=LYZ
Q8N114 Protein shisa-5 GN=SHISA5
Table 15: Band 15
Accession Class Protein name
number
P08238 Heat shock protein HSP 90-beta GN=HSP90AB1
P68104 NAB Elongation factor 1-alpha 1 GN=EEF1A1
P02675 ABP Fibrinogen beta chain GN=FGB
Q8TF72 Protein Shroom3 GN=SHROOM3
POCGO5 ABP Ig lambda-2 chain C regions GN=IGLC2
P78386 CA/CK Keratin, type II cuticular Hb5 GN=KRT85
Q7Z5Y6 Bone morphogenetic protein 8A GN=BMP8A
014633 CA/CK Late comified envelope protein 2B GN=LCE2B
Table 16: Band 17
Accession Class Protein name
number
P02538 CA/CK Keratin, type II cytoskeletal 6A GN=KRT6A
P01834 ABP Ig kappa chain C region GN=IGKC
P06702 Protein S100-A9 GN=S100A9
P68104 NAB Elongation factor 1-alpha 1 GN=EEF1A1
P01024 Complement C3 GN=C3
P81605 Dermcidin GN=DCD
P05109 Protein S100-A8 GN=S100A8
Q5T751 CA/CK Late comified envelope protein 1C GN=LCE1C
Table 17: Band 19
Accession Class Protein name
number
P02768 NAB Serum albumin GN=ALB
POCGO5 ABP Ig lambda-2 chain C regions GN=IGLC2
P06702 Protein S100-A9 GN=S100A9
P08238 Heat shock protein HSP 90-beta GN=HSP90AB1
P60709 CA/CK Actin, cytoplasmic 1 GN=ACTB
P13647 CA/CK Keratin, type II cytoskeletal 5 GN=KRT5
P01616 ABP Ig kappa chain V-II region MIL
Q86YZ3 CA/CK Homerin GN=HRNR
P01857 ABP Ig gamma-1 chain C region GN=IGHG1
P62805 NAB Histone H4 GN=HIST1H4A
P59665 Neutrophil defensin 1 GN=DEFA1
P61626 Lysozyme C GN=LYZ
P01024 ABP Complement C3 GN=C3
Q8TF72 Protein Shroom3 GN=SHROOM3
P83593 ABP Ig kappa chain V-IV region STH (Fragment)
P01700 ABP Ig lambda chain V-I region HA
-154-
CA 03018066 2018-09-17
WO 2017/161357 PCT/US2017/023108
P01877 ABP Ig alpha-2 chain C region GN=IGHA2
Q9UL12 Sarcosine dehydrogenase, mitochondrial GN=SARDH
Q6NXT2 NAB Histone H3.3C GN=H3F3C
P02788 NAB Lactotransferrin GN=LTF
P02787 ABP Serotransferrin GN=TF
[00705] Certain proteins were identified in multiple bands. For example, IGLC2
was identified in bands 3,
15 and 19 and SHROOM3 was identified in bands 7, 15, 19. This may be due to
degradation products,
isoforms or the like. These experiments identified 108 proteins (plus 2
lysozyme controls), comprising
among others 34 Nucleic Acid Binding Proteins (NAB) where 7 of the 34 are
putative tumor
suppressors/repressors; 37 cell adhesion/cytoskeletal (CA/CK); and 14 abundant
plasma proteins (ABP).
All of the tumor suppressors/repressors are DNA/RNA binding proteins. Other
proteins comprise
chaperones, signaling molecules etc.
[00706] The biomarkers in this Example can be used to detect microvesicles
that are indicative of cancer
or non-cancer samples.
Example 10: Identification of biomarkers through affinity enrichment with an
enriched
oligonucleotide library and mass spectrometry
[00707] This Example continues upon the Example above. Identification of
protein-protein and nucleic
acid-protein complexes by affinity purification mass spectrometry (AP-MS) can
be hampered in samples
comprising complex mixtures of biological components (e.g., bodily fluids
including without limitation
blood and derivatives thereof). For example, it may be desireable to detect
low abundance protein and
nucleic acid-protein complexes in a complex milieu comprising various
components that may interact
promiscuously with specific binding sites such as high abundance proteins that
interact non-specifically
with the affinity resin. AP-MS has been used previously to enrich for pre-
identified targets of interest
using individual DNA or RNA aptamers or specific nucleic acid binding domains.
In this Example, an
enriched oligonucleotide probing library was used as the affinity reagent.
This approach combined with
mass spectrometry enables the identification of differentially expressed
biomarker from different disease
states or cellular perturbations without relying on a priori knowledge of the
targets of interest. Such
biomarker may comprise proteins, nucleic acids, miRNA, mRNA, carbohydrates,
lipid targets,
combinations thereof, or other components in a biological system.
[00708] The method comprises identification of an enriched oligonucleotide
probe library according to the
methods of the invention followed by target identification with affinity
purification of the bound probing
library and mass spectrometry. The members of the enriched oligonucleotide
probing library comprise an
affinity tag. A biological sample is probed with the oligonucleotide probe
library, affinity purification of
the oligonucleotide probe library via the affinity tag is performed which will
accordingly purify biological
entities in complex with various members of the probe library, and read-out of
targets that purified with
the members of the probe library is performed using liquid chromatography-
tandem mass spectrometry
(LC-MS/MS) for proteins or oligonucleotide targets (e.g., miRNA or mRNA) with
next generation
sequencing (NGS). Confirmation of protein targets is performed using
quantitative mass spectrometry
(MS), e.g., using MRM/SRM or SWATH based methods.
-155-
CA 03018066 2018-09-17
WO 2017/161357 PCT/US2017/023108
[00709] The method of the Example lends itself to various options. For
example, any appropriate affinity
tags can be used for affinity pull-down, including without limitation anti-
sense oligonucleotides, biotin,
polyhistidine, FLAG octapeptide (i.e., N-DYKDDDDK-C (SEQ ID NO. 7), where N
stands for Amino-
terminus and C stands for Carboxy terminus), 3X FLAG, Human influenza
hemagglutinin (HA)-tag (i.e.,
N-YPYDVPDYA-C (SEQ ID NO. 8)), myc-tag (N-EQKLISEEDL-C (SEQ ID NO. 9)), other
such as
known in the art, and combinations thereof Similarly, any appropriate
enrichment support can be used in
addition to the magnetic streptavidin beads exemplified herein, including
without limitation other bead
systems, agarose beads, planar arrays or column chromatography supports. It
follows that the various
supports can be coupled with the various affinity reagents appropriate for the
oligonucleotide library,
including without limitation streptavidin, avidin, anti-His tag antibodies,
nickel, and the like. The different
affinity tags and supports can be combined as desired. This Example used cross-
linking but in certain
cases such cross-linking is not necessary and may even be undesirable, e.g.,
to favor identification of high
affinity complex formation. When cross-linking is desired, any appropriate
cross-linkers can be used to
carry out the invention, including BS2G, DSS, formaldehyde, and the like.
Other appropriate cross-linkers
and methods are described herein. See, e.g., Section "Aptamer Target
Identification." Lysis buffers and
wash stringencies can be varied, e.g, depending on whether complexes are cross-
linked or not. Less
stringent lysis/wash conditions may produce a wider array of potential protein
complexes of interest
whereas more stringent lysis/wash conditions may favor higher affinity oligo-
target complexes and/or
targets comprising specific proteins (e.g., by disassociating larger complexes
bound to the oligos). One of
skill will further appreciate that qualitative and/or quantitative LC-MS/MS
may be used for target
detection and verification. Similarly, metabolic labeling and label-free
approaches may be used for
quantitative MS, including without limitation spectral counting, SILAC,
dimethyl labeling, TMT labeling,
Targeted MS with SRM/MRM or SWATH, and the like.
[00710] References:
[00711] Vickenborg et al. "Aptamer based affinity labeling of proteins", Angew
Chem Int. 51(36):9176-
80 (2012).
[00712] Tacheny, M, Arnould, T., Renard, A. "Mass spectrometry-based
identification of proteins
interacting with nucleic acids", Journal of Proteomics 94; 89-109 (2013).
[00713] Faoro C and Ataide SF. "Ribonomic approaches to study the RNA-binding
proteome.", FEBS
Lett. 588(20):3649-64 (2014).
[00714] Budayeva HG, Cristea, IM, "A mass spectrometry view of stable and
transient protein
inteeractions." Adv Exp Med Biol. 806:263-82 (2014).
Example 11: Protocol for Affinity capture using oligonucleotide probing
library
[00715] This Example presents a detailed protocol for the method of affinity
capture using an
oligonucleotide probing library presented in the Example above.
[00716] Protocol:
[00717] The oligonucleotide probe library comprises F- IRin-35n-B-8-3s
described herein either
desthiobiotin labeled or unlabeled library and binding to normal (i.e., non-
cancer) female plasma. The
-156-
CA 03018066 2018-09-17
WO 2017/161357 PCT/US2017/023108
oligonucleotide probe library is enriched against the plasma samples as
described elsewhere (e.g., in
Example 7). The plasma samples are processed separately against the
desthiobiotin labeled or unlabeled
oligonucleotide libraries. General parameters included the following:
[00718] 48 normal plasma samples are pooled for enrichment of each
oligonucleotide library
(Desthiobiotin or Unlabeled)
[00719] 200 pl input plasma per sample
[00720] Ultracentrifugation (UC) is used to pre-clear the samples
[00721] 5 ng of each aptamer library is added to each sample
[00722] Binding competitors for all library samples include 0.01X Si (dextran
sulfate), 340ng for tRNA
and 340 ng Salmon sperm DNA as described elsewhere herein
[00723] 6% PEG 8000 is used for precipitation of microvesicles within the
samples
[00724] Affinity purification is performed with Cl Streptavidin beads (MyOne
Strptavidin Beads Cl-
65001, lot 2m1 (10mg/m1))
[00725] Buffers:
[00726] Plasma dilution: 6 mM MgCl2 in 2X PBS
[00727] Pellet Wash Buffer: 1X PBS, 3mM MgCl2
[00728] PEG Ppt Buffer: 20% Peg8000 in 1X PBS, 3mM MgCl2
[00729] Bead Prep Buffer: 1XPBS containing 0.01% Triton X-100
[00730] Lysis Buffer: prepare a 2X stock solution consisting of 100mM Tris-
HC1, 20mM MgCl2, 400mM
NaCl, 1% Triton X-100, 10% glycerol, pH 7.5. Diluted to 1X with water 1:1
prior to using.
[00731] AP Wash buffer 1: 10mM Tris-HC1, 1mM EDTA, 2M NaCl, 1% Triton X-100,
pH 7.5
[00732] AP wash buffer 2: 10mM Tris-HCL, 1mM EDTA, 2M NaCl, 0.01% Triton X-
100, pH 7.5
[00733] Biotin Elution buffer 1: 5mM Biotin, 20mM Tris, 50mM NaCl, pH 7.5
[00734] 1X LDS, 1X Reducing buffer 2
[00735] Reagent/Instrument Prep:
[00736] Pre-chill Ultracentrifuge to 4 C.
[00737] Protease inhibition: dissolve 2 tablets of "cOmplete ULTRA MINI EDTA-
free EASYpack"
protease inhibitor in 1100 IA of H20 (20x stock of protease inhibitor).
[00738] Plasma Preparation (for each of Desthiobiotin or Unlabeled
oligonucleotide libraries):
[00739] 1. Add 50 1 of protease inhibitor to each ml of sample (on top of
frozen plasma) in a room
temperature (RT) water bath. Will use 20 mls of pooled plasma, so 1100 1
inhibitor.
10074012. To remove cell/debris, spin samples at 7500 xg 20min, 4 C in the
Ultracentrifuge.
[00741] 3. Collect the supernatant, pool and measure volume & record.
10074214. Add an equal volume of 2X PBS, 6mM MgCl2 to the plasma.
10074315. Label low-retention eppendoif tubes 1-96.
10074416. Transfer 400 1 of each sample to eppendorf tubes based on
appropriate tube map
10074517. Using an electronic P200, add competitors: 8.6 1 of 4Ong/ 1
Salmon sperm DNA; 8.6 il
of 40ng/til tRNA; 8.6 1 of 0.5X 51.
-157-
CA 03018066 2018-09-17
WO 2017/161357 PCT/US2017/023108
[00746] 8. Incubate at RT with end over end rotation for 10 min.
[00747] 9. Add 10 L of appropriate oligo library, mix well. Save any
leftover diluted library for gel
control (see below).
[00748] 10. Incubate 1 hr at RT with end over end rotation.
[00749] 11. Using an electronic repeat P100, add 187 1 of 20% PEG 8000 to
sample for a final 6%
concentration to the 435.5 I of sample/oligo library. Invert a few times to
mix and incubate for 15 min at
4 C
[00750] 12. Spin each sample in table top centrifuge at 10,000 xg for 5
min.
[00751] 13. Remove supernatant and discard, add lml lx PBS, 3mM MgCl2 to
pellet.
[00752] 14. Wash pellet by gentle inversion
[00753] 15. Remove buffer, re-suspend pellets in 100 1 1X PBS, 3mM MgCl2:
incubate at RT for 10
min on mixmate @ 900rpm to re-suspend. Make sure each sample is well re-
suspended by pipetting.
[00754] 16. Pool all desthiobiotin library samples into one 50m1 falcon
tube, and the unlabeled library
into another, total volume for each should be 4800111.
[00755] 17. Take 10 L aliquot for the input into AP sample for gel (add 10
pt of 2x LDS buffer w/
2X reducing agent.
[00756] Affinity Purification:
[00757] 18. Prepare 10 L of MyOne Strep-coated Magnetic beads per each
condition into a 1.5 ml
eppendorf tube and place on a magnetic bead rack. Have a Bead only control as
well (n=3)
[00758] 19. Remove supernatant and wash 1X 500111 with Bead buffer.
[00759] 20. Discard supernatant
[00760] 21. Resuspend beads in an equal volume of 1X PBS, 3mM MgCl2 (equal
vol to what was
taken out originally = 100)
[00761] 22. Add the 100 of beads directly to the 47804 from step 19. To
Bead only control add
PBS.
[00762] 23. Incubate samples with streptavidin beads lhr RT on plate shaker
(taped).
[00763] 24. Place on the large magnetic stand for 1 min and remove
supernatant
[00764] 25. Add 1.5 mL of lx lysis buffer to the samples (do 3 X 500111
with a good rinse of the
50mL falcon tube for each to collect all the beads) and transfer to a new set
of eppendorf tubes.
[00765] 26. Incubate for 20 min on ice.
[00766] 27. Place tubes in magnetic bead rack, let equilibrate 1 min and
remove the supernatant.
[00767] 28. Wash the beads with wash buffer #1 via vortexing. Resuspend
well.
[00768] 29. Place tubes on magnetic bead rack, let equilibrate 1 min and
remove the supernatant
[00769] 30. Wash 2 additional times as with wash buffer # 1 steps 27-29
(total 3 washes with wash
buffer #1)
[00770] 31. Repeat steps 27-29 (2) additional times with wash buffer #2
[00771] 32. During the last wash transfer beads to a new eppendorf tube.
(to reduce non-specific
binding)
-158-
CA 03018066 2018-09-17
WO 2017/161357 PCT/US2017/023108
[00772] 33. Do one dry spin to make sure all residual wash buffer is
removed.
[00773] 34. Add 10iil of Biotin Elution buffer 1 to beads
[00774] 35. Incubate for 15 minutes at 37 C.
[00775] 36. Place on magnetic stand for 1 min, collect sup and transfer to
anew tube, add 101AL of 2X
LDS, 2X Reducing agent to eluted sample. Save as Elution #1.
[00776] 37. Add 10iil of lx LDS Sample Buffer, 1X Reducing buffer to
magnetic beads.
[00777] 38. Boil the samples for 15 min at 90 C. The boiling time is 15
minutes to essure the
streptavidin on the beads unfolds and releases the biotinylated aptapmer-
protein complex.
[00778] 39. Place samples on magnetic stand on ice and collect the eluted
sample. This is Elution #2.
Discard the beads.
[00779] 40. Gel 1 layout:
[00780] Lane 1: 5ng Desthiobiotin library
[00781] Lane 2: 1X LDS
[00782] Lane 3: Marker
[00783] Lane 4: Desthiobiotin Elution #1
[00784] Lane 5: Unlabeled Elution #1
[00785] Lane 6: Bead only Elution #1
[00786] Lane 7: Desthiobiotin Elution #2
[00787] Lane 8: Unlabeled Elution #2
[00788] Lane 9: Bead only Elution #2
[00789] Lane 10: Input for AP (saved from step 17)
[00790] Running Reducing SDS gel:
[00791] Prepare 1X MOPS SDS Running Buffer from 20X MOPS SDS Buffer
[00792] Use 10 or 12 well 4 -12 % Bis Tris gel
[00793] Peel off tape seal and place in the gel box. Insert spacer for second
gel cassette if needed
[00794] Fill the inside/upper chamber with running buffer MOPS (1X) and 500u1
Antioxidant
[00795] Remove the comb carefully, not disturbing the wells
[00796] Rinse the wells with the running buffer to remove the storage buffer
which can interfere with
sample running
[00797] Slowly load samples to each well carefully using L-20 tip
[00798] Fill the outer/lower chamber with approximately 600m1 of running
buffer MOPS (1X)
[00799] Place top portion of unit and secure correct electrodes
[00800] Run the gel to migrate proteins
[00801] 100 V constant for samples to move through stack (until all samples
line up) for 15 min
[00802] Increase to 150 V constant for running (until visible sample buffer
comes to bottom) for ¨1 hr
[00803] At the end of the run, stop the power supply and remove the gel
cassettes from cell
[00804] Disassemble the gel cassette by with gel knife.
[00805] Remove one side of cassette case. Trim off the gel foot and wells
(avoid drying gel).
-159-
CA 03018066 2018-09-17
WO 2017/161357 PCT/US2017/023108
[00806] Transfer gel into container filled with Mili Q water and perform a
quick wash.
[00807] Silver staining:
[00808] Materials:
[00809] ProteoSilver TMSilver Stain Kit, Sigma Catalog No. PROT-SILl, Lot No.
SLBJ0252V
[00810] Ethanol, Fisher Scientific Catalog No. BP2818-4, Lot No. 142224
[00811] Acetic acid, Acros organics Catalog No. 14893-0025, Lot No. B0520036
[00812] Water, Sigma Catalog No. W4502, Lot No. RNBD1581
[00813] Preparation:
[00814] 1. Fixing solution. Add 50 ml of ethanol and 10 ml of acetic acid
to 40 ml of ultrapure
water.
[00815] 2. 30% Ethanol solution. Add 30 ml of ethanol to 70 ml of ultrapure
water.
[00816] 3. Sensitizer solution. Add 1 ml of ProteoSilver Sensitizer to 99
ml of ultrapure water.The
prepared solution should be used within 2 hours. A precipitate may form in the
ProteoSilver Sensitizer.
This precipitate will not affect the performance of the solution. Simply allow
the precipitate to settle and
remove 1 ml of the supematant.
[00817] 4. Silver solution. Add 1 ml of ProteoSilver Silver Solution to 99
ml of ultrapure water. The
prepared solution should be used within 2 hours.
[00818] 5. Developer solution. Add 5 ml ProteoSilver Developer 1 and 0.1 ml
ProteoSilver
Developer 2 to 95 ml of ultrapure water. The developer solution should be
prepared immediately (<20
minutes) before use.
[00819] 6. All steps should be carried out in the hood and waste needs to be
collected in toxic designated
container.
[00820] Procedure
[00821] A. Direct Silver Staining
[00822] = All steps are carried out at room temperature on an orbital shaker
at 60 to 70 rpm.
[00823] 1. Fixing - After electrophoresis of the proteins in the mini
polyacrylamide gel, place the gel
into a clean tray with 100 ml of the Fixing solution overnight in the hood.
Cover tightly.
[00824] 2. Ethanol wash - Decant the Fixing solution and wash the gel for
10 minutes with 100 ml of
the 30% Ethanol solution.
[00825] 3. Water wash ¨ Decant the 30% Ethanol solution and wash the gel
for 10 minutes with 200
ml of ultrapure water.
[00826] 4. Sensitization ¨ Decant the water and incubate the gel for 10
minutes with 100 ml of the
Sensitizer solution.
[00827] 5. Water wash ¨ Decant the Sensitizer solution and wash the gel
twice, each time for 10
minutes with 200 ml of ultrapure water.
[00828] 7. Silver equilibration ¨ Decant the water and equilibrate the gel
for 10 minutes with 100 ml
of the Silver solution.
-160-
CA 03018066 2018-09-17
WO 2017/161357 PCT/US2017/023108
[00829] 8. Water wash ¨ Decant the Silver solution and wash the gel for 1
to 1.5 minutes with 200
ml of ultrapure water.
[00830] 9. Gel development ¨Decant the water and develop the gel with 100
ml of the Developer
solution. Development times of 3 to 7 minutes are sufficient to produce the
desired staining intensity for
most gels. Development times as long as 10 to 12 minutes may be required to
detect bands or spots with
very low protein concentrations (0.1 ng/mm2).
[00831] 10. Stop - Add 5 ml of the ProteoSilver Stop Solution to the
developer solution to stop the
developing reaction and incubate for 5 minutes. Bubbles of CO2 gas will form
in the mixture.
[00832] 11. Storage ¨ Decant the Developer/Stop solution and wash the gel
for 15 minutes with 200
ml of ultrapure water. Store the gel in fresh, ultrapure water and take
picture for documentation.
[00833] Protein identification
[00834] Protein bands of interest were excised from the gradient gels and
subjected to liquid
chromatography-tandem mass spectrometry (LC-MS/MS) as above.
Example 12: Use of an oli2onucleotide probe library to characterize Breast
Cancer samples
[00835] An oligonucleotide probe library comprising approximately 2000
different probe sequences was
constructed and used to probe approximately 500 individual breast cancer and
non-cancer samples. The
probe sequences were derived from different screening experiments and are
listed herein in SEQ ID NOs
10-2921. The oligonucleotides listed in these tables were synthesized and
pooled together. The samples
were plasma samples from 212 breast cancer patients, 177 biospy confirmed non-
cancer patients, and 117
normal control patients (self-reported as non-cancer). The plasma samples were
contacted with the
oligonucleotide probe library and microvesicles were isolated using PEG
precipitation. Oligonucleotides
that were recovered with the microvesicles were isolated. Next Generation
Sequencing (Illumina HiSeq)
was used to identify the isolated sequences for each sample.
[00836] Analysis of significance of difference identified 18 aptamers with p-
values below 0.01 when
compared Cancer/Normal, 15 aptamers with p-values below 0.001 when compared
cancer/Non-Cancer,
28 aptamers with p-values below 0.001 when compared Non-Cancer/Normal.
[00837] Multi-oligonucleotide panels were next contructed using a cross-
validation approach. Briefly, 50
samples were randomly withheld from the sample cohort. The performance of
individual oligonucleotides
to distinguish the remaining cancers and non-cancer/normals was determined
using logistic regression
methodology. Additional oligonucleotides were added iteratively and
performance was assessed using
logistic regression until further performance improvements were no longer
obtained with additional
oligonucleotides. The approach generally led to panels of approximately 20-100
different probe
sequences. The contructed panels were then used to classify the 50 withheld
samples and diagnostic
performance was assessed using Receiver Operating Curve (ROC) analysis and
estimation of the Area
under the Curve (AUC).
[00838] In approximately 300 rounds of cross-validation, the average AUC was
0.6, thus showing that the
average performance was statistically better than random (i.e., AUC of 0.5)
and that the probe library
could distinguish breast cancer and non-breast cancer/normal patient samples.
AUC values as high as 0.8
-161-
CA 03018066 2018-09-17
WO 2017/161357 PCT/US2017/023108
were observed for particular cross validations. FIGs. 7A-B illustrate a model
generated using a training
(FIG. 7A) and test (FIG. 7B) set from a round of cross validation. The AUC was
0.803. The variable
regions of the sequences used to build this model are shown in Table 18.
Another exemplary round of
cross-validation is shown in FIGs. 7C-D. The AUC was 0.678.
[00839] The SEQ ID NOs. of the sequences used in the model in FIGs. 7A-B are
listed in rank in Table
18. The oligonucleotides were synthesized with a 5' region consisting of the
sequence (5 -
CTAGCATGACTGCAGTACGT (SEQ ID NO. 4)) and a 3' region consisting of the
sequence (5' -
CTGICICTTATACACATCTGACGCTGCCGACGA (SEQ ID NO. 5)) flanking the variable
regions.
Table 18: Oligonucleotide Probe Variable Regions
Rank Ordered SEQ ID NOs
88, 1057, 834, 1608, 653, 1090, 2803, 499, 2587, 1082, 237, 2873, 2886, 759,
287, 390, 472, 119, 289,
96, 380, 459, 1226, 1331, 1012,2542, 1284, 2765, 2528, 334, 1688, 949, 172,
1180, 832, 658, 195, 509,
1015, 538, 465, 696, 41, 954, 2771, 55, 407, 1351, 2524, 2760, 1728, 2600,
1731, 729, 2920, 156, 1322,
1745, 478, 236, 139, 2911, 2013, 1077, 525, 507, 2534, 1041, 1499, 766, 1037,
1143, 912, 1502, 968,
1420
[00840] The data presented in this Example demonstrate that an oligonucleotide
pool comprising members
having the variable regions listed in SEQ ID NOs 10-2921, e.g., a pool of
probes having the variable
regions listed in Table 18, can be used to distinguish plasma from individuals
having breast cancer versus
plasma from non-breast cancer individuals.
Example 13: Single stranded DNA (ssDNA) oligonucleotide library preparation
for library
development
[00841] The preparation of high yield and high quality ssDNA libraries is a
critical step in SELEX
(Systematic Evolution of Ligands by EXponential enrichment) [1, 21 as well as
in other biological
applications, such as DNA chips and microarrays [3], and single-stranded
conformation polymorphism
technique (SSCP) [4]. The standard approach for preparing ssDNA libraries
includes PCR amplification
to first generate a double stranded (dsDNA) library, followed by ssDNA
separation and purification.
Several strategies of ssDNA preparation have been developed to date, each with
advantages and
disadvantages:
[00842] Lambda exonuclease digestion [2, 5-71
[00843] The dsDNA standard PCR product is followed by Lambda exonuclease to
digest the
complementary strand and leave the target ssDNA. ssDNA purification is then
performed to remove
enzymes and unwanted buffer.
[00844] Advantages: Regular PCR amplification has high yield in generating
dsDNA.
[00845] Disadvantages: The purity of final ssDNA is limited by enzyme
digestion efficiency. Also
dsDNA needs to be purified prior to digestion, together with post-digestion
purification there will be two
purifications, which results in substantial loss of input material. The
digestion usually requires at least 2
hours. The digestion rate may not be consistent.
[00846] Asymmetric PCR [8, 9]
-162-
CA 03018066 2018-09-17
WO 2017/161357 PCT/US2017/023108
[00847] The procedure generates target ssDNA as the main product and less
dsDNA products and non-
target ssDNA. The band corresponding to the target ssDNA is cut from a native
gel.
[00848] Advantages: The final ssDNA product potentially has high purity.
[00849] Disadvantages: Separation of strands is possible in the native gel,
but the yield is typically low
and the presence of non-target strand cannot be excluded. The yield cannot be
increased on denaturing gel
because the strands have the same length.
[00850] Biotin-streptavidin magnetic beads separation 110, 11]
[00851] The non-target PCR primer is biotinylated so final PCR products are
Biotinylated-dsDNA, which
can be captured by streptavidin magnetic beads and denatured to release the
non-biotin labeled target
ssDNA.
[00852] Advantages: The final ssDNA product has relatively high purity.
[00853] Disadvantages: In most cases, the input library needs to be
biotinylated, but it may be difficult to
replace or release the captured target strands from streptavidin beads. Post-
denaturing purification is
required to remove NaOH and/or acid used for neutralization.
[00854] Unequal primer length PCR [12]
[00855] The non-target PCR primer has a chemical modified spacer and a few
extra nucleotides following.
In the PCR reaction, the DNA polymerase will stop at the spacer, resulting in
unequal length of PCR
dsDNA product. Then target ssDNA can be cut from a denaturing PAGE gel.
[00856] Advantages: The final ssDNA product has high purity because the target
ssDNA is not mixed
with non-target strands.
[00857] Disadvantages: ssDNA cannot be seen on native gel. Requires time
consuming denaturing PAGE
gel. It may be difficult to denature some dsDNA library, which can limit the
final yield.
[00858] Indirect purification method [13]
[00859] The indirect purification strategy combines Asymmetric PCR and Biotin-
streptavidin magnetic
beads separation. In short, regular PCR is used to generate sufficient
template, then asymmetric PCR with
excess of target primer and less biotinylated complementary primers, followed
by biotin-streptavidin
separation.
[00860] Advantages: May increase yield and purity of ssDNA product.
[00861] Disadvantages: It cannot produce biotinylated target ssDNA library.
The process is relatively
long and complicated and may be prone to generate mutants of the original
sequence.
[00862] The invention provides methods of enriching oligonucleotide probe
libraries against a target of
interest. As the probes comprise ssDNA, the process may comprise PCR
amplification then conversion
back into ssDNA after each round of enrichment. In this Example, we developed
a strategy for preparation
of a ssDNA oligonucleotide library. The goals were to develop a process that
is efficient and quick, while
delivering high quality/purity ssDNA. We aimed to combine PCR and ssDNA prep
in one step, remain
efficient in the presence of selection buffer, target molecules, other sample
components (e.g., highly
abundant proteins for plasma samples) and other assay components (e.g., PEG
precipitation solution that
-163-
CA 03018066 2018-09-17
WO 2017/161357 PCT/US2017/023108
may be used to precipitate microvesicles). In addition, we desired the method
to be able to generate
ssDNA library with any modification, including without limitation Biotin.
[00863] We have used an optimized version of Lambda exonuclease digestion
protocol for preparation of
ssDNA oligonucleotide library. However, the digestion yield limits the overall
recovery and is not
consistent between different library preparations. In some cases, the ssDNA
band is hardly visible on the
gel following digestion. We have also observed incomplete digestion of dsDNA
in the ssDNA product. In
this Example, we developed an alternative protocol, termed "ssDNA by Unequal
length PRimer
Asymmetric PCR," or SUPRA. It lacks disadvantages from the known methods
listed above, and provides
high quality and yield up to 10x higher yield of ssDNA oligonucleotide library
as compared to the
previous methods. It is relatively fast and convenient technically, since
target ssDNA can be distinguished
from non-target DNA on a gel.
[00864] A schematic comparing standard PCR 900 and unequal length PCR 910 is
shown in FIG. 9A. In
regular PCR 900, a formard primer 901 and reverse primer 903 are hybridized
with the reverse strand of
an aptamer library 902. The PCR reaction is performed, thereby creating equal
length forward 904 and
reverse strands 902. The strands are denatured in equal length single strands
905. In unequal length PCR
901, a formard primer 911 having a lengthener segment and terminator segment
and a reverse primer 913
are hybridized with the reverse strand of an aptamer library 912. The PCR
reaction is performed, thereby
creating unequal length forward 914 and reverse strands 912. The strands are
denatured into unequal
length single strands 914 and 912 that can be separated by size, e.g., on a
denaturing gel.
[00865] The steps of SUPRA include: (i) Modification of regular non-target
primer with two Isp9 (Internal
Spacer 9; triethylene glycol spacer) as terminator and 32 extra nucleotides
(e.g., poly-A) as lengthener. It
is referred as Unequal-Forward-Double isp9 primer (UF-D9); (ii) Perform
asymmetric PCR, by mixing
DNA template, UF-D9 and regular target (reverse) primer at ratio that favors
the reverse primer, e.g.,
1:37.5. The PCR program has longer elongation step (e.g., 3 min instead of
standard 1 min) and more
cycles due to linear amplification mode (instead of exponential). The PCR
product contains a majority of
target ssDNA and small portion of dsDNA. (iii) Mix PCR reaction products 1:1
with denaturing buffer
(e.g., 180 mM NaOH and 6 mM EDTA) and denature samples by heating (e.g., 70 C
for 10 min) and
cooling (e.g., incubation on ice for 3 min); (iv) Run denatured products in
denaturing buffer on an agarose
gel stained with SybrGold. The non-target strand, which is longer due to the
lengthener, will appear as
upper band (if visible) and the target strand (strong lower band) is cut and
purified. The process can
include optional steps, including without limitation: (v) Weigh the gel pieces
and purify ssDNA from the
gel pieces (e.g., using the ssDNA Nucleospin kit or the like); (vi)
quantification of the yield and native gel
can be used to check the purity and yield of final product (e.g., using the
ssDNA Qubit kit or the like).
[00866] The first step (i) uses a specific design of the forward primer with
efficient terminator and
lengthener, which creates non-target strand of unequal length. The DNA
polymerase used to build the
target strand will stop polymerization once it reaches the terminator, and the
lengthener facilitates
differentiation between the target and non-target strands. In the second step
(ii), the ratio between the two
primers is shifted toward the reverse primer, to produce a majority of target
ssDNA. The ratio, however,
-164-
CA 03018066 2018-09-17
WO 2017/161357 PCT/US2017/023108
should not limit double strand templates production to keep reaction running.
FIG. 9B is a gel showing
titration of forward and reverse primers input in asymmetrical PCR. The
optimal condition, at which
target strand is clearly visible, is in the range 1:20-1:50 F:R primers ratio.
As shown in the figure, the ratio
between two primers in asymmetric PCR can affect dsDNA and ssDNA amount in
final products. The
PCR thermocycler program is also adjusted to provide efficiency in the
asymmetric PCR. In the third step
(iii), a reliable denaturing method is used to separate target ssDNA to ensure
the final yield and high
purity.
[00867] As desired, the final step (vi) estimates the ratio of residual dsDNA,
e.g., using ssDNA Qubit kit.
In cases where the yield is not critical, the denaturing steps (iii and iv)
can be skipped and the PCR
products can be directly run on native gel. There will be a dsDNA band, but
lower MW target ssDNA
band can be distinguished and purified from gel. This is also a way to
visualize the target band directly
after PCR for a quality check or purification without denaturing. The purity
of final product will be the
same but yield will be lower.
[00868] A comparison of native versus denatured gel purification is shown in
FIG. 9C. A post-probing
oligonucleotide probe library was PCRed using unequal length primers mixed at
a ratio of 1:38
(Forward/Reverse). In the figure, the left lane on each gel is a 50 bp
molecular weight ladder and the
lower band is the reverse primer. The positions of the dsDNA and ss DNA are
indicated. A native gel
showed the presence of both dsDNA and ssDNA (target strand) (FIG. 9C, panel
A). Here, part of the
target reverse strand is migrating in dsDNA. Thus, using the native gel, one
can purify target ssDNA with
moderate recovery. When a higher yield is desired, the PCR products can be run
on denaturing agarose
gel as described above. This approach provides maximal recovery wherein only
target strand is visible,
and can be cut from gel and purified (FIG. 9C, panel B). In this case, the
reverse strand ssDNA, which is
part of the dsDNA on native gel (FIG. 9C, panel A), is denatured and migrates
together with other free
molecules of target ssDNA strand, while forward strand becomes invisible due
to limited amplification.
[00869] Compared to standard asymmetric PCR, which has relatively low yield
and does not allow to
distinguish target and non-target strands on denaturing gel, SUPRA delivers
different lengths of target and
non-target that can be purified on both native gel and denaturing gels.
Compared to unequal primer length
PCR, which uses lengthy Urea-PAGE protocol and produces only dsDNA, SUPRA has
less dsDNA and
free target ssDNA can be cut even from native gel if yield is not critical.
[00870] SUPRA has been used in the oligonucleotide probe library enrichment
methods provided by the
invention. The method is robust. In the presence of enrichment buffer,
target/non-target molecules,
proteins, exosomes/microvesicles, PEG and other components, SUPRA provides
high quality and quantity
of the ssDNA oligonucleotide library.
[00871] References:
[00872] 1. Comparison of different methods for generation of single-stranded
DNA for SELEX processes.
Anal. Bioanal. Chem. 2012, 404, 835-842.
[00873] 2. Upgrading SELEX Technology by Using Lambda Exonuclease Diogestion
for Single-Straded
DNA Generation. Molecules 2010, 15, 1-11.
-165-
CA 03018066 2018-09-17
WO 2017/161357 PCT/US2017/023108
10087413. Tang, K.; Fu, D.J.; Julien, D.; Braun, A.; Cantor, CR.; Koster, H.
Chip-based genotyping by
mass spectrometry. Proc. Natl. Acad. Sci. USA 1999, 96, 10016-10020.
10087514. Kuypers, A.W.; Linssen, P.C.; Willems, P.M.; Mensink, E.J. On-line
melting of double-
stranded DNA for analysis of single-stranded DNA using capillary
electrophoresis. J. Chromatogr. B
Biomed. App!. 1996, 675, 205-211.
10087615. Higuchi, R.G.; Ochman, H. Production of single-stranded DNA
templates by exonuclease
digestion following the polymerase chain reaction. Nucleic Acids Res. 1989,
17, 5865.
[00877] 6. Jones, L.A.; Clancy, L.E.; Rawlinson, W.D.; White, P.A. High-
affinity aptamers to subtype 3a
hepatitis C virus polymerase display genotypic specificity. Antimicrob. Agents
Chemother. 2006, 50,
3019-3027.
[00878] 7. S. S. Oh, K. Ahmads, M. Cho, Y. Xiao, H. T. Soh, "Rapid, Efficient
Aptamer Generation:
Kinetic-Challenge Microfluidic SELEX," presented in the 12th Annual UC
Systemwide Bioengineering
Symposium, Jun. 13-15, 2011, Santa Barbara, U.S.A
[00879] 8. Gyllensten, U.B.; Erlich, H.A. Generation of single-stranded DNA by
the polymerase chain
reaction and its application to direct sequencing of the HLA-DQA locus. Proc.
Natl. Acad. Sci. USA
1988, 85, 7652-7656.
10088019. Wu, L.; Curran, J.F. An allosteric synthetic DNA. Nucleic Acids Res.
1999, 27, 1512-1516.
[00881] 10. Espelund, M.; Stacy, R.A.; Jakobsen, K.S. A simple method for
generating single-stranded
DNA probes labeled to high activities. Nucleic Acids Res. 1990, 18, 6157-6158.
[00882] 11. A. Paul, M. Avci-Adali, G. Ziemer, H.P. Wendel. Streptavidin-
coated magnetic beads for
DNA strand separation implicate a multitude of problems during cell-SELEX.
Oligonucleotides 2009, 19,
243-254.
[00883] 12. Williams K., Bartel D. PCR product with strands of unequal length.
Nucleic Acids Research,
1995, Vol. 23, No. 20.
[00884] 13. Indirect purification method provides high yield and quality ssDNA
sublibrary for potential
aptamer selection. Anal. Biochem. 2015, online available.
Example 14: 01i2onucleotide pools to characterize cell lines
[00885] In this Example, an oligonucleotide library was enriched using a
combination of cells from
different cancer cell lines to create cancer specific pools and against a pool
of non-cancer cells. The
enrichment is performed to identify cancer specific oligonucleotides and
oligonucleotide pools that can be
used in various applications, including without limitation diagnostic assays,
as drugs or in drug delivery.
[00886] The unscreened library comprised F-Trin-B primers (i.e., 5'
CTAGCATGACTGCAGTACGT (SEQ
ID NO 4) and 5' CTGICTCTTATACACATCTGACGCTGCCGACGA (SEQ ID NO 5) as shown
above)
surrounding a region of randomly generated nucleotides. The enrichment was
performed using
methodology presented herein. See Examples above. Detailed protocols are below
in Examples 15 and
16. One round of enrichment consisted of a series of positive, negative and
positive selections before
amplification via PCR of the enriched oligonucleotides. See FIG. 13, which
shows a diagram of one
round of enrichment. The amplified library (PCR) is used as the input into the
next round or enrichment.
-166-
CA 03018066 2018-09-17
WO 2017/161357 PCT/US2017/023108
The cell lines used consisted of nine lung cancer lines, five prostate cancer
lines and nine non-cancer lines
as listed in Table 19.
Table 19: Cell Lines
Indication Cell Line Tissue Disease
Morphology
Lung Pool A549 Lung Carcinoma Epithelial
NCI-H1395 Lung Adenocarcinoma Epithelial
NCI-I11838 Lung Adenocarcinoma; Non-Small
Epithelial
Cell Lung Cancer
NCI-H1975 Lung Adenocarcinoma; Non-Small
Epithelial
Cell Lung Cancer
NCI-H2122 Lung; Derived From Adenocarcinoma; Non-Small Rounded
Metastatic Site: Pleural Cell Lung Cancer And
Effusion Epithelial
Cells
NCI-H460 Lung; Pleural Effusion Carcinoma; Large Cell Lung
Epithelial
Cancer
H69AR Lung Carcinoma; Small Cell Lung
Epithelial
Cancer
HCC827 Lung Adenocarcinoma Epithelial
NCI-I11688 Lung; Derived From Carcinoma; Small Cell Lung
Epithelial
Metastatic Site: Liver Cancer
Prostate 22RV1 Prostate Carcinoma Epithelial
Pool DU145 Prostate; Derived From Carcinoma Epithelial
Metastatic Site: Brain
LnCaP Prostate; Derived From Carcinoma Epithelial
Metastatic Site: Left
Supraclavicular Lymph Node
PC3 Prostate; Derived From Carcinoma Epithelial
Metastatic Site: Bone
VCaP Prostate; Derived From Cancer Epithelial
Metastatic Site: Vertebral
Metastasis
Non-Cancer CCD-16Lu Lung Normal Fibroblast
Pool
CCD-19Lu Lung Normal Fibroblast
CCD841CoN Colon Normal Epithelial
CCD-18Co Colon Normal Fibroblast
HCC1143BL B Lymphoblast; Peripheral Normal
Lymphoblast
Blood Lymphocytes
NCI-BL1395 Peripheral Blood; B Normal
Lymphoblast
Lymphoblast; Epstein-Barr
Virus (EBV) Transformed
NCI-BL128 Peripheral Blood; B Normal
Lymphoblast
Lymphoblast; Epstein-Barr
Virus (EBV) Transformed
Primary Prostate Normal Epithelial
Prostate
Epithelial
Cells
PNT2 Prostate Normal Epithelial
100887] Nine rounds of enrichment were performed against the lung cancer
sample pool. The variable
regions of the top five most enriched sequences are shown in Table 20. The
enriched libraries consisted of
-167-
CA 03018066 2018-09-17
WO 2017/161357
PCT/US2017/023108
the Variable Region as shown in the table inserted between the flanking
sequences shown above as 5'
CTAGCATGACTGCAGTACGT (SEQ ID NO 4) - [Variable Region] ¨
CTGTCTCTTATACACATCTGACGCTGCCGACGA (SEQ ID NO 5). The sequences were also 5'
biotinylated. 25 ng of starting library was used in the enrichment. As control
sequences, the reverse
complements were synthesized as shown in Table 20. These are reverse
complements of the entire
oligonucleotides including the flanking regions. S1LCa25-R9S1RC-5'biotin and
S1LCa25-R9S3RC-
5'biotin are the reverse complements of S1LCa25-R9S1-5'biotin and S1LCa25-R9S3-
5'biotin,
respectively. The reverse complements can be used as negative controls as they
should not specifically
bind the targets of the enriched sequences.
Table 20: Lung Cancer Enriched Oligonucleotides
Sequence Variable Region (5'->3') SEQ ID
name NO.
Most S1LCa25- GGGGTTGTTTTGGGATGCCTTTTTCTCTGTATTTCA 2922
enriched R9S1-5'biotin
sequences S1LCa25- GTCCTCGCCCGGGCTTCTGTTTGTTTTTTGGATTCGA 2923
R9S2-5'biotin
S1LCa25- AACGCTTGATTTGGGIGGITGGATTGACCITITTATGA 2924
R9S3-5'biotin
S1LCa25- TTTTTTATTGGGTGCGCATAGGCGAGTGGTCTCTT 2925
R9S4-5'biotin
S1LCa25- TGATTACATCGCCTGTATGGGTTGTTGTTTGTGTC 2926
R9S5-5'biotin
Full Sequence (5'->3')
Reverse S1LCa25- TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGTGAAAT 2927
compleme R9S1RC- ACAGAGAAAAAGGCATCCCAAAACAACCCCACGTACTGC
nt 5'biotin AGTCATGCTAG
sequences S1LCa25- TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGTCATAA 2928
R9S3RC- AAAGGTCAATCCAACCACCCAAATCAAGCGTTACGTACT
5'biotin GCAGTCATGCTAG
[00888] Nine rounds of enrichment were also performed against the prostate
cancer sample pool. The
variable regions of various enriched sequences are shown in Table 21. The
amount of starting library used
in the enrichment is indicated in the table. The libraries consisted of the
Variable Region as shown in the
table inserted between the flanking sequences (SEQ ID NOs 4-5) as shown above.
After the enrichment,
the libraries were used to probe the cell pools and NGS was used to determine
the identity and counts of
the bound sequences. Table 21 shows the counts of sequences in prostate cancer
(PCA) or non-PCA and
the fold-change between PCA and non-PCA. Probing was performed in triplicate.
The sequences in Table
30 had a coefficient of variation (%CV) < 20% across normalized counts for
three probing replicates and
fold changes cancer / non-cancer < 0.6 or > 1.4. The average percent variation
(%CV) was ¨11% for the
PCA pools and ¨12% for the non-PCA pools.
Table 21: Prostate Cancer Enriched Oligonucleotides
PCA Non-PCA Fold
SEQ
Average Average Change -
Variable Region (5'->3')
ID NO normalize normalize Cancer/No
d counts d counts n-Cancer
-168-
CA 03018066 2018-09-17
WO 2017/161357
PCT/US2017/023108
Enrichment GGITTTATCGTTICITTAGTTGGGTICTIGGG 2929 475 346 1.4
with 5 ng TGA
initially GGATCTIGGITAGTATTITTGGTATITTCTGT 2930 415 300 1.4
GGT
GGATGCTGGITAGTATTITTGGTATITTCTGT 2931 564 408 1.4
GGT
TATTTAGGGGITGTGGGICTAATTTITGITTG 2932 551 397 1.4
TICGA
Enrichment TCCIGGITTCTGGTGGITTCATTTAGCTIGTT 2933 376 276 1.4
with 25 ng ACCTGA
initially TCCTGGITTCTGGTGGTITAATITTGCTIGTT 2934 934 687 1.4
ACATGA
TCCTGGTTTCTGGTGGTTTCATTTTGATTGTT 2935 2036 1485 1.4
ACCTGA
TITGGTIGGICCATGGGIAAGCTIGGTGATTC 2936 438 315 1.4
TCTTGA
TCCTGGITTCTGGTGGTITCATITTGCTIGTT 2937 2194 1565 1.4
ACATGA
Enrichment ACATGCACTGAGCCCGACACACCCGCCTGAAC 2938 361 570 0.6
with 50 ng TAT
initially ACTAATTGTITTGGGGGIAGTTGITITTITTC 2939 3984 2893 1.4
TGT
GGATCCIGGITAGTATTITTGGTATATTCTGT 2940 277 201 1.4
GGT
TATGITCTITTTATITTAGTGGITGIGGCCTA 2941 506 367 1.4
TCTA
[00889] The sequences above were 5' biotinylated for capture. As control
sequences, reverse complements
were synthesized as shown in Table 22. These are reverse complements of the
entire oligonucleotides
including the flanking regions. S1PCa5-R9S1RC-5'biotin and S1PCa25-R9S1RC-
5'biotin are the reverse
complements of the complete S1PCa5-R9S1-5'biotin and S1PCa25-R9S1-5'biotin
sequences with flanking
regions, respectively. The reverse complements can be used as negative
controls as they should not
specifically bind the targets of the enriched sequences.
Table 22: Prostate Cancer Enriched Oligonucleotides
Sequence Variable Region (5'->3') SEQ
ID NO
name
Enrichmen S1PCa5-R9S1- GGITTTATCGTTICTITAGTTGGGITCTIGGGTGA 2942
t with 5 ng 5'biotin
initially S1PCa5-R954- TATTTAGGGGTTGTGGGTCTAATTTTTGTTTGTTCG 2943
5'biotin A
Enrichmen S1PCa25- TCCTGGITTCTGGIGGITTCATTIAGCTIGTTACCT 2944
t with 25 R951-5'biotin GA
ng initially S1PCa25- TCCTGGITTCTGGIGGITTCATTITGCTIGTTACAT 2945
R9S5-5'biotin GA
Enrichmen S1PCa50- ACATGCACTGAGCCCGACACACCCGCCTGAACTAT 2946
t with 50 R951-5'biotin
ng initially S1PCa50- GGATCCIGGITAGTATTITTGGTATATTCTGIGGT 2947
R953-5'biotin
Full Sequence
Reverse S1PCa5- /5Biosg/TCGTCGGCAGCGTCAGATGTGTATAAGA 2948
compleme R9S1RC- GACAGTCACCCAAGAACCCAACTAAAGAAACGATAA
nt 5'biotin AACCACGTACTGCAGICATGCTAG
sequences
-169-
CA 03018066 2018-09-17
WO 2017/161357 PCT/US2017/023108
to 5 ng
library
Reverse S1PCa25- /5Biosg/TCGTCGGCAGCGTCAGATGTGTATAAGA 2949
compleme R9S1RC- GACAGTCAGGTAACAAGCTAAATGAAACCACCAGAA
nt 5'biotin ACCAGGAACGTACTGCAGTCATGCTAG
sequences
to 25 ng
library
[00890] Additional sequences as in Table 21 are shown in Table 23. Table 23
includes sequences with
%CV > 20%, as indicated.
Table 23: Additional Prostate Cancer Enriched Oligonucleotides
Prostate Non-Cancer
Cancer Pool Pool
Variable Region (5'->3') SEQ ID Average
% Average % Fold
NO normalize CV normaliz CV Change -
d counts ed counts
Cancer/Non
-Cancer
Enrichment AGTTCTTGGGGGTTTTGGTTGG 2950 670 10 266 41% 2.5
with5ng TGCCTTGTATGTTA
initially AGTICTIGGGGGITTIGGITGT 2951 11 60 1 0% 10.7
TGCCTTGTCTATTA
Enrichment TTGCCGCCCTTTATGGTTTGTT 2952 45 49 8 90% 5.4
with 25 ng TTTTGCGATGTGGGA
initially
[00891] Assays such as qPCR, cell enzyme linked assay (ELA), confocal
microscopy and cell viability
assays are performed to verify binding of oligonucleotides to cells and
identify potential cell killing
properties of certain oligonucleotides.
Example 15: Enrichment Protocol
[00892] Re-amplification of original F-TRin-35n-B oligonucleotide library.
[00893] Samples for one round of enrichment
[00894] 900,000 cells from pool of Prostate/ Lung cell lines (split 3 times in
300,000 each)
[00895] 900,000 cells from pool of Normal cell lines (split 3 times in 300,000
each)
[00896] Preparations
[00897] Pre-chill tabletop centrifuge at 4 C.
[00898] Bring 300,000 of Prostate/Lung cells to 140 ul with 1X PBS with 3mM
MgCl2 (138.6 ul PBS +
1.4 ul 300mM MgCl2), add competitors listed below and incubate for 20 min with
end-over-end rotation.
[00899] Mixture of two competitors: Salmon DNA+tRNA.
[00900] Competitor salmon DNA: add 800ng of salmon DNA (Stock lOug/u1 ->
Dilute 1:250 with 1X
PBS + 3 mM MgCl2 [40 ng/u1] -> 20u1 input).
[00901] Competitor tRNA: add 800ng of tRNA (Stock lOug/u1 -> Dilute 1:250 with
1X PBS + 3 mM
MgCl2 [40 ng/u11 -> 20u1 input).
-170-
CA 03018066 2018-09-17
WO 2017/161357 PCT/US2017/023108
[00902] Library / sample incubation (positive selection)
[00903] Prepare 5, 25, 50ng for first round and same corresponding for
following rounds of
oligonucleotide library in 20 ul of 1 x PBS with 3 mM MgCl2. After heating the
DNA for 3 min @ 95C,
put it on ice immediately for 5 min. Add DNA to the blocked cells and incubate
them for 30 min at RT,
with end-over-end rotation
[00904] Spinning cells
[00905] Spin cells from step II at 500x g for 5 min (spin at 4C) and discard
supernatant by pipetting it out.
[00906] Re-suspend pellet in lml of 1 X PBS + 3 mM MgCl2; vortex/mix and
centrifuge again at 500x g
for 5 min (spin at 4C)
[00907] Repeat the wash one more time.
[00908] Re-suspend pellet in 50 ul of water.
[00909] Use pellet in step IV.
[00910] Oligonucleotide elution
[00911] Add 25 ul of 0.1N NaOH to cells from III, incubate for 10 min at 50C,
mixmate and agitate for
sec at 550 rpm -> Add 25 ul of 0.1N HCL -> Spin at 12000 x g for 10 min at 4C -
> proceed with
NucleoSpin ssDNA purification MAKE SURE TO USE CORRECT BUFFER TO BIND (NTC)
ssDNA
(number of columns to be identified) -> Elute, each column in 20 ul of water
(incubation time before
elution is 5 min). Add 4 ul of 5X PBS+15mM MgCl2 solution, before proceeding
to the next enrichment.
[00912] Library / sample incubation (negative selection)
[00913] Bring 300,000 of Normal cells (depending on number of steps) to 140 ul
with 1 X PBS with 3
mM MgCl2 (138.6 ul PBS + 1.4 ul 300 mM MgCl2) and mix with the mixture of
competitors as described
above in step I.c (40 ul total), incubate for 20 min with end-over-end
rotation. Then, add eluted
oligonucleotide libraries (-20 ul) (heat treat 3 min@ 95C, put it on ice
immediately for 5 min) from step
IV and incubate 30 min at RT.
[00914] Spinning cells
[00915] Spin cells from step V at 500x g for 5 min (spin at 4C) and collect
supernatant.
[00916] Treatment of supernatant with NucleoSpin ssDNA purification. MAKE SURE
TO USE
CORRECT BUFFER TO BIND (NTC) ssDNA (number of columns to be identified) ->
Elute, each
column in 20 ul of water (incubation time before elution is 5 min).
[00917] Add 4 ul of 5X PBS+15mM MgCl2 solution, before proceeding to the next
enrichment.
[00918] Library / sample incubation (positive selection)
[00919] Bring 300,000 of Prostate / Lung cells to 140 ul with 1 x PBS with 3
mM MgCl2 (138.6 ul PBS +
1.4 ul 300 mM MgCl2) and mix with the mixture of competitors as described
above in step I.c (40 ul
total), incubate for 20 min with end-over-end rotation. Mix with libraries
from step VI (heat treat 3 min@
95C, put it on ice immediately for 5 min) and incubate for 30 min at RT with
end-over-end rotation.
[00920] Spinning cells
[00921] Spin cells from step VII at 500x g for 5 min (spin at 4C) and discard
supernatant by pipetting it
out.
-171-
CA 03018066 2018-09-17
WO 2017/161357 PCT/US2017/023108
[00922] Re-suspend pellet in lml of 1 X PBS + 3 mM MgCl2; vortex/mix and
centrifuge again at 500x g
for 5 min (spin at 4C).
[00923] Repeat the wash one more time.
[00924] Re-suspend pellet in 50 ul of water.
[00925] Follow the oligonucleotide elution (IV) and then nucleospin
purification to get the ssDNA in 20u1
water.
[00926] The ssDNA in water (20u1) will be used entirely for PCR amplification.
Example 16: Enrichment Protocol
[00927] Samples for one round of enrichment
[00928] 900,000 cells from pool of Prostate/ Lung cell lines (split 3 times in
300,000 each)
[00929] 900,000 cells from pool of Normal cell lines (split 3 times in 300,000
each)
[00930] No cells enrichment for every library input
Table 24: Buffers
Exp. ID Buffers
B1 PBS + 3mM MgCl2
B2 PBS + 3mM MgCl2 + 0.5% F-127 + 0.5% PEG4000
B3 PBS + 3mM MgCl2 + 0.5% F-127 + lmg/m1HSA
[00931] Or the titers of buffer with F-127 and H SA ¨ F-127 @ 0.5, 1 and 2%
[00932] Cells are available in 1X PBS + 3mM MgCl2 buffer and need to be
transferred.
100933]!. Preparations
[00934] Pre-chill tabletop centrifuge at 4 C.
[00935] Transfer 300,000 cancer cells ¨ 140u1 into 3 fresh tubes. Spin at 500x
g for 5mins. Remove the
supernatant buffer and add 70u1 of the buffer B2.
[00936] Add competitors listed below and incubate for 20 min with end-over-end
rotation.
[00937] Mixture of two competitors:
a. Competitor salmon DNA: add 800ng of salmon DNA (Stock lOug/u1 -> Dilute
1:125 with
B2 180 ng/u1] -> lOul input).
b. Competitor t-RNA: add 800ng of tRNA (Stock lOug/u1 -> Dilute 1:125 with
B2 180
ng/u11 -> lOul input).
[00938] Bring up the volume to 180u1 with 90u1 of Buffer B2, for the blocking.
100939]!!. Library! sample incubation (positive selection)
[00940] Prepare 5/25/50ng of F-TRin-35n-B Starting Library for first round in
20u1 of buffer B2. After
heating the DNA for 3 mm @ 95C, put it on ice immediately for 5 min. Add DNA
to the blocked cells
and incubate them for 30 min at RT, with end-over-end rotation.
100941]!!!. Spinning cells
[00942] Spin cells from step II at 500x g for 5 min at 4C and discard
supernatant by pipetting it out.
[00943] Re-suspend pellet in lml of B2; vortex and centrifuge again at 500x g
for 5 mm at 4C.
[00944] Repeat the wash one more time. (Additional Wash)
-172-
CA 03018066 2018-09-17
WO 2017/161357 PCT/US2017/023108
[00945] Re-suspend pellet in 30u1 of buffer B2.
[00946] Use pellet in step IV.
[00947] IV. Oligonucleotide elution
[00948] Add lOul of 0.25N NaOH to cells from III, incubate for 10 min at 50C,
mix-mate and agitate for
5-10 sec at 550 rpm -> Add lOul of 0.25N HCL -> Spin at 16000 x g for 10 min
at 4C. Collect the
supernatant; this will be used as library for the next step.
[00949] V. Library / sample incubation (negative selection)
[00950] Transfer 300,000 normal cells ¨ 140u1 into 3 fresh tubes. Spin @ 500x
g for 5mins. Remove the
supernatant buffer and add 70u1 of the buffer B2.
100951] Mix with the mixture of competitors (10u1 of Salmon sperm DNA @
80ng/u1 + lOul of Yeast t-
RNA @ 8011g/u1), bring up the volume to 150u1 (add 60u1) of Buffer B2,
incubate for 20 min with end-
over-end rotation. Then, add eluted oligonucleotide libraries (-50 ul) (heat
treat for 3 min@ 95C, put it on
ice immediately for 5 min) from step IV and incubate 30 min at RT.
[00952] VI. Spinning cells
[00953] Spin cells from step V at 500x g for 5 min at 4C and collect
supernatant as library for next step
(200u1).
[00954] VII. Library / sample incubation (positive selection)
[00955] Transfer 300,000 cancer cells ¨ 140u1 into 3 fresh tubes. Spin at 500x
g for 5mins. Remove the
supernatant buffer and add 70u1 of the buffer B2.
[00956] Mix with the mixture of competitors (10u1 of Salmon sperm DNA @
80ng/u1 + lOul of Yeast t-
RNA @ 80ng/u1), incubate for 20 min with end-over-end rotation. Mix with
libraries from step VI (heat
treat 3 min@ 95C, put it on ice immediately for 5 min) and incubate for 30 min
at RT with end-over-end
rotation (total 290u1).
[00957] VIII. Spinning cells
[00958] Spin cells from step VII at 500x g for 5 min at 4C and discard
supernatant by pipetting it out.
[00959] Re-suspend pellet in lml of B2; vortex and centrifuge again at 500x g
for 5 min at 4C.
[00960] Repeat the wash one more time. (Additional Wash)
[00961] Re-suspend pellet in 50u1 of water; it will be used entirely for PCR
amplification.
Example 17: Oligonucleotide pools to characterize cell line microvesicles
[00962] In this Example, an oligonucleotide library was enriched using
microvesicles shed from various
cancer cell lines. The enrichment is performed as in Example 14 as above
except that the sample
comprised microvesicles as opposed to cells. This method can be performed to
identify disease specific
oligonucleotides and oligonucleotide pools that can be used in various
applications, including without
limitation diagnostic assays, as drugs or in dnig delivery.
[00963] The unscreened library comprised F-Trin-B primers (i.e., 5'
CTAGCATGACTGCAGTACGT (SEQ
ID NO 4) and 5' CTGICTCTTATACACATCTGACGCTGCCGACGA (SEQ ID NO 5)) flanking a
random
variable region. Enrichment was performed on microvesicles from cell lines as
described further in
Example 18 below. FIG. 14A shows copies per species of five rounds of
enrichment on exosomes from
-173-
CA 03018066 2018-09-17
WO 2017/161357
PCT/US2017/023108
VCaP and LNCaP cells as indicated in the figure. Positive selection was
performed on VCAP
microvesicles shed from VCAP cells and negative selection was performed on
LNCaP microvesicles shed
from LNCaP cells. The figure shows that the copies numbers of various
oligonucleotide probe species
increased with each round, indicating that the oligonucleotide probe library
is being enriched with those
species. The variable regions of several enriched oligonucleotide probes are
shown in Table 25. The
probes are 5' biotinylated. These probes are from the enrichment performed
with 5 ng library on
exosomes from VCaP and LnCaP cells. Table 25 shows nine sequences with fold
changes of at least 4.0-
fold elevated in VCaP versus LNCaP. Each sequence also had averaged normalized
counts of at least 500
for probing on VCaP exosomes. Fold changes are shown in the table. FIG. 14B
shows copies recovered
after probing (see Example below for protocol) with the nine oligonucleotide
probes in the table. Also as
shown in the table, the reverse complement of the entire probe sequences
(i.e., including the F-Trin-B
primers shown above) are used as controls.
Table 25: Variable Regions of Oligonucleotide probes
Variable Regions (5'->3') SEQ ID Fold
NO
Change
(VCaP /
LNCaP)
ATATGGGGTTTATGGGGATGGTGTTATGGGTGGAATGA 2953 5.4
ATGGGGAGGGGGGTAGGCTGTCTTAATTGGTGGTT 2954 4.3
ATTAATGGGTGGGGGGTTTAGCTTGATGTGGGTTGTGA 2955 4.0
GAATGGGGGGATACTGTTAGTGTGGGTCTGGGGGT 2956 6.7
GGCGGGGGCTITTTATGGITTCTGGGCGACCTGCT 2957 4.9
GGIGATGAATTAAATGGGGGGGGTATCAAGTGIGGA 2958 6.5
TACTTAATTGGGGGGGGGGATTCTGTITTGTCTCT 2959 6.2
TAGCCTTTGGGGGTTGTTTTGGGGGATTGGGTTGTTGA 2960 6.3
TAGTGACTACGGGTATGGGGATTGGGGGTTTGGTTTGA 2961 4.5
Reverse Complements (5'->3') SEQ
ID
NO
/5Biosg/TCGTCGGCAGCGTCAGATGIGTATAAGAGACAGTCATTCCACCCATAACACCA 2962
TCCCCATAAACCCCATATACGTACTGCAGTCATGCTAG
/5Biosg/TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGAACCACCAATTAAGACAGCC 2963
TACCCCCCTCCCCATACGTACTGCAGTCATGCTAG
/5Biosg/TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGTCACAACCCACATCAAGCTA 2964
AACCCCCCACCCATTAATACGTACTGCAGTCATGCTAG
/5Biosg/TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGACCCCCAGACCCACACTAAC 2965
AGTATCCCCCCATTCACGTACTGCAGTCATGCTAG
/5Biosg/TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGAGCAGGTCCCCCAGAAACCA 2966
TAAAAAGCCCCCCCCACGTACTGCAGICATGCTAG
/5Biosg/TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGTCCACACTTGATACCCCCCC 2967
CATTTAATTCATCACCACGTACTGCAGTCATGCTAG
/5Biosg/TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGAGAGACAAAACAGAATCCCC 2968
CCCCCCAATTAAGTAACGTACTGCAGTCATGCTAG
/5Biosg/TCGTCGGCAGCGTCAGATGIGTATAAGAGACAGTCAACAACCCAATCCCCCAA 2969
AACAACCCCCAAAGGCTAACGTACTGCAGTCATGCTAG
/5Biosg/TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGTCAAACCAAACCCCCAATCC 2970
CCATACCCGTAGICACTAACGTACTGCAGICATGCTAG
-174-
CA 03018066 2018-09-17
WO 2017/161357 PCT/US2017/023108
[00964] FIG. 14C shows higher recovery on six out of seven batches of isolated
VCaP exosomes
compared to exosomes from LNCaP cells as seen by probing with a library of the
nine individual DNA
sequences in Table 25. The figure also shows probing with the reverse
complement controls. As expected,
these sequences showed little recovery with the exosomes as compared to the
oligonucleotide probe
sequences with variable regions SEQ ID NOs 2953-2961.
[00965] Several proteins have been identified by probing of exosomes from VCaP
cells with an aptamer
having variable region 5 -TACTTAATTGGGGGGGGGGATTCTGTTTTGTCTCT-3 (i.e., SEQ ID
NO
2959) followed by pull downs and analysis by mass spectrometry. See Example 9
for methodology.
Exemplary results are shown in Table 26. These experiments identified key
proteins in the regulation of
exosome biogenesis (ESCRT, Syntenin) and endocytic trafficking (chemokine
CXCL11) overexpressed in
Cancer. The ESCRT machinery (ESCRT-0, I, II and III) participates in exosomes
biogenesis and the
proteins have been observed to be overexpressed in human cancers. See, e.g,
Kowal et al., Biogenesis and
secrection of exosomes, Current Opinion in Cell Biology, 2014, 29:116-125;
Hurley and Hanson,
Membrane budding and scission by the ESCRT machinery: it's all in the neck,
Nat Rev Mol Cell Biol,
2010 11:556-566; Raiborg and Stenmark, The ESCRT machinery in endosomal
sorting of ubiquitylated
membrane proteins, Nature 2009 458: 45-52, all of which proteins are
incorporated by reference herein in
their entirety. The experiments further identified cold shock proteins whose
miRNA suppression
sensitizes cells to chemotherapeutic agents.
Table 26: Proteins from VCaP exosomes pulled down with Sequence 7
Accession Description Cellular role
014625 C-X-C motif chemokine 11 GN= CXCL11 chemokine that is
overexpressed in blood
(also Interferon-inducible T-cell and tissue of men with advanced
prostate
alpha chemoattractant (I-TAC)) adenocarcinomas
Q92616 Translational activator GCN1 GN= GCN1
Q9H444 Charged multivesicular body protein 4b ESCRT-III; membrane
scission
GN= CHMP4B
Q14767 Latent-transforming growth factor beta-
binding protein 2 GN= LTBP2
P26599-3 Isoform 3 of Polypyrimidine tract-binding cancer associated
splicing factor
protein 1 GN= PTBP1 (also Heterogeneous
nuclear ribonucleoprotein I (hnRNP I))
P98179 RNA-binding protein 3 GN= RBM3 part of ESCRT-III; membrane
scission;
cold shock protein. Knock-down has been
shown to enhance chemotherapeutic cell
killing of prostate cells
043633 Charged multivesicular body protein 2a
GN= CHMP2A
P62888 60S ribosomal protein L30 GN= RPL30
Q9UK41-2 Isoform 2 of Vacuolar protein sorting- part of ESCRT-I;
membrane budding with
associated protein 28 homolog GN= VPS28 ESCRT-II
060884 DnaJ homolog subfamily A member 2 GN=
DNAJA2
Q14011-3 Isoform 3 of Cold-inducible RNA-binding cold shock protein.
Knock-down has been
protein GN= CIRBP (A18 hnRNP) shown to enhance chemotherapeutic
cell
killing of prostate cells
Q8N684-3 Cleavage and polyadenylation specificity
-175-
CA 03018066 2018-09-17
WO 2017/161357 PCT/US2017/023108
factor subunit 7 GN= CPSF7
P05109 Protein S100-A8 GN= S100A8
P05386 60S acidic ribosomal protein P1 GN=
RPLP1
Q7LBR1 Charged multivesicular body protein lb associated to ESCRT-III;
regulation of
GN= CHMP1B membrane scission and ESCRT-III
disassembly
000560-1 Syntenin-1 GN= SDCBP adaptor protein that binds to
syndecans
and ALIX which interacts with multiple
ESCRT proteins
[00966] Negative controls from the above enrichment with 5 ng library on
exosomes from VCaP and
LnCaP cells were also identified. Several are shown in Table 27. The Table
shows 3 sequences with fold
changes of at least 4.0 higher on LNCaP exosomes and 2 sequences with fold
changes of 1 (indicating no
fold change between VCaP and LNCaP exosomes). The variable regions are shown
in Table 27. Also as
shown in the table, the reverse complement of the entire probe sequences
(i.e., including the F-Trin-B
primers shown above) are used as controls.
Table 27: Variable Regions of Oligonucleotide probes
Variable Regions (5'->3') SEQ ID Fold
NO.
change
(VCaP /
LNCaP)
TCCGTTTATCTACTTTTCCGGTACTGTTCCCGTTT 2971 0.2
ATCGCGTCGCCCCCGGATATTATTGTTTCTTGTTC 2972 0.2
TTGCTTGCCCGGCCATAAACACGATCITGITCTCTA 2973 0.2
GATACGGTCTTTGGTGCTTGTGTGAATCTATGGGGTGA 2974 1.0
TCCTGGTTTCTGGTGGTTTATTTAGCTTGTTACCTGA 2975 1.0
AGTGGGTGGTGGGTTCGGTTTGCTTGGTTCCCTGTTGA 2976
ATTGAGGTGGTTTTGAGGTGGGCTATCTGAGGGAT 2977
GGGGGGGGCTTTTTATGGTTTCTGGGGGACCTGCT 2978
ATATGGGGTTTATGGGGATGGTGTTATGGGTGGAATGT 2979
SEQ ID
Reverse Complements (5'->3')
NO
/5Biosg/TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGAAACGGGAACAGTACCGGAAA 2980
AGTAGATAAACGGAACGTACTGCAGTCATGCTAG
/5Biosg/TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGGAACAAGAAACAATAATATCC 2981
GGGGGCGACGCGATACGTACTGCAGTCATGCTAG
/5Biosg/TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGTAGAGAACAAGATCGTGTTTA 2982
TGGCCGGGCAAGCAAACGTACTGCAGTCATGCTAG
/5Biosg/TCGTCGGCAGCGTCAGATGIGTATAAGAGACAGTCACCCCATAGATTCACACAA 2983
GCACCAAAGACCGTATCACGTACTGCAGTCATGCTAG
/5Biosg/TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGTCAGGTAACAAGCTAAATAAA 2984
CCACCAGAAACCAGGAACGTACTGCAGTCATGCTAG
/5Biosg/TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGTCAACAGGGAACCAAGCAAAC 2985
CGAACCCACCACCCACTACGTACTGCAGTCATGCTAG
/5Biosg/TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGATCCCTCAGATAGCCCACCTC 2986
AAAACCACCTCAATACGTACTGCAGTCATGCTAG
/5Biosg/TCGTCGGCAGCGTCAGATGIGTATAAGAGACAGAGCAGGICCCCCAGAAACCAT 2987
-176-
CA 03018066 2018-09-17
WO 2017/161357 PCT/US2017/023108
AAAAAGCCCCCCCCACGTACTGCAGTCATGCTAG
/5Biosg/TCGTCGGCAGCGTCAGATGIGTATAAGAGACAGACATTCCACCCATAACACCAT 2988
CCCCATAAACCCCATATACGTACTGCAGTCATGCTAG
[00967] Assays such as qPCR, cell enzyme linked assay (ELA), confocal
microscopy and cell viability
assays are performed to verify binding of oligonucleotides to cells and
identify potential cell killing
properties of certain oligonucleotides.
Example 18: Enrichment Protocol for Microvesicles
[00968] Samples:
[00969] Experiment 1: (F98 cells: Organism: Rattus norvegicus; Cell Type:
Glioblastoma; Tissue: brain;
Disease: undifferentiated malignant glioma)
[00970] 25 ug of microvesicles from transfected F98 cells (EGFR+) for each
positive step
[00971] 25 ug of microvesicles from parental F98 cells for each negative step
[00972] Experiment 2: (Prostate Cancer cell lines)
[00973] 25 ug of microvesicles from VCaP cells for each positive step
[00974] 25 ug of microvesicles from LnCaP cells for each negative step
[00975] Controls:
[00976] Reaction buffer with no microvesicles for each positive and negative
step
[00977] Reaction buffer: 1xPBS + 3 mM MgCl2 + 0.5% F127 + 1 mg/ml HSA
[00978] Sample preparation: prepare 25 ug of microvesicles in 35 ul 1xPBS and
add 35 ul of 1xPBS + 6
mM MgCl2 + 1% F127 + 2 mg/ml HSA to obtain 25 ug of microvesicles in 70 ul of
1xPBS + 3 mM
MgCl2 + 0.5% F127 + 1 mg/ml HSA
[00979] Enrichment scheme:
[00980] First round: only positive step
[00981] Second round: positive step -> negative step -> positive step
[00982] Third round: positive step -> negative step -> positive step
[00983] Fourth round: positive step -> negative step -> positive step
[00984] Each round ends with PCR followed by purification of ssDNA after gel
electrophoresis
100985]!. Preparations
[00986] a) Pre-chill tabletop centrifuge at 4 C.
[00987] b) Add competitors as listed below to each 25 ug of transfected F98 or
VCaP microvesicles in 70
ul reaction buffer and incubate for 20 min with shaking at 500 rpm on mixmate.
[00988] c) Mixture of two competitors:
[00989] Competitor salmon DNA: add 800 ng of salmon DNA (Stock 10 ug/ul ->
Dilute 1:125 with
reaction buffer 180 ng/ul] -> 10 ul input).
[00990] Competitor t-RNA: add 800 ng of tRNA (Stock 10 ug/ul -> Dilute 1:125
with reaction buffer [80
ngiull -> 10 ul input).
[00991] d) Bring the volume to 180 ul with 90 ul of reaction buffer, for the
blocking.
100992]!!. Library / sample incubation (positive selection)
-177-
CA 03018066 2018-09-17
WO 2017/161357 PCT/US2017/023108
[00993] Prepare 5 ng and 50 ng of F-TRin-35n-B Starting Library for first
round in 20u1 of reaction
buffer. After heating the DNA for 3 min @ 95C, put it on ice immediately for 5
min. Add DNA to the
blocked cells and incubate them for 30 min at RT, with end-over-end rotation.
100994]!!!. Precipitation protocol with 6% PEG8000
[00995] a) Use microvesicles from step II as sample.
[00996] b) Add 200 ul of 12% PEG8000 to 200 ul of sample.
[00997] c) Leave sample on ice for 30 min.
[00998] d) Spin at 16000 x g for 10 min and discard supernatant.
[00999] e) Re-suspend pellet in 200 ul reaction buffer and centrifuge again at
16000xg for 10 min
[001000] f) Re-suspend pellet in 30 ul of reaction buffer.
[001001] g) First round: go straight to PCR. Following rounds: go to IV.
[001002] IV. Oligonucleotide probe elution
[001003] Add 10 ul of 0.25N NaOH to cells from III, incubate for 10 min at
50C, mix-mate and
agitate for 5-10 sec at 550 rpm -> Add 10 ul of 0.25 N HCL -> Spin at 16000 x
g for 10 min at 4C.
Collect the supernatant; this will be used as library for the next step.
[001004] V. Library / sample incubation (negative selection)
[001005] To each 25 ug of parental F98 or LnCaP exsomes in 70 ul reaction
buffer add the mixture
of competitors (10 ul of Salmon sperm DNA @ 80 ng/ul + 10 ul of Yeast t-RNA @
80 ng/ul), bring the
volume to 150 ul by addition of 60 ul reaction buffer and incubate for 20 min
with shaking at 500 rpm on
mixmate. Then add eluted oligonucleotide probe libraries (-50 ul) (heat treat
for 3 min@ 95C, incubate
on ice immediately for 5 min) from step IV and incubate 30 min at room
temperature (RT).
[001006] VI. Precipitation protocol with 6% PEG8000 (using sample from III)
[001007] a) Use microvesicles / DNA mixture from step V.
[001008] b) Add 200 ul of 12% PEG8000 to 200 ul of sample.
[001009] c) Leave sample on ice for 30 min.
[001010] d) Spin at 16000 x g for 10 min and collect supernatant.
[001011] VII. Library / sample incubation (positive selection)
[001012] To each 25 ug of transfected F98 or VCaP exsomes in 70 ul reaction
buffer add the
mixture of competitors (10 ul of Salmon sperm DNA @ 80 ng/ul + 10 ul of Yeast
t-RNA @ 80 ng/ul) and
incubate for 20 min with shaking at 500 rpm on mixmate. Then, add
oligonucleotide probe libraries (-400
ul) (heat treat for 3 min@ 95C, put it on ice immediately for 5 min) from step
VI and incubate 30 min at
RT (total volume of 490 ul).
[001013] VIII. Precipitation protocol with 6% PEG8000
[001014] a) Use microvesicles from step VII as sample.
[001015] b) Add 490 ul of 12% PEG8000 to 490 ul of sample.
[001016] c) Leave sample on ice for 30 min.
[001017] d) Spin at 16000 x g for 10 min and discard supernatant.
[001018] e) Re-suspend pellet in 200 ul reaction buffer and centrifuge
again at 16000xg for 10 min
-178-
CA 03018066 2018-09-17
WO 2017/161357 PCT/US2017/023108
[001019] f) Re-suspend pellet in 30 ul of reaction buffer.
[001020] g) Go to PCR.
[001021] Probing
[001022] Exosomes can be probed with the enriched oligonucleotide probe
libraries. For these
experiments, exosomes are contacted with ssDNA enriched oligonucleotide probe
libraries, precipitated
with 6% PEG8000, and the co-precipitated oligonucleotide probes are amplified
by qPCR.
Example 19: Oligonucleotide enrichment on HER2+ tissue samples
[001023] Receptor tyrosine-protein kinase erbB-2 (ERBB2) is a protein
encoded by the ERBB2
gene, which is also frequently called HER2 (human epidermal growth factor
receptor 2) or HER2/neu.
About 20% of breast cancers overexpress the HER2 gene, which causes cells to
receive improper signals
to grow and divide. HER2+ cancers tend to be aggressive and fast-growing. For
individuals with HER2+
breast cancers, the anti-HER2 monoclonal antibody trastuzumab (trade name
Herceptin) has been shown
to dramatically reduce the risk of recurrence.
[001024] In this Example, we enriched a naive F-Trim-B oligonucleotide
probe library against
HER2 positive (HER2+) fixed tissue samples. The probe library is as described
herein, i.e., each member
has a 5' primer CTAGCATGACTGCAGTACGT (SEQ ID NO 4) and a 3' primer
CTGICICTTATACACATCTGACGCTGCCGACGA (SEQ ID NO 5) surrounding a variable region.
Enrichment was performed as described herein using six rounds of selection
against FFPE (fresh frozen
paraffin embedded) tissue from five patients with HER2+ invasive breast cancer
(the HER2+ cohort) and
six patients with HER2- invasive breast cancer (the HER2- cohort). HER2 status
was determined by IHC
assay. The blocking buffer used during selection comprised Salmon sperm DNA,
tRNA, F127 polymer,
and BSA protein. The enrichment scheme is detailed in FIG. 15A. As indicated
in the figure, rounds 1-3
were performed using positive selection only (i.e., to enrich binders to the
HER2+ samples). Rounds 4-6
used both positive selection against the HER2+ samples and negative selection
against the HER2-
samples. The enriched library at the end of round 6 was used in further
studies as the Enriched Probing
Library. Attributes of the Enriched Probing Library are shown in FIG. 15B,
wherein the number of
unique valid sequences is plotted against the numbers of copies of each
sequence, as determined by NGS.
The Enriched Probing Library comprised 3.6 x 10 unique sequences. The variable
regions of the 50 most
prevalent sequences are listed in order of highest prevalence to lower
prevalence in SEQ ID NOs 2989-
3038.
[001025] The Enriched Probing Library was used to stain HER2+ and HER2-
breast cancer tissue.
FIG. 15C shows representative staining of a HER2+ tumor sample after no
enrichment (Round 0, "RO" in
the figure, left panel) or after the six rounds of enrichment (post-Round 6,
"R6" in the figure, right panel).
As seen in the figure, much higher amounts of stain were observed with the
enriched R6 probe library as
compared to the naive RO library. Similarly, FIG. 15D shows representative
staining of a HER2- tumor
sample after no enrichment (RO, left panel) or after the six rounds of
enrichment (R6, right panel). As seen
in the figure, little to no staining was observed with either the enriched R6
probe library or the naive RO
library.
-179-
CA 03018066 2018-09-17
WO 2017/161357 PCT/US2017/023108
[001026] To identify specific members of the Enriched Probing Library that
bind HER2, the
experimental plan outlined in FIG. 15E was performed. Recombinant HER2 carring
a histadine tag
("recHer2 His Tag") was conjugated to magnetic beads ("Ni magnetic beads").
The beads were mixed
with the Enriched Probing Library ("Oligonucleotide library") and allowed to
incubate to allow binding of
probes to the HER2 beads. The bound beads were washed and probe binders were
recovered and
identified by next generation sequencing (NGS). Similar experiments were
performed with negative
controls to filter out probes that bind assay components, including No protein
beads and Non-enriched
library. A known HER2 aptamer was used as a positive control. The experiments
were performed twice
and a number of filters were applied, such as sequences that appeared in both
sets of binding experiments
and did not bind the protein beads. With all controls filtered out, there were
404 sequences remaining. The
variable regions of the most prevalent sequences, ordered by prevalence, are
listed as SEQ ID NOs 3039-
3061. These sequences are ordered individually and used in an immunoassay
format to identify HER2
binders.
[001027] We next explored targets of the R6 library. The R6 library and the
unenriched RO library
were amplified with a Biotin-C3-C6-amine primer. The libraries were TBE gel
purified, conjugated with
the amine reactive diazirine crosslinker, Sulfo-NHS-SS-Diazirine (Sulfo-SDAD)
(sulfosuccinimidyl 2-
[(4,4'-azipentanamido)ethy1]-1,3'- dithioproprionate) (Thermo Scientific) and
purified by HPLC to
remove the unconjugated oligonucleotides. The SDAD conjugated library was then
qualified for staining
HER2+ or HER2- FFPE tissue slides compared to the biotinylated library used
for enrichment as detailed
above.
[001028] Binding of the conjugated library was done under similar
conditions used for the selection
on HER2+ or HER2- tissue on a Ventana Discovery Ultra instrument (Ventana
Medical Systems, Tucson,
AZ). One set of slides for each tissue (HER2+ or HER2) were stained with the
R6 library, the RO library,
or no library to assess the level of specific binding. In parallel, nine
slides per condition was removed
prior to detection with Streptavidin-horse radish peroxidase (Strept-HRP) and
were subjected to photo-
crosslinking 2 cm above the slide at 365 nm with a handheld UV light for 10
minutes on ice. Slides were
then scraped into QProteome buffer without beta-mercaptoethanol added (Qiagen)
and extracted
according to manufacturer's instructions. Detergent was removed with HiPPR
detergent removal columns
(Thermo Fisher Scientific) and protein concentration was then determined with
the BCA assay. Cross-
linked protein-aptamer complexes were then affinity purified from 200 jag of
FFPE tissue lysate by
incubation with 10 L of Dynabeads0 MyOneTM Streptavidin Cl (Thermo Scientific)
for 30 mills at room
temperature, washed twice with lx TBS, washed twice with high stringency wash
buffer (10mM Tris, 2M
NaCl, 1mM EDTA, 1% Triton X-100), followed by two washes with low stringency
wash buffer to
remove the NaCl, resuspended in 1X PBS and eluted by boiling in 1X lauryl
dodecyl sulfate (LDS) with
reducing agent. Reducing the samples transfers the crosslinker from the
aptamer to the protein targets.
The reduced samples were run under reducing conditions in a 4-12% SDS-PAGE gel
at 150 volts for 15
min. The entire lane was excised and subjected to in-gel trypsin digestion.
Alkylation with iodoacetamide
-180-
CA 03018066 2018-09-17
WO 2017/161357 PCT/US2017/023108
was replaced with Iodoacetyl Tandem Mass TagTm (iodoTMT; Thermo Fisher
Scientific) to facilitate
identification of crosslinked targets by LC-MS/MS.
[001029] Results for one HER2+ case are shown in Table 28. These results
were filtered to remove
proteins that also cross-linked with the unenriched RO library. Background
binding with the RO library
appeared to be most prevalent in the nucleus. The table indicates whether the
identified proteins have been
reported in association with HER2 or breast cancer (BrCa) or a clinical trial
(for any indication), or have
been used or suggested as a drug target for any indication. References are
noted in brackets.
Table 28: Targets of R6 Identified for One HER2+ Tissue Sample
Accession Gene ID Description Her2 or BrCa related? Drug Clinical
Target Trial
P60709 ACTB Actin, cytoplasmic 1 Her2 and ATPase2 in actin
rich membrane domains [1]
P14618 PKM Pyruvate kinase PKM Early marker for response to Yes
Yes
trastuzumab therapy-tumor
M2-PK (alias for PKM)
determination in the plasma
of patients with metastasized
breast cancer could be a
helpful tool for monitoring
therapeutic
success. Dichloroacetate
(DCA, an inhibitor of the
mitochondrial pyruvate
dehydrogenase kinase) was
able to depolarize cancer (but
not normal) mitochondria
and induce apoptosis in
cancer but not normal tissues
[2]
P17858-1 PFKL ATP-dependent 6- pentose phosphate pathway Yes
Yes
phosphofructokinase, liver gene; hexokinase-2, a key
type mediator of aerobic
glycolysis, and the
downstream proteins PFKL
and EN01; activated by p53
[31
P25705-1 ATP5A1 ATP synthase subunit Ectopic ATP synthase is a Yes
Yes
alpha, mitochondrial drug target for breast cancer;
ATP synthase inhibitor
citreoviridin [4], [5]
P06576 ATP5B ATP synthase subunit beta, Ectopic ATP synthase is a Yes
Yes
mitochondrial drug target for breast cancer;
ATP synthase inhibitor
citreoviridin [4], [5]
P47914 RPL29 60S ribosomal protein L29 up in MCF-7 with treated Yes
with recombinant bromelain
vs untreated MCF-7 [6]
P62917 RPL8 60S ribosomal protein L8 The RPL8 antigen
may Yes
represent a relevant vaccine
target for patients with
melanoma, glioma, and
breast carcinoma whose
tumors express this protein
-181-
CA 03018066 2018-09-17
WO 2017/161357 PCT/US2017/023108
I71
Q8TEJ3 SH3RF3 SH3 domain-containing E3 ligase activity; anti- Yes
RING finger protein 3 apoptotic regulator for the c-
Jun N-terminal kinase (JNK)
pathway [8], [9]
P21802 FGFR2 Fibroblast growth factor Target for triple
negative Bca Yes Yes
receptor 2 therapies. Gain of function
mutations in FGFRs were
also identified in a variety of
human cancers such as
myeloproliferative
syndromes, lymphomas,
prostate and breast cancers as
well as other malignant
diseases [10], [11]
P02675 FGB Fibrinogen beta chain High plasma fibrinogen is Yes
Yes
correlated with poor response
to trastuzumab treatment in
HER2 positive breast cancer
[12]
060506 SYNCRIP Heterogeneous nuclear Component of the hepatocyte
ribonucleoprotein Q exosomal machinery
controlling microrna sorting
[001030] References in Table 28:
[001031] [1] Jeong et al., PMCA2 regulates HER2 protein kinase localization
and signaling and
promotes HER2-mediated breast cancer, PNAS, E282¨E290 (pub'd online Jan 4,
2016).
[001032] [2] Hoopmann et al., Tumor M2 pyruvate kinase--determination in
breast cancer patients
receiving trastuzumab therapy. Cancer Lett. 2002 Dec 10;187(1-2):223-8.
[001033] [3] Liu et al, Comprehensive Proteomics Analysis Reveals Metabolic
Reprogramming of
Tumor-Associated Macrophages Stimulated by the Tumor Microenvironment. J
Proteome Res. 2017 Jan
6;16(1):288-297.
[001034] [4] Chang et al., Combination therapy targeting ectopic ATP
synthase and 26S
proteasome induces ER stress in breast cancer cells, Cell Death and Disease
(2014) 5, e1540
[001035] [5] Pan et al., ATP synthase ecto-a-subunit: a novel therapeutic
target for breast cancer,
Journal of Translational Medicine 2011, 9:211
[001036] [6] Fouz et al., Gene expression analysis in MCF-7 breast cancer
cells treated with
recombinant bromelain. Appl Biochem Biotechnol. 2014 Aug;173(7):1618-39.
[001037] [7] Swoboda, et al., Shared MHC Class II¨Dependent Melanoma
Ribosomal Protein L8
Identified by Phage Display. Cancer Res 2007; 67: (8). April 15, 2007
[001038] [8] Karkkainen et al., POSH2 is a RING finger E3 ligase with Racl
binding activity
through a partial CRIB domain. FEBS Lett. 2010 Sep 24;584(18):3867-72
[001039] [9] Wilhelm et al., Sh3rf2/POSHER protein promotes cell survival
by ring-mediated
proteasomal degradation of the c-Jun N-terminal kinase scaffold POSH (Plenty
of SH3s) protein. J Biol
Chem. 2012 Jan 13;287(3):2247-56.
-182-
CA 03018066 2018-09-17
WO 2017/161357 PCT/US2017/023108
[001040] [10] Eswarakumar et al., Cellular signaling by fibroblast growth
factor receptors.
Cytokine Growth Factor Rev. 2005 Apr;16(2):139-49
[001041] [11] Wang and Guda. Integrative exploration of genomic profiles
for triple negative
breast cancer identifies potential drug targets. Medicine (Baltimore). 2016
Jul;95(30):e4321.
[001042] [12] Liu et al., High Plasma Fibrinogen is Correlated With Poor
Response to
Trastuzumab Treatment in HER2 Positive Breast Cancer, Medicine. 94(5) February
2015.
[001043] [13] Santangelo et al., The RNA-Binding Protein SYNCRIP Is a
Component of the
Hepatocyte Exosomal Machinery Controlling MicroRNA Sorting. Cell Rep. 2016 Oct
11;17(3):799-808.
[001044] This Example presents an approach wherein oligonucleotide probes
can be identified
using tissue sample input. The resulting oligonucleotides can be used to
identify HER2+ tissue samples
and distinguish HER2- tissues. General applications of this approach include
without limitation
identifying predictive biomarkers and identifying drug targets. In this
specific case, oligonucleotide
probes are identified that indicate aggressive phenotype (i.e., HER2+ tumors
are known to be aggressive)
but that can be targeted by anti-HER2 treatments. We also identified certain
targets of the R6 library in a
HER2+ breast cancer sample and specifically identified several drug targets.
Moreover, the
oligonucleotides themselves can be used to target these proteins, and thus
comprise drug candidates at the
same time they identify drug targets.
[001045] This approach in this Example can be used for any other
appropriate biomarkers.
Example 20: 01i20nuc1eotide enrichment on tissue samples to identify dru2
responders
[001046] This Example follows the work presented in Example 19 above. The
task was to develop
an oligonucleotide library capable of distinguishing Breast Cancer (BCa)
patients that respond or not to
trastuzumab treatment. Often administered together with various
chemotherapeutic agents, trastuzumab
alone shows efficacy in some patients (<20%) that overexpress HER2 as
determined by IHC assay. For
purposes of this Example, responders and non-responders are based upon each
patient's time-to-next-
treatment ("TNT" or "TTNT") as a proxy for response. FIG. 16A illustrates
treatment schemes for BCa
along with a timeline differentiating between responders and non-responders.
As shown the non-
responders are treated with another chemotherapy treatment within six months
of initiation of treatment
with trastuzamab. The resulting oligonucleotides can be used to predict
response and direct therapy to
proper population of patients.
[001047] Methodology was similar to that described above in Example 19. A
general scheme for
enrichment of the naive F-trin-35 library is shown in FIG. 16B (AL = aptamer
library). In the figure,
responders are shown as positive samples for selection, but enrichments were
similarly performed with
non-responders as the positive samples for enrichment. Six rounds of
enrichment were performed. 17
enriched oligonucleotide libraries were obtained, wherein eight libraries were
trained towards non-
responder and nine libraries were trained toward responders. The 17 libraries
are referred to as libraries A-
S.
[001048] The libraries were trained on a set of 20 non-responders and 20
responders. Given this
patient cohort, responders were defined as patients treated for 212 days and
up with trastuzamab and non-
-183-
CA 03018066 2018-09-17
WO 2017/161357 PCT/US2017/023108
responders were defined as those treated for 8-119 days with trastuzumab. FIG.
16C shows staining of
non-responder and responder samples using oligonucleotide probe library A
sorted by staining intensity.
As can be observed in the figure, staining was more prevalent in the non-
responder samples. Summary
results for staining the training samples the Non-responder selected library A
and responder selected
library M are shown in FIG. 16D. The variable regions of the 100000 most
prevalent sequences in library
A are included herein as SEQ ID NOs. 3062-103061, ordered by prevalence. The
variable regions of the
100000 most prevalent sequences in library Mare included herein as SEQ ID NOs.
103062-203061, also
ordered by prevalence. ROC curves generated for each library separately and
the combined A & M
libraries are shown in FIG. 16E. Joint performance was determined using
logistic regression. Several
non-responder samples without sufficient slides were removed from these data.
As shown in FIG. 16E,
the trained library A and library M had excellent performance for
distinguishing the responder and non-
responder samples. As a control, library A was used to stain slides from
breast cancer cases that were not
treated with trastuzumab. No differential staining patterns were observed
(data not shown). FIG. 16F
shows results of using the trained libraries to classify two small test sets
with significant AUC values as
shown. The combined AUC was 0.78, which indicates clinical utility.
[001049] Thus, the oligonucleotide probe libraries can be used to identify
trastuzumab responder
tissues instead of only HER2+ tissues per currently available companion
diagnostics.
[001050] As in Example 19 above, targets are identified that are
responsible for the response (or its
absence) to trastuzumab and which can be used to develop more efficient
treatment.
Example 21: Polyligand profiling differentiates cancer patients according to
their benefit of
treatment
[001051] Patient response to specific cancer treatment is dependent upon
subtle differences in
tumor systems states that can be difficult to access. Highly multiplexed
measurement techniques can be
advantageous to assess these perturbations. In this Example, we used
polyligand profiling with
oligonucleotide probe libraries as described herein to perform such analysis.
We generated two single-
stranded oligodeoxynucleotide probe libraries that distinguish between tumor
tissue from breast cancer
patients who either did or did not derive benefit from trastuzumab-based
regimens. Testing of an
independent sample set verified the ability of the libraries to differentiate
patients, as assessed by
calculating AUC values from ROC curves in comparison to standard HER2-
immunohistochemical
scoring. Kaplan-Meier plots confirmed that outcomes were in accordance with
test results: Test-positive
patients had a median duration of 604 days of trastuzumab treatment, whereas
test-negative patients had a
median duration of 129 days of trastuzumab treatment. Thus, this Example
demonstrates use of polyligand
profiling to classify distinct clinical outcomes.
[001052] Precision oncology seeks to adapt the treatment of individual
cancer patients to the
specific mutations and unique molecular interaction networks of each tumor.
The genomic complexity and
heterogeneity of the underlying molecular signatures is vast and each tumor
can have its unique profile,
even within the same patient (1-3). Patients that benefit from specific
treatment regimens often differ from
those that do not in features other than merely the expression status of
single or small numbers of
-184-
CA 03018066 2018-09-17
WO 2017/161357
PCT/US2017/023108
biomarkers. Consequently, the current paradigms for precision oncology rely on
three major pillars: First,
the identification of mutations by DNA/RNA sequencing in patients' tumors;
second, the quantification of
known biomarkers in tumor tissue; third, the identification of new biomarkers
and master regulator genes.
However, based on the limited success of several recent clinical trials, the
prospect and potential of
precision oncology has recently been challenged (4, 5). Thus, limitations have
become evident and call for
a paradigm-shift to facilitate the identification of patients who will or will
not benefit from a particular
cancer treatment (6-8) and the development of improved companion diagnostic
tests (CDx) (9). Because
single or small numbers of biomarkers may not always adequately predict
treatment benefit, in these cases
a more effective CDx would simultaneously access the multitude of intricate
molecular features that
underlie the vastly complex and currently largely unpredictable phenotype of
drug response. Accessing
the phenotypic diversity conferred by tumor heterogeneity and the changes in
the tumor
microenvironment that are induced by tumor cells may require identification of
subtle variations in the
underlying molecular interaction network, or interactome, the complexity of
which is estimated to consist
of several hundred thousand, or even millions of multi-molecular complexes
(10). Such identification may
benefit from an unbiased, hypothesis-free approach to access informative and
highly complex molecular
characteristics, a challenge that could require an equal or greater number of
potential detector molecules.
[001053] Here we report one approach to achieve this comprehensive goal:
polyligand profiling. In
this Example, we assessed the ability of polyligand profiling to differentiate
between patients who do or
do not derive benefit from a particular cancer treatment, which may also be
referred to as responders or
non-responders, respectively. We then compare polyligand profiling to
immunohistochemical (IHC)
analysis of HER2, one of the most successful and widely applied CDx. Her2 is
overexpressed in fifteen to
thirty percent of human breast cancers (11, 12). Because HER2 amplification is
associated with increased
tumor cell proliferation and poor prognosis, patients with HER2 positive
(HER2+) breast cancer are
candidates for treatment with trastuzumab. However, only 30% of patients with
HER2+ breast cancer
benefit from trastuzumab mono-therapy (/3). Trastuzumab (Herceptin) is a
monoclonal antibody that
binds human epidermal growth factor receptor 2 (HER2, ErbB2) and inhibits its
function (14-16).
[001054] Materials and Methods for the experiments described in this
Example are provided in
Example 22 below. Clinical information for patients included in this Example
is provided in Tables 29-
32. In the tables, "CPP" stands for cyclophosphamide. All samples were breast
carcinomas.
Table 29: Patient Information: Training toward Non-Benefiters (NB)
Enrichment HER2 HER2 First line Next line Additional
TTNT
Clinical
case ID ISH HIC regimen regimen treatments
TL-NB+ 158 + + carboplatin recombinant pegylated
liposomal Diagnosis: Ultrasound-
paclitaxel interferon alfa-2b doxon.tbicin guided
core biopsy,
trastuzumab pertuzumab hydrochloride right breast:
Infiltrating
gemcitabine carcinoma
involving all
hydrochloride cores.
cisplatin Stage: Unknown
vinorelbine tartrate Grade: 3/ Poorly
fluorouracil differentiated
eribulin mesylate
-185-
CA 03018066 2018-09-17
WO 2017/161357 PCT/US2017/023108
TL-NB- 335 + + carboplatin
Diagnosis: Left breast,
docetaxel lumpectomy:
Invasive
trastuzumab ductal carcinoma.
Stage: I
Grade: 2 / Moderately
differentiated
TL-NB- 280 + + carboplatin ado-trastuzumab
Diagnosis: Left breast
paclitaxel emtansine and axilla
(modified
trastuzumab mastectomy):
Invasive
ductal carcinoma,
poorly differentiated.
Stage: IIIC
Grade: 3/ Poorly
differentiated
Alt. lib.1+ 119 - - trastuzumab eribulin mesylate trastuzumab
vinorelbine nab-paclitaxel
tartrate
Alt. lib.1- 321 - - trastuzumab
vinorelbine
tartrate
Alt. lib.1- 225 + + trastuzumab ado-trastuzumab docetaxel
vinorelbine emtansine pertuzumab
tartrate nab-paclitaxel
Alt. lib.2+ 21 + trastuzumab docetaxel
carboplatin
Alt. lib.2- 294 + + trastuzumab carboplatin ado-
trastuzumab
gemcitabine emtansine
hydrochloride
Alt. lib.2- 349 + - trastuzumab
Alt. lib.3+ 15 + trastuzumab docetaxel carboplatin
nab-paclitaxel
Alt. lib.3- 294 + + trastuzumab carboplatin ado-
trastuzumab
gemcitabine emtansine
hydrochloride
Alt. lib.3- 349 + - trastuzumab
Alt. lib.4+ 109 + + paclitaxel cyclophosphamide
pertuzumab doxorubicin
trastuzumab hydrochloride
Alt. lib.4- 263 + + docetaxel
pertuzumab
trastuzumab
Alt. lib.4- 217 - +/- nab-paclitaxel letrozole
pertuzumab fulvestrant
trastuzumab
Alt. lib.5+ 56 +/- nab-paclitaxel carboplatin ado-
trastuzumab
pertuzumab gemcitabine emtansine
trastuzumab hydrochloride eribulin mesylate
Alt. lib.5- 263 + + docetaxel
-186-
CA 03018066 2018-09-17
WO 2017/161357
PCT/US2017/023108
pertuzumab
trastuzumab
Alt. lib.5- 217 - +/- nab-paclitaxel letrozole
pertuzumab fulvestrant
trastuzumab
Alt. lib.6+ 56 + +/- trastuzumab carboplatin ado-trastuzumab
vinorelbine emtansine
tartrate trastuzumab
fulvestrant
cyclophosphamide
methotrexate
fluorouracil
leuprolide acetate
docetaxel
gemcitabine
hydrochloride
Alt. lib.6- 321 - - trastuzumab
vinorelbine
tartrate
Alt. lib.6- 225 + + trastuzumab ado-trastuzumab docetaxel
vinorelbine emtansine pertuzumab
tartrate nab -paclitaxel
Alt. lib.7+ 69 n.p. - docetaxel leuprolide acetate docetaxel
pertuzumab
trastuzumab
Alt. lib.7- 263 + + docetaxel
pertuzumab
trastuzumab
Alt. lib.7- 217 - nab-paclitaxel letrozole
pertuzumab fulvestrant
trastuzumab
Table 30: Patient Information: Training toward Benefiters (B)
Enrichment TTNT HER2 First line Next line
HER2 IHC Additional treatments
Clinical
case ID ISH regimen regimen
Alt. lib.8+ 364 + trastuzumab ado-
vinorelbine trastuzumab
tartrate emtansine
Alt. lib.8- 33 + trastuzumab docetaxel
vinorelbine
tartrate
Alt. lib.8- 85 trastuzumab docetaxel docetaxel
vinorelbine investigational agent
tartrate cyclophosphamide
fluorouracil
Alt. lib.9+ 369 - Equivocal trastuzumab docetaxel ado-trastuzumab
pertuzumab emtansine
Alt. lib.9- 56 n.p. trastuzumab leuprolide vinorelbine tartrate
acetate eribulin mesylate
bevacizumab
nab-paclitaxel
ado-trastuzumab
-187-
CA 03018066 2018-09-17
WO 2017/161357 PCT/US2017/023108
trastuzumab
Alt. lib.9- 20 - trastuzumab nab- vinorelbine
tartrate
paclitaxel gemcitabine
hydrochloride
TL-B+ 371 + carboplatin Diagnosis: Left
breast,
docetaxel lumpectomy:
trastuzumab Infiltrating
ductal
carcinoma, poorly
differentiated/grade 3.
Stage: IIIA
Grade: 3/ Poorly
differentiated
TL-B- 42 + carboplatin pegylated cyclophosphamide
Diagnosis: Right
nab- liposomal breast mass,
excision:
paclitaxel doxorubicin Multifocal
invasive
trastuzumab hydrochloride ductal
carcinoma.
Stage: IV
Grade: 3/ Poorly
differentiated
TL-B- 91 + carboplatin letrozole Diagnosis:
Breast, left,
docetaxel Mammotome
biopsy:
trastuzumab Infiltrating
ductal
carcinoma, no special
type. High combined
histologic grade
(3,3,2).
Stage: I
Grade: 3/ Poorly
differentiated
Alt. lib.10+ 406 + trastuzumab
Alt. lib.10- 56 n.p. trastuzumab leuprolide vinorelbine tartrate
acetate eribulin mesylate
bevacizumab
nab-paclitaxel
ado-trastuzumab
emtansine
trastuzumab
Alt. lib.10- 20 - trastuzumab nab- vinorelbine tartrate
paclitaxel gemcitabine
hydrochloride
Alt. lib.11+ 598 + trastuzumab vinorelbine trastuzumab
vinorelbine tartrate gemcitabine
tartrate trastuzumab hydrochloride
docetaxel
pertuzumab
eribulin mesylate
Alt. lib.11- 33 + trastuzumab docetaxel
vinorelbine
tartrate
Alt. lib.11- 85 trastuzumab docetaxel docetaxel
vinorelbine investigational agent
tartrate cyclophosphamide
-188-
CA 03018066 2018-09-17
WO 2017/161357
PCT/US2017/023108
fluorouracil
Alt. lib.12+ 604 - carboplatin gemcitabine
docetaxel hydrochloride
trastuzumab
Alt. lib.12- 42 + carboplatin pegylated cyclophosphamide
nab- liposomal
paclitaxel doxorubicin
trastuzumab hydrochloride
Alt. lib.12- 91 + carboplatin letrozole
docetaxel
trastuzumab
Alt. lib.13+ 623 + nab- gemcitabine ado-trastuzumab
paclitaxel hydrochloride emtansine
trastuzumab
Alt. lib.13- 67 + docetaxel pertuzumab fulvestrant
trastuzumab
Alt. lib.13- 70 +1- paclitaxel nab- cyclophosphamide
trastuzumab paclitaxel doxorubicin
hydrochloride
docetaxel
pertuzumab
ado-trastuzumab
emtansine
docetaxel
trastuzumab
pertuzumab
Alt. lib.14+ 391 + trastuzumab
Alt. lib.14- 56 n.p. trastuzumab leuprolide vinorelbine tartrate
acetate te eribulin mesylate
bevacizumab
nab-paclitaxel
ado-trastuzumab
emtansine
trastuzumab
Alt. lib.14- 20 - trastuzumab nab vinorelbine tartrate
paclitaxel gemcitabine
hydrochloride
Alt. lib.15+ 1202 - paclitaxel nab-
trastuzumab paclitaxel
gemcitabine
hydrochloride
Alt. lib.15- 67 + docetaxel pertuzumab fulvestrant
trastuzumab
Alt. lib.15- 70 +1- paclitaxel nab- cyclophosphamide
trastuzumab paclitaxel doxorubicin
hydrochloride
docetaxel
pertuzumab
ado-trastuzumab
emtansine
docetaxel
-189-
CA 03018066 2018-09-17
WO 2017/161357 PCT/US2017/023108
trastuzumab
pertuzumab
Table 31: Patient Information: Test Herceptin TTNT
ID Type Diagnosis TTNT Censored First line
Next line Stage Grade Specimen Age HER2 HER2 ER
cite IHC
ISH
ALx- R Mid chest wall, biopsy: 219 Y trastuzumab
IV Grade 3/ Chest, 58 NA +
R-18 Poorly differentiated nab- Poorly NOS
carcinoma, involving paclitaxel differentiated
dermis and
subcutaneous
fibroadipose tissue.
ALx- NR Liver; biopsy: 78 N gemcitabine carboplatin
IV Unknown Liver 52 - - -
NR- Malignant epithelial hydrochloride
neoplasm, consistent trastuzumab
withn metastatic docetaxel
invasive lobular
carcinoma.
ALx- R Left breast mass, 391 Y trastuzumab Unknown Grade
3/ Breast 60 + + -
R-20 excision: Invasive Poorly
ductal carcinoma, grade differentiated
3.
ALx- R Breast, left, 3 o'clock, 7 287 Y gemcitabine
Unknown Grade 3/ Breast 52 - +/- +
R-10 cm from nippled hydrochloride Poorly
(ultrasound guided core carboplatin differentiated
biopsy): Invasive ductal trastuzumab
carcinoma.
ALx- R Mass, left axilla, needle 321 Y trastuzumab IV
Grade 3/ Connective 46 - - +
R-19 biopsy: Invasive vinorelbine Poorly & Soft
adenocarcinoma, tartrate differentiated Tissue
morphologically
consistent with
recurrent breast
carcinoma.
ALx- R Left breast, 765 N fulvestrant IV Grade 3/
Breast 65 - +/- +
R-14 mastectomy: In situ carboplatin Poorly
intraductal and docetaxel differentiated
infiltrating duct trastuzumab
carcinoma. Tumor
emboli in dermal
lymphatics of skin and
nipple.
ALx- NR Lymph node, right 70 N trastuzumab nab-paclitaxel
IV Grade 3/ Lymph 40 - +/- +
NR- axillaly (needle core paclitaxel Poorly Nodes
biopsy): Metastatic differentiated
high-grade carcinoma,
consistent with breast
primaty.
ALx- NR Liver mass, biopsy: 67 N
trastuzumab pertuzumab IV Grade 2 / Liver 63 + + +
NR- Metastatic docetaxel Moderately
18 adenocarcinoma, differentiated
compatible with breast
primaty.
ALx- R Left breast, 2:00, 339 Y CPP I
Grade 2/ Breast 52 + + +
R-5 lumpectomy: docetaxel Moderately
Infiltrating ductal trastuzumab differentiated
carcinoma, moderately
differentiated, grade
ALx- NR Right supraclavicular 56 N trastuzumab
gemcitabine IIIC Unknown Lymph 47 +/- - +
NR-7 lymph node: Single nab- hydrochloride Nodes
lymph node (3cm), paclitaxel carboplatin
replaced by metastatic pertuzumab
carcinoma.
ALx- R Liver, partial 294 N trastuzumab gemcitabine
IV Unknown Liver 54 + + +
R-4 hepatectomy, section 5: hydrochloride
Metastatic invasive carboplatin
-190-
CA 03018066 2018-09-17
WO 2017/161357 PCT/US2017/023108
mammary carcinoma.
ALx- R Right breast, 8:00 272 N trastuzumab
fulvestrant IV Grade 2/ Breast 49 - - +
R-16 N+10, biopsy: Invasive docetaxel Moderately
ductal carcinoma, no carboplatin differentiated
special type (1.1 cm).
ALx- R Breast, right, core 238 Y trastuzumab I
Grade 3/ Breast 55 + + -
R-8 biopsy: Infiltrating Poorly
ductal carcinoma. differentiated
ALx- R Left breast mass, core 623 N trastuzumab
gemcitabine Unknown Grade 3/ Breast 46 + + -
R-17 biopsy: Poorly nab- hydrochloride Poorly
differentiated paclitaxel differentiated
infiltrating ductal
carcinoma.
ALx- R Left breast 604 N carboplatin gemcitabine MC Grade 2 /
Breast 82 - - +
R-9 mastectomy: Invasive docetaxel hydrochloride
Moderately
lobular carcinoma. trastuzumab differentiated
ALx- R Left breast mass: 406 Y trastuzumab IV Grade 3/
Breast, 35 + + +
R-15 Infiltrating ductal Poorly NOS
carcinoma, Nottingham differentiated
combined histologic
grade III.
ALx- NR Metastatic carcinoma 82 N trastuzumab CPP
I Grade 2 / Axillaty 46 + + -
NR-9 involving one out of pertuzumab doxorubicin Moderately lymph
seventeen (1/17) trastuzumab hydrochloride differentiated
node
axillaty lymph nodes. docetaxel
ALx- R Right breast, "masses" 1202 N trastuzumab
gemcitabine IV Grade 3/ Breast, 79 - - +
R-11 at 10 and 2 o'clock paclitaxel hydrochloride Poorly
NOS
positions, resection: nab-paclitaxel differentiated
Invasive lobular
carcinoma.
ALx- R 369 N trastuzumab pertuzumab II
Grade 3/ Breast, 52 +/- - -
R-7 docetaxel Poorly NOS
differentiated
ALx- NR Peritoneal mass, needle 69 N trastuzumab
leuprolide IV Unknown Peritoneal 35 - - +
NR- core biopsy: Metastatic docetaxel acetate
cavity
14 carcinoma, with pertuzumab
morphologic and
immunohistochemical
features consistent with
the patient's known
breast center.
ALx- R Skin, "lesion" on right 598 N trastuzumab
trastuzumab IV Grade 3/ Skin of 62 + + -
R-13 anterior chest wall, vinorelbine vinorelbine Poorly chest
wall
excisional biopsy: tartrate tartrate differentiated
Metastatic carcinoma
of mammaty origin
with prominent
apocrine features.
ALx- R Left axillary sentinel 301 Y fluorouracil
Unknown Grade 3/ Breast, 66 +/- +/- -
R-1 nodes, left breast: CPP Poorly NOS
Invasive ductal methotrexate differentiated
carcinoma. Nottingham trastuzumab
grade 3.
ALx- NR Right chest wall mass 109 N trastuzumab CPP I
Grade 2 / Chest wall, 53 + + -
NR- excision: Invasive paclitaxel doxorubicin
Moderately NOS
12 ductal carcinoma, grade pertuzumab hydrochloride differentiated
2.
ALx- R Breast, right, 291 Y trastuzumab II
Grade 2 / Breast, 56 - - +
R-6 mastectomy: docetaxel Moderately NOS
Infiltrating mammary CPP differentiated
carcinoma with mixed
ductal and lobular
phenotype.
ALx- NR Right adrenalectomy: 56 N vinorelbine
carboplatin IV Unknown Adrenal 54 +/- + +
NR- Adenocarcinoma, tartrate gland,
11 consistent with trastuzumab NOS
metastatic mammaty
carcinoma.
-191-
CA 03018066 2018-09-17
WO 2017/161357 PCT/US2017/023108
ALx- NR Lymph node, right 113 N nab- capecitabine
IIIA Grade 1/ Axillary 51 +/- - -
NR-4 axillary, excision: paclitaxel Well lymph
Metastatic carboplatin differentiated node
adenocarcinoma pertuzumab
consistent with breast trastuzumab
primary.
ALx- R Left breast, simple 190 Y pertuzumab
II Grade 3/ Breast, 34 +/- - +
R-41 mastectomy: Invasive docetaxel Poorly NOS
ductal carcinoma, carboplatin differentiated
Nottingham grade III. trastuzumab
ALx- R Right breast, core 196 Y trastuzumab I
Grade 3/ Breast 52 - - +
R-42 biopsy: Infiltrating pertuzumab Poorly
ductal carcinoma. docetaxel differentiated
ALx- R Right breast, simple 375 Y trastuzumab II
Grade 3/ Breast 41 + + -
R-43 mastectomy: Recurrent docetaxel Poorly
invasive grade 3 ductal carboplatin differentiated
carcinoma. trastuzumab
ALx- R 334 Y trastuzumab IV Unknown
Liver 64 - + +
R-44
ALx- R Left breast scar 406 Y trastuzumab I
Grade 3/ Breast 54 - + +
R-45 revision: Invasive fulvestrant Poorly
poorly-differentiated differentiated
ductal carcinoma.
ALx- R Left breast 546 Y trastuzumab I Unknown Skin 55
+ + -
R-47 inframammary crease:
Metastatic carcinoma
involving dermal
lymphovascular spaces.
ALx- R Left breast and axillary 856 Y trastuzumab IV
Grade 3/ Axillary 40 - +/- -
R-48 contents, modified Poorly lymph
radical mastectomy: differentiated node
Invasive ductal
carcinoma.
ALx- NR Liver, biopsy: 106 N trastuzumab bevacizumab
IV Grade 3/ Liver 46 + + +
R-49 Metastatic carcinoma. carboplatin Poorly
differentiated
ALx- R Skin, left breast, 186 N trastuzumab
vinorelbine I Unknown Connective 41 + + -
R-50 biopsy: Dermal tartrate & Soft
intralymphatic tumor, Tissue
consistent with
inflammatory
carcinoma.
ALx- R Right axillary/pectoral 196 N trastuzumab
vinorelbine I Grade 3/ Connective 55 + + +
R-51 tumor, excision: tartrate Poorly & Soft
Infiltrating ductal trastuzumab differentiated Tissue
carcinoma involving
subcutaneous
fibroadipose tissue and
adjoining skeletal
muscle.
ALx- NR Liver, segment VI, 80 N
trastuzumab octreotide IV Unknown Liver 46 + + -
R-52 partial resection: pertuzumab acetate
Consistent with fulvestrant
metastatic mammary
carcinoma.
ALx- R Right liver lobe, partial 190 N trastuzumab
fulvestrant IV Unknown Liver 63 - - +
R-53 lobectomy: Metastatic
carcinoma, consistent
with breast primary.
ALx- R Left breast mass: 433 N leuprolide paclitaxel IV
Grade 3/ Breast 44 QNS
R-54 Infiltrating duct acetate Poorly
carcinoma with lobular docetaxel differentiated
features, grade 3. trastuzumab
pertuzumab
ALx- R Pelvic mass, biopsy: 183 N trastuzumab nab-
paclitaxel IV Unknown Pelvis, 42 +/- + +
R-55 Metastatic carcinoma. vinorelbine NOS
tartrate
ALx- R Liver, needle biopsy 250 N
trastuzumab ado- IV Unknown Liver 68 + + -
R-56 (SS-13-01227): Mild pertuzumab trastuzumab
steatosis and docetaxel emtansine
-192-
CA 03018066 2018-09-17
WO 2017/161357 PCT/US2017/023108
chole stasis.
ALx- NR Breast, left, simple 49 N trastuzumab ado- II
Grade 2 / Breast, 44 + + -
R-57 mastectomy: Residual trastuzumab Moderately NOS
infiltrative mammary emtansine differentiated
carcinoma with ductal
and lobular features.
ALx- NR SU-12-02676: Right 154 N
trastuzumab docetaxel -- Unknown Grade 3/ -- Breast, 41 -- - -- - -- -
R-58 breast (lumpectomy): Poorly NOS
Residual poorly differentiated
differentiated
adenocarcinoma,
multifocal.
ALx- NR Right axillary mass: 128 N
trastuzumab docetaxel Unknown Grade 3/ Breast, 62 + + -
R-59 High grade infiltrating Poorly NOS
ductal carcinoma. differentiated
ALx- NR Bone, right distal femur 129 N trastuzumab pertuzumab
IV Unknown Femur 51 + + +
R-60 tumor, excision: docetaxel
Metastatic
adenocarcinoma,
compatible with breast
primary.
Table 32: Patient Information: Test Platinum/Taxane TTNT
ID Type Diagnosis TTNT Censored First line Next line
Stage Grade Specimen cite Age HER2 HER2 ER
IHC ISH
= NR Right breast and medial 22 N docetaxel CPP UnknownNA
Breast 73 - - -
portion of
1 inframammary bridge,
simple mastectomy:
Infiltrating ductal
carcinoma, grade 2
(Nottingham
classification).
= R Left masectomy breast 822 Y nab-
IBA Grade 2 / Breast 49 - - +
tissue: Invasive paclitaxel Moderately
2 mammary carcinoma, fluorouracil differentiated
= R Right breast (simple 461 N nab-
gemcitabine II Grade 3/ Breast 43 - - +
mastectomy): paclitaxel hydrochloride Poorly
3 Infiltrating ductal bevacizumab differentiated
carcinoma. carboplatin
= NR Lymph node from left 21 N
nab- eribulin UnknownNA Lymph Nodes 40 - +/- +
neck (biopsy): paclitaxel mesylate
4 Metastatic poorly
differentiated
carcinoma involving
one out of one lymph
node' (1/1).
= NR Right axillaty lymph 40 N
docetaxel doxorubicin I Unknown Lymph Nodes 43 - - -
node (biopsy): hydrochloride
Metastatic carcinoma. CPP
= NR Liver "mass" 29 N
carboplatin gemcitabine IV Grade 2 / Liver 47 - others -
(percutaneous needle nab- hydrochloride Moderately
6 core biopsies): paclitaxel differentiated
Metastatic bevacizumab
adenocarcinoma,
consistent with breast
primary.
= NR Touch preps and core 84 N
nab- patupilone IV Unknown Bones & Joints 60 - - +
biopsy, left iliac crest: paclitaxel
7 Positive for
malignancy.
= NR Breast, left, 12-3:00: 62 N docetaxel
doxorubicin II Grade 3/ Breast 62 - - +
Invasive lobular CPP hydrochloride Poorly
8 carcinoma, differentiated
pleomorphic type.
-193-
CA 03018066 2018-09-17
WO 2017/161357 PCT/US2017/023108
= NR Mass, retroperitoneum; 59 N
nab- patupilone IV Unknown Retroperitoneum 55 - - +
biopsy: Metastatic paclitaxel & Peritoneum
9 carcinoma, consistent
with breast primary.
= NR Left breast (182 grams), 98 N
paclitaxel CPP II Grade 3/ Breast 39 - - -
simple mastectomy: doxorubicin Poorly
Infiltrating ductal hydrochloride differentiated
carcinoma. fluorouracil
= NR Left breast, simple 70 N docetaxel
fluorouracil IV Grade 2/ Breast 44 - - +
mastectomy: patupilone Moderately
11 Infiltrating lobular differentiated
carcinoma.
= R Lymph nodes, right 402 N
paclitaxel gemcitabine IV Grade 2 / Lymph Nodes 56 - - -
axillary, excision: bevacizumab hydrochloride Moderately
12 Metastatic nab- differentiated
adenocarcinoma paclitaxel
consistent with breast
primary involving one
of three lymph nodes
(1/3).
= R Ascites fluid, cytology: 631 N
gemcitabine gemcitabine IV Unknown Peritoneal Fluid 70 - - +
Metastatic hydrochloride hydrochloride
13 adenocarcinoma, docetaxel
consistent with lobular
breast carcinoma.
= NR Left breast, needle 56 N nab-
doxorubicin IIIA Grade 3/ Breast 62 - - -
biopsies: Invasive paclitaxel hydrochloride Poorly
14 ductal carcinoma, grade CPP differentiated
3 (of 3).
= R Core needle biopsy, left 449 N
CPP eribulin IV Grade 3/ Lymph Nodes 73 - - -
lateral breast/axillary epinibicin mesylate Poorly
lymph node mass: hydrochloride differentiated
Metastatic poorly paclitaxel
differentiated
adenocarcinoma,
moiphologically and
immunohistochemically
compatible with
primary ductal breast
origin.
= R Right breast mass, 343 N doxorubicin
gemcitabine II Grade 3/ Breast 44 - - -
excision: Invasive hydrochloride hydrochloride Poorly
16 ductal carcinoma. CPP differentiated
docetaxel
= NR Supraclavicular node 99 N
docetaxel gemcitabine IV Unknown Lymph Nodes 57 - - -
left: Lymph node carboplatin hydrochloride
17 totally replaced by
metastatic carcinoma,
consistent with primary
breast carcinoma. The
tumor extends
completely through the
node capsule to the
surrounding fatty
tissues.
= R Chest wall mass, right 341 N
carboplatin eribulin IV Grade 2 / Connective & 80 +/- - +
posterior, biopsy: docetaxel mesylate Moderately
Soft Tissue
18 Metastatic carcinoma, differentiated
favor mammaiy
primary.
Pl- NR Reamings, hip, right, 105 N paclitaxel
gemcitabine IV Grade 3/ Bones & Joints 64 - - -
biopsy: Metastatic carboplatin hydrochloride Poorly
19 poorly differentiated bevacizumab differentiated
carcinoma consistent
with breast origin.
= R Right breast, 10 674 Y CPP
IIIA Grade 3/ Breast 69 - - +
o'clock, lumpectomy: docetaxel Poorly
Infiltrating ductal differentiated
adenocarcinoma.
-194-
CA 03018066 2018-09-17
WO 2017/161357 PCT/US2017/023108
= NR Liver, needle biopsies: 21 N docetaxel
doxorubicin IV Grade 2 / Liver 45 +/- - +
Metastatic carcinoma hydrochloride Moderately
21 moiphologically differentiated
consistent with breast
primary.
= NR Left breast 49 N docetaxel
gemcitabine IIIC Grade 3/ Breast 71 - - -
lumpectomy, 2 o'clock: CPP hydrochloride' Poorly
22 Infiltrating ductal differentiated
adenocarcinoma, Elston
grade III, 4 cm
maximum dimension,
present 1 mm from the
inferior margin.
= R Left breast mass, 686 Y docetaxel II
Grade 3/ Breast 72 - - -
additional margins left therapeutic Poorly
23 breast, axillaiy immune differentiated
contents, and additional globulin
axillary contents: CPP
Invasive lobular
carcinoma.
= NR Breast, right, 22 N nab-
pegylated I Grade 3/ Breast, NOS 43 - - -
Mammotome biopsy: paclitaxel liposomal Poorly
24 Infiltrating ductal carboplatin doxorubicin differentiated
carcinoma, no special hydrochloride
type.
= NR Duodenum, biopsy: 63 N
carboplatin capecitabine IV Grade 3/ Duodenum 31 +1- - -
Poorly-differentiated gemcitabine Poorly
25 carcinoma, compatible hydrochloride differentiated
with metastatic
mammary carcinoma.
= NR Right breast mass core 106 N
paclitaxel IV Grade 3/ Breast, NOS 56 - - -
needle biopsies (image Poorly
26 directed): Infiltrating differentiated
duct carcinoma, high
grade (grade 3).
= NR Right breast mass: 43 N
carboplatin methotrexate UnknownNA Breast, NOS 59 - - -
Invasive ductal docetaxel
27 carcinoma. Nottingham
grade 3.
= NR Left breast, modified 70 N
carboplatin Methotrexate IIIA Grade 3/ Breast, NOS 61 - - -
radical mastectomy fluorouracil Poorly
28 with level I/II node differentiated
dissection: 3.5 cm
poorly differentiated
invasive ductal
carcinoma with focal
necrosis and foci of
high grade ductal
carcinoma in situ
(comedo type).
= NR Left breast mass, left 70 N
nab- gemcitabine Unknown Grade 3/ Breast, NOS 53 - - -
breast core biopsy: paclitaxel hydrochloride Poorly
29 Infiltrating ductal carboplatin differentiated
carcinoma.
= NR Left breast 83 N nab- pegylated II
Grade 3/ Breast, NOS 58 - - -
Mammotome biopsy: paclitaxel liposomal Poorly
30 Infiltrating carcinoma. carboplatin doxorubicin differentiated
hydrochloride'
= NR Right breast segment, 22 N carboplatin CPP
II Grade 3/ Breast, NOS 62 - - -
segmental mastectomy: docetaxel Poorly
31 Poorly-differentiated differentiated
invasive ductal
carcinoma.
= NR Right neck node, core 58 N nab-
eribulin Unknown NA Connective, 45 NA NA
biopsy: Metastatic paclitaxel mesylate
subcutaneous
32 poorly differentiated and other soft
adenocarcinoma tissues of head,
face and neck
Pl- NR 28 N carboplatin pemetrexed IIIA Grade 3/
Breast, NOS 57 - - -
gemcitabine disodium Poorly
-195-
CA 03018066 2018-09-17
WO 2017/161357 PCT/US2017/023108
33 hydrochloride differentiated
pj_ R Breast, left, core 630 N carboplatin pegylated
IV Grade 2 / Breast, NOS 78 - - -
biopsy: Invasive liposomal Moderately
34 carcinoma, grade 2 (of doxorubicin differentiated
3). hydrochloride
pj_ NR Left breast and axilla, 80 N
carboplatin doxorubicin MC Grade 3/ Breast, NOS 75 - - -
modified radical gemcitabine hydrochloride Poorly
35 mastectomy: Invasive hydrochloride differentiated
ductal carcinoma,
pj_ NR Left breast biopsy: 91 N nab- pegylated
Unknown Grade 3/ Breast, NOS 50 - - -
Infiltrating ductal paclitaxel liposomal Poorly
36 carcinoma. High carboplatin doxorubicin differentiated
combined histologic hydrochloride
grade (3,3,3).
pj_ NR T9 bone, core biopsy: 56 N bevacizumab CPP
IV Unknown Bone, NOS 45 +/- - +
Metastatic carcinoma, paclitaxel doxorabicin
37 compatible with breast hydrochloride
pj_ NR Breast, left 2:00 N10 40 N carboplatin doxorubicin
I Grade 3/ Breast, NOS 46 - - -
(ultrasound-guided, paclitaxel hydrochloride Poorly
38 vacuum-assisted CPP differentiated
biopsy): Invasive ductal
carcinoma, grade 3.
pj_ NR Right breast, 63 N docetaxel Fluorouracil II
Grade 3/ Breast, NOS 83 - - -
mastectomy: carboplatin CPP Poorly
39 Infiltrating ductal differentiated
carcinoma.
pj_ NR Left breast mass, core 84 N paclitaxel CPP IV
Grade 3/ Breast, NOS 37 - - -
biopsy: Infiltrating doxorubicin Poorly
40 ductal carcinoma, hydrochloride differentiated
pj_ NR Breast, left (biopsies): 73 N gemcitabine
doxorubicin IV Grade 2 / Breast, NOS 56 +/- - -
Infiltrating ductal hydrochloride hydrochloride Moderately
41 carcinoma, grade 2. carboplatin CPP differentiated
[001055] In this Example, we subjected a library of 1013 unique single-
stranded DNA
oligodeoxynucleotides (ssODNs; which may also be referred to as aptamers or
oligonucleotide probes
herein) (17, 18) to several rounds of positive and negative selection in situ
for subsets of sequences that
preferentially bind to formalin-fixed and paraffin-embedded (FFPE) tumor
tissue slices from breast cancer
patients who did or did not derive benefit from regimens containing
trastuzumab. We refer to this process
as library training. Each patient's time to next therapy (TTNT), i.e. the time
that elapsed until
trastuzumab-based treatment changed defined whether a patient belonged to the
group that derived benefit
from trastuzumab containing treatment (B) or to the group that did not (NB)
(19). The definition of
treatment benefit (B) and no benefit (NB) by TTNT is consistent with recently
published FDA guidance
(20). For the purpose of library training, cases with TTNT greater than 180
days were considered as B and
cases with TTNT fewer than 180 days were considered NB. In total, 8 NB cases
(see Table 29) and 9 B-
cases (see Table 30) were used for the training of 17 different libraries.
Among them were two best-
performing trained libraries, TL-B and TL-NB (see "Enrichment case ID" in
Tables 29-30), which we
employed to generate a predictive assay based on polyligand profiling that
differentiates B from NB
patients.
[001056] FIGs. 17A-B show the rationale for the selection of patients
(FIG. 17A) and the
workflow of the training and testing procedure of the ssODN library, including
the number of cases used
in each step (FIG. 17B). Clinical information for each of the patients
included in this process, such as
-196-
CA 03018066 2018-09-17
WO 2017/161357 PCT/US2017/023108
tumor anatomical site, treatment, hormonal status, etc. is provided in Tables
29-32. The starting library
was subjected to positive selection using one NB case (rounds 1-6) and
negative selection using two B
cases (rounds 4-6) to generate TL-NB, and vice versa for generating TL-B. In
Tables 29-30, the cases are
grouped in triads. For example, positive selection was performed using NB
case, TL-NB+, and negative
selection in the same enrichment was performed using the two B cases just
below identified as TL-NB-
and TL-NB-. For addition details of the selection schemes and protocols, see
FIG. 17C and Example 22.
Testing readout is based on polyligand-histochemistry ("PHC") staining of FFPE
slides from cases
independent of those used for training. All tissue samples used for training
and testing were collected
prior to treatment to ensure that library training is independent of molecular
changes in the tumor tissue
that occur as a result of treatment.
[001057] FIG. 17C provides an overview of the procedure for ssODN library
training. FIG. 17Ci
outlines positive training steps towards a library that identifies non-
benefitting (NB) cases: (i) incubation
of the ssODN library with the NB tissue; (ii) removal of unbound sequences,
(iii) dissection of tumor
tissue and recovery of the subset of sequences, specific to the NB cancer
tissue. SN: supernatant.
Recovered ssODNs were amplified by PCR, converted to ssODNs and used for the
next training round.
The slide images on the left show tissue appearance: Slide 1) Hematoxylin and
eosin (H&E) staining of
NB tissue (tumor area outlined in green); Slide 2) Nuclear Fast Red (NFR)
stained tissue after partitioning
before dissection; Slide 3) Remaining normal tissue after dissection of cancer
tissue with bound ssODNs.
FIG. 17Cii outlines training steps with additional counter-selection steps on
benefit (B) cases: (i)
incubation of the ssODN library with the 1st B tissue; (ii) incubation of the
supernatant from (i) with the
2nd B case; (iii) incubation of the supernatant from (ii) with the NB case
from A; (iv) and (v) correspond
to the steps (ii) and (iii) in A. The slide images on the left show tissue
appearance: Slide 4) Hematoxylin
and eosin (H&E) staining of 1st B tissue (tumor area outlined in green); Slide
5) Hematoxylin and eosin
(H&E) staining of 2nd B tissue (tumor area outlined in green); Slides 2 and 3
are the same as in FIG.
17Ci. FIG. 17Ciii outlines the entire ssODN library training, which is
comprised of three training rounds
as shown in FIG. 17Ci (indicated "i)"); followed by three training rounds as
shown in FIG. 17Cii
(indicated "ii)"). FIG. 17D1 shows staining of the tissue from the NB-case
that was used during the
selection process with untrained library (round 0), compared to the trained TL-
NB library (round 6; upper
panel: 4x, lower panel: 20x). FIG. 17Dii shows staining of tissue from an NB
case not used during the
selection process with untrained library (round 0), compared to the trained
library TL-NB (round 6; upper
panel: 4x, lower panel: 20x). FIG. 17Diii shows staining of the tissue from
the responder case employed
for counter selection in the training of TL-NB, using the output ssODNs from
round 3 (left), compared to
the output ssODNs from round 5 (right).
[001058] In more detail, the training library for non-benefiting patients
TL-NB was obtained by
incubating the starting library directly with FFPE-fixed breast tumor tissue
from a trastuzumab NB-
patient. After one hour of incubation (step i), non-binding ssODNs were
removed by washing (step ii),
followed by a dissection of the tumor tissue away from normal adjacent tissue
(step iii) and asymmetric
PCR-amplification of ssODNs bound to the dissected tumor tissue. See FIG. 17Ci
and Example 22.
-197-
CA 03018066 2018-09-17
WO 2017/161357 PCT/US2017/023108
These positive selection steps were performed a total of three times on serial
tissue sections of the same
case (rounds 1-3; FIG. 17Ci, iii). The ssODN-library from the third round of
enrichment was then
subjected to two consecutive counter-selection steps by incubating with FFPE
tissue from two
trastuzumab B-patients. The supernatant from the second counter-selection
step, i.e. the library that is
depleted of ssODNs that are associated with binding to B-tumor tissue, was
transferred to a new tissue
section from the original NB-patient's tumor for one final positive selection
step as described above and
the subset of bound ssODNs was PCR-amplified (FIG. 17Cii). The negative-
negative-positive steps were
performed a total of three times (SELEX rounds 4-6; FIG. 17Ciii). A comparison
of the staining
intensities of the unselected library with that of the round 6 TL-NB library
on the NB case used for the
selection showed a significant increase of staining for the enriched library
(FIG. 17Di, round 6), whereas
no or weak staining was seen for the unselected library (FIG. 17Di, round 0).
Similar staining was
observed on a separate NB case not used for the library training (FIG. 17Dii).
Not unexpectedly, staining
intensity was also high when the PCR-amplified library from round 3 (the
enriched library before counter
selection) was applied to a B case (FIG. 17Diii, left panel). However, after
round 5 a notable decrease in
staining intensity was observed for TL-NB applied to the same B case,
indicating that the counter-
selection steps were effective (FIG. 17Diii, right panel). Thus, TL-NB shows
high staining intensities on
NB tissue, while it stains the B-case used for counter selection with
considerably weaker intensity. TL-NB
was therefore suitable for PHC staining on an independent test-set.
[001059] To test whether we could also train a random library for a set of
ssODNs that
preferentially stain B-cases, we carried out a separate enrichment process in
the opposite direction, using
B-cases for positive, and NB-cases for counter-selection. The resulting
trained library, TL-B, showed
preferential staining of B-cases compared to the NB-cases or the untrained
starting library. FIG. 17E
shows staining of library TL-B on B and NB tissues. FIG. 17Ei shows staining
of tissue from a B case not
used during the selection process with untrained library (round 0), compared
to the trained library TL-B
(round 6; upper panel: 4x, lower panel: 20x) FIG. 17Eii shows staining of the
tissue of a patient who did
not derive benefit from trastuzumab-based regimens (NB) by polyligand-
histochemistry (PHC), using the
library enriched on a benefiting case (B) at round 4, compared to TL-B after
round 6.
[001060] Taken together, the PHC staining characteristics observed with TL-
NB and TL-B indicate
sufficient selection pressure and successful enrichment toward their targeted
phenotypes. The variable
regions of the 100000 most prevalent sequences in the NB selected enrichment
(library TL-NB) are
included herein as SEQ ID NOs. 3062-103061, ordered by prevalence. The
variable regions of the 100000
most prevalent sequences in the B selected enrichment (library TL-B) are
included herein as SEQ ID
NOs. 103062- 203061, also ordered by prevalence.
[001061] To evaluate the performance of TL-NB and TL-B on cases independent
from those used
for training, we verified that histological H-scoring of the tissue staining
intensity obtained with the
trained libraries can be employed for the quantitative comparison of the
cases, similar to standard
pathological practice for IHC (21). The scoring for both cytoplasmic and
nuclear staining was performed
by a board-certified pathologist who was blinded to the patient outcomes.
Protocols are found in FIGs.
-198-
CA 03018066 2018-09-17
WO 2017/161357
PCT/US2017/023108
17F-H and Example 22 and scoring results are shown in Tables 33-36. Examples
of PHC staining
intensity levels in the cytoplasm and the nuclei of breast cancer FFPE tissue
ranging from 0 to 3 are
shown in FIG. 17F. See also FIGs. 17I-J, which show polyligand histochemistry
(PHC) staining profiles
comparison of the non-enriched starting library (RO) and enriched libraries TL-
NB and TL-B on patients
not benefiting (NB) and benefiting (B) from trastuzumab containing treatment.
The view areas are
matched in each row between libraries within each panel. The library RO
usually exhibits little to no
staining, while the enriched libraries can be scored from 1+ to 3+. Library TL-
NB, which was enriched
toward a trastuzumab non-benefiting case exhibits stronger intensity on NB
cases, except for NB-15.
Library TL-B, which was enriched toward a Trastuzumab responder case, exhibits
stronger intensity on
the B cases. The magnification in FIGs. 17I-J is 20x. The histological scores
were calculated by standard
methods by determining the percentages of cells on the entire tissue,
classified to fall within each PHC
intensity level in the cytoplasm and the nucleus. See FIG. 17G and Example 22.
To evaluate staining and
scoring reproducibility, we selected cases that showed weak and strong
staining with TL-NB and then
scored nuclear staining (22) between technical replicates (FIG. 17H, first
panel "Intra-assay"), different
operators (FIG. 17H, second panel "Inter-operator"), different batches of
library (FIG. 17H, third panel
:Inter-batch"), and different instruments (FIG. 17H, fourth panel "Inter-
instrument"). The classification of
four strongly and weakly staining cases was consistent and independent of
these variables, indicating that
the staining and scoring is reproducible. To further assess the technical
reproducibility of PCR amplified
versions of TL-NB and TL-B, both libraries were amplified for up to ten PCR-
generations. See FIGs.
17K-L, which show technical reproducibility of the staining with libraries TL-
NB and TL-B resulting
from different PCR-generations 1-5 (FIG. 17K), and 6-10 (FIG. 17L). Examples
from two different cases
(Her2+ and Her2-/low) at 20x magnifications are shown. For each PCR
generation, an aliquot (0.4 ng) of
each preceding library generation was amplified for 10 PCR cycles. Each PCR
generation of TL-NB and
TL-B was then used for the staining of consecutive tissue sections from the
same NB patient for TL-NB
and the same B patient for TL-B. Each PCR generation of TL-NB and TL-B was
used for the staining of
consecutive tissue sections from the same NB patient for TL-NB and the same B
patient for TL-B. No
significant difference in the staining was observed from generation to
generation, indicating highly robust
performance of both libraries after excessive PCR amplification.
Table 33: Histological Scoring, TL-NB, Trastuzamab TTNT
Case ID in Her2 status Nuclear Cytoplasmic
Nuclear score Cytoplasmic score Total score
the test set 0 1 2 3 0 1 2 3
ALx-R-42 Neg 80 0 20 0 0 100 0 0 40 100
140
ALx-R-53 Neg 20 80 0 0 0 100 0 0 80 100
180
ALx-R-41 Neg 5 10 85 0 0 100 0 0 180
100 280
ALx-R-55 Neg 30 60 10 0 0 100 0 0 80 100
180
ALx-R-58 Pos 30 40 30 0 0 70 30 0 100
130 230
ALx-R-60 Pos 15 30 55 0 100 0 0 0 140 0
140
ALx-R-59 Pos 20 50 30 0 30 50 20 0 110 90
200
ALx-R-50 Neg 100 0 0 0 30 70 0 0 0 70
70
ALx-R-51 Pos 5 90 5 0 0 100 0 0 100
100 200
ALx-R-43 Pos 1 20 79 0 0 100 0 0 178
100 278
ALx-NR-4 Neg 10 90 0 0 0 100 0 0 90 100
190
ALx-NR-7 Neg 60 40 0 0 80 20 0 0 40
20 60
ALx-NR-9 Pos 20 80 0 0 0 100 0 0 80 100
180
ALx-NR-10 Neg 30 40 30 0 0 60 40 0 100
140 240
-199-
CA 03018066 2018-09-17
WO 2017/161357
PCT/US2017/023108
ALx-NR-11 Pos 50 40 10 0 30 70 0 0 60 70 130
ALx-NR-12 Pos 20 50 30 0 0 100 0 0 110 100 210
ALx-NR-14 Neg 10 0 80 10 0 100 0 0 190 100 290
ALx-NR-18 Pos 60 20 20 0 0 90 10 0 60 110 170
ALx-NR-20 Neg 90 10 0 0 0 80 20 0 10 120 130
ALx-R-1 Neg 40 60 0 0 5 20 75 0 60 170 230
ALx-R-4 Pos 100 0 0 0 0 40 60 0 0 160 160
ALx-R-5 Pos 60 40 0 0 5 85 10 0 40 105 145
ALx-R-6 Neg 10 60 30 0 10 90 0 0 120 90 210
ALx-R-7 Neg 40 60 0 0 100 0 0 0 60 0 60
ALx-R-8 Pos 95 5 0 0 99 1 0 0 5 1 6
ALx-R-9 Neg 50 50 0 0 50 50 0 0 50 50 100
ALx-R-10 Neg 60 40 0 0 0 80 20 0 40 120 160
ALx-R-11 Neg 90 10 0 0 30 70 0 0 10 70 80
ALx-R-13 Pos 90 10 0 0 90 10 0 0 10 10 20
ALx-R-14 Neg 90 10 0 0 10 90 0 0 10 90 100
ALx-R-15 Pos 100 0 0 0 10 85 5 0 0 95 95
ALx-R-16 Pos 100 0 0 0 0 100 0 0 0 100 100
ALx-R-17 Neg 100 0 0 0 10 50 40 0 0 130 130
ALx-R-18 Pos 15 85 0 0 0 80 20 0 85 120 205
ALx-R-19 Neg 95 5 0 0 10 90 0 0 5 90 95
ALx-R-20 Pos 50 40 10 0 20 70 10 0 60 90 150
ALx-R-45 Neg 20 60 20 0 100 0 100
ALx-R-44 Neg 80 20 0 0 20 0 20
ALx-R-48 Neg 0 60 40 0 140 0 140
ALx-R-47 Neg 0 100 0 0 100 0 100
ALx-R-54 Pos 100 0 0 0 0 0 0
ALx-R-56 Pos 20 70 10 0 90 0 90
ALx-R-52 Neg 20 80 0 0 80 0 80
ALx-R-57 Pos 0 50 50 0 150 0 150
ALx-R-49 Pos 90 10 0 0 10 0 10
Table 34: Histological Scoring, TL-NB, Platinum/Taxane TTNT
Case ID in Her2 Nuclear Cytoplasmic Nuclear Cytoplasmic
Total score
the test set status 0 1 2 3 0 1 2 3
score score
P1-1 Neg 5 45 50 0 0 100 0 0 145 100 245
P1-2 Pos 70 30 0 0 10 70 20 0 30 110 140
P1-3 Neg 10 55 35 0 0 100 0 0 125 100 225
P1-4 Neg 30 70 0 0 0 100 0 0 70 100 170
P1-5 Neg 45 50 5 0 0 100 0 0 60 100 160
P1-6 Pos 20 40 40 0 0 100 0 0 120 100 220
P1-7 Neg 60 30 10 0 10 90 0 0 50 90 140
P1-8 Pos 35 45 20 0 0 70 30 0 85 130 215
P1-9 Pos 0 0 0
P1-10 Neg 0 10 90 0 100 0 0 0 190 0 190
P1-11 Pos 5 90 5 0 0 100 0 0 100 100 200
P1-12 Neg 20 40 40 0 10 90 0 0 120 90 210
P1-13 Pos 50 40 10 0 0 100 0 0 60 100 160
P1-14 Pos 80 20 0 0 50 50 0 0 20 50 70
P1-15 Neg 0 0 0
P1-16 Neg 20 80 0 0 0 60 40 0 80 140 220
P1-17 Neg 20 80 0 0 100 0 0 0 80 0 80
P1-18 Neg 0 0 0
P1-19 Neg 0 0 0
P1-20 Neg 10 90 0 0 0 100 0 0 90 100 190
P1-21 Pos 5 10 85 0 100 0 0 0 180 0 180
P1-22 Pos 60 30 10 0 70 30 0 0 50 30 80
P1-23 Neg 10 30 60 0 10 90 0 0 150 90 240
P1-24 Pos 5 70 25 0 0 100 0 0 120 100 220
P1-25 Pos 0 0 0
P1-26 Pos 10 80 10 0 0 80 20 0 100 120 220
P1-27 Neg 10 70 20 0 20 80 0 0 110 80 190
P1-28 Pos 35 40 25 0 0 60 40 0 90 140 230
P1-29 Pos 3 67 30 0 0 100 0 0 127 100 227
P1-30 Pos 10 80 10 0 10 90 0 0 100 90 190
-200-
CA 03018066 2018-09-17
WO 2017/161357
PCT/US2017/023108
P1-31 Pos 20 60 20 0 0 100 0 0 100 100 200
P1-32 Neg 20 80 0 0 0 80 20 0 80 120 200
P1-33 Neg 40 60 0 0 100 0 0 0 60 0 60
P1-34 Pos 70 30 0 0 20 60 20 0 30 100 130
P1-35 Pos 50 50 0 0 10 90 0 0 50 90 140
P1-36 Pos 80 10 10 0 0 100 0 0 30 100 130
P1-37 Neg 20 10 70 0 30 70 0 0 150 70 220
P1-38 Neg 30 60 10 0 10 90 0 0 80 90 170
P1-39 Pos 10 90 0 0 0 100 0 0 90 100 190
P1-40 Neg 60 35 5 0 20 80 0 0 45 80 125
P1-41 Neg 5 45 50 0 0 80 20 0 145 120 265
Table 35: Histological Scoring, TL-B, Trastuzamab TTNT
Case ID in the test Her2 status Nuclear
Cytoplasmic Nuclear score Cytoplasmic score Total score
set 0 1 2 3 0 1 2 3
ALx-R-42 Neg 35 45 20 0 0 100 0 0 85 100 185
ALx-R-53 Neg 30 70 0 0 0 100 0 0 70 100 170
ALx-R-41 Neg 10 80 10 0 10 90 0 0 100 90 190
ALx-R-55 Neg 90 10 0 0 0 100 0 0 10 100 110
ALx-R-58 Pos 20 80 0 0 0 100 0 0 80 100 180
ALx-R-60 Pos 10 40 50 0 10 90 0 0 140 90 230
ALx-R-59 Pos 15 85 0 0 0 100 0 0 85 100 185
ALx-R-50 Neg 50 50 0 0 0 100 0 0 50 100 150
ALx-R-51 Pos 5 95 0 0 0 100 0 0 95 100 195
ALx-R-43 Pos 5 45 50 0 5 95 0 0 145 95 240
ALx-NR-4 Neg 25 65 10 0 0 90 10 0 85 110 195
ALx-NR-7 Neg 70 30 0 0 100 0 0 0 30 0 30
ALx-NR-9 Pos 40 60 0 0 0 100 0 0 60 100 160
ALx-NR-10 Neg 80 10 10 0 10 80 10 0 30 100 130
ALx-NR-11 Pos 90 10 0 0 10 90 0 0 10 90 100
ALx-NR-12 Pos 10 20 70 0 0 100 0 0 160 100 260
ALx-NR-14 Neg 50 20 30 0 10 20 70 0 80 160 240
ALx-NR-18 Pos 88 10 2 0 2 88 10 0 14 108 122
ALx-NR-20 Neg 80 20 0 0 20 50 30 0 20 110 130
ALx-R-1 Neg 10 10 80 0 0 90 10 0 170 110 280
ALx-R-4 Pos 20 80 0 0 0 60 40 0 80 140 220
ALx-R-5 Pos 20 40 40 0 0 60 40 0 120 140 260
ALx-R-6 Neg 5 35 60 0 0 100 0 0 155 100 255
ALx-R-7 Neg 10 45 45 0 0 80 20 0 135 120 255
ALx-R-8 Pos 10 25 25 40 0 40 60 0 195 160 355
ALx-R-9 Neg 5 35 60 0 0 100 0 0 155 100 255
ALx-R-10 Neg 5 95 0 0 0 100 0 0 95 100 195
ALx-R-11 Neg 2 30 68 0 0 100 0 0 166 100 266
ALx-R-13 Pos 93 5 2 0 25 75 0 0 9 75 84
ALx-R-14 Neg 10 80 10 0 0 50 50 0 100 150 250
ALx-R-15 Pos 20 20 60 0 0 80 20 0 140 120 260
ALx-R-16 Pos 10 60 30 0 0 20 80 0 120 180 300
ALx-R-17 Neg 70 30 0 0 0 50 50 0 30 150 180
ALx-R-18 Pos 5 15 80 0 0 0 100 0 175 200 375
ALx-R-19 Neg 100 0 0 0 10 20 70 0 0 160 160
ALx-R-20 Pos 20 50 30 0 0 100 0 0 110 100 210
ALx-R-45 Pos 50 40 10 0 10 70 20 0 60 110 170
ALx-R-44 Neg 0 50 50 0 80 20 0 0 150 20 170
ALx-R-48 Neg 20 70 10 0 0 100 0 0 90 100 190
ALx-R-47 Pos 0 100 0 0 0 100 0 0 100 100 200
ALx-R-54 Neg 100 0 0 0 0 100 0 0 0 100 100
ALx-R-56 Neg 60 40 0 0 0 70 30 0 40 130 170
ALx-R-52 Pos 20 80 0 0 10 60 30 0 80 120 200
ALx-R-57 Pos 0 100 0 0 0 100 0 0 100 100 200
ALx-R-49 Neg 95 5 0 0 30 70 0 0 5 70 75
Table 36: Histological Scoring, TL-B, Platinum/Taxane TTNT
Case ID in Her2 status
Nuclear Cytoplasmic Nuclear score Cytoplasmic score Total score
the test set 0 1 2 3 0 1 1 2 3
-201-
CA 03018066 2018-09-17
WO 2017/161357
PCT/US2017/023108
P1-1 Neg 5 95 0 0 0 80 20 0 95 120
215
P1-2 Pos 80 20 0 0 20 80 0 0 20 80
100
P1-3 Neg 5 95 0 0 0 100 0 0 95 100
195
P1-4 Neg 10 90 0 0 0 100 0 0 90 100
190
P1-5 Neg 60 39 1 0 0 100 0 0 41 100
141
P1-6 Pos 0 0 0
P1-7 Neg 70 30 0 0 70 30 0 0 30
30 60
P1-8 Pos 80 20 0 0 60 40 0 0 20
40 60
P1-9 Pos 0 0 0
P1-10 Neg 0 50 50 0 0 100 0 0 150
100 250
P1-11 Pos 5 95 0 0 0 100 0 0 95 100
195
P1-12 Neg 30 70 0 0 30 70 0 0 70 70
140
P1-13 Pos 30 40 30 0 0 100 0 0 100
100 200
P1-14 Pos 90 10 0 0 40 60 0 0 10
60 70
P1-15 Neg 0 0 0
P1-16 Neg 5 95 0 0 0 100 0 0 95 100
195
P1-17 Neg 50 50 0 0 0 100 0 0 50 100
150
P1-18 Neg 0 0 0
P1-19 Neg 0 0 0
P1-20 Neg 10 90 0 0 70 30 0 0 90 30
120
P1-21 Pos 5 45 50 0 0 100 0 0 145
100 245
P1-22 Pos 50 50 0 0 40 60 0 0 50 60
110
P1-23 Neg 20 80 0 0 0 80 0 0 80 80
160
P1-24 Pos 20 70 10 0 20 40 40 0 90 120
210
P1-25 Pos 0 0 0
P1-26 Pos 60 40 0 0 0 60 40 0 40 140
180
P1-27 Neg 0 50 50 0 0 100 0 0 150
100 250
P1-28 Pos 5 95 0 0 0 40 60 0 95 160
255
P1-29 Pos 0 5 95 0 0 100 0 0 195
100 295
P1-30 Pos 5 95 0 0 5 95 0 0 95 95 190
P1-31 Pos 5 85 10 0 0 100 0 0 105
100 205
P1-32 Neg 50 50 0 0 0 70 30 0 50 130
180
P1-33 Neg 40 60 0 0 0 100 0 0 60 100
160
P1-34 Pos 100 0 0 0 100 0 0 0 0 0
0
P1-35 Pos 10 85 5 0 0 100 0 0 95 100
195
P1-36 Pos 30 60 10 0 20 75 5 0 80 85
165
P1-37 Neg 20 20 60 0 100 0 0 0 140 0
140
P1-38 Neg 50 40 10 0 0 100 0 0 60 100
160
P1-39 Pos 30 70 0 0 20 70 10 0 70 90
160
P1-40 Neg 60 40 0 0 0 100 0 0 40 100
140
P1-41 Neg 20 80 0 0 0 50 50 0 80 150
230
[001062] With two libraries in hand that reciprocally show preferential
staining for either B or NB
cases, we tested use fo PHC scores for the differentiation and prediction of
responders and non-responders
to trastuzumab-based regimens in the 45 independent test cases. See FIG. 17A.
We assessed the PHC
scores of TL-B and TL-NB by receiver operating characteristic (ROC) curves,
and calculated area under
the curve (AUC) values (FIGs. 17Mi-ii). For TL-NB, an AUC value of 0.703 was
obtained based on the
scoring of the nucleus (22) (FIG. 17Mi), whereas TL-B yielded an AUC value of
0.688 (FIG. 17Mii)
based on the scoring of both nucleus and cytoplasm. These AUC values from the
individual libraries
indicate that TL-NB and TL-B provide reliable information that distinguishes
the NB and B phenotypes.
To predict the patient's response to trastuzumab-based regimens with a
multivariate method that uses
PHC scores from both TL-NB and TL-B staining, a logistic regression model was
developed. Specifically,
the binary outcome of benefit- or non-benefit status was used as the dependent
variable; the staining
scores of TL-NB and TL-B, respectively, were treated as independent variables.
We then assessed the
performance of the model by ROC curve analysis. As a result, by combining the
data from the two
libraries, the AUC-value increased to 0.804, indicating improved performance
due to the reciprocal nature
-202-
CA 03018066 2018-09-17
WO 2017/161357 PCT/US2017/023108
of the training schemes (FIG. 17Miii, indicated by AUC = 0.804). The
statistical reliability of this
analysis was further verified by 10-fold cross validation (CV), which resulted
in an AUC value of 0.760
(FIG. 17Miii, indicated by AUC = 0.760). We then compared these PHC-based NB
and B classifications
with those predicted by HER2 immunohistochemistry scoring of the same 45 cases
test set (FIG. 17Miii,
indicated by AUC = 0.410). The HER2 IHC results yielded an AUC value of 0.410,
indicating that
TL-NB and TL-B outperformed conventional HER2 IHC in classifying trastuzumab B
and NB cases in
this cohort.
[001063] TL-NB and TL-B were able to effectively classify B and NB patients
that had low levels
of HER2-expression by IHC with an AUC value of 0.8. FIG. 17N shows the
receiver operating
characteristic (ROC) curves for differentiation between patients, benefiting
and not from trastuzumab-
based regimens, using combined histological scores from libraries TL NB and TL
B polyligand
histochemistry (PHC) staining in the test set of 45 cases, shown separately in
the group of HER2+ cases
(A) and in the group of HER2-/low cases (B). Hence, the ability of the
libraries to differentiate NB from
B-cases does not depend solely on the HER2 status.
[001064] To determine whether TL-NB and TL-B were revealing information
about response to
trastuzumab-based regimens and not only classifying patients with a favorable
prognosis regardless of
trastuzumab treatment, we stained FFPE tumor tissues from an independent
cohort of 33 patients who
were treated with a platinum/taxane combination without trastuzumab. Like all
other samples in this
study, the samples from this non-trastuzumab cohort were collected prior to
treatment. The AUC of the
combined libraries on 33 HER2-cases independent from the test set who received
platinum/taxane
combination therapy instead of trastuzumab was 0.302 (FIG. 17Miii, indicated
by AUC = 0.302),
indicating that the performance of TL-NB and TL-B relate to the molecular
profile determining the
response to the presence of trastuzumab in the treatment regimens. Moreover,
trastuzumab has been
reported to be substantially less effective in estrogen receptor (ER)-positive
breast cancer (23, 24), but we
found that the ER status of all cases enrolled in our study showed no
correlation with the benefit from
trastuzumab-based therapy. See FIG. 170, which shows that in the tested
population, benefit from
trastuzumab does not correlate with hormonal status. ER status for the
patients in this Example is shown
in Tables 31-32. Taken together, these data indicate that the application of
these libraries to the 45-cases
test-set classifies patients with benefit from patients without benefit from
trastuzumab-containing
treatment with high accuracy, regardless of their HER2-status.
[001065] We next sought to evaluate the ability of PHC to select the
fraction of patients that benefit
from trastuzumab-based regimens for more than 180 days. FIG. 17Pi-ii show
Kaplan-Meier curves of
trastuzumab-treated breast cancer patients stratified by polyligand profiling.
In FIG. 17Pi, the shortest
distance between the ROC curves to point (specificity and sensitivity = 100%)
determines the cutoff of
test positive and negative, and is represented as dot on the line indicated by
AUC = 0.804 in FIG. 17Miii
(Sensitivity: 66.6%; Specificity: 86.7%). An "event" was defined as the time
point (days) at which a
patient either deceased from cancer or at which trastuzumab-based treatment
changed. Median time of
benefit is 604 days for patients tested positive ((FIG. 17Pi, upper curve), n
= 22, event = 11) and 129 days
-203-
CA 03018066 2018-09-17
WO 2017/161357 PCT/US2017/023108
for patients tested negative ((FIG. 17Pi, lower curve), n = 23, event = 18).
HR = 0.320, 95% CI: 0.146 ¨
0.703; log-rank p = 0.003. The small vertical lines mark cases that were
censored due to absence of
treatment follow-up data. See Table 32. FIG. 17Pii shows the Kaplan-Meier
curve of trastuzumab-treated
breast cancer patients stratified by tumors' HER2 status. HER2 status of
patients with both HER2 IHC
and HER2 ISH test results was determined according to the following rules. 1.
HER2 positive, if any test
shows positive result; else 2, HER2-/low, if any test shows negative result;
else 3, NA, if both test show
equivalent result. Median time of benefit was 250 days for HER2 positive cases
((FIG. 17Pii, lower
curve, n = 25, event = 16), and 369 days for HER2-/low cases ((FIG. 17Pii,
upper curve; n = 18, event =
12). HR = 1.39, 95%CI: 0.62 ¨ 3.13; log-rank p = 0.418. Accordingly, the
resulting Kaplan-Meier curves
show that cases with positive test results exhibited a significantly longer
TTNT (FIG. 17P1, upper curve)
than those tested negative (FIG. 17Pi, lower curve). The median event-free
time, i.e. the time that elapsed
before the treatment regimens changed, increased from 129 days for the test-
negative to 604 days for the
test-positive cases. For comparison, we analyzed the prognostic value based on
the tumors' HER2 status
as determined by IHC. In this case, the KM-curves did not reveal any
significant difference in TTNT
between patients that were HER2+ or Her2-/low (FIG. 17Pii). These data
indicate that polyligand
profiling can be employed to generate a predictive assay that differentiates
between patients that benefit
from a certain treatment regimens from those that do not.
[001066] In this Example, we demonstrated a prototypical polyligand
profiling approach with
potential to improve patient stratification for cancer therapy. The approach
was applied to train the
libraries TL-B and TL-NB for classifying trastuzumab response by TTNT.
Polyligand profiling is not
limited to this condition and will be applicable for differentiating a wide
variety of phenotypes depending
on the question at hand and the availability of suitable samples. Previous
studies have used morphology-
based enrichment of ssODN libraries on cancer tissues (see herein, references
25, 26) in order to identify
new biomarkers. In this study, to account for the heterogeneity of molecular
composition and the complex
interactomes that reflect intra- and inter-tumoral variability it is
reasonable that library training as
introduced here enriches for a complex variety of ligands.
[001067] Without optimization, the PHC-test developed in this Example
outperformed the standard
HER2 IHC in differentiating the patients in this cohort who benefit from
trastuzumab-based treatment
from those that do not. See FIGs. 17M, P and related discussion above. These
data indicate that the PHC-
test can provide a CDx, in this case one that aims at identifying the 50-70%
of HER2+ patients who will
not benefit from trastuzumab. Conversely, it has been reported that 16-45% of
patients with breast cancer
who express low levels of Her2 derived benefit from adjuvant trastuzumab in
combination chemotherapy
(27-29). The data shown in FIGs. 17M, P indicate that a CDx based on
polyligand profiling also has the
potential to identify the patients who benefit from trastuzumab-containing
regimens from the group
expressing low levels of Her2.
[001068] Polyligand profiling allows accessing the molecular information
that is reflected by the
perturbations within the vast diversity of biological complexes that
constitute cellular interactomes within
or among tumors. In addition to predicting patients with benefit or without
benefit from a given drug
-204-
CA 03018066 2018-09-17
WO 2017/161357 PCT/US2017/023108
treatment regimens, the PHC approach can advance precision oncology in
additional ways. For example,
when applied to existing therapies as well as to new compounds in clinical
trials polyligand profiling
could reduce the administration of toxic therapies that are ineffective, and
thereby could increase the
success rate of new drugs.
[001069] References cited in this Example, all incorporated by reference
herein in their
entirety.
[001070] 1. D. Hanahan, R. A. Weinberg, Hallmarks of cancer: the next
generation. Cell 144, 646-
674 (2011).
[001071] 2. M. Gerlinger et al., Intratumor heterogeneity and branched
evolution revealed by
multiregion sequencing. N Engl J Med 366, 883-892 (2012).
[001072] 3. L. A. Garraway, E. S. Lander, Lessons from the cancer genome.
Cell 153, 17-37
(2013).
[001073] 4. V. Prasad, Perspective: The precision-oncology illusion. Nature
537, S63 (2016).
[001074] 5. V. Prasad, T. Fojo, M. Brada, Precision oncology: origins,
optimism, and potential.
Lancet Oncol 17, e81-86 (2016).
[001075] 6. G. L. Klement et al., Future paradigms for precision oncology.
Oncotarget 7, 46813-
46831 (2016).
[001076] 7. R. Kurzrock, F. J. Giles, Precision oncology for patients with
advanced cancer: the
challenges of malignant snowflakes. Cell Cycle 14, 2219-2221 (2015).
[001077] 8. J. Shrager, J. M. Tenenbaum, Rapid learning for precision
oncology. Nat Rev Clin
Oncol 11, 109-118 (2014).
[001078] 9. M. J. Duffy, J. Crown, Companion biomarkers: paving the pathway
to personalized
treatment for cancer. Clin Chem 59, 1447-1456 (2013).
[001079] 10. M. P. Stumpf et al., Estimating the size of the human
interactome. Proc Natl Acad Sci
U S A 105, 6959-6964 (2008).
[001080] 11. Z. Mitri, T. Constantine, R. Regan, The HER2 Receptor in
Breast Cancer:
Pathophysiology, Clinical Use, and New Advances in Therapy. Chemother Res
Pract 2012, 743193
(2012).
[001081] 12. H. J. Burstein, The distinctive nature of HER2-positive breast
cancers. N Engl J Med
353, 1652-1654 (2005).
[001082] 13. R. Bartsch, C. Wenzel, G. G. Steger, Trastuzumab in the
management of early and
advanced stage breast cancer. Biologics 1, 19-31 (2007).
[001083] 14. I. Petak, R. Schwab, L. Orfi, L. Kopper, G. Keri, Integrating
molecular diagnostics
into anticancer drug discovery. Nat Rev Drug Discov 9, 523-535 (2010).
[001084] 15. D. J. Slamon et al., Human breast cancer: correlation of
relapse and survival with
amplification of the HER-2/neu oncogene. Science 235, 177-182 (1987).
[001085] 16. J. Horton, Trastuzumab use in breast cancer: clinical issues.
Cancer Control 9, 499-
507 (2002).
-205-
CA 03018066 2018-09-17
WO 2017/161357 PCT/US2017/023108
[001086] 17. M. Famulok, J. S. Hartig, G. Mayer, Functional aptamers and
aptazymes in
biotechnology, diagnostics, and therapy. Chem. Rev. 107, 3715-3743 (2007).
[001087] 18. M. Famulok, G. Mayer, Aptamer modules as sensors and
detectors. Ace Chem Res
44, 1349-1358 (2011).
[001088] 19. TTNT is a FDA-approved clinical endpoint that is robustly
captured by electronic
medical record systems and therefore is generally available.
[001089] 20. U.S. Department of Health and Human Services Food and Drug
Administration
Center for Drug Evaluation and Research (CDER), Guidance for industry:
clinical trial endpoints for the
approval of cancer drugs and biologics.,
hap://www.fda.gov/downloads/Drugs/.../Guidances/ucm071590.pdf (2007).
[001090] 21. Z. Gatalica, S. M. Lele, B. A. Rampy, B. A. Norris, The
expression of Fhit protein is
related inversely to disease progression in patients with breast carcinoma.
Cancer 88, 1378-1383 (2000).
[001091] 22. TL-NB staining of the cytoplasm was not informative for the
differentiation of B and
NB cases.
[001092] 23. L. Lousberg, J. Collignon, G. Jerusalem, Resistance to therapy
in estrogen receptor
positive and human epidermal growth factor 2 positive breast cancers: progress
with latest therapeutic
strategies. Ther Adv Med Oncol 8, 429-449 (2016).
[001093] 24. S. Loi et al., Effects of Estrogen Receptor and Human
Epidermal Growth Factor
Receptor-2 Levels on the Efficacy of Trastuzumab: A Secondary Analysis of the
HERA Trial. JAMA
Oncol 2, 1040-1047 (2016).
[001094] 25. H. Wang et al., Morph-X-Select: Morphology-based tissue
aptamer selection for
ovarian cancer biomarker discovery. Biotechniques 61, 249-259 (2016).
[001095] 26. S. Li et al., Identification of an aptamer targeting hnRNP Al
by tissue slide-based
SELEX. J Pathol 218, 327-336 (2009).
[001096] 27. S. Paik, C. Kim, N. Wolmark, HER2 status and benefit from
adjuvant trastuzumab in
breast cancer. N Engl J Med 358, 1409-1411 (2008).
[001097] 28. S. Ithimakin et al HER2 drives luminal breast cancer stem
cells in the absence of
HER2 amplification: implications for efficacy of adjuvant trastuzumab. Cancer
Res 73, 1635-1646
(2013).
[001098] 29.
clinicaltrials.gov/ct2/show/NCT01275677?term=NSABP+B012756478zrank=01275671.
Example 22: Polyligand profiling Materials and Methods
[001099] This Example provides Marterials and Methods used in Example 21
above.
[001100] FFPE tissue cases
[001101] The study was performed with Western Institutional Review Board
approval, 45 CFR
46.101(b)(4).
[001102] This study included cases from women with invasive breast cancer
that received
trastuzumab-based treatment first line after tissue collection with a
sufficient number of properly fixed
-206-
CA 03018066 2018-09-17
WO 2017/161357 PCT/US2017/023108
and embedded slides available. Cases with in situ cancer, improperly fixed or
crushed tissue sections were
not included in this study. Cases with incomplete staining (i.e. insufficient
coverage of the tissue with
binding solution) and other technical problems with the assay performance were
excluded from analysis.
[001103] Serial tissue sections of 51 patients with breast cancer that had
time-to-next treatment
(TTNT) data from trastuzumab therapy were used for training of the ssODN
libraries and testing of TL-
NB and TL-B. A separate group of 33 cases that had TTNT data from platinum-
taxane treatment was used
as a control set to evaluate the specificities of TL-NB and TL-B towards
trastuzumab-based TTNT.
Excised tissue containing both tumor and normal parts, was formalin-fixed,
paraffin-embedded and
serially sectioned (4 !um). Haematoxylin and eosin (H&E) staining was
performed for 1-2 slides of each
case and served for initial pathological diagnosis. Pre-treatment of the FFPE
tissue slides before the
enrichment included incubating slides at 60 C for 1.5 h, followed by
automated deparaffinization and
epitope retrieval on the Ventana UltraView Autostainer (Ventana Medical
Systems, Inc., Tuscon, AZ).
Specifically, deparaffinization at 72 C for 24 min, dehydration by ethanol,
epitope retrieval at 90 C for
36 min and 100 C for 4 min (pH 8), followed by peroxidase inhibition (H202,
1% x < 5%) and washing
slides with detergent (Dawn 1-00; P&G Professional, The Procter & Gamble
Company, Cincinnati, OH)
to remove residual liquid coverslip. For testing of the enriched libraries,
deparaffinization was performed
manually, by incubation at 60 C for 1.5 hour, followed by epitope retrieval
on PT-Linker (Dako, Agilent
Technologies, Santa Clara, CA) at 97 C for 20 min, pH 9.
[001104] Treatment regimens and pathological diagnoses for 84 cases can be
found in Tables 29-
32. A subset of 3 non-benefiting (NB) breast cancer cases and 3 benefiting (B)
breast cancer cases was
selected for enrichment. Patients who stayed on their initially prescribed
trastuzumab therapy for at least
181 days were classified as B; patients whose treatment changed within 180
days were classified as NB.
Clinical information for the training cases can be found in Tables 29-30. For
enrichment purposes, tissue
areas with breast carcinoma were utilized as positive selection targets, while
adjacent non-malignant
tissue as well as carcinoma tissue from patients with alternative response was
used as counter selection
targets.
[001105] ssDNA library design and reproduction with unequal length primers
asymmetrical PCR
[001106] The random ssDNA library (naïve F-TRin-35n-B 8-3s library)
contains 35 random
nucleotides flanked by constant regions. Specifically, the naïve library
comprises a 5' region (5'
CTAGCATGACTGCAGTACGT (SEQ ID NO. 4)) followed by a random naïve
oligonucleotide sequence of
35 nucleotides and a 3' region (5' CTGTCTCTTATACACATCTGACGCTGCCGACGA (SEQ ID
NO. 5)).
This library was synthesized at Integrated DNA Technologies (IDT, Coralville,
Iowa, USA), pooled in
equimolar amounts and PCR amplified to add biotin to the 5'-end. The library
constant regions are
complimentary to primers: reverse: 5'-Biosg-CTAGCATGACTGCAGTACGT-3' (SEQ ID
NO. 4) and
forward: 5' - (SEQ ID NO. 203062) /iSp9/ /iSp9/
TCGTCGGCAGCGTCA-3' (SEQ ID NO. 203063)), which were used in asymmetric PCR to
generate
majority of the target strand. The internal spacers iSp9 (Internal triethylene
glycol Spacer, IDT) of the
forward primer prevented extension of the complimentary strand, while the
addition of poly-A tail
-207-
CA 03018066 2018-09-17
WO 2017/161357 PCT/US2017/023108
resulted in longer length of forward strands, allowing for size separation and
target strand ssDNA
recovery following gel excision from 4% denaturing agarose E-gels with final
purification by gel
extraction column (Nucleospin, MACHEREY-NAGEL GmbH & Co. KG, Duren, DE).
Biotinylated
antisense library was used for enrichment. Asymmetric PCR mixture (100 I)
contained 5x Q5 PCR
buffer, 0.2 mM dNTPs, 0.08 p.M of forward primer, 30 iuM of reverse primer,
0.01 pmol template (of pure
library) or 57 1 of post-dissection solution containing library/tissue (after
enrichment) and 2U of Q5 Hot
Start High-Fidelity DNA polymerase (New England Biolabs, Ipswich, MA). PCR
program included initial
denaturation at 98 C for 30sec, followed by cycle of denaturation, annealing
(60 C for 30 sec) and
extension (72 C for 3 min), and final extension was at 72 C for 5 min. For
pure library 15 cycles of
amplification were performed, for libraries during enrichment number of cycles
varies between 15 and 30
depends on the recovery. Asymmetric PCR products were mixed with denaturing
buffer (180 mM NaOH,
6 mM EDTA), heated at 70 C for 10 min, cooled down on ice for 3 min, loaded
¨20 .1 on 4% agarose
SYBRGold gel (E-GEL EX Gels, G401004, Life Technologies), separated for 15
min. Single stranded
reverse strand was cut, gel pieces were combined with NTC buffer (Nucleospin,
Macherey-Nagel), melted
at 50 C for 5-10 min until all pieces got molten. 700 1 of melted agarose
was loaded onto Nucleospin
column and then followed standard procedure for ssDNA purification. Purified
DNA was eluted with 30
Jul of NE buffer.
[001107] FFPE tissue slide-based SELEX
[001108] Enrichment of ssODNs libraries toward Trastuzumab response was
performed according
to the scheme in FIG. 17C. Treatment regimens for enrichment cases can be
found in Table 29-30. In the
enrichment of each library, first three rounds were performed on positive
cases only, followed by
additional three rounds with two counter selections cases and one positive
case. For positive selection,
400 jil of blocking buffer (0.8 ng/ul Salmon DNA (Life Technologies, Thermo
Fisher Scientific Inc.,
Waltham, Massachusetts, USA), 0.8 ng/ 1tRNA (Life Technologies), 1 g/ 1HSA
(Sigma), 0.5% F127
(Thermo Fisher) and 3 mM MgCl2 in lx PBS) was mixed with 90 1 of ssODN
library solution (7 pmol
for round 1, 3.5 pmol for following rounds in 1xPBS, 3 mM MgCl2) on top of the
Agilent gasket slide
(Agilent Technologies, Santa Clara, CA). FFPE tissue slide, after
deparaffinization and epitope retrieval,
was mounted on top of the gasket slide containing binding cocktail and
incubated for 1 hour in Agilent
microarray hybridization chambers with rotation at RT. After incubation,
slides were washed by dipping
into 2x750 ml washing buffer (1xPBS, 3 mM MgCl2) buffer, 3 dips into each jar.
Next, 490 1 of nuclear
fast red (NFR), supplemented with 3 mM MgCl2, was added to the slide for 45 s
and washed by 6 times
dipping in 750 ml washing buffer. Based on the initial pathological diagnosis
from corresponding H&E
slides, cancer areas were dissected and transferred into 180 p.1 water, which
served as a template for
asymmetric PCR with unequal length primers to generate single stranded library
for next round (see
protocol above). Remaining normal tissue served for internal counter
selection. This protocol was
repeated for 3 rounds. For negative selection, binding cocktail was added
directly to the tissue of counter
selection slides and incubated for 1 hour in humidity chamber. After
incubation, maximum volume of
supernatant was collected. Additionally, 50 1 of blocking buffer was applied
to collect the unbound
-208-
CA 03018066 2018-09-17
WO 2017/161357 PCT/US2017/023108
ssODNs. Combined supernatant was added to the 2" counter selection slide and
incubated for 1 hour.
After incubation supernatant was collected the same way as before and applied
to the slide from positive
case for another hour incubation, done this time in the Agilent microarray
hybridization chamber. The
following steps, washing, staining and PCR, were the same as described above.
[001109] Polyligand-histochemistry (PHC) screening of the enriched
libraries
[001110] Staining of FFPE tissue slides with enriched libraries was
performed on Dako
Autostainer. After baking slides at 60 C for 1.5 hour, epitope retrieval was
done on Dako PT-Linker at
pH9, 98 C, 22 min. The staining on Dako Autostainer includes 5 min peroxidase
inhibition with 450 1 of
solution, containing disodium hydrogenorthophosphate 5%<= x< 7%, H202 3%<= x<
5%, phosphoric
acid, monosodium salt, monohydrate 1%<= x< 2%, 1 hour incubation with 450 ul
of binding cocktail (3.5
pmol of enriched library, 0.65 ng/u1 Salmon DNA, 0.65 ng/ultRNA, 10% BlockAid
(Life Technologies),
30 min incubation with 450 1.1.1 of Streptavidin Poly-HRP, supplemented with 3
mM Mg C12, 10 min
staining with DAB solution, supplemented with 3 mM MgCl2, followed by 5 min
incubation with 450 ul
of Hematoxylin (2ng/ 1 final conc.). Rinsing with 1xPBS, 3 mM MgCl2 buffer was
done between each
step. Finally, the stained slides were dehydrated with ethanol, xylene and
covered by coverslip for long-
term storage. Microscopy was done on Olympus BX41 (Olympus Corporation of the
Americas, Center
Valley, PA, USA).
[001111] Histological scores for both nuclear and cytoplasmic staining were
calculated as sum
between intensity levels (1, 2 and 3) multiplied by the percentage of the
cells with this particular intensity.
[001112] Statistical analysis
[001113] Firstly, the ability of each single library to classify
Trastuzumab responders and non-
responders was assessed by ROC curves and AUCs. See, e.g., FIGs. 17J-K. To
predict the patient's
response to trastuzumab therapy with a multivariate method using PHC scores
from both library TL-NB
and TL-B staining, a logistic regression model was developed. Specifically, a
binary outcome of
responder/non-responder was used as the response variable, and staining scores
of libraries TL-NB and
TL-B were treated as independent variables (FIG. 17J (C), solid line labeled
AUC = 0.804). A 10-fold
cross-validation was conducted to assess the generalizability of the model's
prediction performance, in
which the data set was randomly split into 10 equal parts exclusively. A
logistic regression model was
built on 9 parts, and subsequently tested on the 1 hold-out part. This process
was iterated throughout the
parts, and only the predicted probability was collected for further assessment
(FIG. 17J (C), dashed
line labeled AUC = 0.760).
[001114] The end points of time to next treatment (TTNT) were defined as
either the time of next
non-trastuzumab treatment or death. Patients without the next non-trastuzumab
treatment or death
information were censored at the last contact date (see vertical marks in the
Kaplan-Meier curves (FIG.
17M). A Cox-PH model was fitted using either tumors' HER2 status or PHC test
results as the
independent variable. Median survival time was calculated from the Kaplan-
Meier estimate. The Log-rank
test was performed to evaluate the significance of TTNT survival between
groups. All analysis was
conducted using the "survival" r package.
-209-
CA 03018066 2018-09-17
WO 2017/161357 PCT/US2017/023108
Example 23: Alternate oliaonucleotide probe assay classifies outcomes of
breast cancer patients
treated with trastuzumab-based therapy
[001115] Background: Although trastuzumab is a highly effective targeted
therapy, approximately
50% of patients with HER2+ breast cancers do not benefit from trastuzumab-
based regimens. We
developed a poly-ligand aptamer-based approach that outperforms traditional
HER2 testing in its ability to
classify patients likely to derive benefit from trastuzumab.
[001116] Methods: A library of 1013 biotinylated ssDNA
oligodeoxynucleotides (ssODN) was
incubated on FFPE tissue slides of patients who either benefitted (B) or did
not benefit (NB) from
trastuzumab-based therapies based on time to next treatment. Unbound ssODNs
were discarded and
bound ssODNs were retained for two subsequent rounds of positive selection.
Starting at round 4, the
partially enriched library was applied to cases representing the alternate
phenotype (NB for B and vice
versa) for negative selection and supernatant containing unbound ssODNs was
collected and retained.
Libraries obtained after two more rounds of negative selection were used as
probes to stain and score 30 B
and 15 NB independent cases by Polyligand Histochemistry (PHC). The ability of
the trained libraries to
classify patients who benefitted from trastuzumab-based treatment was assessed
by calculating AUC
values from ROC curves. Kaplan-Meier (KM) plots were used to compare outcomes
with test results.
[001117] Results: Two libraries effectively classified B and NB groups (ROC
AUC of 0.8). In
contrast, standard HER2 IHC yielded an AUC of 0.4. Median duration of
trastuzumab treatment was 604
days for test-positive patients and 129 days for test-negative patients
(HR=0.320, 95% CI:0.146-0.703;
log-rank p = 0.003), indicating that PHC scoring was highly effective for
classifying distinct clinical
outcomes. By HER2 status alone (IHC), median duration of trastuzumab treatment
of 250 days for
HER2+ cases and 369 days for HER2-/low cases (HR = 1.39, 95% CI: 0.62-3.13;
log-rank p = 0.418).
[001118] Conclusions: These results indicate that polyligand profiling
provides a high-
performance systems biology approach to generating predictive assays that can
be used to identify patients
more or less likely to benefit from targeted therapies such as trastuzumab.
Example 24: Selection of aptamers on FFPE tissue from individuals diaanosed
with colorectal
cancer and treated with FOLFOX and bevacizumab
[001119] Bevacizumab is a recombinant humanized monoclonal antibody that
blocks angiogenesis
by inhibiting vascular endothelial growth factor A (VEGF-A). VEGF-A is a
chemical signal that
stimulates angiogenesis in a variety of diseases, especially in cancer.
Bevacizumab, sold under the trade
name Avastin, was approved by the FDA in February 2004 for use in metastatic
colorectal cancer (CRC)
when used with standard chemotherapy treatment (as first-line treatment) and
with 5-fluorouracil-based
therapy for second-line metastatic colorectal cancer. FOLFOX is a chemotherapy
regimen for treatment of
colorectal cancer, made up of three drugs: 1) FOL¨ Folinic acid (leucovorin);
2) F ¨ Fluorouracil (5-FU);
and 3) OX ¨ Oxaliplatin (Eloxatin). FOLFOX and bevacizumab may be used as
first-line treatment for
metastatic CRC.
[001120] Currently, there is no good way to predict efficacy of FOLFOX with
Bevacizumab as a
treatment in cancer therapy. The goal of this Example was the development of
oligonucleotide probe
-210-
CA 03018066 2018-09-17
WO 2017/161357 PCT/US2017/023108
libraries that can be used in an assay that predicts the response to a
combinational therapy with FOLFOX /
bevacizumab in individuals diagnosed with colorectal cancer. The approach
taken is similar to Examples
19-20 above. Briefly, the selection of oligonucleotide probes was performed on
FFPE CRC tissue
samples. Patients were divided into two cohorts based on the time they have
stayed on FOLFOX (TNT;
time to next treatment): responder and non-responder. A non-responder stayed
on FOLFOX for a
maximum of 124 days while a responder was on this treatment for at least 241
days. Bevazicumab
treatment varied from patient to patient. It might have started at the same
time as FOLFOX or later and
ended at the same time, earlier or later than FOLFOX. An enrichment scheme is
outlined in FIG. 18A
with positive and negative selection steps illustrated in FIG. 18B and FIG.
18C, respectively.
[001121] Six rounds of positive selection of 7 enrichments for responder
and 4 enrichments for
non-responders were performed, creating 11 pools of enriched oligonucleotide
probes. Counter selection
was performed for responder cases on the non-responder samples and vice versa.
An exemplary set of
slides is shown in FIGs. 18D-E, which shows staining of an FFPE sample used
for positive selection in
enrichment "M" stained with H&E (FIG. 18D) or the probe library M (FIG. 18E).
The figure shows
staining for cancer tissue; tumor site: colon; specimen: colon. The slides are
shown at 20X magnification.
Table 37 shows results of staining intensity of the indicated tissue samples
with the indicated probe
library.
Table 37: Enriched oligonucleotide probes
Specimen used
Enriched
for positive Cancer Non-Cancer
Probe Library
selection
A Rectum ++
+++ No data
Non-responder
+++ No data
++
++ ++
++
Colon
+++ +++
Responder J +++
++ ++
++
+++
[001122] To test the enriched libraries, one non-responder case and 5
responder cases that were not
part of the enrichment were stained with all 11 libraries. In addition, the
cases used for positive selection
were stained with the corresponding libraries. Examplary results for staining
of one test sample, Sample 2,
are shown in FIGs. 18F-G. The sample characteristics include: Responder; tumor
site: descending colon;
specimen: descending colon. FIG. 18F shows staining of a cancer sample from
the Sample 2 slide. The
-211-
CA 03018066 2018-09-17
WO 2017/161357
PCT/US2017/023108
library (A-M) are indicated over each slide in the figure. As shown, slightly
darker staining was observed
in slides H-M as compared to the others. FIG. 18G shows staining of non-cancer
tissue from the Sample 2
slide. In this setting, staining was lighter and of similar intensity across
all samples.
[001123] Another set of enrichment experiments was performed on a fixed
sample comprising
tumor tissue from an individual considered to be a responder to bevacizumab.
For positive selection, the
oligonucleotide probe library was binding to the entire tissue on the slide
but only the cancer tissue was
scraped off the slide, then the library was recovered from the scraped tissue
and amplified. After three
such rounds, three rounds of two steps of negative selection (tissue from two
individuals not responding to
Avastin) and one positive selection as before were performed. Round 7 included
one more positive
selection. For round 8, the enrichment strategy was altered. Instead of doing
enrichment of tissue fixed to
slides, the cancer tissue and the non-cancer tissue were scraped and separated
in different tubes. To
perform enrichments in tubes, we used centrifugation at 100,000 x g to
separate the tissue from unbound
library. Four rounds of enrichment on scraped cancer tissue with counter
selection on scraped non-cancer
tissue were performed. The library after 12 rounds was used for probing and
selection of aptamer that
bound stronger to cancer relative to non-cancer tissue. Four sequences
recovered from the enrichment are
shown in Table 38. The table indicates the variable region of the identified
sequences along with the full
length sequence with 5' region CTAGCATGACTGCAGTACGT (SEQ ID NO 4) and a 3'
region
CT GT CT CTTATACACATCTGACGCTGCCGACGA (SEQ ID NO 5) surrounding the variable
region. These
sequences can be used to identify, e.g., by staining, cancer tissue from a
responder to bevacizumab. In the
table, the sequences with name comprising "RC" are the reverse complement
sequences used as non-
binding controls.
Table 38: Oligonucleotide probes that bind bevacizumab responder cancer tissue
Variable SEQ ID Seq name Full sequence (5'->3') SEQ ID
Region NO NO
(5'->3')
GCTTCCCGC 203064 5825D-R12c- / 5 Bio s g / CTAGCATGACTGCAGTACGTGCT 203068
AACCGTCCT Si -5'biotin TCCCGCAACCGTCCTACCCATCCTACGCCTC
ACCCATCCT CCTGTCTCTTATACACATCTGACGCTGCCGA
ACGCCT CC CGA
5825D-R12c- /5Biosg/TCGTCGGCAGCGTCAGATGIGTA 203069
S1RC- TAAGAGACAGGGAGGCGTAGGATGGGTAGGA
5'biotin CGGTTGCGGGAAGCACGTACTGCAGT CATGC
TAG
TGGTCACCG 203065 5825D-R12c- / 5 Bio s g / CTAGCATGACTGCAGTACGTTGG 203070
CT TCCGCTG S2-5'biotin TCACCGCT TCCGCT GGTACGCCCCACCCCAT
GTACGCCCC AACTGT CT CT TATACACATCTGACGCTGCCG
AC CC CATAA AC GA
5825D-R12c- /5Biosg/TCGTCGGCAGCGTCAGATGIGTA 203071
S2RC- TAAGAGACAGTTATGGGGTGGGGCGTACCAG
5'biotin CGGAAGCGGIGACCAACGTACTGCAGICATG
CTAG
ACCTAGCTG 203066 5825D-R12c- /5Biosg/CTAGCATGACTGCAGTACGTACC 203072
CT CCCTACT 53-5'biotin TAGCTGCTCCCTACTCCCTTCTTATGTACAT
CCCTTCTTA TACTGT CT CT TATACACATCTGACGCTGCCG
T GTACAT TA AC GA
-212-
CA 03018066 2018-09-17
WO 2017/161357 PCT/US2017/023108
5825D-R12c- /5Biosg/TCGTCGGCAGCGTCAGATGIGTA 203073
S3RC- TAAGAGACAGTAATGTACATAAGAAGGGAGT
5'biotin AGGGAGCAGCTAGGTACGTACTGCAGTCATG
CTAG
TTCATGCTG 203067 5825D-R12c- /5Biosg/CTAGCATGACTGCAGTACGTTTC 203074
TTCCATGAC S4-5'biotin ATGCTGITCCATGACCTCCACATTICTCACG
CTCCACATT CTGACTGTCTCTTATACACATCTGACGCTGC
TCTCACGCT CGACGA
GA 5825D-R12c- /5Biosg/TCGTCGGCAGCGTCAGATGIGTA 203075
S4RC- TAAGAGACAGT CAGCGT GAGAAAT GI GGAGG
5'biotin TCATGGAACAGCATGAAACGTACTGCAGTCA
TGCTAG
[001124] Additional sequences were determined after round 9 above. Tissue
from responder cancer
(i.e., cancer tissue from responder patients), responder non-cancer (i.e., non-
cancer tissue from responder
patients), non-responder cancer (i.e., cancer tissue from non-responder
patients) and non-responder non-
cancer (i.e., non-cancer tissue from non-responder patients) were scraped and
bound oligonucleotides
were sequenced. The fold changes between the non-responder cancer and other
tissues were calculated
after normalization of read counts from the sequencing to the tissue sizes.
Table 39 shows fold changes
for the non-responder cancer over the other three tissue types as indicated.
The table indicates the variable
region of the identified sequences. The full length sequences comprised 5'
region
CTAGCATGACTGCAGTACGT (SEQ ID NO 4) and a 3' region
CTGTCTCTTATACACATCTGACGCTGCCGACGA (SEQ ID NO 5) surrounding the variable
region. Any
appropriate flanking sequences can be used. In Table 40, the complete
sequences for the first six variable
regions in Table 39 along with the complete sequences with flanking regions.
These sequences can be
used to identify, e.g., by staining, cancer tissue from a responder to
bevacizumab. The variables regions of
additional sequences with fold changes of at least 100% in one comparson are
listed in SEQ ID NOs.
203114-206478. In Table 40, the sequences with name comprising "RC" are the
reverse complement
sequences and can be used as non-binding controls. The sequences in Table 40
are further shown labeled
with digoxigenin (DIG). Anti-digoxigenin antibodies with high affinities and
specificity can be used in a
variety of biological immuno-assays, e.g., to visualize the oligonucleotide
staining as described herein.
Both biotin and digoxigenin labeling can be used in such applications, in
addition to any other such useful
labeling systems. Any desired number or combination of the sequences in Table
39 can be used to create
oligonucleotide probes such as in Table 40.
Table 39: Sequences with fold-change differences between bevacizumab non-
responders and
responders
Sample Type! Fold changes
SEQ ID Responder, Non-responder,
Responder,
Variable Sequence 5' ->3' NO Cancer non-cancer non-cancer
ATATGCGATGCTAGCTCGAAGCGTGTGCAGTCCCT 203076 2 4 2
GT CCAGCTCGCAATTACACTAGTTTGCCAGTAAAAG 203077 3 4 3
TCCGGAGTCCATAAGACTACGGATAGCTTTGACCG 203078 3 3 9
CATGCACATCGCGTTTCGGAAACAAAAGTGTAGATA 203079 2 3 4
CCACACGACGTGTGACCTCGGATTCCTCATACACT 203080 2 3 3
ACTGGGTACTTGAATCATTGTCGCATTTCCCTATT 203081 4 3 11
-213-
CA 03018066 2018-09-17
WO 2017/161357 PCT/US2017/023108
CGTAGTTAAGACGCCTCAAGACACATACGGCTTGAA 203082 0 49 0
TCATGACCGAGTAACGACCGACCCACATATCCGC 203083 1 37 2
GTTGGCTCCCTCTAGCATATCCCCACTAGCTGG 203084 1 26 1
CGCCCACTCTTGTTGTTACCGTGCTGTCCTCGGTC 203085 1 22 1
GCATGTGTGGTTTCCCCAGCGCACTCGAGACGACT 203086 0 22 1
GAAAAGTCAGACTTTTGAAGGATTGTGCTGGAACT 203087 1 20 1
GAACATGAAGCATCGAAAGCACTTCACGTAGATTCGA 203088 1 17 0
TTGTGGATTCAAGCGGTCACCACTATGCCAACTTCCA 203089 1 14 1
CCACCTTTTCCACCCATTCCAGGATAGTCGCCCACGA 203090 0 13 0
GTTCGGATGCCCACAGCCCGTTAAGGTATTTTCACGA 203091 0 11 0
TTGTGGGGGACGTATGAGCAGATCCATGCGCGCCA 203092 0 9 1
AGATCTCCGGTACGCCACCGGCGATACCGATTCAG 203093 1 9 1
GTAACCCGATTTTCACGGCCGACCGCATACGCGCC 203094 0 8 1
GCTAGACACTTACAGTGACGTTACTGTCTTGAGCT 203095 0 8 1
GGACATTCAGGTGTCGCTCATCCAAAGCTACGTGC 203096 1 7 6
GTTATCGCACTGAAAAGTAATTCCTTGTATACTCT 203097 1 7 1
GCAAAGGATCCTGGTTGGGCACTTTGTTCCTTTCC 203098 0 7 0
ACCCACTAGGAGGTCGTTAAAGGATAGTTGTAAACTC 203099
A 2 7 2
TCTTGCCTCTGTATGAGCGAGAACTTCTCGCGCGTTC 203100
A 1 7 1
GTCAGTCCCTGGAGTCCATGTGCTTTACCGCCGTC 203101 0 7 0
GAAAGACAACACGTATACATCCCTGAGCCACCCACGA 203102 0 6 0
CCATTGCTCTTACACCGCCTGTCCTTACGGTTGTGGA 203103 1 6 4
TGTTTGCCGATCTCTCATCTGGAGGAACGGGGCA 203104 0 6 1
GTAGTATGTTCTCTTTACTGCGACATGAGTTTCGGTC 203105
A 1 6 1
CGTCACGACACCTACACAAAGCCGCACTCCCTCTGGA 203106 1 6 1
GTATGGTTAACACCAATTACCGGATCCGTAGATTCA 203107 0 6 0
AACAATACCACAGTGGATGCTACCAGTCCCATTAT 203108 1 6 1
GACCCGTTTTGTCGTTGTATTGATATGGTACGTCTTG 203109
A 1 6 1
AAATCGCGACCGGGACAGTGCCGATATTTTTCACG 203110 0 6 1
CTATCCGATGCTACCACTGTTTGAAATCAACAGCC 203111 1 6 0
CTTCATTCGGTTCGGCCGTTCGAACACACTTGTCCCA 203112 1 6 1
GCTAATGCTCGGTGAGGATCGAGCTCCGGTGCCTC 203113 1 6 1
Table 40: Oligonucleotide probes that bind bevacizumab responder cancer tissue
Variable Seq name Full sequence (5'->3') SEQ
ID NO
Region
SEQ ID NO
203076 5825C-R9- /5DIG/CTAGCATGACTGCAGTACGTATATGCGATGCTA 206479
GCTCGAAGCGTGIGCAGTCCCTCTGICTCTTATACACAT
S1-5 DIG
CTGACGCTGCCGACGA
5825C-R9- /5DIG/TCGTCGGCAGCGTCAGATGTGTATAAGAGACAG 206480
AATAGGGAAATGCGACAATGATTCAAGTACCCAGTACGT
S 1-RC-
ACTGCAGTCATGCTAG
5'DIG
203077 5825C-R9- /5DIG/CTAGCATGACTGCAGTACGTGTCCAGCTCGCAA 206481
TTACACTAGITTGCCAGTAAAAGCTGICICTTATACACA
S2-5 DIG
TCTGACGCTGCCGACGA
5825C-R9- /5DIG/TCGTCGGCAGCGTCAGATGTGTATAAGAGACAG 206482
AGGGACTGCACACGCTTCGAGCTAGCATCGCATATACGT
S2-RC-
ACTGCAGTCATGCTAG
5'DIG
-214-
CA 03018066 2018-09-17
WO 2017/161357
PCT/US2017/023108
203078 5825C-R9- /5DIG/CTAGCATGACTGCAGTACGTTCCGGAGTCCATA 206483
AGACTACGGATAGCTTTGACCGCTGICTCTTATACACAT
S3-5 DIG
CTGACGCTGCCGACGA
5825C-R9- /5DIG/TCGTCGGCAGCGTCAGATGTGTATAAGAGACAG 206484
TATCTACACITTIGTTTCCGAAACGCGAIGTGCATGACG
S3-RC-
TACTGCAGTCATGCTAG
5'DIG
203079 5825C-R9- /5DIG/CTAGCATGACTGCAGTACGTCATGCACATCGCG 206485
S4-5'DIG TITCGGAAACAAAAGTGTAGATACTGTCICTTATACACA
TCTGACGCTGCCGACGA
5825C-R9- /5DIG/TCGTCGGCAGCGTCAGATGTGTATAAGAGACAG 206486
S4-RC-
AGTGIATGAGGAATCCGAGGICACACGTCGTGTGGACGT
5'DIG ACTGCAGTCATGCTAG
203080 5825C-R9- /5DIG/CTAGCATGACTGCAGTACGTCCACACGACGTGT 206487
S5-5'DIG GACCICGGATTCCTCATACACTCTGICTCTTATACACAT
CTGACGCTGCCGACGA
5825C-R9- / 5DIG/TCGTCGGCAGCGTCAGATGTGTATAAGAGACAG 206488
S5-RC-
CITTIACTGGCAAACTAGTGIAATTGCGAGCTGGACACG
5'DIG TACTGCAGTCATGCTAG
203081 5825C-R9- /5DIG/CTAGCATGACTGCAGTACGTACTGGGTACTTGA 206489
56-5'DIG ATCATTGTCGCATTTCCCTATTCTGICTCTTATACACAT
CTGACGCTGCCGACGA
5825C-R9- / 5DIG/TCGTCGGCAGCGTCAGATGTGTATAAGAGACAG 206490
S6-RC-
CGGICAAAGCTATCCGTAGICTTATGGACTCCGGAACGT
5'DIG ACTGCAGTCATGCTAG
Example 25: Background optimization and automation
[001125] In this Example, we optimized fixed tissue staining with
oligonucleotide probe libraries
as in the experiments described in the Examples above. For example, such
optimization was performed to
reduce non-specific background staining with enriched oligonucleotide probe
libraries when using
polyligand histochemistry (PHC). Certain conditions were found to address non-
specific background
staining. Certain changes in the staining protocols are shown in Table 41. The
-New" and -New+"
improved protocols were optimized and automated using the Ventana Discovery
platform. In the table,
BA refers to BlockAid Blocking Solution (Thermo Fisher Scientific), and PBS
refers to phosphate
buffered saline. As seen from the table, the blocking conditions are more
stringent in the New and New+
protocols.
Table 41: Background optimization conditions
Original Protocol New Protocol New+
Protocol
Permeabilization No Yes Yes
(0.1%Triton-100 for 10 (0.1%Triton-100 for 10
mins) mins)
Deparaffinization 69 C for 32 mins 69 C for 32 mins 69 C for 32 mins
Antigen Retrieval 95 C for 32 mins 95 C for 32 mins 95 C for 32 mins
-215-
CA 03018066 2018-09-17
WO 2017/161357 PCT/US2017/023108
Library cocktail 10% BA (no Triton) 25% BA (0.01% 25% BA (0.01%
Triton) Triton)
Rinses 1 rinse 4 rinses 4 rinses
Str-HRP+MgC12 In PBS In PBS In 25% BA
[001126] The complete protocol is as follows. Examples of staining various
tissues will follow.
Reagents are shown in Table 42. The equipment is a Ventana Discovery
Autostainer.
Table 42: Raw Materials
Reagent Vendor cat #
Salmon DNA Life Tech 15632-011
tRNA Life Tech AM7119
BlockAid Life Tech B10710
Streptavidin Poly-HRP Life Tech 21140
MgCl2 Affymetrix 78641
Hyclone PBS V.W.R. International SH30256.01
Sigma PBS Packet Sigma-Aldrich P3813
H20 Sigma-Aldrich W4502
Molecular Grade Water Life Tech 10977-015
DAB Buffer Dako SM803
[001127] Reagent Preparation
[001128] Step 1: Permeabilization of all slides immediately prior to
epitope retrieval. Completely
immerse slides in 0.1% Triton X 100 in lx PBS, incubate for 10 mills at room
temperature (RT).
[001129] Step 2: Wash the slide by dipping 10 x in 750mL 1X PBS (1Liter
copling jar).
[001130] Step 3: Prepare Competitor/Block/Aptamer Library cocktail. In
Table 43, the SA-poly
HRP cocktail is shown. SA-poly HRP refers to Streptavidin Poly-HRP conjugate,
which is biotin-binding
protein conjugated with polymers of horseradish peroxidase that enables signal
amplification and
detection of biotinylated binding agents (e.g., antibodies or aptamers) for
IHC and other methods.
Table 43: SA-poly HRP cocktail
Stock Cocktail Volume from Final
Reagent
Concentration Concentration stock, ul
Concentration
H20 0.00
SA-poly HRP, x 250 4 384.0 1.00
PBS, x 20 4 4800.0 1.00
MgC12, mM 1000 12 288.0 3.00
BlockAid, % 100 77.2 18528.0 19.30
-216-
CA 03018066 2018-09-17
WO 2017/161357
PCT/US2017/023108
[001131] The biotinylated oligonucleotide probe library is mixed with MgCl2
prior to addition to
the Competitor/Block master mix shown in Table 44:
Table 44: Block! Aptamer master mix
Reagent Stock Intermediate Cocktail Volume of Final
Concentration stock (in Concentration stock to
Concentration
1120) make
cocktail, ul
H20 72.5
Triton, % 100 1 0.03 14.2 0.01
Salmon DNA, ng/ul 300 1.96 3.1 0.65
tRNA, ng/u1 300 1.96 3.1 0.65
BlockAid, % 100 75.00 354.4 25.00
MgCl2, mM 1000 9.00 4.3 3.00
PBS, x 20 0.00 0.0 0.00
Oligo library ng/ I 15 0.67 21.0 0.22
[001132] Staining
[001133] Step 4: Aptohistochemistry on Ventana Discovery autostainer
[001134] Deparaffinization and Epitope Retrieval
[001135] All Slides: Apply corresponding block/aptamer solution 1501.il
(Table 44), incubate for
lh RT (300 1 of Running buffer will be added automatically)
[001136] All Slides: Apply 100 IA of SA-HRP +MgC12 + 19% BA SA-poly HRP
cocktail (Table
43)
[001137] Apply DAB buffer
[001138] Apply Hematoxylin
[001139] Post Staining
[001140] Step 5: Pour off liquid coverslip and use paper towel to wick off
residual oil from edge of
glass.
[001141] Step 6: Standard coverslipping.
[001142] Step 7: Score slide staining.
[001143] Tissue staining
[001144] The protocol above was used to stain fixed tissues from various
anatomical locales,
including tumor samples from ovarian, breast, pancreatic, bladder, melanoma,
head&neck, kidney, non-
small cell lung (NSCLC), glioblastoma (GBM), hepatocellular carcinoma (HCC)
and colon origin. The
oligonucleotide probe library used was the R6 library from HER2+ breast tissue
enrichment in Example
19. The unenriched library (RO) was used as a control. Accordingly, the probe
library was not optimized
for each tissue but nonetheless provided discernible staining in various
tissues as shown in FIGs. 19A-K.
The figures show H&E stained slides with the original protocol and the
optimized protocol presented in
this Example. FIG. 19A shows results for ovarian cancer samples. The darkest
staining of all samples was
observed with the original protocol, though discernible brown stain was
observed in the No Library
sample that was absent any oligonucleotide probes. With the optimized library,
staining was most evident
-217-
CA 03018066 2018-09-17
WO 2017/161357 PCT/US2017/023108
with R6 and no brown staining was observed in the No Library sample. Without
being bound by theory,
the staining observed in the absence of probe library with the original
protocol may be derived from non-
specific binding of the SA-HRP, or in some cases due to endogenous biotin.
Qualitatively similar results
were observed with breast cancer tissue (FIG. 19B), pancreatic cancer tissue
(FIG. 19C), bladder cancer
tissue (FIG. 19D), melanoma tissue (FIG. 19E), head and neck cancer tissue
(FIG. 19F), kidney cancer
cancer tissue (FIG. 19G), NSCLC tissue (FIG. 19H), GBM tissue (FIG. 19I), HCC
tissue (FIG. 19J),
and colon cancer tissue (FIG. 19K). With melanoma and GBM tissues, slight
staining was observed in the
optimized no library samples, but this staining was nonetheless noticeably
reduced as compared to the
original no library samples. With the NCSLC and colon tissues, little staining
was observed in the no
library samples under either set of conditions.
Example 26: 01i2onucleotide probe enrichment on TUBB3+ pancreatic cancer
tissue
[001145] In this Example, we used the FFPE tissue enrichment protocol
developed in the Examples
above (see, e.g., Examples 21-22 and 25) to enrich a naive oligonucleotide
probe library against TUBB3+
pancreatic cancer tissue samples.
[001146] The random ssDNA library (naive F-TRin-35n-B 8-3s library)
contains 35 random
nucleotides flanked by constant regions. Specifically, the naive library
comprises a 5' region (5'
CTAGCATGACTGCAGTACGT (SEQ ID NO. 4)) followed by a random naive
oligonucleotide sequence of
35 nucleotides and a 3' region (5' CTGICTCTTATACACATCTGACGCTGCCGACGA (SEQ ID
NO. 5)).
The samples were pancreatic FFPE tissue samples with TUBB3 status confirmed by
conventional IHC.
Seven rounds of enrichment were performed. We initially performed enrichment
with the full protocol
from Example 25 but no enrichment was observed. Without being bound by theory,
it is likely the
optimized protocol in Example 25 is too stringent as it was optimized for
probing and not enrichment.
Thus, the optimized protocol was adapted for the enrichment process as shown
in FIG. 20A. In this
scheme, enrichment was performed according to the order P->P->P->(N->P)->(N-
>P)->(N->P)->P, where
"P" ("Pos" in FIG. 20A) refers to positive selection against TUBB3+ samples
and "N" ("Neg" in FIG.
20A) refers to negative selection against TUBB3- samples. The enrichment was
performed with low
stringency in early rounds using the conditions as shown in FIG. 20A. For
example, the figure shows that
the concentration of detergent (Triton X100) and blocking agents (BlockAid)
were increased in later
rounds of enrichment. Further as indicated in the figure, staining as
described in Example 25 was
performed after later rounds of enrichment to observe the enrichment process.
An example in shown in
FIG. 20B, where much higher levels of brown stain are observed in the Positive
sample as compared to
the Negative sample.
[001147] The final enriched library after seven rounds of enrichment is
referred to as the TUBB3-
R7 library. The TUBB3-R7 library was used to probe nine TUBB3+ and nine TUBB3-
pancreatic cancer
tissue slides that were not used in the enrichment process (i.e., non-
enrichment cases). Staining intensity
was determined by blinded pathologists. H-Scores (i.e., [1 x (% cells 1+) + 2
x (% cells 2+) + 3 x (% cells
3+)1) were calculated based on the staining intensity for both overall slide
staining and nuclear staining.
Results are shown in FIG. 20C, which plots total (i) or nuclear (ii) H-score
for the indicated groups of
-218-
CA 03018066 2018-09-17
WO 2017/161357 PCT/US2017/023108
samples (i.e., TUBB3+ or TUBB3-). The p-values for the differences between the
groups are indicated
beneath each plot. The H-Scores were also used to generate ROC plots and
calculate ROC AUC values, as
shown in FIG. 20D. This figure provides plots for total (i) or nuclear (ii)
ROC curves. The AUC value for
total (i) was 0.843 and the AUC value for nuclear (ii) was 0.889. Thus, in
both cases the TUBB3-R7
library had very high performance at differentiating TUBB3+ and TUBB3-
pancreatic cancer tissue
specimens.
[001148] In Example 19, we presented an oligonucleotide probe library that
was able to distinguish
HER2+ and HER2- breast cancer samples. Similarly, in this Example, we
developed an oligonucleotide
probe library that was able to distinguish TUBB3+ and TUBB3- pancreatic cancer
samples.
Example 27: TTNT for Platinum/Taxane treatment in Ovarian Cancer
[001149] In this Example, we used the FFPE tissue enrichment protocol as in
Example 26 to enrich
a naive oligonucleotide probe library against ovarian cancer tissue samples
that were considered as
responders or non-responders to platinum / taxane treatment. Responder
(benefit) / non-responder (non-
benefit) status was determined using time-to-next-treatment (TTNT) after
platinum/taxane treatment, also
known as drug free interval (DFI), as described in Examples 20-22. For this
Example, non-responders
were those with DFI < 6 months and responders were those with DFI > 6 months.
[001150] Methodology was similar to that in Example 26 with modifications
described here. The
enrichment process is outlined in FIG. 21A. Enrichment was performed according
to the order P->P->P-
>(2N*->P)->(2N*->P)->(2N*->P, where "P" ("Pos" in FIG. 21A) refers to positive
selection against
responder tissue samples, "N" ("Neg" in FIG. 21A) refers to negative selection
against non-responder
tissue samples, and * indicates that two negative slides were used in
parallel, the supernatants were pooled
and the probes were purified with Streptavidin beads before PCR. The reverse
process was also
performed, wherein positive selection was against non-responder tissue samples
and negative selection
was against responder tissue samples. As in Example 26, more stringent
conditions were used in later
rounds of enrichment. See FIG. 2IA for enrichment conditions. FIG. 21B shows
examples of staining
with six enriched libraries, three libraries trained toward non-responders and
three trained toward
responders, as indicated. The library in FIG. 21B showed the expected staining
pattern with greater
staining in the positive enrichment cases (here responders). This library will
be used to probe non-
enrichment ovarian cancer samples that benefit/respond or not from platinum /
taxane treatment as
described above.
Example 28: Detection of oli2onucleotide probe bindin2 to tissue samples
[001151] Protocols similar to the Examples above were used to enrich the
naive F-TRin-35n-B 8-3s
library against FFPE kidney tissue slides. The biotinylated library after 6
rounds of enrichment was used
to probe fixed kidney tissue similar to Example 25. Slides were also probed
with biotinylated unenriched
F-TRin-35n-B 8-3s library as a control. The oligonucleotide probe binding was
visualized as above using
Steptavidin-horse radish peroxidase (SA-HRP) (Life Technologies, cat#
11207733910). Despite stringent
probing conditions, notable levels of background staining seen with the
unenriched library control. In this
-219-
CA 03018066 2018-09-17
WO 2017/161357 PCT/US2017/023108
Example, we used an alternative staining protocol to visualize oligonucleotide
probe binding to the kidney
samples.
[001152] Without being bound by theory, we examined whether non-specific
binding of SA-HRP
to the samples could be responsible and developed an alternate visualization
methodology. Biotin-
avidin/streptavidin biological assays have many desirable characteristics such
as well known methods and
reagents, do not require antibodies due to the strong and specific biotin-
avidin binding, and steptavidin
beads are available for pull down experiments / immunoprecipitation. However,
in some cases
endogenous biotin in the tissue could lead to problematic background binding.
In this Example, we tested
a digoxigenin (DIG) modified oligonucleotide library with anti-DIG-HRP
antibody detection. Unlike
biotin, digoxigenin is a steroid found exclusively in the flowers and leaves
of certain plants.
[001153] FIG. 22A show staining of kidney FFPE slides using the indicated
DIG modified
oligonucleotide libraries and anti-DIG-HRP antibody detection. FIG. 22Ai shows
a no-library control,
FIG. 22Aii shows staining with 5 ng of the unenriched (RO) library, FIG.
22Aiii shows staining with 5 ng
of the round (R6) library, FIG. 22Aiv shows staining with 50 ng of the
unenriched (RO) library, and FIG.
22Av shows staining with 50 ng of the round 6 (R6) library. All images were
taken at a 20x
magnification. In the figures, no brown staining was observed with no-library
control (FIG. 22Ai) and 5
ng RO samples (FIG. 22Aii). Only slight staining was observed with the 50 ng
RO samples (FIG. 22Aiv).
More staining was observed with the 5 ng R6 samples (FIG. 22Aiii), and strong
stain was observed when
using 50 ng of the R6 library (FIG. 22Av). These data indicate that the DIG
modified oligonucleotide
libraries were effective at eliminating background staining observed with the
biotin modified
oligonucleotide libraries in the fixed kidney tissue samples used in this
study.
[001154] We also examined whether the incubation times during enrichment
would influence the
enrichment process. Four different enrichments were performed against kidney
tissue wherein the library
incubation time during enrichment was varied at 30 min, 1 h, 2 h, and 3 h. We
then performed anti-DIG
staining with 50 ng of libraries from six rounds of enrichment under each of
the incubation conditions. We
found that incubation time correlated with staining intensity: the longer the
incubation time the stronger
the staining. See FIG. 22B, which shows slides from six rounds of enrichment
with incubation times of 30
min (FIG. 22Bi), 1 h (FIG. 22Bii), 2 h (FIG. 22Biii), and 3 h (FIG. 22Biv).
Example 29: On-slide Olizonucleotide Probe Enrichment nainst FFPE Tissue
Lvsate
[001155] In certain instances, such as in the experiments described above
in Examples 19-28,
paraffin blocks comprising tumor samples, or multiple slides comprising
sections from such blocks are
available. In such cases, multiple slides from a single sample, including
without limitation multiple
sections from a tumor, can be used for oligonucleotide probe library
enrichment and/or probing. In this
Example, we developed a method for on-slide oligonucleotide probe enrichment
against FFPE tissue
lysate. Lysates from FFPE tissue slides were arrayed onto nitrocellulose film
slides for enrichment and
analysis. Such alternate methods may prove beneficial in certain cases, e.g.,
where limited samples are
available, such as a single FFPE tissue slide per patient or tumor sample.
-220-
CA 03018066 2018-09-17
WO 2017/161357 PCT/US2017/023108
[001156] Methodology 2300 is outlined in FIG. 23A. As shown, 1 L of 2.5
ug/u1FFPE lysate is
arrayed onto nitrocellulose film slides (AVID Film Slide + 64-well ProPlate;
Grace Bio-Labs, Bend,
Oregon) 2301. The slides are air dried overnight (0/N) at 4 C 2302. The slides
are washed six times in
wash buffer comprising 50 IA of 1X PBS, 3 mM MgCl2 2303. The naïve F-Trin
library as described herein
is added in various concentrations (0.1/0.5/2.5 ng) to certain wells in 20 1
with blocking buffer
comprising 1X PBS (pH 7.4), 3 mM MgCl2, 1% HSA, 0.5% F127, 8 ng/u1 Salmon
Sperm DNA and 8
ng/ 1 Yeast tRNA 2304. The library is incubated on the film slides for 1 hour
at room temperature (RT)
with shaking at 100 rpm. After incubation, the film slides are washed five
times with wash buffer 2305.
The wells of the film slides are scraped with a pipet tip and transferred to
30 ul H20 2306.
Oligonucleotides recovered in the scraping are amplified by asymmetric PCR as
described herein and
single stranded oligonucleotide probes (ssDNA) are purified 2307. For the
desired number of rounds of
enrichment, 0.1/0.5/2.5 ng of the previous round's enriched library in
blocking solution is added to fresh
film slides 2308. After incubation, the oligonucleotide probes that bound to
the sample are recovered and
amplified as in round 1 2309. The recovered library was sequenced using next-
generation sequencing
2310 after round 3.
[001157] The above procedure was performed on film slides arrayed with
lysates from FFPE tissue
slides from human subjects with various anatomical origins, including breast,
colon, kidney, lung and
pancreas. After three rounds of enrichment, the "Rd3" libraries were sequenced
as described above 2310.
In all cases, the largest number of sequences was observed in the samples
incubated with 0.1 ng of
oligonucleotide library.
[001158] Three more rounds of enrichment were performed as above with
breast & pancreas FFPE
lysates. In one set of enrichments, the methodology 2300 was as above. The
library resulting from six
rounds of positive selection on lysate from breast tissue is referred to as
the Br_Rd6_Lib. In a next set of
enrichments, the methodology 2300 was as above with addition of a competitor
tissue lysate during
incubation 2304. For this step in rounds 4-6, we added 0.1/0.5/2.5 ng of the
0.1 ng Rd3 library from a
different tissue's enrichment in 80 ul of blocking buffer. For example, the
Rd3 library from the breast
lysate enrichments was incubated with breast and pancreatic lysates at the
same time. The sequences
bound to the breast lysate were retained, while sequences bound to pancreatic
lysate were discarded. The
library resulting from six rounds of positive selection on lysate from breast
tissue wherein the last three
rounds of einrichment included competition with lysates from pancreas tissue
is referred to as the
Br_Rd6+_Lib.
[001159] After enrichment, we used the Br_Rd6_Lib and Br_Rd6+_Lib as well
as starting naive F-
TRin library (i.e., Rd0) to stain normal breast, colon, kidney and lung tissue
slides. Slides were stained
generally as described in Example 40 above using a SA-HRP system using 50 ng
of library per slide. We
observed higher level of staining when probing breast tissue with the
Br_Rd6_Lib and Br_Rd6+_Lib
oligonucleotide probe libraries than with the Rd0 naïve control.
Representative results are shown in FIG.
23B. Some background staining was observed in the Rd0 slides (FIG. 23Bi) but
much higher levels of
staining with the Br_Rd6+_Lib (FIG. 23Bii) and Br_Rd6_Lib slides (FIG.
23Biii).
-221-
CA 03018066 2018-09-17
WO 2017/161357
PCT/US2017/023108
[001160] The above results demonstrated oligonucleotide probe library
enrichment with selection
on FFPE tissue lysate bound to film slides. We further showed that the
enriched aptamers can stain FFPE
tissue slides. See, e.g., FIG. 23B. This approach has utility if the amount of
working material is limited
and has the ability to perform competitive selection using the same library
against multiple targets.
[001161] We next selected certain high abundance and high fold-change
oligonucleotide aptamers
from the Rd6_Lib and Br_Rd6+_Lib oligonucleotide probe libraries for use in on-
slide staining of normal
breast tissue. As controls for the staining experiments, we used
oligonucleotides with complement
sequences in the variable regions. The selected sequences were synthesized
with 5'-biotin. Each group of
sequences was pooled at a fmal concentration of 10 ng/p.L. For example, eight
probes with high
abundance sequences selected from the Br_Rd6_Lib and Br_Rd6+_Lib library were
combined in a single
tube and the eight corresponding reverse complement oligonucleotides were
pooled in a separate tube. We
applied 25 ng, 50 ng or 100 ng of each oligonucleotide pools to the tissue
slides for staining. Normal
breast tissue slides from the same block as those used for lysate preparation
were used for staining. Slides
were pre-treated for 10 minutes in 0.1% Triton X-100 and rinsed in distilled
H20. Epitope retrieval was
performed at 96 C for 45 minutes. The staining protocol is as described in
this Example above uing a
streptavidin-HRP system. The selected sequences are shown in Table 45. The
table indicates the variable
region of the identified sequences. The full length sequences comprised 5'
region 5'-
CTAGCATGACTGCAGTACGT (SEQ ID NO 4) and a 3' region 5'-
CTGTCTCTTATACACATCTGACGCTGCCGACGA (SEQ ID NO 5) surrounding the variable
region.
Table 45: Sequences Selected for Staining
Criteria Variable Sequence (5' - 3') SEQ
ID NO
High Abundance GGGGGCCCCTTTTGTTTTCTTTTTGTTATTTTTGC 206491
(Br_Rd6_Lib and GGCTTCCTGGGGGITTTIGTAATTGTATTITCTGTTGA 206492
Br_Rd6+_Lib) ACCCTTTAGGTGTTTTTTTTGGTTTTCATTTTTTA 206493
TTCGCCGTTITTGITTIGTTGICTTAGGITACCTC 206494
High Abundance TGCTGGGTGGTTTGITTTTITATTTGGIGCATTCT 206495
(Br_Rd6_Lib) GCCGTGATTCATTTGAGGGTTCCTTGTTTGATTTTA 206496
TTAGGTATGCCACGIGCCTAATIGGGGITTITGITTGA 206497
TGICATCTCACCTAACCACACAACCTACTACCTCA 206498
High Fold-Difference TTCAATCTACACTGGTATTTCGCCTCCTCGCTGGGTGA 206499
(Br_Rd6_Lib and GGTCCTCCGGCGCATATTCCTTACCGTAAATTATA 206500
Br_Rd6+_Lib) TTGITICCAACTCITGAATTICTIGGTACITGICCA 206501
TGGACTCTCTCCTCTGCCTCTGIGATAGCGGTTITTGA 206502
High Fold-Difference CTTGAATTCCCATGICTCTCCTGCCCCCCTCACTA 206503
(Br_Rd6_Lib) TTCTGAGGCTCACCACTTTGCACAAACTTTTCACCGA 206504
GGGITTATTCTGCTTATCCITICGTTITCITGTTGA 206505
ATGCCACCACTGATCGCTAAGT TACCCCAACTGTT TGA 206506
[001162] We observed greater staining the higher the input of probes. Thus,
probing with 100 ng of
the oligonucleotide probes yielded the highest level staining, albeit with the
highest levels of background
staining. Representative results are shown in FIG. 23C and FIG. 23D (both are
20 x magnifications).
-222-
CA 03018066 2018-09-17
WO 2017/161357 PCT/US2017/023108
FIG. 23C shows results for probing with 100 ng pools of eight sequences
selected by abundance (i.e., first
eight sequences in Table 45), which shows the most staining intensity. FIG.
23D shows results for
probing with 25 ng pools of eight sequences selected by high fold change
(i.e., last eight sequences in
Table 45), which shows lower staining intensity but also reduced background
with the negative controls.
In both figures, the left most panel (i) shows slides stained with these
oligonucleotides wherein the right
panel (ii) shows the staining with their reverse complements.
Example 30: Oligonucleotide Probe Enrichment on Scraped Tissue
[001163] As another alternate enrichment scheme, in this Example we
performed oligonucleotide
probe library enrichment in an Eppendorf tube on tissue scraped from an FFPE
slide. As in Example 29,
this approach may be beneficial in certain scenarios, including without
limitation when limited tissue is
available, such as a single FFPE slide.
[001164] We started with the naive F-Trin library described herein.
Positive selection was
performed on colon cancer tissue samples with negative selection on non-cancer
tissue from the same
slide. Regions of cancer and non-cancer tissue were determined by a
pathologist. Selected regions were
scraped from the slide then placed in an Eppendorf tube. Three rounds of
enrichment were performed with
positive selection against cancer tissue. Five more rounds of enrichment were
performed with positive
selection against cancer tissue and negative selection on non-cancer tissue.
In these experiments,
separation of unbound library was performed by ultracentrifugation. For
example, positive selection was
performed by incubating the oligonucleotide probes with tumor tissue, and
collecting oligonucleotides
that co-precipitated with the tissue during ultracentrifugation. Similarly,
negative selection was performed
by incubating the oligonucleotide probes with non-cancer tissue, then
collecting the supernatant after
ultracentrifugation.
[001165] We used the library enriched after eight rounds (the "R8" library)
to stain fixed tissue
from four colon cancer cases used in the enrichment process. We used the
unenriched library ("RO") as
control. Staining was performed with the Ventana Discovery system as in
Example 25 using 50 ng of
library per slide with an SA-HRP system. We compared staining intensity on
cancer and non-cancer
regions from a single slide. See FIG. 24A. The figure shows staining with the
RO control library on
cancer tissue (i), the R8 enriched library on cancer tissue (ii), the RO
control library on non-cancer tissue
(iii), and the R8 enriched library on non-cancer tissue (iv). As shown in the
figure, the strongest staining
was observed on cancer tissue with enriched (round 8) library. Minimal
staining was observed on non-
cancer tissue with enriched (round 8) library. Finally, no staining was
observed on any tissue with the
unenriched (round 0) library. These results indicate the enrichment process
was effective to generate an
oligonucleotide probe library that can distinguish colon cancer tissue.
[001166] We also used the R8 library to stain fixed tissue from four colon
cancer cases that were
not used in the enrichment process. Representative results are shown in FIG.
24B. The figure shows
staining with the RO control library on cancer tissue (i), the R8 enriched
library on cancer tissue (ii), the
RO control library on non-cancer tissue (iii), and the R8 enriched library on
non-cancer tissue (iv). As
shown in the figure, the strongest staining was observed on cancer tissue with
enriched (round 8) library.
-223-
CA 03018066 2018-09-17
WO 2017/161357 PCT/US2017/023108
For three cases we observed no staining on non-cancer tissue with the enriched
(round 8) library, whereas
one case showed slight staining. In addition, we observed no staining on any
tissue with unenriched
(round 0) library, whereas the same case that showed slight staining with the
R8 library on non-cancer
tissue also showed slight staining with the RO library as well. These results
indicate that the enriched
oligonucleotide probe library can distinguish colon cancer tissue with high
accuracy as we observed no
false negatives and one potential false positive with this sample set.
Example 31: Oligonucleotide Probe Enrichment using Microdissection
[001167] Laser capture microdissection (LCM), also called microdissection,
laser microdissection
(LMD), or laser-assisted microdissection (LMD or LAM), is a method for
isolating specific cells of
interest from microscopic regions of tissue/cells/organisms. In this Example,
we used LCM as a method to
extract tissue for oligonucleotide probe enrichment as described herein. The
method comprises dissection
on a microscopic scale with the help of a laser. LCM technology can harvest
the cells of interest directly
or can isolate specific cells by cutting away unwanted cells to give
histologically pure enriched cell
populations. A laser is coupled into a microscope and focuses onto the tissue
on the slide. By movement
of the laser an element is cut out and separated from the adjacent tissue.
[001168] An extraction process follows the cutting process. In one such
method, a sticky surface is
pressed onto the sample, which is then torn out. This extracts the desired
region, but can also remove
particles or unwanted tissue on the surface. In another method, a plastic
membrane is melted onto the
sample, which is then tom out. The membrane is heated with a laser to melt it
to the sample. This method
may also extract undesired debris. Extraction can also occur without contact.
In one such approach, the
sample is transported by laser pressure and gravity (gravity-assisted
microdissection). In another
approach, a cap coated with an adhesive is positioned directly on the thinly
cut tissue section, the section
itself resting on a thin membrane (e.g., polyethylene naphtalene). A laser
gently heats the adhesive on the
cap fusing it to the underlying tissue and another laser cuts through tissue
and underlying membrane. The
membrane-tissue entity now adheres to the cap and the cells on the cap can be
used in downstream
applications (DNA, RNA, protein analysis).
[001169] FFPE samples are commonly fixed to glass slides. We found that not
all LCM methods
are appropriate for oligonucleotide probe enrichment with such samples. For
example, LCM after epitope
retrieval but before addition of the oligonucleotide probe library is
problematic because the sample should
not be dehydrated after epitope retrieval. LCM before epitope retrieval can be
problematic with heat
induced epitope retrieval if the transfer film doesn't hold up during the
standard heat epitope retrieval. For
example, we tested sample extraction using the CapSure0 Macro LCM Caps and the
ArcturusXT
Microdissection System from ThermoFisher Scientific (Waltham, MA) and found
that standard heated
epitope retrieval conditions (95 C) may either melt or destroy the capture
film.
[001170] To address such issues, we performed four rounds of enrichment
starting with the naive
F-Trin library described herein on breast tissue attached to LCM SureCaps with
epitope retrieval at 75 C.
We used the resulting R4 oligonucleotide probe library to stain fixed breast
tissue using the Dako platform
as in Example 19, with epitope retrieval at 75 C or 97 C with between one and
three wash steps after
-224-
CA 03018066 2018-09-17
WO 2017/161357 PCT/US2017/023108
addition of library. With epitope retrieval at 75 C and one wash step (i.e.,
least stringent wash conditions),
no staining was observed. Epitope retrieval at 97 C and one wash step produced
the strongest staining
with the enriched library (R4). Under these conditions, we obtained slightly
less staining with RO library
and minimal background with a no DNA control. Conditions including epitope
retrieval at 97 C and
stringent three wash steps resulted in the strongest staining with enriched
library (R4) and slightly less
staining with the RO library. Minimal background was found the no DNA control
but clearly less than
with one wash step. We then tested both the Dako and Ventana IHC systems for
staining of fixed breast
tissue. See Examples 19 and 25, respectively. We performed library inputs
titers (Dako: 50 ng, 25 ng and
12 ng; Ventana: 50 ng and 25 ng) in combination with a stringent staining
protocol, comprising 25%
BlockAid in library, 19% BlockAid in SA-HRP, 0.01% Triton X-100 and four
washes after addition of
library. When using the Dako system, we observed stronger staining with the R4
library than the
unenriched RO library with all library inputs (i.e., 50 ng, 25 ng and 12 ng).
Representative results are
shown in FIG. 25A, which shows the samples stained with 50ng of the R4 library
(FIG. 25Ai) or RO
control (FIG. 25Aii). When using the Ventana system, we also observed stronger
staining with the R4
library than the unenriched RO library with both library inputs (i.e., 50 ng
and 25 ng). Representative
results are shown in FIG. 25B, which shows the samples stained with 25 ng of
the R4 library (FIG. 25Bi)
or RO control (FIG. 25Bii). Under these conditions, background staining was
minimal with the RO
control.
[001171] These results demonstrate enrichment of an oligonucleotide probe
library using
microdissected FFPE tissue samples. As with Example 30, this approach may
provide more pure samples,
e.g., by dissecting purely cancer cells for analysis. As with Examples 30-31,
approach may also prove
beneficial under some conditions such as when limited sample is available. And
as in Example 30, cancer
and non-cancer samples can be extracted from a single slide.
[001172] Although preferred embodiments of the present invention have been
shown and described
herein, it will be obvious to those skilled in the art that such embodiments
are provided by way of
example only. Numerous variations, changes, and substitutions will now occur
to those skilled in the art
without departing from the invention. It should be understood that various
alternatives to the embodiments
of the invention described herein may be employed in practicing the invention.
It is intended that the
following claims define the scope of the invention and that methods and
structures within the scope of
these claims and their equivalents be covered thereby.
-225-
